WorldWideScience

Sample records for bnct radiation treatment

  1. BNCT-RTPE: BNCT radiation treatment planning environment

    Energy Technology Data Exchange (ETDEWEB)

    Wessol, D.E.; Wheeler, F.J. [Idaho National Engineering Lab., Idaho Fall, ID (United States); Babcock, R.S. [and others

    1995-11-01

    Several improvements have been developed for the BNCT radiation treatment planning environment (BNCT-Rtpe) during 1994. These improvements have been incorporated into Version 1.0 of BNCT-Rtpe which is currently installed at the INEL, BNL, Japanese Research Center (JRC), and Finland`s Technical Research Center. Platforms supported by this software include Hewlett-Packard (HP), SUN, International Business Machines (IBM), and Silicon Graphics Incorporated (SGI). A draft version of the BNCT-Rtpe user manual is available. Version 1.1 of BNCT-Rtpe is scheduled for release in March 1995. It is anticipated that Version 2.x of BNCT-Rtpe, which includes the nonproprietary NURBS library and data structures, will be released in September 1995.

  2. Implementation of BNCT treatment planning procedures

    International Nuclear Information System (INIS)

    Estimation of radiation doses delivered during boron neutron capture therapy (BNCT) requires combining data on spatial distribution of both the thermal neutron fluence and the 10B concentration, as well as the relative biological effectiveness of various radiation dose components in the tumor and normal tissues. Using the treatment planning system created at Idaho National Engineering and Environmental Laboratory and the procedures we had developed for clinical trials, we were able to optimize the treatment position, safely deliver the prescribed BNCT doses, and carry out retrospective analyses and reviews. In this paper we describe the BNCT treatment planning process and its implementation in the ongoing dose escalation trials at Brookhaven National Laboratory. (author)

  3. Combination of fractionated photon radiation and BNCT

    International Nuclear Information System (INIS)

    Because of the relatively low normal brain dose, BNCT allows additional photon radiation sufficient to maintain a total normal brain dose below the tolerance limit. We started a new protocol with a combination of fractionated, extended local photon radiation, and BPA- and BSH-mediated BNCT. In this protocol, newly diagnosed glioblastoma were treated with BPA (250 mg/kg) - and BSH (100 mg/kg) - mediated BNCT followed by fractionated photon radiation. The BNCT dose for the normal brain was restricted to less than 13 GyEq. The fractionated photon radiation at a dose of 30/15 fr or 30.6 Gy/17 fr was planned to irradiate a T2 high-intensity area of post-BNCT MRI. So far, 6 patients have been treated by this protocol. The clinical course, dose distribution, tumor response, and adverse events will be discussed herein. (author)

  4. Dose estimation of the THOR BNCT treatment room

    International Nuclear Information System (INIS)

    BNCT beam of Tsing Hua Open-pool Reactor (THOR) was designed and constructed since 1998. A treatment room for the newly modified THOR BNCT beam was constructed for the next clinical-stage trials in 2004. Dose distribution in a patient (or a phantom) is important as irradiated with the BNCT beam. The dose distributions for different type of radiations such as neutron and photons in the treatment room are strongly becoming the index or reference of success for a BNCT facility. An ART head phantom was placed in front of the THOR BNCT beam port and was irradiated. In each section of the head phantom, numbers of small holes are inside and separated uniformly. Dual detector: TLD-600 and TLD-700 chips were placed inside these holes within the phantom to distinct doses of neutron and photon. Besides, Dual-TLD chips were latticed placed in the horizontal plane of beam central axis, in the treatment room to estimate the spatial dose distribution of neutron and photon. Gold foils were assisted in TLD dose calibrations. Neutron and photon dose distributions in phantom and spatial dose distributions in the THOR BNCT treatment room were both estimated in this work. Testing and improvement in THOR BNCT beam were continuative during these years. Results of this work could be the reference and be helpful for the further clinical trials in nearly future. (author)

  5. Radiation Dosimetry in the BNCT Patient Treatment Room at the Brookhaven Medical Research Reactor

    International Nuclear Information System (INIS)

    The BMRR was a 3 MW light water reactor that had an epithermal neutron beam that was used to perform clinical trials on patients with malignant brain tumors. A series of measurements and calculations had been performed in the treatment room both prior to the trials and during the trials. The details of the measurements and the Monte Carlo calculations are presented and compared.

  6. Introducing BNCT treatment in new treatment facilities

    International Nuclear Information System (INIS)

    The physical and radiobiological studies that should be performed before the initiation of BNCT are discussed. The need for dose-escalation versus response studies in large animal models is questioned. These studies are time consuming, expensive and legally difficult in some countries and may be dispensable. (author)

  7. Radiation shielding evaluation of the BNCT treatment room at THOR: A TORT-coupled MCNP Monte Carlo simulation study

    International Nuclear Information System (INIS)

    This study investigates the radiation shielding design of the treatment room for boron neutron capture therapy at Tsing Hua Open-pool Reactor using 'TORT-coupled MCNP' method. With this method, the computational efficiency is improved significantly by two to three orders of magnitude compared to the analog Monte Carlo MCNP calculation. This makes the calculation feasible using a single CPU in less than 1 day. Further optimization of the photon weight windows leads to additional 50-75% improvement in the overall computational efficiency

  8. Voxel model in BNCT treatment planning: performance analysis and improvements

    Science.gov (United States)

    González, Sara J.; Carando, Daniel G.; Santa Cruz, Gustavo A.; Zamenhof, Robert G.

    2005-02-01

    In recent years, many efforts have been made to study the performance of treatment planning systems in deriving an accurate dosimetry of the complex radiation fields involved in boron neutron capture therapy (BNCT). The computational model of the patient's anatomy is one of the main factors involved in this subject. This work presents a detailed analysis of the performance of the 1 cm based voxel reconstruction approach. First, a new and improved material assignment algorithm implemented in NCTPlan treatment planning system for BNCT is described. Based on previous works, the performances of the 1 cm based voxel methods used in the MacNCTPlan and NCTPlan treatment planning systems are compared by standard simulation tests. In addition, the NCTPlan voxel model is benchmarked against in-phantom physical dosimetry of the RA-6 reactor of Argentina. This investigation shows the 1 cm resolution to be accurate enough for all reported tests, even in the extreme cases such as a parallelepiped phantom irradiated through one of its sharp edges. This accuracy can be degraded at very shallow depths in which, to improve the estimates, the anatomy images need to be positioned in a suitable way. Rules for this positioning are presented. The skin is considered one of the organs at risk in all BNCT treatments and, in the particular case of cutaneous melanoma of extremities, limits the delivered dose to the patient. Therefore, the performance of the voxel technique is deeply analysed in these shallow regions. A theoretical analysis is carried out to assess the distortion caused by homogenization and material percentage rounding processes. Then, a new strategy for the treatment of surface voxels is proposed and tested using two different irradiation problems. For a parallelepiped phantom perpendicularly irradiated with a 5 keV neutron source, the large thermal neutron fluence deviation present at shallow depths (from 54% at 0 mm depth to 5% at 4 mm depth) is reduced to 2% on average

  9. Voxel model in BNCT treatment planning: performance analysis and improvements

    International Nuclear Information System (INIS)

    In recent years, many efforts have been made to study the performance of treatment planning systems in deriving an accurate dosimetry of the complex radiation fields involved in boron neutron capture therapy (BNCT). The computational model of the patient's anatomy is one of the main factors involved in this subject. This work presents a detailed analysis of the performance of the 1 cm based voxel reconstruction approach. First, a new and improved material assignment algorithm implemented in NCTPlan treatment planning system for BNCT is described. Based on previous works, the performances of the 1 cm based voxel methods used in the MacNCTPlan and NCTPlan treatment planning systems are compared by standard simulation tests. In addition, the NCTPlan voxel model is benchmarked against in-phantom physical dosimetry of the RA-6 reactor of Argentina. This investigation shows the 1 cm resolution to be accurate enough for all reported tests, even in the extreme cases such as a parallelepiped phantom irradiated through one of its sharp edges. This accuracy can be degraded at very shallow depths in which, to improve the estimates, the anatomy images need to be positioned in a suitable way. Rules for this positioning are presented. The skin is considered one of the organs at risk in all BNCT treatments and, in the particular case of cutaneous melanoma of extremities, limits the delivered dose to the patient. Therefore, the performance of the voxel technique is deeply analysed in these shallow regions. A theoretical analysis is carried out to assess the distortion caused by homogenization and material percentage rounding processes. Then, a new strategy for the treatment of surface voxels is proposed and tested using two different irradiation problems. For a parallelepiped phantom perpendicularly irradiated with a 5 keV neutron source, the large thermal neutron fluence deviation present at shallow depths (from 54% at 0 mm depth to 5% at 4 mm depth) is reduced to 2% on average

  10. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Emiliano C. C. Pozzi; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Silvia I. Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz; Veronica A. Trivillin; Amanda E. Schwint

    2011-04-01

    In the present study we evaluated the therapeutic effect and/or potential radiotoxicity of the novel “Tandem” Boron Neutron Capture Therapy (T-BNCT) for the treatment of oral cancer in the hamster cheek pouch model at RA-3 Nuclear Reactor. Two groups of animals were treated with “Tandem BNCT”, i.e. BNCT mediated by boronophenylalanine (BPA) followed by BNCT mediated by sodium decahydrodecaborate (GB-10) either 24 h (T-24h-BNCT) or 48 h (T-48h-BNCT) later. A total tumor dose-matched single application of BNCT mediated by BPA and GB-10 administered jointly [(BPA + GB-10)-BNCT] was administered to an additional group of animals. At 28 days post-treatment, T-24h-BNCT and T-48h-BNCT induced, respectively, overall tumor control (OTC) of 95% and 91%, with no statistically significant differences between protocols. Tumor response for the single application of (BPA + GB-10)-BNCT was 75%, significantly lower than for T-BNCT. The T-BNCT protocols and (BPA + GB-10)-BNCT induced reversible mucositis in dose-limiting precancerous tissue around treated tumors, reaching Grade 3/4 mucositis in 47% and 60% of the animals respectively. No normal tissue radiotoxicity was associated to tumor control for any of the protocols. “Tandem” BNCT enhances tumor control in oral cancer and reduces or, at worst, does not increase, mucositis in dose-limiting precancerous tissue.

  11. Computational dosimetry of a simulated combined standard X-Rays and BNCT treatment

    Energy Technology Data Exchange (ETDEWEB)

    Casal, M.R., E-mail: mcasal@cnea.gov.ar [Instituto de Oncologia ' Angel H. Roffo' , Universidad de Buenos Aires, Av. San Martin 5481, Bs.As. (Argentina)] [Comision Nacional de Energia Atomica, Av. General Paz 1499, San Martin, Buenos Aires (Argentina); Herrera, M.S., E-mail: mariettaherrera@gmail.com [Comision Nacional de Energia Atomica, Av. General Paz 1499, San Martin, Buenos Aires (Argentina)] [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Av. Rivadavia 191, Buenos Aires (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad de General San Martin, 25 de Mayo and M. de Irigoyen, San Martin (Argentina); Gonzalez, S.J., E-mail: srgonzal@cnea.gov.ar [Comision Nacional de Energia Atomica, Av. General Paz 1499, San Martin, Buenos Aires (Argentina)] [Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) Av. Rivadavia 191, Buenos Aires (Argentina)

    2011-12-15

    There has been increasing interest in combining Boron Neutron Capture Therapy (BNCT) with standard radiotherapy, either concomitantly or as a BNCT treatment of a recurrent tumor that was previously irradiated with a medical electron linear accelerator (LINAC). In this work we report the simulated dosimetry of treatments combining X-rays and BNCT

  12. Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation Facility (EORTC Protocol 11961)

    International Nuclear Information System (INIS)

    The boron neutron capture therapy is based on the reaction occurring between the isotope 10B and thermal neutrons. A low energy neutron is captured by the nucleus and it disintegrates into two densely ionising particles, Li nucleus and He nucleus (α particle), with high biological effectiveness. On the basis of comprehensive preclinical investigations in the frame of the European Collaboration with Na2B12H11SH (BSH), as boron delivery agent, the first European phase I, clinical trial was designed at the only available epithermal beam in Europe, at the High Flux Reactor, Petten, in the Netherland. The goal of this study is to establish the safe BNCT dose for cranial tumors under defined conditions. BNCT is applied as postoperative radiotherapy in 4 fractions, after removal of the tumor for a group of patients suffering from glioblastoma, who would have no benefit from conventional treatment, but have sufficient life expectancy to detect late radiation morbidity due to BNCT. The starting dose is set at 80% of the dose where neurological effects occured in preclinical large animal experiments following a single fraction. The radiation dose will be escalated, by constant boron concentration in blood, in 4 steps for cohorts of ten patients, after an observation period of at least 6 months after the end of BNCT of the last patient of a cohort. The adverse events on healthy tissues due to BSH and due to the radiotherapy will be analysed in order to establish the maximal tolerated dose and dose limiting toxicity. Besides of the primary aim of this study the survival will be recorded. The first patient was treated in October 1997, and further four patients have been irradiated to date. The protocol design proved to be well applicable, establishing the basis for scientific evaluation, for performance of safe patient treatment in a very complex situation and for opening the possibility to perform further clinical research work on BNCT. (orig.)

  13. Treatment Planning Systems for BNCT Requirements and Peculiarities

    CERN Document Server

    Daquino, G G

    2003-01-01

    The main requirements and peculiarities expected from the BNCT-oriented treatment planning system (TPS) are summarized in this paper. The TPS is a software, which can be integrated or composed by several auxiliary programs. It plays important roles inside the whole treatment planning of the patient's organ in BNCT. However, the main goal is the simulation of the irradiation, in order to obtain the optimal configuration, in terms of neutron spectrum, patient positioning and dose distribution in the tumour and healthy tissues. The presence of neutrons increases the level of complexity, because much more nuclear reactions need to be monitored and properly calculated during the simulation of the patient's treatment. To this purposes several 3D geometry reconstruction techniques, generally based on the CT scanning data, are implemented and Monte Carlo codes are normally used. The TPSs are expected to show also the results (basically doses and fluences) in a proper format, such as isocurves (or isosurfaces) along t...

  14. Computational study of room scattering influence in the THOR BNCT treatment room

    International Nuclear Information System (INIS)

    BNCT dosimetry has often employed heavy Monte Carlo calculations for the beam characterization and the dose determination. However, these calculations commonly ignored the scattering influence between the radiations and the room structure materials in order to facilitate the calculation speed. The aim of this article attempts to explore how the room scattering affects the physical quantities such as the capture reaction rate and the gamma-ray dose rate under in-phantom and free-air conditions in the THOR BNCT treatment room. The geometry and structure materials of the treatment room were simulated in detail. The capture reaction rates per atom, as well as the gamma-ray dose rate were calculated in various sizes of phantoms and in the free-air condition. Results of this study showed that the room scattering has significant influence on the physical quantities, whether in small phantoms or in the free-air condition. This paper may be of importance in explaining the discrepancies between measurements and calculations in the BNCT dosimetry using small phantoms, in addition to provide a useful consideration with a better understanding of how the room scattering influence acts in a BNCT facility. - Highlights: • The room scattering effect at THOR BNCT room was discussed in this paper. • The room scattering factors of 4 different sizes of PMMA phantoms were calculated. • The room scattering effect was significant in small size phantom. • The room scattering neutron and gamma-ray spectra were calculated free-in-air. • The room scattering contributions of supporting table and materials were discussed

  15. Radiation field characterization of a BNCT research facility using Monte Carlo Method - Code MCNP-4B

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy - BNCT- is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an AmBe neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these BNCT studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluency ΝΤ = 1,35x108 n/cm2, a fast neutron dose of 5,86x-10 Gy/ΝΤ and a gamma ray dose of 8,30x-14 Gy/ΝΤ. (author)

  16. Assessment of dose rate scaling factors used in NCTPlan treatment planning code for the BNCT beam of THOR

    International Nuclear Information System (INIS)

    Tsing Hua open-pool reactor (THOR) at Tsing Hua University in Taiwan has been used to investigate the feasibility and to enhance the technology of boron neutron capture therapy (BNCT) for years. A rebuilt epithermal beam port for BNCT at THOR was finished in the summer of 2004, and then researches and experiments were performed to hasten the first clinical treatment case of BNCT in Taiwan in the near future. NCTPlan, a Monte Carlo-based clinical treatment planning code, was used to calculate the dose-rate distributions of BNCT in this work. A self-made Snyder head phantom with a servo-motor control system was irradiated in front of the THOR BNCT beam exit. The phantom was made from a 3 mm shell of quartz wool impregnated with acrylic casting resin mounted on an acrylic base, and was filled with water. Gold foils (bare and cadmium-covered) and paired ion chambers (one with graphite wall and filled with CO2 gas, another with A-150 plastic tissue equivalent wall and filled with tissue equivalent gas) were placed inside the Snyder phantom to measure and estimate the depth-dose distributions in the central axis of the beam. Dose components include the contribution of thermal neutrons, fast neutrons, photons and emitted α particles from 10B(n,α)7Li reaction. Comparison and analysis between computed and measured results of depth-dose distributions were made in this work. Dose rate scaling factors (DRSFs) were defined as normalization factors derived individually for each dose component in the BNCT in-phantom radiation field that provide the best agreement between measured and computed data. This paper reports the in-phantom calculated and experimental dosimetry and the determined DRSFs used in NCTPlan code for the BNCT beam of THOR.

  17. Some recent developments in treatment planning software and methodology for BNCT

    International Nuclear Information System (INIS)

    Over the past several years/the Idaho National Engineering Laboratory (INEL) has led the development of a unique, internationally-recognized set of software modules (BNCT rtpe) for computational dosimetry and treatment planning for Boron Neutron Capture Therapy (BNCT). The computational capability represented by this software is essential to the proper administration of all forms of radiotherapy for cancer. Such software addresses the need to perform pretreatment computation and optimization of the radiation dose distribution in the target volume. This permits the achievement of the optimal therapeutic ratio (tumor dose relative to critical normal tissue dose) for each individual patient via a systematic procedure for specifying the appropriate irradiation parameters to be employed for a given treatment. These parameters include angle of therapy beam incidence, beam aperture and shape,and beam intensity as a function of position across the beam front. The INEL software is used for treatment planning in the current series of human glioma trials at Brookhaven National Laboratory (BNL) and has also been licensed for research and developmental purposes to several other BNCT research centers in the US and in Europe

  18. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Chadha, M. [Beth Israel Medical Center, NY (United States). Dept. of Radiation Oncology; Coderre, J.A.; Chanana, A.D. [Brookhaven National Lab., Upton, NY (United States)] [and others

    1996-12-31

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT.

  19. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT

  20. Radiation-induced meningiomas after BNCT in patients with malignant glioma.

    Science.gov (United States)

    Kageji, T; Sogabe, S; Mizobichi, Y; Nakajima, K; Shinji, N; Nakagawa, Y

    2015-12-01

    Of the 180 patients with malignant brain tumors whom we treated with boron neutron capture therapy (BNCT) since 1968, only one (0.56%) developed multiple radiation-induced meningiomas. The parasagittal meningioma that had received 42 Gy (w) for BNCT showed more rapid growth on Gd-enhanced MRI scans and more atypical features on histopathologic studies than the temporal convexity tumor that had received 20 Gy (w). Long-term follow up MRI studies are necessary in long-survivors of malignant brain tumors treated by BNCT. PMID:26122975

  1. TIDBIT - the INEL database of BNCT information and treatment

    Energy Technology Data Exchange (ETDEWEB)

    Mancuso, C.A.

    1995-11-01

    The INEL Database of BNCT Information and Treatment (TIDBIT) has been under development for several years. Late in 1993, a new software development team took over the project and did and assessment of the current implementation status, and determined that the user interface was unsatisfactory for the expected users and that the data structures were out of step with the current state of reality. The team evaluated several tools that would improve the user interface to make the system easier to use. Uniface turned out to be the product of choice. During 1994, TIDBIT got its name, underwent a complete change of appearance, had a major overhaul to the data structures that support the application, and system documentation was begun. A prototype of the system was demonstrated in September 1994.

  2. Radiation field characterization of a BNCT research facility using Monte Carlo method - code MCNP-4B

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy - BNCT - is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an Am Be neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these Becton studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluencyNT = 1,35x108 n/cm , a fast neutron dose of 5,86x10-10 Gy/NT and a gamma ray dose of 8,30x10-14 Gy/NT. (author)

  3. Comparison of the radiobiological effects of Boron neutron capture therapy (BNCT) and conventional Gamma Radiation

    International Nuclear Information System (INIS)

    BNCT is an experimental radiotherapeutic modality that uses the capacity of the isotope 10B to capture thermal neutrons leading to the production of 4He and 7Li, particles with high linear energy transfer (LET). The aim was to evaluate and compare in vitro the mechanisms of response to the radiation arising of BNCT and conventional gamma therapy. We measured the survival cell fraction as a function of the total physical dose and analyzed the expression of p27/Kip1 and p53 by Western blotting in cells of colon cancer (ARO81-1). Exponentially growing cells were distributed into the following groups: 1) BPA (10 ppm 10B) + neutrons; 2) BOPP (10 ppm 10B) + neutrons; 3) neutrons alone; 4) gamma-rays. A control group without irradiation for each treatment was added. The cells were irradiated in the thermal neutron beam of the RA-3 (flux= 7.5 109 n/cm2 sec) or with 60Co (1Gy/min) during different times in order to obtain total physical dose between 1-5 Gy (±10 %). A decrease in the survival fraction as a function of the physical dose was observed for all the treatments. We also observed that neutrons and neutrons + BOPP did not differ significantly and that BPA was the more effective compound. Protein extracts of irradiated cells (3Gy) were isolated to 24 h and 48 h post radiation exposure. The irradiation with neutrons in presence of 10BPA or 10BOPP produced an increase of p53 at 24 h maintain until 48 h. On the contrary, in the groups irradiated with neutrons alone or gamma the peak was observed at 48 hr. The level of expression of p27/Kip1 showed a reduction of this protein in all the groups irradiated with neutrons (neutrons alone or neutrons plus boron compound), being more marked at 24 h. These preliminary results suggest different radiobiological response for high and low let radiation. Future studies will permit establish the role of cell cycle in the tumor radio sensibility to BNCT. (author)

  4. Dose characterization in radiation mixed field using thermoluminescent dosemeters at the installation for studies on BNCT

    International Nuclear Information System (INIS)

    This work presents the methodology used for characterization of the absorbed dose due to the gamma radiation (in mixed field of neutrons and gamma), at the installation for studies on BNCT, using thermoluminescent dosemeters. Information is supplied concerning to the obtention of the Victoreen 2800M TL reader parameters, used for performing the TLDs readings, and are presented the construction results of the calibration curves for the TLDs 400 and TLDs 700. From these calibration curves it was determined the absorbed dose due to the gamma radiation in the position of sample irradiation at the installation for the BNCT studies

  5. Investigation of development and management of treatment planning systems for BNCT at foreign facilities

    International Nuclear Information System (INIS)

    A new computational dosimetry system for BNCT: JCDS is developed by JAERI in order to carry out BNCT with epithermal neutron beam at present. The development and management situation of computational dosimetry system, which are developed and are used in BNCT facilities in foreign countries, were investigated in order to accurately grasp functions necessary for preparation of the treatment planning and its future subjects. In present state, 'SERA', which are developed by Idaho National Engineering and Environmental Laboratory (INEEL), is used in many BNCT facilities. Followings are necessary for development and management of the treatment planning system. (1) Reliability confirmation of system performance by verification as comparison examination of calculated value with actual experimental measured value. (2) Confirmation systems such as periodic maintenance for retention of the system quality. (3) The improvement system, which always considered relative merits and demerits with other computational dosimetry system. (4) The development of integrated system with patient setting. (author)

  6. Investigation of development and management of treatment planning systems for BNCT at foreign facilities

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2001-03-01

    A new computational dosimetry system for BNCT: JCDS is developed by JAERI in order to carry out BNCT with epithermal neutron beam at present. The development and management situation of computational dosimetry system, which are developed and are used in BNCT facilities in foreign countries, were investigated in order to accurately grasp functions necessary for preparation of the treatment planning and its future subjects. In present state, 'SERA', which are developed by Idaho National Engineering and Environmental Laboratory (INEEL), is used in many BNCT facilities. Followings are necessary for development and management of the treatment planning system. (1) Reliability confirmation of system performance by verification as comparison examination of calculated value with actual experimental measured value. (2) Confirmation systems such as periodic maintenance for retention of the system quality. (3) The improvement system, which always considered relative merits and demerits with other computational dosimetry system. (4) The development of integrated system with patient setting. (author)

  7. Photoneutron source for in-hospital BNCT treatment. Feasibility study

    International Nuclear Information System (INIS)

    Some recent studies in Italy have focused on the possibility of exploiting high energy electron linear accelerators, normally used in gamma radiotherapy, as photo-neutrons source for in-hospital medical applications. Neutrons are produced by Giant Dipole Resonance (GDR) reactions from high energy photons on high Z targets; by proper material and geometry optimization, interesting fluence rates of thermalized neutrons can be made available, with minimized fast neutron and gamma backgrounds, for a fractionated type of Boron Neutron Capture Therapy (BNCT) devoted to external treatment of some specific tumors. A photoneutron converter, constituted by high Z core and surrounded by Low Z materials, is shaped to produce thermal beam inside an irradiation cavity. A feasibility study on Beam Shaping Assembly using MCNPGN simulation code is performed on various geometrical shapes and material selection. A first prototype of the photoconverter has been realized and tested at some hospital high energy medical LINAC facilities. In this paper the preliminary experimental results of neutron fluence rate and neutron spectra produced by the photoconverter prototype are compared to the simulation data. (author)

  8. First clinical results from the EORTC phase I Trial ''postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility''

    International Nuclear Information System (INIS)

    Based on the pre-clinical work of the European Collaboration on Boron Neutron Capture Therapy a study protocol was prepared in 1995 to initiate Boron Neutron Capture Therapy (BNCT) in patients at the High Flux Reactor (HFR) in Petten. Bio-distribution and pharmacokinetics data of the boron drug Na2B12H11SH (BSH) as well as the radiobiological effects of BNCT with BSH in healthy brain tissue of dogs were considered in designing the strategy for this clinical Phase I trial. The primary goal of the radiation dose escalation study is the investigation of possible adverse events due to BNCT; i.e. to establish the dose limiting toxicity and the maximal tolerated dose. The treatment is delivered in 4 fractions at a defined average boron concentration in blood. Cohorts of 10 patients are treated per dose group. The starting dose was set at 80% of the dose at which neurological symptoms occurred in preclinical dog experiments following a single fraction. After an observation period of at least 6 months, the dose is increased by 10% for the next cohort if less then three severe side effects related to the treatment occurred. The results of the first cohort are presented here. The evaluated dose level can be considered safe. (author)

  9. A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J.; Coderre, J.A.; Chanana, A.D.

    1996-12-31

    Accurate delivery of the prescribed dose during clinical BNCT requires knowledge (or reasonably valid assumptions) about the boron concentrations in tumor and normal tissues. For conversion of physical dose (Gy) into photon-equivalent dose (Gy-Eq), relative biological effectiveness (RBE) and/or compound-adjusted biological effectiveness (CBE) factors are required for each tissue. The BNCT treatment planning software requires input of the following values: the boron concentration in blood and tumor, RBEs in brain, tumor and skin for the high-LET beam components, the CBE factors for brain, tumor, and skin, and the RBE for the gamma component.

  10. Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    The purpose of this study was to clarify the correlation between the radiation dose and histopathological findings in patients with glioblastoma multiforme (GBM) treated with boron neutron capture therapy (BNCT). Histopathological studies were performed on specimens from 8 patients, 3 had undergone salvage surgery and 5 were autopsied. For histopathological cure of GBM at the primary site, the optimal minimal dose to the gross tumor volume (GTV) and the clinical target volume (CTV) were 68 Gy(w) and 44 Gy(w), respectively. - Highlights: • It is very important to determine the curable BNCT radiation dose on histopathological aspect in BNCT. • Of 23 patients with GBM treated with BNCT, autopsy was performed in 5, salvage surgery in 3, and histopathological study in 8. • To achieve the histopathological cure of GBM at the primary site, the optimal minimal dose to the GTV and CTV was 68 Gy(w) and 44 Gy(w), respectively

  11. Quality assurance of BNCT dosimetry

    International Nuclear Information System (INIS)

    The Phase I clinical trials for boron neutron capture therapy (BNCT) started in May 1999 in Otaniemi, Espoo. For BNCT no uniform international guidance for the quality assurance of dosimetry exists, so far. Because of the complex dose distribution with several different dose components, the international recommendations on conventional radiotherapy dosimetry are not applicable in every part. Therefore, special guidance specifically for BNCT is needed. To obtain such guidelines a European collaboration project has been defined. The aim of the project is a generally accepted Code of Practice for use by all European BNCT centres. This code will introduce the traceability of the dosimetric methods to the international measurement system. It will also ensure the comparability of the results in various BNCT beams and form the basis for the comparison of the treatment results with the conventional radiotherapy or other treatment modalities. The quality assurance of the dosimetry in BNCT in Finland covers each step of the BNCT treatment, which include dose planning imaging, dose planning, boron infusion, boron kinetics, patient positioning, monitoring of the treatment beam, characterising the radiation spectrum, calibration of the beam model and the dosimetric measurements both in patients (in viva measurements) and in various phantoms. The dose planning images are obtained using a MR scanner with MRI sensitive markers and the dose distribution is computed with a dose planning software BNCTRtpe. The program and the treatment beam (DORT) model used have been verified with measurements and validated with MCNP calculations in phantom. Dosimetric intercomparison has been done with the Brookhaven BNCT beam (BMRR). Before every patient irradiation the relationship between the beam monitor pulse rate and neutron fluence rate in the beam is checked by activation measurements. Kinetic models used to estimate the time-behavior of the blood boron concentration have been verified

  12. Influence of BNCT radiations on the blood-brain barrier in terms of boron-10 uptake

    International Nuclear Information System (INIS)

    A key issue is to determine whether fractionated BNCT is a feasible proposition. This issue has been reviewed by Dorn et al, who call for further experimental investigation of BNCT induced changes in the blood brain barrier and investigated by Hatanaka et al. In order to investigate the effect on BNCT, the authors measured 10B concentration and water content in the normal brain which has been subjected to BNCT regimen

  13. Design of epithermal neutron beam for clinical BNCT treatment at Slovenian TRIGA research reactor

    International Nuclear Information System (INIS)

    The Monte Carlo feasibility study of development of epithermal neutron beam for BNCT clinical trials on Jozef Stefan Institute (JSI) TRIGA reactor is presented. The investigation of the possible use of fission converter for the purpose of enhancement of neutron beam, as well as the set-up of TRIGA reactor core is performed. The optimization of the irradiation facility components is carried out and the configuration with the most favorable cost/performance ratio is proposed. The simulation results prove that a BNCT irradiation facility with performances, comparable to existing beams throughout the world, could be installed in the thermalizing column of the TRIGA reactor, quite suitable for the clinical treatments of human patients. (author)

  14. Design of epithermal neutron beam for clinical BNCT treatment at Slovenian TRIGA research reactor

    Energy Technology Data Exchange (ETDEWEB)

    Maucec, Marko [Jozef Stefan Institute, Reactor Physics Division, Lubljana (Slovenia). E-mail: marko.mauce@ijs.si

    1999-07-01

    The Monte Carlo feasibility study of development of epithermal neutron beam for BNCT clinical trials on Jozef Stefan Institute (JSI) TRIGA reactor is presented. The investigation of the possible use of fission converter for the purpose of enhancement of neutron beam, as well as the set-up of TRIGA reactor core is performed. The optimization of the irradiation facility components is carried out and the configuration with the most favorable cost/performance ratio is proposed. The simulation results prove that a BNCT irradiation facility with performances, comparable to existing beams throughout the world, could be installed in the thermalizing column of the TRIGA reactor, quite suitable for the clinical treatments of human patients. (author)

  15. 'Sequential' Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with a thermal or epithermal neutron beam. The minor abundance stable isotope of boron, 10B, interacts with low energy (thermal) neutrons to produce high linear energy transfer (LET) a-particles and 7Li ions. These disintegration products are known to have a high relative biological effectiveness (RBE). Their short range (<10 (micro)m) would limit the damage to cells containing 10B (1,2). Thus, BNCT would target tumor tissue selectively, sparing normal tissue. Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane (BSH) as the 10B carriers, have been performed or are underway in Argentina, Japan, the US and Europe (e.g. 3-8). To date, the clinical results have shown a potential, albeit inconclusive, therapeutic advantage for this technique. Contributory translational studies have been carried out employing a variety of experimental models based on the implantation of tumor cells in normal tissue (e.g. 5).

  16. "Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model

    Energy Technology Data Exchange (ETDEWEB)

    Ana J. Molinari; Andrea Monti Hughes; Elisa M. Heber; Marcela A. Garabalino; Veronica A. Trivillin; Amanda E. Schwint; Emiliano C. C. Pozzi; Maria E. Itoiz; Silvia I. Thorp; Romina F. Aromando; David W. Nigg; Jorge Quintana; Gustavo A. Santa Cruz

    2011-04-01

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with a thermal or epithermal neutron beam. The minor abundance stable isotope of boron, 10B, interacts with low energy (thermal) neutrons to produce high linear energy transfer (LET) a-particles and 7Li ions. These disintegration products are known to have a high relative biological effectiveness (RBE). Their short range (<10 {micro}m) would limit the damage to cells containing 10B (1,2). Thus, BNCT would target tumor tissue selectively, sparing normal tissue. Clinical trials of BNCT for the treatment of glioblastoma multiforme and/or melanoma and, more recently, head and neck tumors and liver metastases, using boronophenylalanine (BPA) or sodium mercaptoundecahydrododecaborane (BSH) as the 10B carriers, have been performed or are underway in Argentina, Japan, the US and Europe (e.g. 3-8). To date, the clinical results have shown a potential, albeit inconclusive, therapeutic advantage for this technique. Contributory translational studies have been carried out employing a variety of experimental models based on the implantation of tumor cells in normal tissue (e.g. 5).

  17. Effective dose evaluation for BNCT brain tumor treatment based on voxel phantoms

    International Nuclear Information System (INIS)

    For BNCT treatments, in addition to tumor target doses, non-negligible doses will result in all the remaining organs of the body. This work aims to evaluate the effective dose as well as the average absorbed doses of each of organs of patients with brain tumor treated in the BNCT epithermal neutron beam at THOR. The effective doses were evaluated according to the definitions of ICRP Publications 60 and 103 for the reference male and female computational phantoms developed in ICRP Publication 110 by using the MCNP5 Monte Carlo code with the THOR-Y09 beam source. The effective dose acquired in this work was compared with the results of our previous work calculated for an adult hermaphrodite mathematical phantom. It was found that the effective dose for the female voxel phantom is larger than that for the male voxel phantom by a factor of 1.2–1.5 and the effective dose for the voxel phantom is larger than that for the mathematical phantom by a factor of 1.3–1.6. For a typical brain tumor BNCT, the effective dose was calculated to be 1.51 Sv and the average absorbed dose for eye lenses was 1.07 Gy. - Highlights: • For a typical brain tumor BNCT, the effective dose was calculated to be 1.51 Sv. • The average absorbed dose for eye lenses was 1.07 Gy. • The effective doses for both male and female voxel phantoms were calculated. • The effective doses were compared between voxel and mathematical phantoms

  18. Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina

    International Nuclear Information System (INIS)

    In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research. - Highlights: • A new proposal of BNCT for HER2+ breast cancer treatment is introduced. • The proposal considers development of immunoliposomes as boron carrier nanovehicles. • Locoregional recurrences after treatment were identified as candidates for initial BNCT studies. • First analysis show acceptable neutron flux distributions provided by RA-6 BNCT facility

  19. Estimation of photon and neutron dose distributions in the THOR BNCT treatment room using dual TLD method

    International Nuclear Information System (INIS)

    Dual detector dosimetry using the paired detectors, TLD-600 and TLD-700 chips, were selected in this study to distinguish the doses of neutrons and photons in Tsing Hua Open-pool Reactor (THOR) boron neutron capture therapy (BNCT) preclinical test. Since the neutron response of TLD is dependent on the neutron spectrum, responses of TLD-600 and TLD-700 for neutrons and photons were estimated by irradiation methods and in addition the effect of the neutron spectrum on the TLD response was studied by Monte Carlo simulations in present work. A sectional ART head phantom was used to be irradiated with the THOR BNCT beam. TLD-600 and TLD-700 chips were placed inside the phantom to measure and distinct the doses of neutrons from photons. Besides, dual TLD chips were placed in plane of the room space area to estimate the spatial dose distributions in the THOR BNCT treatment room. A cube water phantom was used to consider the deviation between the two algorithms used in this work. In the results, neutron and photon dose distributions in phantom and the spatial dose distributions in THOR BNCT treatment room were estimated; characteristics and the treatment indexes for BNCT were also assessed

  20. Preliminary evaluations of the undesirable patient dose from a BNCT treatment at the ENEA-TAPIRO reactor

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is an experimental technique for the treatment of certain kinds of tumors. Research in BNCT is performed utilizing both thermal and epithermal neutron beams. Epithermal neutrons (0.4 eV-10 keV) penetrate more deeply into tissue and are thus used in non-superficial clinical applications such as the brain glioma. In the last few years, the fast reactor TAPIRO (ENEA-Casaccia Rome) has been employed as a neutron source for research into BNCT applications. Recently, an 'epithermal therapeutic column' has been designed and its construction has been completed. The Monte Carlo code MCNPX was employed to optimize the design of the column and to evaluate the dose profiles and the therapeutic parameters in the cranium of the anthropomorphic phantom ADAM. In the same context, some preliminary evaluations of the undesirable doses to the patient were performed with MCNPX. A hermaphrodite phantom derived from ADAM and EVA was employed to evaluate the energy deposition in some organs during a standard BNCT treatment. The total dose consists of the contributions from the primary neutron beam, the neutron interactions with boron and the neutron induced photons generated in the epithermal column structures and in the patient's tissues. The paper summarizes the computational procedure and provides a general dosimetric framework of the patient radiological protection aspects related to a BNCT treatment scenario at the TAPIRO reactor. (authors)

  1. Design of a beam shaping assembly and preliminary modelling of a treatment room for accelerator-based BNCT at CNEA

    International Nuclear Information System (INIS)

    This work reports on the characterisation of a neutron beam shaping assembly (BSA) prototype and on the preliminary modelling of a treatment room for BNCT within the framework of a research programme for the development and construction of an accelerator-based BNCT irradiation facility in Buenos Aires, Argentina. The BSA prototype constructed has been characterised by means of MCNP simulations as well as a set of experimental measurements performed at the Tandar accelerator at the National Atomic Energy Commission of Argentina. - Highlights: ► Characterisation of a neutron beam shaping assembly for accelerator-based BNCT. ► Measurements: total and epi-cadmium neutron fluxes and beam homogeneity. ► Calculations: Monte Carlo simulations with the MCNP code. ► Measured and calculated figure-of-merit parameters in agreement with those of IAEA. ► Initial MCNP dose calculations for a treatment room to define future design actions.

  2. Co-registration of the BNCT treatment planning images for clinical practice

    International Nuclear Information System (INIS)

    We have co-registered MRI, CT and FBPA-PET images for BNCT in clinical practice. Co-registration improves the spatial accuracy of the treatment planning by enabling use of information from all the co-registered modalities. The multimodal co-registration has been implemented as a service product provided by the Imaging Center of Helsinki University Central Hospital to other departments. To increase the accuracy of co-registration and patient positioning in the head area BNCT, a patient-specific fixation mask suitable for PET, MRI and CT was developed. The goal of the fixation mask is to normalize the orientation of the patient's head and neck. Co-registration is performed at the image processing unit by using a rigid body model, mutual-information based algorithms and partly in-house developed software tools. The accuracy of co-registration is verified by comparing the locations of the external skin markers and anatomical landmarks in different modalities. After co-registration, the images are transformed and covered into a format required by the BNCT dose-planning software and set to the dose-planning unit of the hospital. So far co-registration has been done for 22 patients. The co-registration protocol has proved to be reliable and efficient. Some registration errors are seen on some patients in the neck area because the rigid-body model used in co-registration is not fully valid for the brain-neck entity. The registration accuracy in this area could likely be improved by implementing a co-registration procedure utilizing a partly non-rigid body model. (author)

  3. INEL BNCT Research Program annual report 1994

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included

  4. Effective dose evaluation for BNCT treatment in the epithermal neutron beam at THOR

    International Nuclear Information System (INIS)

    This paper aims to evaluate the effective dose as well as equivalent doses of several organs of an adult hermaphrodite mathematical phantom according to the definition of ICRP Publication 60 for BNCT treatments of brain tumors in the epithermal neutron beam at THOR. The MCNP5 Monte Carlo code was used for the calculation of the average absorbed dose of each organ. The effective doses for a typical brain tumor treatment with a tumor treatment dose of 20 Gy-eq were evaluated to be 0.59 and 0.35 Sv for the LLAT and TOP irradiation geometries, respectively. In addition to the stochastic effect, it was found that it is also likely to produce deterministic effects, such as cataracts and depression of haematopoiesis.

  5. Dose calculation for the BNCT treatment room at THOR by the TORT-coupled MCNP4C technique

    International Nuclear Information System (INIS)

    This study investigates the radiation shielding design of the boron neutron capture therapy (BNCT) treatment room at THOR using Monte Carlo method. Since the size of the treatment room including the concrete walls surrounding is very large, effective variance reduction technique is required to make the calculation feasible within reasonable time. The TORT-coupled MCNP4C technique based on CADIS theory is used in this study. The results show that the computing efficiency can be improved by two orders of magnitude, which makes the calculation feasible using a single PC in reasonable computing time. The main contribution to the dose outside the treatment room is found to be from the neutron-induced secondary gamma rays produced near the detector point. When patient is treated or water phantom is presented in front of the beam exit, the dose rate outside the treatment room is well below the safety limit. When the beam is on and with nothing placed in front of the beam exit, the dose rate outside door of the treatment room is two times higher than the recommended value. The shielding design should be further revised. (authors)

  6. Design of a BNCT facility at HANARO

    International Nuclear Information System (INIS)

    Based on the feasibility study of the BNCT at HANARO, it was confirmed that only thermal BNCT is possible at the IR beam tube if appropriate filtering system be installed. Medical doctors in Korea Cancer Center Hospital agreed that the thermal BNCT facility would be worthwhile for the BNCT technology development in Korea as well as superficial cancer treatment. For the thermal BNCT to be effective, the thermal neutron flux should be high enough for patient treatment during relatively short time and also the fast neutron and gamma-ray fluxes should be as low as possible. In this point of view, the following design requirements are set up: 1) thermal neutron flux at the irradiation position should be higher than 3x109 n/cm2-sec, 2) ratio of the fast neutrons and gamma-rays to the thermal neutrons should be minimized, and 3) patient treatment should be possible without interrupt to the reactor operation. To minimize the fast neutrons and gamma-rays with the required thermal neutrons at the irradiation position, a radiation filter consisting of single crystals of silicon and bismuth at liquid nitrogen temperature is designed. For the shielding purpose around the irradiation position, polyethylene, lead, LiF, etc., are appropriately arranged around the radiation filter. A water shutter in front of the radiation filter is adopted so as to avoid interrupt to the reactor operation. At present, detail design of the radiation filter is ongoing. Cooling capabilities of the filter will be tested through a mockup experiment. Dose rate distributions around the radiation filter and a prompt gamma-ray activation analysis system for the analyses of boron content in the biological samples are under design. The construction of this facility will be started from next year if it is permitted from the regulatory body this year. Some other future works exist and are described in the paper. (author)

  7. Experimental approach to the BNCT treatment of human liver

    International Nuclear Information System (INIS)

    The research program named Taormina, is concerned with an attempt to set up a method to use Boron neutron capture therapy for liver metastases in diffused tumours. According to our project, the liver will be explanted, treated with a solution of organic Boron compound, then irradiated in a thermal neutron field. Such modalities give the significant advantage to preserve the remaining patient organs from damage. A collaboration including nuclear physicists and surgeons of the University of Pavia planned the original research project. Researchers in the fields of chemistry and anatomy gave contributions during the experiment in their particular fields of competence. The conditions which must be satisfied to get a safe neutron treatment are given. The Thermal Column (TC) of the reactor Triga Mark II of the University of Pavia was modified to reach the objectives. The possibility to get useful values of T parameter by searching the modalities to take the greatest possible advantage from the so called blood-brain barrier is investigated. Such a barrier effect, due to the particular metabolism of tumour cells, produces Boron accumulation into tumour tissues while Boron solutions are circulating inside the blood channels. The results of processing of 24 rats are given. The rather poor statistics do not allow meaningful conclusions but only some optimistic hope

  8. Accelerator-based BNCT

    International Nuclear Information System (INIS)

    The activity in accelerator development for accelerator-based BNCT (AB-BNCT) both worldwide and in Argentina is described. Projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators are briefly presented. In particular, the present status and recent progress of the Argentine project will be reviewed. The topics will cover: intense ion sources, accelerator tubes, transport of intense beams, beam diagnostics, the 9Be(d,n) reaction as a possible neutron source, Beam Shaping Assemblies (BSA), a treatment room, and treatment planning in realistic cases. - Highlights: • The activity in accelerator development for accelerator-based BNCT (AB-BNCT) both worldwide and in Argentina is described. • Projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators are briefly presented. • The present status and recent progress of the Argentine project will be reviewed. • Topics cover intense ion sources, accelerator tubes, transport of intense beams and beam diagnostics, among others

  9. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: application to the treatment of experimental oral cancer.

    Science.gov (United States)

    Pozzi, E; Nigg, D W; Miller, M; Thorp, S I; Heber, E M; Zarza, L; Estryk, G; Monti Hughes, A; Molinari, A J; Garabalino, M; Itoiz, M E; Aromando, R F; Quintana, J; Trivillin, V A; Schwint, A E

    2009-07-01

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1 x 10(9) n cm(-2)s(-1) and the fast neutron flux was 2.5 x 10(6) n cm(-2)s(-1), indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in (6)Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated. PMID:19380233

  10. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    International Nuclear Information System (INIS)

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x109 n cm-2 s-1 and the fast neutron flux was 2.5x106 n cm-2 s-1, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in 6Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  11. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

    Energy Technology Data Exchange (ETDEWEB)

    Pozzi, E. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)], E-mail: epozzi@cnea.gov.ar; Nigg, D.W. [Idaho National Laboratory, Idaho Falls (United States); Miller, M.; Thorp, S.I. [Instrumentation and Control Department, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Zarza, L.; Estryk, G. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Monti Hughes, A.; Molinari, A.J.; Garabalino, M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Quintana, J. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Trivillin, V.A.; Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)

    2009-07-15

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10{sup 9} n cm{sup -2} s{sup -1} and the fast neutron flux was 2.5x10{sup 6} n cm{sup -2} s{sup -1}, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in {sup 6}Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  12. Monte Carlo simulation to study the doses in an accelerator BNCT treatment

    International Nuclear Information System (INIS)

    In this work the 7Li(p, n)7Be reaction has been studied as a neutron source for accelerator-based BNCT (Boron Neutron Capture Therapy). In order to optimize the design of the neutron production target and the beam shaping assembly, extensive MCNP simulations have been performed. These simulations include a thick Li metal target, a whole-body phantom, a moderator-reflector assembly (Al/AlF3 as moderator and graphite as reflector) and the treatment room. The doses were evaluated for two proton bombarding energies of 1.92 MeV (near to the threshold of the reaction) and 2.3 MeV (near to the resonance of the reaction) and for three Al/ALF3 moderator thicknesses (18, 26 and 34 cm). To assess the doses, a comparison using a Tumor Control Probability (TCP) model was done. In a second instance, the effect of the specific skin radiosensitivity (an RBE of 2.5 for the 10B(n,α)7Li reaction) and a 10B uptake of 17 ppm was considered for the scalp. Finally, the simulations show the advantage of irradiating with near-resonance-energy protons (2.3 MeV) because of the high neutron yield at this energy, leading to the lowest treatment times. Moreover, the 26 cm Al/AlF3 moderator has shown the best performance among the studied cases. (author)

  13. BDTPS The BNCT Treatment Planning System jointly developed at DIMNP and JRC/IE

    CERN Document Server

    Daquino, G G; Mazzini, M; Moss, R; Muzi, L; International Workshop on "Neutron Capture Therapy: State of the art"

    2003-01-01

    The idea to couple the Treatment Planning System (TPS) to the information on the real boron distribution in the patient is the main added value of the new methodology set-up at DIMNP of University of Pisa, in collaboration with the JRC of Petten (NL). The methodology has been implemented in the new TPS, called BDTPS (Boron Distribution Treatment Planning System), which takes into account the actual boron distribution in the patient brain, while the standard TPS assumes a uniform boron distribution, absolutely far from the reality. Nowadays, Positron Emission Tomography (PET) is able to provide this in vivo information. The new TPS, based on the Monte Carlo technique, has been validated comparing the main BNCT parameters (thermal flux, boron dose, etc.) as measured during the irradiation of a special heterogeneous boron phantom (HEBOM), ad hoc designed, as calculated by the BDTPS and by the standard TPS SERA. An evident SERA overestimation of the thermal neutron flux, as well as the boron dose, has been detect...

  14. Dosimetric feasibility study for an extracorporeal BNCT application on liver metastases at the TRIGA Mainz.

    Science.gov (United States)

    Blaickner, M; Kratz, J V; Minouchehr, S; Otto, G; Schmidberger, H; Schütz, C; Vogtländer, L; Wortmann, B; Hampel, G

    2012-01-01

    This study investigates the dosimetric feasibility of Boron Neutron Capture Therapy (BNCT) of explanted livers in the thermal column of the research reactor in Mainz. The Monte Carlo code MCNP5 is used to calculate the biologically weighted dose for different ratios of the (10)B-concentration in tumour to normal liver tissue. The simulation results show that dosimetric goals are only partially met. To guarantee effective BNCT treatment the organ has to be better shielded from all gamma radiation. PMID:21872481

  15. Development and verification of THORplan—A BNCT treatment planning system for THOR

    International Nuclear Information System (INIS)

    THORplan is a treatment planning system under continuous development and refinement at Tsing Hua University, Taiwan, for BNCT purpose. New features developed for homogeneous model calculation include material grouping model, and voxel data reconstruction model. Material grouping model is a two-step grouping method, tissue-volume-percent grouping method followed by atom-gram-density grouping method. The root mean square difference of neutron flux due to material grouping is <0.8%. In the voxel data reconstruction model, voxel neutron dose is calculated based on the material composition and dose of individual atom of each voxel, which is calculated by linear interpolation from the dose of individual atom of neighboring cells tallied in MCNP calculation. The detailed voxel model is used to benchmark the accuracy of the new features developed for the homogeneous model calculation. The maximum error of the neutron flux and dose of voxels using the homogeneous cell model is 5% and 7%, respectively. Big improvement of accuracy of voxel dose over the original dose calculation model based on F6 tally is observed at locations containing very heterogeneous compositions.

  16. Design of a BNCT facility at HANARO

    International Nuclear Information System (INIS)

    Based on the feasibility study of the BNCT at HANARO, it was confirmed that only thermal BNCT is possible at the IR beam tube if appropriate filtering system be installed. Medical doctors in Korea Cancer Center Hospital agreed that the thermal BNCT facility would be worthwhile for the BNCT technology development in Korea as well as superficial cancer treatment. For the thermal BNCT to be effective, the thermal neutron flux should be high enough for patient treatment during relatively short time and also the fast neutron and gamma-ray fluxes should be as low as possible to avoid high dose on the patient during treatment. In this point of view, the following design requirements are set up; 1) thermal neutron flux at the irradiation position should be higher than 2 X 109 n/cm2 . sec, 2) ration of the fast neutrons and gamma-rays to the thermal neutrons should be minimized, and 3) patient treatment should be possible during reactor operation. To minimize the fast neutrons and gamma-rays with the required thermal neutrons at the irradiation position, a radiation filter consisting of single crystals of silicon and bismuth at liquid nitrogen temperature is design d. For the shielding purpose around the irradiation position, polyethylene, lead, LiF, etc., are appropriately arranged around the radiation filter. A water shutter in front of the radiation filter is adopted so as to avoid interrupt to the reactor operation. While the shutter is filled in water during on power, the radiation level in the irradiation room is sufficiently low for the preparation work for patient irradiation including temporary surgery. At present, detail design of the radiation filter is ongoing. cooling capabilities of the filter will be tested through a mockup experiment. Dose rate distributions around the radiation filter are under analysis for the configuration of the irradiation room. A prompt gamma-ray activation analysis system for the analyses of boron content in the biological samples, is

  17. Liposome and co-spray-dried PVP / o-carborane formulations for BNCT treatment of cancer

    OpenAIRE

    Olusanya, Temidayo; Stich, Theresia; Higgins, Samantha Caroline; Lloyd, Rhiannon Eleanor Iris; Pilkington, Geoffrey John; Fatouros, Dimitrios; Calabrese, Gianpiero; Smith, James Richard; Tsibouklis, John

    2015-01-01

    Purpose: Boron neutron capture therapy (BNCT) is a method for selectively destroying malignant (normally glioma) cells whilst sparing normal tissue. Irradiation of 10B (large neutron capture cross-section) with thermal neutrons effects the nuclear fission reaction: 10B + 1n → → 7Li+ + α + γ; where the penetration of α-particles and 7Li+ is only 8 and 5 µm, respectively, i.e., within a single cell thickness. Poor selectivity is the main reason why BNCT has not become a mainstream cancer therap...

  18. Employment of MCNP in the study of TLDS 600 and 700 seeking the implementation of radiation beam characterization of BNCT facility at IEA-R1

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy, BNCT, is a bimodal radiotherapy procedure for cancer treatment. Its useful energy comes from a nuclear reaction driven by impinging thermal neutron upon Boron 10 atoms. A BNCT research facility has been constructed in IPEN at the IEA-R1 reactor, to develop studies in this area. One of its prime experimental parameter is the beam dosimetry which is nowadays made by using activation foils, for neutron measurements, and TLD 400, for gamma dosimetry. For mixed field dosimetry, the International Commission on Radiation Units and Measurements, ICRU, recommends the use of pair of detectors with distinct responses to the field components. The TLD 600/ TLD 700 pair meets this criteria, as the amount of 6Li, a nuclide with high thermal neutron cross section, greatly differs in their composition. This work presents a series of experiments and simulations performed in order to implement the mixed field dosimetry based on the use of TLD 600/TLD 700 pair. It also intended to compare this mixed field dosimetric methodology to the one so far used by the BNCT research group of IPEN. The response of all TLDs were studied under irradiations in different irradiation fields and simulations, underwent by MCNP, were run in order to evaluate the dose contribution from each field component. Series of repeated irradiations under pure gamma field and mixed field neutron/gamma field showed differences in the TLD individual responses which led to the adoption of a Normalization Factor. It has allowed to overcome TLD selection. TLD responses due to different field components and spectra were studied. It has shown to be possible to evaluate the relative gamma/neutron fluxes from the relative responses observed in the two Regions of Interest, ROIs, from TLD 600 and TLD 700. It has also been possible to observe the TLD 700 response to neutron, which leads to a gamma dose overestimation when one follows the ICRU recommended mixed field dosimetric procedure. Dose

  19. INEEL BNCT Research Program Annual Report, CY-2000

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, James Robert

    2001-03-01

    This report is a summary of the activities conducted in conjunction with the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 2000. Applications of supportive research and development, as well as technology deployment in the fields of chemistry, radiation physics and dosimetry, neutron source design and demonstration, and support the Department of Energy’s (DOE) National BNCT Program goals are the goals of this Program. Contributions from the individual contributors about their projects are included, specifically described are the following, chemistry: analysis of biological samples and an infrared blood-boron analyzer, and physics: progress in the patient treatment planning software, measurement of neutron spectra for the Argentina RA-6 reactor, and recalculation of the Finnish research reactor FiR 1 neutron spectra, BNCT accelerator technology, and modification to the research reactor at Washington State University for an epithermal-neutron beam.

  20. TL detectors in BNCT dosimetry

    International Nuclear Information System (INIS)

    The main detectors for characterising and controlling of BNCT beams are activation foils and paired ionisation chambers. Thermoluminescent (TL) dosimeters are also of interest because of their following advantages: i) small physical size, ii) no need for high voltage or cables, i.e. stand alone character, and iii) suitability for large scale measurements; with TL dosimeters it is possible to measure depth dose curves and profiles at the same time, with one irradiation. Also, TL dosimeters may be possible detectors for in vivo use. At the Finnish BNCT facility, a TL detector MTS-Ns of TLD Niewiadomski and Co. (Krakow, Poland) with an ultrathin active LiF:Mg,Ti layer for small self-shielding of thermal neutrons was selected for use as a neutron sensitive dosimeter. A TL detector MCP-7s (7LiF:Mg,Cu,P) of the same manufacturer was used for gamma detection because of its high sensitivity to gamma radiation compared to that to high LET radiation. The gamma dose and neutron fluence distributions have been measured in PMMA, water and brain substitute liquid phantoms at the BNCT beam. Gamma dose and neutron fluence profiles measured with TL detectors correlate with those calculated using DORT (Two Dimensional Discrete Ordinates Transport Code) and measured with ionisation chambers. NITS-Ns TL detectors were found to measure accurately (8%, 1 S.D.) the relative neutron fluence, and therefore to be a useful addition to the activation foils in BNCT neutron dosimetry. Due to the high uncertainty of the thermal neutron sensitivity of the MCP-7s TL detectors, the absorbed gamma doses can be measured with MCP-7s detectors within 20% in the mixed neutron-gamma field of BNCT. The treatments of glioma patients at the Finnish BNCT facility will start in the spring 1999. The doses to the target volume and sensitive organs, i.e. brain, will be calculated individually in the dose planning. Since it is also necessary to monitor the absorbed doses to the head and to the body, in vivo

  1. BNCT of canine osteosarcoma

    International Nuclear Information System (INIS)

    A dog was diagnosed with osteosarcoma (8x6x5cm) in the right wing of ilium by radiography, radionuclide scintigraphy and histological study of biopsy material. The treatment plan was as follows: γ-therapy in combination with chemotherapy; prevention of hematogenous pulmonary metastases by the transfusion of 130 ml of allogenic marrow from a healthy donor; administration of 11.4g 10B-boronphenylalanine into the right iliac artery; resection of the right iliac wing with the osteosarcoma lesion; neutron irradiation (MEPhI Reactor) of the bone fragment (dose on healthy osteocytes - 15±4 Gy (W), on tumor - 50±9 Gy (W); reimplantation and fixation of the fragment; three courses of adjuvant chemotherapy. The doses were determined in full-scale calculations of the reactor radiation fields with a model of the bone under the code RADUGA. The 10B concentration (μg/g) in the bone was: normal tissue - 9±3, tumor - 28±5. In 24 hours post operation the dog was able to walk using the treated limb, and 6 months later it moved freely. The patient has been under observation for 30 months. The results of the research demonstrate complete cure. The use of similar treatment plans improves the therapeutic efficiency of BNCT. (author)

  2. BNCT and dose fractionation

    International Nuclear Information System (INIS)

    Some portion of the radiation dose received by a patient during BNCT consists of primary and secondary gammas. The biological effect of that portion of the dose will depend upon the time history of the delivered dose. The well-known models for relating time-dose effects to clinical experience, are of questionable value in understanding dose effects in the time regime of a few hours, and for doses of less than tolerance. In order to examine the time-dose effect in the regime of interest to BNCT a simple phenomenological model was developed and normalized to the accepted body of clinical experience. The model has been applied to the question of fractionation of BNCT and the results are presented. The model is simply a linear healing model with two time constants. In other words, a first hit of radiation is assumed to wound (or potentiate) a cell. Given time, the cell will fully repair itself. If a second hit occurs before the cell has healed, the cell is killed. Apparently, there are two kinds of healing, one which occurs in 30 to 60 minutes, the other in two to four days. A small fraction of the cells will die on the first hit

  3. Microdosimetry study of THOR BNCT beam using tissue equivalent proportional counter

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a cancer treatment modality using a nuclear reactor and a boron compound drug. In Taiwan, Tsing Hua open-pool reactor (THOR) has been modulated for the basic research of BNCT for years. A new BNCT beam port was built in 2004 and used to prepare the first clinical trial in the near future. This work reports the microdosimetry study of the THOR BNCT beam by means of the tissue equivalent proportional counter (TEPC). Two self-fabricated TEPCs (the boron-doped versus the boron-free counter wall) were introduced. These dual TEPCs were applied to measure the lineal energy distributions in air and water phantom irradiated by the THOR BNCT mixed radiation field. Dose contributions from component radiations of different linear energy transfers (LETs) were analyzed. Applying a lineal energy dependent biological weighting function, r(y), to the total and individual lineal energy distributions, the effective relative biological effectiveness (RBE), neutron RBE, photon RBE, and boron capture RBE (BNC RBE) were all determined at various depths of the water phantom. Minimum and maximum values of the effective RBE were 1.68 and 2.93, respectively. The maximum effective RBE occurred at 2 cm depth in the phantom. The average neutron RBE, photon RBE, and BNC RBE values were 3.160±0.020, 1.018±0.001, and 1.570±0.270, respectively, for the THOR BNCT beam.

  4. BNCT and Targeted Radiotherapy (TRT) developments in Romania

    International Nuclear Information System (INIS)

    There are a number of treatment modalities for cancer including surgery, chemotherapy and radiation therapy. However, these treatments are not always effective. The search for new and more efficient ways to combat cancer has opened new perspectives. Boron neutron capture therapy (BNCT) is a new approach in cancer treatment that has been proposed to combat glioblastomas of the brain, neck cancer and malignant melanomas, tumors that are resistant to traditional cancer therapies. BNCT is based on the 10B(n,α)7Li nuclear reaction, which can potentially deliver a very high and fatal radiation dose to cancerous cells by concentrating boron in them. It is a promising, though complicated treatment. This type of therapy offers a number of potentially significant advantages compared to traditional radiation therapy. Treatment is better targeted to cancerous cells so that when a tumour is irradiated with neutrons, the damage to normal tissue is respectively less. It is also less demanding for the patient as treatment is only one to two sessions, compared to conventional radiation therapy where patients can be treated up to 30 times. It provides an excellent example of the importance of innovation in the search for a cure to cancer. The recent developments in BNCT in Romania as well as the major drawbacks will be presented. (authors)

  5. INEL BNCT Research Program annual report 1994

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1995-11-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1994. Contributions from the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (treatment planning software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of BSH and BPA is presented and results of 21 spontaneous tumor bearing dogs that have been treated with BNCT at Brookhaven National Laboratory (BNL) are discussed. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Highlights from the First International Workshop on Accelerator-Based Neutron Sources for BNCT are included. Selected papers have been indexed separately for inclusion in the Energy Science and Technology Database.

  6. Depth-dose evaluation for lung and pancreas cancer treatment by BNCT using an epithermal neutron beam

    International Nuclear Information System (INIS)

    The depth-dose distributions were evaluated for possible treatment of both lung and pancreas cancers using an epithermal neutron beam. The MCNP calculations showed that physical dose in tumors were 6 and 7 Gy/h, respectively, for lung and pancreas, attaining an epithermal neutron flux of 5x108 ncm-2s-1. The boron concentrations were assumed at 100 ppm and 30 ppm, respectively, for lung and pancreas tumors and normal tissues contains 1/10 tumor concentrations. The dose ratios of tumor to normal tissue were 2.5 and 2.4, respectively, for lung and pancreas. The dose evaluation suggests that BNCT could be applied for both lung and pancreas cancer treatment. (author)

  7. The relationship between boron neutron capture therapy (BNCT) and positron emission tomography (PET) for malignant brain tumors

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a particle irradiation therapy that is theoretically available for selective radiation of tumor cells. Boronophenylalanine-positron emission tomography (18F-BPA-PET) was used in this study. Boron is used as a tracer compound for the neutron capture reaction and has been particularly useful for the recent noncraniotomy BNCT. In this report, we introduce this type of PET as a principal axis in BNCT and relationship with PET. We calculated the drug accumulation to the tumor before neutron irradiation to individualize the treatment. We decided the indication for BNCT on the basis of a PET study and are now expanding the indications to other systemic cancers, including head and neck, lung, and liver cancers. In addition, other irradiation modalities have developed a radiation plan on the basis of a PET study, and several studies attempted improving the results; however, the lesion is exposed to high radiation doses and appear as high accumulation on BPA-PET during BNCT. We determined the neutron exposure time from the dosage for normal tissue in the actual treatment, but the lesion/normal tissue ratio obtained from BPA-PET is for evaluating the tumor dose and following the treatment plan. We also found that a PET study was useful in the follow-up stage to aid in diagnosis of pathologic conditions such as increase in tumor volume, recurrence, or radiation necrosis and for patients who had already been treated for malignant brain tumor. (author)

  8. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma

    International Nuclear Information System (INIS)

    The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment. - Highlights: ► In this study, we evaluate the clinical outcome of boron neutron capture therapy (BNCT) for malignant brain tumors. ► We have treated 23 glioblastoma (GBM) patients with BNCT without any additional chemotherapy. ► Clinical results of BNCT in patients with GBM are superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.

  9. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba

    Energy Technology Data Exchange (ETDEWEB)

    Aiyama, H. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nakai, K., E-mail: knakai@Neurosurg-tsukuba.com [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Yamamoto, T. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyouku (Japan); Kumada, H. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Ishikawa, E. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Isobe, T. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan); Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba (Japan)

    2011-12-15

    We have evaluated the efficacy and safety of boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor using a new protocol. One of the two patients enrolled in this trial is a man with recurrent glioblastoma and the other is a woman with anaplastic meningioma. Both are still alive and no severe adverse events have been observed. Our findings suggest that NCT will be safe as a palliative therapy for malignant brain tumors. - Highlights: Black-Right-Pointing-Pointer Boron neutron capture therapy (BNCT) for recurrent glioma and malignant brain tumor. Black-Right-Pointing-Pointer Two cases with recurrent glioblastoma and anaplastic meningioma. Black-Right-Pointing-Pointer No severe adverse events have been observed using BNCT. Black-Right-Pointing-Pointer BNCT has a possibility of a safe palliative therapy for malignant brain tumors.

  10. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    Energy Technology Data Exchange (ETDEWEB)

    Hampel, G.; Grunewald, C.; Schutz, C.; Schmitz, T.; Kratz, J.V. [Nuclear Chemistry, University of Mainz, D-55099 Mainz (Germany); Brochhausen, C.; Kirkpatrick, J. [Department of Pathology, University of Mainz, D-55099 Mainz (Germany); Bortulussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Kudejova, P. [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Appelman, K.; Moss, R. [Joint Research Centre (JRC) of the European Commission, NL-1755 ZG Petten (Netherlands); Bassler, N. [University of Aarhus, Norde Ringade, DK-8000, Aarhus C (Denmark); Blaickner, M.; Ziegner, M. [Molecular Medicine, Health and Environment Department, AIT Austrian Institute of Technology GmbH (Austria); Sharpe, P.; Palmans, H. [National Physical Laboratory, Teddington TW11 0LW, Middlesex (United Kingdom); Otto, G. [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, D-55099 Mainz (Germany)

    2011-07-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed in Pavia (Italy) a few years ago, where patients with liver metastases were treated by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and the treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appears to be an appropriate dosimetry technique. (author)

  11. Dosimetric feasibility study for an extracorporeal BNCT application on liver metastases at the TRIGA Mainz

    International Nuclear Information System (INIS)

    This study investigates the dosimetric feasibility of Boron Neutron Capture Therapy (BNCT) of explanted livers in the thermal column of the research reactor in Mainz. The Monte Carlo code MCNP5 is used to calculate the biologically weighted dose for different ratios of the 10B-concentration in tumour to normal liver tissue. The simulation results show that dosimetric goals are only partially met. To guarantee effective BNCT treatment the organ has to be better shielded from all gamma radiation. - Highlights: ► Monte Carlo simulations demonstrate the potential for BNCT treatment at TRIGA Mainz. ► Simulation shows the necessity of gamma shielding for the organ from all sides. ► Secondary photons induced within the graphite contribute considerably to gamma dose.

  12. Employment of MCNP in the study of TLDS 600 and 700 seeking the implementation of radiation beam characterization of BNCT facility at IEA-R1; Emprego do MCNP no estudo dos TLDS 600 e 700 visando a implementacao da caracterizacao do feixe de irradiacao da instalacao de BNCT do IEA-R1

    Energy Technology Data Exchange (ETDEWEB)

    Cavalieri, Tassio Antonio

    2013-07-01

    Boron Neutron Capture Therapy, BNCT, is a bimodal radiotherapy procedure for cancer treatment. Its useful energy comes from a nuclear reaction driven by impinging thermal neutron upon Boron 10 atoms. A BNCT research facility has been constructed in IPEN at the IEA-R1 reactor, to develop studies in this area. One of its prime experimental parameter is the beam dosimetry which is nowadays made by using activation foils, for neutron measurements, and TLD 400, for gamma dosimetry. For mixed field dosimetry, the International Commission on Radiation Units and Measurements, ICRU, recommends the use of pair of detectors with distinct responses to the field components. The TLD 600/ TLD 700 pair meets this criteria, as the amount of {sup 6}Li, a nuclide with high thermal neutron cross section, greatly differs in their composition. This work presents a series of experiments and simulations performed in order to implement the mixed field dosimetry based on the use of TLD 600/TLD 700 pair. It also intended to compare this mixed field dosimetric methodology to the one so far used by the BNCT research group of IPEN. The response of all TLDs were studied under irradiations in different irradiation fields and simulations, underwent by MCNP, were run in order to evaluate the dose contribution from each field component. Series of repeated irradiations under pure gamma field and mixed field neutron/gamma field showed differences in the TLD individual responses which led to the adoption of a Normalization Factor. It has allowed to overcome TLD selection. TLD responses due to different field components and spectra were studied. It has shown to be possible to evaluate the relative gamma/neutron fluxes from the relative responses observed in the two Regions of Interest, ROIs, from TLD 600 and TLD 700. It has also been possible to observe the TLD 700 response to neutron, which leads to a gamma dose overestimation when one follows the ICRU recommended mixed field dosimetric procedure. Dose

  13. The Finnish Boron neutron capture therapy (BNCT) project

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a new, binary radiotherapy, which has been developed especially for severe brain tumours, incurable by the present means. A suitable 10B containing carrier compound is injected into the blood circulation and taken up selectively by the cancer cells. When these cells are subjected to a thermal neutron field, the 10B atoms capture the neutrons and undergo fission reaction. The energy thereby released is killing the cancerous cell. The Finnish BNCT research and development project is in the situation where all the basic conditions exist to start clinical trials. An epithermal neutron irradiation facility has been constructed at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. This article is an overview over the developments within the Finnish BNCT project. A research project to carry out clinical application of BNCT was established in Finland in the early 1990's. It was motivated both by the need to create new uses for FiR 1 and by the ideas to start research and production of new boron carriers for BNCT in Finland. Soon also other medical, medical physics and chemistry disciplines joined the project. Now the project involves scientists from different departments of University of Helsinki (HU), Helsinki University Central Hospital (HUCH), Technical Research Centre of Finland (VTT), Finnish Radiation and Nuclear Safety Authority (STUK) and of the Helsinki University of Technology (HUT) and other Finnish universities. The aim of this project has been to start BNC-treatment of malignant brain tumours in Finland by the end of the century

  14. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    DEFF Research Database (Denmark)

    Hampel, G.; Grunewald, C.; Schütz, C.;

    2011-01-01

    years ago, where patients with liver metastases were treated successfully by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests...... have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appear to be an appropriate dosimetry technique....

  15. An optimum source neutron spectrum and holder shape for extra-corporal treatment of liver cancer by BNCT

    International Nuclear Information System (INIS)

    In extra-corporal treatment of liver cancer by BNCT, it is desired to have an as homogeneous as possible thermal neutron field throughout the organ. Previous work has shown that when using an epithermal neutron beam, the shape of the holder in which the liver is placed is the critical factor. This study develops the notion further as to what is the optimum neutron spectrum to perform such treatments. In the design calculations, when using Monte Carlo techniques, it is shown that when the expected contributions of the source neutrons in every part of the liver is calculated, a linear optimization scheme such as the Simplex method results in a mix of thermal and epithermal source neutrons to get the highest homogeneity for the thermal neutron field. This optimisation method is demonstrated in 3 holder shapes: cuboid, cylindrical and spherical with each 3 volumes of 2, 4 and 6 litres. A 10 cm thick cuboid model, irradiated from both sides gives the highest homogeneity. The spherical (rotating) holder has the lowest homogeneity but the highest contribution of every source neutron to the thermal neutrons in the liver. This can be advantageous when using a relatively small sized neutron beam with a low strength. (author)

  16. First clinical results on the finnish study on BPA-mediated BNCT in glioblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Kankaanranta, L. [Helsinki University Hospital, Dept. of Oncology, Helsinki (Finland); Seppaelae, T. [University of Helsinki, Department of Physics, Helsinki (Finland); Kallio, M. [Helsinki University Hospital, Dept. of Neurology, Helsinki (Finland)] [and others

    2000-10-01

    An open phase I dose-escalation boron neutron capture therapy (BNCT) study on glioblastoma multiforme (GBM) was initiated at the BNCT facility FiR 1, Espoo, Finland, in May 1999. The aim of the study is to investigate the safety of boronophenylalanine (BPA)-mediated BNCT. Ten GBM patients were treated with a 2-field treatment plan using one fraction. BPA-F was used as the {sup 10}B carrier infused as a fructose solution 290 mg BPA/kg over 2-hours prior to irradiation with epithermal neutrons. Average doses to the normal brain, contrast enhancing tumour, and the target ranged from 3.0 to 5.6 Gy (W), from 35.1 to 66.7 Gy (W), and from 29.6 to 53.6 Gy (W), respectively. BNCT was associated with acceptable toxicity. The median follow-up is 9 months (range, 3 to 16 months) post diagnosis in July 2000. Seven of the 10 patients have recurrent or persistent GBM, and the median time to progression is 8 months. Only one patient has died, and the estimated 1-year overall survival is 86%. Five of the recurrent tumours were treated with external beam photon radiation therapy to the total dose of 30-40 Gy with few acute side-effects. These preliminary findings suggest that acute toxicity of BPA-mediated BNCT is acceptable when average brain doses of 5.6 Gy (W) or less are used. The followup time is too short to evaluate survival, but the estimated 1-year survival of 86% achieved with BNCT followed by conventional photon irradiation at the time of tumour progression is encouraging and emphasises the need of further investigation of BPA-mediated BNCT. (author)

  17. Boron determination in liver tissue by combining quantitative neutron capture radiography (QNCR) and histological analysis for BNCT treatment planning at the TRIGA Mainz.

    Science.gov (United States)

    Schütz, C; Brochhausen, C; Altieri, S; Bartholomew, K; Bortolussi, S; Enzmann, F; Gabel, D; Hampel, G; Kirkpatrick, C J; Kratz, J V; Minouchehr, S; Schmidberger, H; Otto, G

    2011-09-01

    The typical primary malignancies of the liver are hepatocellular carcinoma and cholangiocarcinoma, whereas colorectal liver metastases are the most frequently occurring secondary tumors. In many cases, only palliative treatment is possible. Boron neutron capture therapy (BNCT) represents a technique that potentially destroys tumor tissue selectively by use of externally induced, locally confined secondary particle irradiation. In 2001 and 2003, BNCT was applied to two patients with colorectal liver metastases in Pavia, Italy. To scrutinize the rationale of BNCT, a clinical pilot study on patients with colorectal liver metastases was carried out at the University of Mainz. The distribution of the (10)B carrier (p-borono-phenylalanine) in the liver and its uptake in cancerous and tumor-free tissue were determined, focusing on a potential correlation between the uptake of p-borono-phenylalanine and the biological characteristics of cancerous tissue. Samples were analyzed using quantitative neutron capture radiography of cryosections combined with histological analysis. Methodological aspects of the combination of these techniques and results from four patients enrolled in the study are presented that indicate that the uptake of p-borono-phenylalanine strongly depends on the metabolic activity of cells. PMID:21692653

  18. Tumor control and normal tissue complications in BNCT treatment of nodular melanoma: A search for predictive quantities

    International Nuclear Information System (INIS)

    A previous work concerning tumor control and skin damage in cutaneous melanoma treatments with BNCT has been extended to include doses, volumes and responses of 104 subcutaneous lesions from all patients treated in Argentina. Acute skin reactions were also scored for these patients, and cumulative dose-area histograms and dose-based figures of merit for skin were calculated. Broadening the tumor response analysis with the latest data showed that the (minimum or mean) tumor dose is not a good predictor of the observed clinical outcome by itself. However, when the tumor volume was included in the model as second explicative variable, the dose increases its significance and becomes a critical variable jointly with the volume (p-values3) doses greater than 20 Gy-Eq produce a high tumor control (> 80%). However, when tumor volumes are larger than 0.1 cm3, control is moderate (< 40%) even for minimum doses up to 40 Gy-Eq. Some quantities based on skin doses, areas and complication probabilities were proposed as candidates for predicting the severity of the early skin reactions. With the current data, all the evaluated figures of merit derived similar results: ulceration is present among the cases for which these quantities take the highest values.

  19. BNCT facility development in HANARO

    International Nuclear Information System (INIS)

    An irradiation facility for boron neutron capture therapy (BNCT) was developed using one of the typical tangential beam tubes in HANARO. Thermal neutron was chosen because of the impossibility of sufficient epithermal neutrons for BNCT at the exit of the beam tube. The facility is designed not only for BNCT study but also for dynamic neutron radiography (DNR) and other experiments requiring pure thermal neutrons. Silicon and bismuth single crystals cooled by liquid nitrogen are selected to filter out fast neutrons and γ-rays and to penetrate the thermal neutrons as much as possible. A water shutter is installed in front of the radiation filter to keep the radiation level low in the irradiation room while it is filled with water. A prompt gamma neutron activation analysis (PGNAA) system was also developed to measure the boron concentration quickly from patient's blood samples. A spare neutron beam from a dedicated beam instrument was diffracted upward using pyrolytic graphite to obtain almost pure thermal neutrons at the target position. (author)

  20. Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.); Dorn, R.V. III.

    1990-08-01

    This report discusses monthly progress in the Power Boron Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program for Cancer Treatment. Highlights of the PBF/BNCT Program during August 1990 include progress within the areas of: Gross Boron Analysis in Tissue, Blood, and Urine, boron microscopic (subcellular) analytical development, noninvasive boron quantitative determination, analytical radiation transport and interaction modeling for BNCT, large animal model studies, neutron source and facility preparation, administration and common support and PBF operations.

  1. Preliminary modeling of BNCT beam tube on IRT in Sofia

    Energy Technology Data Exchange (ETDEWEB)

    Belousov, S. [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria)], E-mail: belousov@inrne.bas.bg; Ilieva, K. [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria)

    2009-07-15

    The technical design of the research reactor IRT in Sofia is in progress. It includes an arrangement for a BNCT facility for tumor treatment. Modeling of geometry and material composition of filter/collimator for the BNCT beam tube on IRT has been carried out following the beam tube configuration of the Massachusetts Institute of Technology Reactor [Harling et al., 2002. The fission converter-based epithermal neutron irradiation facility at the Massachusetts Institute of Technology Reactor. Nucl. Sci. Eng. 140, 223-240.] and taking into account an ability to include the tube into the IRT reactor geometry. The results of neutron and gamma transport calculations performed for the model have shown that the facility will be able to supply an epithermal neutron flux of about 5x10{sup 9} n cm{sup -2} s{sup -1}, with low contamination from fast neutrons and gamma rays that would be among the best facilities currently available. An optimiziation study has been performed for the beam collimator, following similar studies for the TAPIRO research reactor in Italy. [Nava et al., 2005. Monte Carlo optimization of a BNCT facility for treating brain gliomas at the TAPIRO reactor. Radiat. Prot. Dosim. 116 (1-4), 475-481.].

  2. Preliminary modeling of BNCT beam tube on IRT in Sofia

    International Nuclear Information System (INIS)

    The technical design of the research reactor IRT in Sofia is in progress. It includes an arrangement for a BNCT facility for tumor treatment. Modeling of geometry and material composition of filter/collimator for the BNCT beam tube on IRT has been carried out following the beam tube configuration of the Massachusetts Institute of Technology Reactor [Harling et al., 2002. The fission converter-based epithermal neutron irradiation facility at the Massachusetts Institute of Technology Reactor. Nucl. Sci. Eng. 140, 223-240.] and taking into account an ability to include the tube into the IRT reactor geometry. The results of neutron and gamma transport calculations performed for the model have shown that the facility will be able to supply an epithermal neutron flux of about 5x109 n cm-2 s-1, with low contamination from fast neutrons and gamma rays that would be among the best facilities currently available. An optimiziation study has been performed for the beam collimator, following similar studies for the TAPIRO research reactor in Italy. [Nava et al., 2005. Monte Carlo optimization of a BNCT facility for treating brain gliomas at the TAPIRO reactor. Radiat. Prot. Dosim. 116 (1-4), 475-481.

  3. INEL BNCT research program: Annual report, 1995

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1996-04-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented.

  4. INEL BNCT research program: Annual report, 1995

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1995. Contributions from the principal investigators about their individual projects are included, specifically, physics (treatment planning software, real-time neutron beam measurement dosimetry), and radiation biology (large animal models efficacy studies). Design of a reactor based epithermal neutron extraction facility is discussed in detail. Final results of boron magnetic resonance imagining is included for both borocaptate sodium (BSH) and boronophenylalanine (BPA) in rats, and BSH in humans. Design of an epithermal neutron facility using electron linear accelerators is presented, including a treatise on energy removal from the beam target. Information on the multiple fraction injection of BSH in rats is presented

  5. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    Energy Technology Data Exchange (ETDEWEB)

    Boggio, E. F.; Longhino, J. M. [Centro Atomico Bariloche, Departamento de Fisica de Reactores y Radiaciones / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina); Andres, P. A., E-mail: efboggio@cab.cnea.gov.ar [Centro Atomico Bariloche, Division Proteccion Radiologica / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina)

    2015-10-15

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single {sup 7}LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 ({sup 6}LiF:Mg,Ti with 95.6% {sup 6}Li) and TLD-700 ({sup 7}LiF:Mg,Ti with 99.9% {sup 7}LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom

  6. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    International Nuclear Information System (INIS)

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single 7LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 (6LiF:Mg,Ti with 95.6% 6Li) and TLD-700 (7LiF:Mg,Ti with 99.9% 7LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom, with representative

  7. BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    BSH-based intra-operative BNCT as an initial treatment underwent in 4 children with malignant brain tumors since 1998. There were 2 glioblastomas, one primitive neuroectodermal tumor (PNET) and one anaplastic ependymoma patient. They included two children under 3-year-old. All GBM patients were died of CSF dissemination without tumor regrowth in the primary site. Another PNET and anaplastic ependymoma patients are still alive without tumor recurrence. We can consider BNCT is optimal treatment modality for malignant brain tumor in children. (author)

  8. The studsvik BNCT project: structure and the proposed protocols

    International Nuclear Information System (INIS)

    The BNCT facility at Studsvik is now ready for clinical trials. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of all major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia and to assure the quality of the research. Proposed clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, initially, will involve two protocols: Protocol no.1. BNCT for glioblastoma patients who have not received any therapy other than surgery (including stereotactic biopsy only). Protocol no.2. BNCT as a palliative treatment for patients with recurrent glioblastoma following conventional therapies or BNCT. In both protocols, BPA, administered by a 6 hour i.v. infusion, will be used as the boron delivery agent. (author)

  9. BNCT Technology Development on HANARO Reactor

    International Nuclear Information System (INIS)

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented

  10. BNCT Technology Development on HANARO Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Chun, Ki Jung; Park, Kyung Bae; Whang, Seung Ryul; Kim, Myong Seop

    2007-06-15

    So as to establish the biological effects of BNCT in the HANARO Reactor, biological damages in cells and animals with treatment of boron/neutron were investigated. And 124I-BPA animal PET image, analysis technology of the boron contents in the mouse tissues by ICP-AES was established. A Standard clinical protocol, a toxicity evaluation report and an efficacy investigation report of BNCT has been developed. Based on these data, the primary permission of clinical application was acquired through IRB of our hospital. Three cases of pre-clinical experiment for boron distribution and two cases of medium-sized animal simulation experiment using cat with verifying for 2 months after BNCT was performed and so the clinical demonstration with a patient was prepared. Also neutron flux, fast neutron flux and gamma ray dose of BNCT facility were calculated and these data will be utilized good informations for clinical trials and further BNCT research. For the new synthesis of a boron compound, o-carboranyl ethylamine, o-carboranylenepiperidine, o-carboranyl-THIQ and o-carboranyl-s-triazine derivatives were synthesized. Among them, boron uptake in the cancer cell of the triazine derivative was about 25 times than that of BPA and so these three synthesized methods of new boron compounds were patented.

  11. Production of epithermal neutron beams for BNCT

    CERN Document Server

    Bisceglie, E; Colonna, N; Paticchio, V; Santorelli, P; Variale, V

    2002-01-01

    The use of boron neutron capture therapy (BNCT) for the treatment of deep-seated tumors requires neutron beams of suitable energy and intensity. Simulations indicate the optimal energy to reside in the epithermal region, in particular between 1 and 10 keV. Therapeutic neutron beams with high spectral purity in this energy range could be produced with accelerator-based neutron sources through a suitable neutron-producing reaction. Herein, we report on different solutions that have been investigated as possible sources of epithermal neutron beams for BNCT. The potential use of such sources for a hospital-based therapeutic facility is discussed.

  12. Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

    International Nuclear Information System (INIS)

    Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina (10BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 106 MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of 10B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37°C and 23°C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R2 = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R2 = 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual

  13. Experimental Studies of Boronophenylalanine ({sup 10}BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

    Energy Technology Data Exchange (ETDEWEB)

    Carpano, Marina; Perona, Marina; Rodriguez, Carla [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); Nievas, Susana; Olivera, Maria; Santa Cruz, Gustavo A. [Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín (Argentina); Brandizzi, Daniel; Cabrini, Romulo [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); School of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Pisarev, Mario [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Department of Human Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires (Argentina); Juvenal, Guillermo Juan [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Dagrosa, Maria Alejandra, E-mail: dagrosa@cnea.gov.ar [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina)

    2015-10-01

    Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina ({sup 10}BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 10{sup 6} MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of {sup 10}B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37°C and 23°C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R{sup 2} = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R{sup 2} = 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT

  14. BNCT. Computational Analysis; BNCT. Analisis computacional

    Energy Technology Data Exchange (ETDEWEB)

    Caro, R.

    2004-07-01

    The BNCT (Boron Neutron Capture Therapy) is a new oncologic radiotherapy technique in the process of research which consists of injecting a non-poisonous pharmacovector into an ill patient in such a way that the tumor receives isotope boron-10, so that the tumoral area can later be bombarded with a beam of neutrons, many of which are captured the isotope in question. (Author)

  15. A case of astrocytoma, 19 year history after BNCT

    International Nuclear Information System (INIS)

    A 39-year-old man had received Boron Neutron Capture Therapy (BNCT) in 1987 for a Grade II Astrocytoma. He gradually exacerbated and received a second operation in 1994. The mass taken in the second operation is almost competent with radiation necrosis. Following that, he shows no signs of recurrence. Currently, he has returned to full time employment in physical labor. This case suggests effectiveness of BNCT for rather low-grade astrocytomas. (author)

  16. In vivo BNCT in experimental and spontaneous tumors at RA-1 reactor

    International Nuclear Information System (INIS)

    Within the search for new applications of Boron Neutron Capture Therapy (BNCT) and the basic research oriented towards the study of BNCT radiobiology to optimize its therapeutic gain, we previously proposed and validated the hamster cheek pouch oral cancer model and showed, for the first time, the success of BNCT to treat oral cancer in an experimental model. The staff of the Ra-1 Reactor (Constituyentes Atomic Center) adapted the thermal beam and physical set-up to perform in vivo BNCT of superficial tumors in small animals. We preformed a preliminary characterization of the thermal beam, performed beam only irradiation of normal and tumor bearing hamsters and in vivo BNCT of experimental oral squamous cell carcinomas in hamsters mediated by boron phenylalanine (BPA) and GB-10 (Na210B10H10). Having demonstrated the absence of radio toxic effects in healthy tissue and a therapeutic effect of in vivo BNCT in hamster cheek pouch tumors employing the Ra-1 thermal beam, we performed a feasibility study of the treatment by BNCT of 3 terminal cases of spontaneous head and neck squamous cell carcinoma in cats following the corresponding biodistribution studies. This was the first treatment of spontaneous tumors by BNCT in our country and the first treatment by BNCT in cats worldwide. This preclinical study in terminal cases showed significant tumor control by BNCT with no damage to normal tissue. (author)

  17. Current practices and future directions of therapeutic strategy in glioblastoma: Survival benefit and indication of BNCT

    International Nuclear Information System (INIS)

    Since 1998, we are performing clinical studies on treatment of GBM using conventional fractionated photon radiation therapy (CRT), proton beam therapy (PBT) or boron neutron capture therapy (BNCT). We investigated whether these radiation modalities improves the survival of patients with GBM. Sixty-eight cases of newly diagnosed GBM have been treated in our institution. After surgery, radiation therapy was performed using CRT with a dose of 60.0-61.2 Gy (n=36), hyperfractionated PBT concomitant with fractionated photon irradiation with a total dose of 96.6 Gy (n=17), or a single fraction of BNCT (n=15). In PBT, the surrounding volume of 2 cm from main tumor mass and the volume of perifocal edema were irradiated at dose of 75.6 and 60 Gy, respectively. The median OS time of the case series of BNCT for GBM has been reported as 13-20.7 M. In this study, the median OS and median time to MR change (TTM) for all patients were 25.7 and 11.9 M, respectively. The 1- and 2-year survival rates were 85.7% and 45.5%, respectively. On the other hand, in the patients who underwent CRT and ACNU-based chemotherapy, OS and 2-year survival rate were 14.2 M and 17.9%, respectively. In the patients who underwent high-dose PBT, OS and 2-year survival rate were 21.3 M and 38.5%, respectively. The present small case series of selected patients showed survival benefit after BNCT. The comparison using previously reported prognostic factor-based classifications suggest that outcome of BNCT in terms of survival appeared to have non-inferiority compared to the standard therapy. With respect to the case series as a high-dose radiation trial, the outcome (OS: 9.5-25 M) of previously reported may still be comparable to that of BNCT. Randomized trials of comparably selected patients are required to demonstrate conclusively that prolonged survival is a result of this tumor-selective radiotherapy.

  18. Design, construction and application of a neutron shield for the treatment of diffuse lung metastases in rats using BNCT

    International Nuclear Information System (INIS)

    A model of multiple lung metastases in BDIX rats is under study at CNEA (Argentina) to evaluate the feasibility of BNCT for multiple, non-surgically resectable lung metastases. A practical shielding device that comfortably houses a rat, allowing delivery of a therapeutic, uniform dose in lungs while protecting the body from the neutron beam is presented. Based on the final design obtained by numerical simulations, the shield was constructed, experimentally characterized and recently used in the first in vivo experiment at RA-3. - Highlights: • A practical shielding device that comfortably houses a rat is presented. • The shield allows a uniform and useful dose in the rat thoracic area. • A novel computational dosimetry in animals based on Multicell is presented. • Experimental characterization evidences the good performance of the shield. • An irradiation based on a diffuse lung metastases model in rats was performed

  19. The therapeutic ratio in BNCT: Assessment using the Rat 9L gliosarcoma brain tumor and spinal cord models

    International Nuclear Information System (INIS)

    During any radiation therapy, the therapeutic tumor dose is limited by the tolerance of the surrounding normal tissue within the treatment volume. The short ranges of the products of the 10B(n,α)7Li reaction produced during boron neutron capture therapy (BNCT) present an opportunity to increase the therapeutic ratio (tumor dose/normal tissue dose) to levels unprecedented in photon radiotherapy. The mixed radiation field produced during BNCT comprises radiations with different linear energy transfer (LET) and different relative biological effectiveness (RBE). The short ranges of the two high-LET products of the 'B(n,a)'Li reaction make the microdistribution of the boron relative to target cell nuclei of particular importance. Due to the tissue specific distribution of different boron compounds, the term RBE is inappropriate in defining the biological effectiveness of the 10B(n,α)7Li reaction. To distinguish these differences from true RBEs we have used the term open-quotes compound biological effectivenessclose quotes (CBE) factor. The latter can be defined as the product of the true, geometry-independent, RBE for these particles times a open-quotes boron localization factorclose quotes, which will most likely be different for each particular boron compound. To express the total BNCT dose in a common unit, and to compare BNCT doses with the effects of conventional photon irradiation, multiplicative factors (RBEs and CBEs) are applied to the physical absorbed radiation doses from each high-LET component. The total effective BNCT dose is then expressed as the sum of RBE-corrected physical absorbed doses with the unit Gray-equivalent (Gy-Eq)

  20. The therapeutic ratio in BNCT: Assessment using the Rat 9L gliosarcoma brain tumor and spinal cord models

    Energy Technology Data Exchange (ETDEWEB)

    Coderre, J.A.; Micca, P.L.; Nawrocky, M.M.; Fisher, C.D.; Bywaters, A. [Brookhaven National Lab., Upton, NY (United States); Morris, G.M.; Hopewell, J.W. [Univ. of Oxford (United Kingdom). CRC Normal Tissue Radiobiological Research Group

    1996-10-01

    During any radiation therapy, the therapeutic tumor dose is limited by the tolerance of the surrounding normal tissue within the treatment volume. The short ranges of the products of the {sup 10}B(n,{alpha}){sup 7}Li reaction produced during boron neutron capture therapy (BNCT) present an opportunity to increase the therapeutic ratio (tumor dose/normal tissue dose) to levels unprecedented in photon radiotherapy. The mixed radiation field produced during BNCT comprises radiations with different linear energy transfer (LET) and different relative biological effectiveness (RBE). The short ranges of the two high-LET products of the `B(n,a)`Li reaction make the microdistribution of the boron relative to target cell nuclei of particular importance. Due to the tissue specific distribution of different boron compounds, the term RBE is inappropriate in defining the biological effectiveness of the {sup 10}B(n,{alpha}){sup 7}Li reaction. To distinguish these differences from true RBEs we have used the term {open_quotes}compound biological effectiveness{close_quotes} (CBE) factor. The latter can be defined as the product of the true, geometry-independent, RBE for these particles times a {open_quotes}boron localization factor{close_quotes}, which will most likely be different for each particular boron compound. To express the total BNCT dose in a common unit, and to compare BNCT doses with the effects of conventional photon irradiation, multiplicative factors (RBEs and CBEs) are applied to the physical absorbed radiation doses from each high-LET component. The total effective BNCT dose is then expressed as the sum of RBE-corrected physical absorbed doses with the unit Gray-equivalent (Gy-Eq).

  1. FIR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

    International Nuclear Information System (INIS)

    Full text: The FIR 1-reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT). The BNCT work dominates the current utilization of the reactor: three or four days per week are reserved for BNCT purposes and the rest for other purposes such as isotope production and neutron activation analysis. In the 1990's a BNCT treatment facility was build at the FiR1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material FluentalTM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality. The ground floor of the reactor hall was provided with a new entrance, easily accessible by any patient vehicle, a radio therapy control room and rooms for patient preparation and laboratories. The top of the reactor tank was separated from the reactor hall in order to confine contamination in case of a leakage from irradiation samples or fuel elements. The ventilation of the building, emergency power supply system, heat exchangers and the secondary cooling circuit of the reactor including cooling towers were completely redesigned and rebuilt. The expenditure of designing and accomplishing the construction work described was about 4 million euros. The costs were partly financed with venture capital via Radtek Ltd., particularly established for this enterprise. Close to thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. VTT as the reactor operator has a long term contract with the Boneca Corp. to provide the facility and irradiation services for the patient treatments. The BNCT facility has been licensed for clinical use and is being surveyed by several national public health authorities including the Finnish Nuclear and Radiation Safety

  2. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues. Hemagglutinating Virus of Japan Envelope (HVJ-E) is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration. In this study, we developed a novel vector for 10B (sodium borocaptate: BSH) delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH), and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution) and effectiveness in BNCT therapy in a murine model of multiple liver tumors. CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10B concentrations in murine osteosarcoma cells (LM8G5) were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p < 0.05). In suppressing the spread of tumor cells in mice, BNCT treatment was as effective with CG-HVJ-E-BSH as with BSH

  3. BNCT-Project at the Finnish TRIGA Reactor

    International Nuclear Information System (INIS)

    An epithermal neutron irradiation station for the Boron Neutron Capture Therapy (BNCT) will be constructed in the thermal column of the Finnish Triga reactor. The first target of the BNCT at FiR 1 is the treatment of malignant brain tumors. The epithermal neutrons have the capability to penetrate deep into the brain tissue thermalizing at the same time. The thermal neutrons are captured by 10B-nuclei situated ideally in the tumor cells only and thus the reaction products destroy selectively only the tumor cells. The graphite filling of the thermal column will be replaced by a special moderator material: Al+AlF3. The moderator material and its thickness has been chosen so that the system produces as much as possible epithermal neutrons with low fast neutron and gamma contamination. Both fast neutrons and gamma radiation are harmful for the patient. To reduce the gamma radiation there is a lead-bismuth gamma shield at the outer end of the moderator block. In spite of the low power (250 kW) of the reactor the needed epithermal neutron dose to destroy the tumor will be accumulated in a reasonable time e.g. 0.5 to 1.5 h. This is possible because of the rather short distance between the reactor core and the irradiation target. (author)

  4. Radiation treatment of keloid

    International Nuclear Information System (INIS)

    A scheme of external beam therapy with different schedules for the treatment of keloid has been presented. The basic correlation of activity of the Keloid, as the guidelines of alloting a schedule appears reasonable in this regional experience. The combination with surgery and intratumoral drug application is not included in this study, nor the brachytherapy used in the clinical material. It is suggested that further observations on the activity of fibroblasts morphologically and the exploration of the dose-fractionation would open up newer dimension in the radiation treatment of keloid. (auth.)

  5. Radiation treatment of benign diseases

    International Nuclear Information System (INIS)

    The report deals with an estimation of the volume of radiation treatment of benign diseases in Norway and gives a survey of the subjective opinion of patients regarding the result of the treatment. Reported subjective recovery after radiation treatment seems to be at the same level as recovery without treatment. For an indication of the objective effect of radiation treatment of benign diseases, the subjective effect of this treatment has to be compared with objective findings

  6. INEL BNCT Program

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-08-01

    This Bulletin presents a summary of accomplishments and highlights in the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for August 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  7. New EORTC clinical trials for BNCT

    International Nuclear Information System (INIS)

    Due to ethical reasons, a separated optimization of the two components of BNCT in the frame of clinical investigations can only be performed applying the whole binary system. The ongoing trial at HFR (High Flux Reactor Petten) has proven the feasibility of BNCT under defined conditions. On that basis the European Commission supported a comprehensive research project on boron imaging including three further clinical studies. In the first trial the boron uptake related to the blood boron concentration and surrounding normal tissue in various solid tumours will be examined using BSH (Sodiumborocaptate), BPA (Boronophenylalanine) or both in order to explore tumour entities, which may gain benefit from BNCT. The major objectives of the second trial are to define the maximum tolerated single and cumulative dose, and the dose limiting toxicity of BSH. The third clinical trial, a phase II study is designed to evaluate the anti-tumour effect of fractionated BNCT at the Petten treatment facility against cerebral metastasis of malignant melanoma using BPA. (author)

  8. Radiation treatment of polypropylene

    International Nuclear Information System (INIS)

    Structural changes in polypropylene resulting from high energy electron beam irradiation have been examined. Polymer irradiated in a nitrogen atmosphere is characterized as containing long chain branch structures. A branching index, defined as the ratio of intrinsic viscosity of irradiated polymer to the intrinsic viscosity of linear polymer of equivalent molecular weight, is used to quantify the extent of branching. Polymer crystallization and solution properties undergo significant changes as a result of radiation treatment. Treated polypropylene is highly nucleated. Nucleation density is several orders of magnitude greater than linear polypropylene. Temperature rising elution fractionation (TREF) indicates that the long-chain branched structure contributes to increasing the solubility of polypropylene without greatly reducing the crystallizability and melting point of the solubilized fractions. The presence of long chain branching has a pronounced effect on the polymers extensional rheology in the molten state. Radiation treated polymer exhibits strain hardening elongational viscosity

  9. Design and testing of a rotating, cooled device for extra-corporate treatment of liver cancer by BNCT in the epithermal neutron beam at the HFR Petten

    International Nuclear Information System (INIS)

    As part of the joint project on extra-corporal treatment of liver cancer by BNCT between JRC Petten and the University Hospital Essen, a facility has been designed and built to contain the liver during its irradiation treatment at the HFR Petten. The design consists of a rotating spheroid shaped PMMA holder, manufactured to open at the equator and closed by screwing together, surrounded by PMMA and graphite blocks. A validation exercise has been performed regarding both the nuclear conditions and the physical conditions. For the former, activation foil sets of Au, Cu and Mn, were irradiated at positions inside the liver holder filled with water, whilst a second measurement campaign has been performed using gel dosimetry. For the physical test, it is required to operate (rotate) the facility for up to 4 hours and to maintain the liver at approximately 4degC. The latter test was performed using 'cold gun sprays' that inject cold air near the liver holder. Both the nuclear and physical validation tests were performed successfully. (author)

  10. Shielding design of a treatment room for an accelerator-based epithermal neutron irradiation facility for BNCT

    International Nuclear Information System (INIS)

    Protecting the facility personnel and the general public from radiation exposure is a primary safety concern of an accelerator-based epithermal neutron irradiation facility. This work makes an attempt at answering the questions open-quotes How much?close quotes and open-quotes What kind?close quotes of shielding will meet the occupational limits of such a facility. Shielding effectiveness is compared for ordinary and barytes concretes in combination with and without borated polyethylene. A calculational model was developed of a treatment room, patient open-quotes scatterer,close quotes and the epithermal neutron beam. The Monte Carlo code, MCNP, was used to compute the total effective dose equivalent rates at specific points of interest outside of the treatment room. A conservative occupational effective dose rate limit of 0.01 mSv h-1 was the guideline for this study. Conservative Monte Carlo calculations show that constructing the treatment room walls with 1.5 m of ordinary concrete, 1.2 m of barytes concrete, 1.0 m of ordinary concrete preceded by 10 cm of 5% boron-polyethylene, or 0.8 m of barytes concrete preceded by 10 cm of 5% boron-polyethylene will adequately protect facility personnel. 20 refs., 8 figs., 2 tabs

  11. An Accelerator Neutron Source for BNCT

    International Nuclear Information System (INIS)

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were (1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, (2) that the patient treatment time be reasonable, (3) that the proton current required to treat patients in reasonable times be technologically achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally (4) that the treatment be safe for the patients

  12. An Accelerator Neutron Source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Blue, Thomas, E

    2006-03-14

    The overall goal of this project was to develop an accelerator-based neutron source (ABNS) for Boron Neutron Capture Therapy (BNCT). Specifically, our goals were to design, and confirm by measurement, a target assembly and a moderator assembly that would fulfill the design requirements of the ABNS. These design requirements were 1) that the neutron field quality be as good as the neutron field quality for the reactor-based neutron sources for BNCT, 2) that the patient treatment time be reasonable, 3) that the proton current required to treat patients in reasonable times be technologially achievable at reasonable cost with good reliability, and accelerator space requirements which can be met in a hospital, and finally 4) that the treatment be safe for the patients.

  13. Clinical practice in BNCT to the brain

    International Nuclear Information System (INIS)

    Our concept of Boron Neutron Capture Therapy (BNCT) is to selectively destroy tumour cells using the high LET particles yielded from the 10B(n,α)7Li reactions. The effort of clinical investigators has concentrated on how to escalate the radiation dose at the target point. BNCT in Japan combines thermal neutrons and BSH (Na2B12H11SH). The radiation dose is determined by the neutron fluence at the target point and the boron concentration in the tumour tissue. According to the recent analysis, the ratio of boron concentration (BSH) in tumour tissue and blood is nearly stable at around 1.2 to 1.69. Escalation of the radiation dose was carried out by means of improving the penetration of the thermal neutron beam. Since 1968, 175 patients with glioblastoma (n=83), anaplastic astrocytoma (n=44), low grade astrocytoma (n=16) or other types of tumour (n=32) were treated by BNCT at 5 reactors (HTR n=13, JRR-3 n=1, MulTR n=98, KUR n=30, JRR-2 n=33). The retrospective analysis revealed that the important factors related to the clinical results and QOL of the patients were minimum tumour volume radiation dose, more than 18Gy of physical dose and maximum vascular radiation dose (less than 15Gy) in the normal cortex. We have planned several trials to escalate the target radiation dose. One trial makes use of a cavity in the cortex following debulking surgery of the tumour tissue to improve neutron penetration. The other trial is introduction of epithermal neutron. KUR and JRR-4 were reconstructed and developed to be able to irradiate using epithermal neutrons. The new combination of surgical procedure and irradiation using epithermal neutrons should remarkably improve the target volume dose compared to the radiation dose treated by thermal neutrons. (author)

  14. Radiation treatment of brain tumors: Concepts and strategies

    Energy Technology Data Exchange (ETDEWEB)

    Marks, J.E. (Loyola Univ. of Chicago Stritch School of Medicine, Maywood, IL (USA))

    1989-01-01

    Ionizing radiation has demonstrated clinical value for a multitude of CNS tumors. Application of the different physical modalities available has made it possible for the radiotherapist to concentrate the radiation in the region of the tumor with relative sparing of the surrounding normal tissues. Correlation of radiation dose with effect on cranial soft tissues, normal brain, and tumor has shown increasing effect with increasing dose. By using different physical modalities to alter the distribution of radiation dose, it is possible to increase the dose to the tumor and reduce the dose to the normal tissues. Alteration of the volume irradiated and the dose delivered to cranial soft tissues, normal brain, and tumor are strategies that have been effective in improving survival and decreasing complications. The quest for therapeutic gain using hyperbaric oxygen, neutrons, radiation sensitizers, chemotherapeutic agents, and BNCT has met with limited success. Both neoplastic and normal cells are affected simultaneously by all modalities of treatment, including ionizing radiation. Consequently, one is unable to totally depopulate a tumor without irreversibly damaging the normal tissues. In the case of radiation, it is the brain that limits delivery of curative doses, and in the case of chemical additives, it is other organ systems, such as bone marrow, liver, lung, kidneys, and peripheral nerves. Thus, the major obstacle in the treatment of malignant gliomas is our inability to preferentially affect the tumor with the modalities available. Until it is possible to directly target the neoplastic cell without affecting so many of the adjacent normal cells, the quest for therapeutic gain will go unrealized.72 references.

  15. Optimization of the irradiation beam in the BNCT research facility at IEA-R1 reactor

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a radiotherapeutic technique for the treatment of some types of cancer whose useful energy comes from a nuclear reaction that occurs when thermal neutron impinges upon a Boron-10 atom. In Brazil there is a research facility built along the beam hole number 3 of the IEA-R1 research reactor at IPEN, which was designed to perform BNCT research experiments. For a good performance of the technique, the irradiation beam should be mostly composed of thermal neutrons with a minimum as possible gamma and above thermal neutron components. This work aims to monitor and evaluate the irradiation beam on the sample irradiation position through the use of activation detectors (activation foils) and also to propose, through simulation using the radiation transport code, MCNP, new sets of moderators and filters which shall deliver better irradiation fields at the irradiation sample position In this work, a simulation methodology, based on a MCNP card, known as wwg (weight window generation) was studied, and the neutron energy spectrum has been experimentally discriminated at 5 energy ranges by using a new set o activation foils. It also has been concluded that the BNCT research facility has the required thermal neutron flux to perform studies in the area and it has a great potential for improvement for tailoring the irradiation field. (author)

  16. Protocols for BNCT of glioblastoma multiforme at Brookhaven: Practical considerations

    Energy Technology Data Exchange (ETDEWEB)

    Chanana, A.D.; Coderre, J.A.; Joel, D.D.; Slatkin, D.N.

    1996-12-31

    In this report we discuss some issues considered in selecting initial protocols for boron neutron capture therapy (BNCT) of human glioblastoma multiforme. First the tolerance of normal tissues, especially the brain, to the radiation field. Radiation doses limits were based on results with human and animal exposures. Estimates of tumor control doses were based on the results of single-fraction photon therapy and single fraction BNCT both in humans and experimental animals. Of the two boron compounds (BSH and BPA), BPA was chosen since a FDA-sanctioned protocol for distribution in humans was in effect at the time the first BNCT protocols were written and therapy studies in experimental animals had shown it to be more effective than BSH.

  17. Requirements for BNCT at a nuclear research reactor. Results from a BNCT workshop organized by the European Commission in Prague, November 2005

    International Nuclear Information System (INIS)

    As part of the European Commission's Enlargement and Integration Action (E and IA), which is intended to improve exchange and relationship within the extended European Union (EU), a Workshop was organized in Prague in November 2005. The purpose of the workshop was to present and discuss technical and organisational requirements in setting up a BNCT facility at a research reactor. Topics included: treatment of a patient by BNCT; organisational aspects and regulatory affairs; BNCT from the nuclear perspective and BNCT from the clinician's perspective. Presentations were given by BNCT experts in their particular field, whilst eleven different national nuclear research centres from the New Member States and Accession Countries, interested in developing a BNCT programme, presented the status of their preparations. The conclusions of the Workshop were that an early and close collaboration between nuclear and medical groups is the basis for BNCT, that a local effort to build a BNCT facility should be supported by a national research programme including basic and clinical science and that the JRC and its partners are ready to support national initiatives within the EU and candidate countries. (author)

  18. Determining and reporting the doses in the treatments of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1)

    International Nuclear Information System (INIS)

    The clinical trials of glioma patients at the Finnish boron neutron capture therapy (BNCT) facility (FiR 1) started in May 1999. The doses of the patient in tumour, target volume and sensitive tissues are calculated individually. The calculated doses are calibrated to the reference monitor units according to the ratio of the independently measured and calculated 197Au(n,g) reactions rates at the depth of 20 mm on the central axis of a cylindrical PMMA phantom chosen as the reference geometry. Absorbed doses to the head and body are monitored individually using in vivo dosimeters. In BNCT the total dose is the weighted sum of the absorbed doses originating from the neutron and gamma interactions in tissues. The material compositions of the head model for the neutron-gamma transport calculation and kerma factors are based on the ICRU report 46. The doses in the clinical research of BNCT should be reported in such a way that the doses are comparable, traceable and can be recalculated, if underlying information, like weighting factors for dose components, are replaced by new ones. The minimum, maximum, average and reference doses are reported for the tumour, target and normal brain. In addition to the total weighted doses the dose components (boron, gamma, nitrogen and fast neutron dose), weighting factors and estimated boron concentration in these tissues are reported. There are no international recommendations available for BNCT dose calculation or reporting. Therefore the BNCT doses reported in the literature may not be comparable and a careless use of values can lead to over- or underdosing. There is an obvious need for standardisation in the medical application of BNCT. In this paper the methods of dose calculation and reporting of the glioma patients at FiR 1 are described. (author)

  19. Development of a Tandem-ElectroStatic-Quadrupole accelerator facility for Boron Neutron Capture Therapy (BNCT)

    International Nuclear Information System (INIS)

    There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). An ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.4-2.5 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p,n)7Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.20-1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7Li(p,n)7Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is one of the technologically simplest and cheapest solutions for optimized AB-BNCT. At present there is no BNCT facility in the world with the characteristics presented in this work. For the accelerator, results on its design, construction and beam transport calculations are discussed. Taking into account the peculiarities of the expected irradiation field, the project also considers a specific study of the treatment room. This study aims at the design of the treatment room emphasizing aspects related to patient, personnel and public radiation protection; dose monitoring; patient positioning and room construction. The design considers both thermal (for the treatment of shallow tumors) and epithermal (for deep-seated tumors) neutron beams entering the room through a port connected to the accelerator via a moderation and neutron beam shaping assembly. Preliminary results of dose calculations for the treatment room design, using the MCNP program, are presented

  20. BNCT irradiation facility at the JRR-4

    Energy Technology Data Exchange (ETDEWEB)

    Torii, Y.; Kishi, T.; Kumada, H.; Yamamoto, K.; Sakurai, F.; Takayanagi, M. [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment

    2000-10-01

    The JRR--4 was modified for fuel enrichment reducing and reactor equipment renewal. And also a medical irradiation facility for the Boron Neutron Capture Therapy (BNCT) was installed at the JRR--4 in that time. The medical irradiation facility has been composed of a heavy water tank, a collimator and an irradiation room. The heavy water tank has four layers of heavy water for spectrum shifter and 75cm-thickness aluminum for the shield of fast neutron. The collimator is for collimating thermal neutron and epithermal neutron using polyethylene with lithium-fluoride and shielding gamma ray by bismuth. The irradiation room has sufficient space at exit side of the beam, to accommodate a large working area for setting the patient. Both of the medical treatment room and the patient-monitoring area were prepared adjacent to the irradiation room. The medical irradiation facility in the JRR-4 is designed to permit selection of neutron energies from thermal neutron to epithermal neutron by changing the thickness of heavy water layers. Therefore it is available to continue the same kind of BNCT with thermal neutron used to perform in the JRR-2, as well as to commence the research and development of BNCT with epithermal neutron, which will make the brain tumor treatment possible at a deep part of brain. The full power operation of the JRR-4 was resumed with LEU fuel in October 1998 and currently performing some experiments to measure the neutron fluxes and physical doses for determinate characterization of the medical irradiation facility. The first medical irradiation for BNCT was carried out on 25th October 1999. The patient was treated by Tsukuba University group using thermal neutron beam included epi-thermal neutrons. (author)

  1. Accelerator technology and SPECT developments for BNCT

    International Nuclear Information System (INIS)

    Accelerator-Based BNCT (AB-BNCT) is establishing itself worldwide as the future modality to start the phase of in-hospital facilities. There are projects in Russia, UK, Italy, Japan, Israel, and Argentina to develop AB-BNCT around different types of accelerators. They will be briefly mentioned. In particular, the present status and recent progress of the Argentine project will be presented. The topics will cover: high power ion sources, power and voltage generation systems for a Tandem- Electrostatic Quadrupole (TES Q) accelerator, acceleration tubes, transport of intense beams, beam diagnostics, control systems, high power targets, the 9Be(d,n) reaction as a possible neutron source, Beam Shaping Assemblies (BSA.s), treatment room design, treatment planning assessment of clinical cases, etc. A complete test stand has been built and commissioned for intense proton beam production and characterization. Beams of 10 to 30 m A have been produced and transported during variable periods of operation by means of a pre accelerator and an electrostatic quadrupole doublet to a suppressed Faraday cup. The beam diagnostics has been performed through the observation with digital cameras of induced fluorescence in the residual gas. A 200 kV TES Q accelerator prototype has been constructed and tested and a 600 keV prototype is under construction. Self consistent space charge beam transport simulations have been performed and compared with experimental results. In addition to the traditional 7Li(p,n)7Be reaction, 9Be(d,n)10B using a thin Be target has been thoroughly studied as a candidate for a possible neutron source for deep seated tumors, showing a satisfactory performance. BSA.s and production targets and a treatment room complying with regulations have also been designed. Realistic clinical treatment planning cases for AB-BNCT have been studied showing very good results. Finally we will present advances in the development of a Single Photon Emission Computed Tomography (SPECT

  2. Antiproliferative effect and apoptosis induction in melanoma treatment by boron neutron capture therapy (BCNT)

    International Nuclear Information System (INIS)

    Full text: Introduction: Boron neutron capture therapy (BNCT) is an experimental radiotherapy where a compound having 10B is administered to cancer patients and is accumulated in tumor tissues. Thus, the tumor is irradiated with thermal neutrons, 10B absorbs and destroys them, producing alpha radiation. Boronophenylalanine (BPA) is the agent responsible for delivering boron to the tumor tissue. After BPA administration, BNCT is used as a localized radiotherapy for many tumors treatment, mainly melanoma, which has a high mortality rate among all types of tumors. The aim of this study was to evaluate in vitro antiproliferative and antitumor effects of BNCT application in human melanoma treatment. Materials and Methods: MEWO cells (human melanoma) were cultured and treated with different concentrations of BPA (8.36 to 0.52 mg/ml). After 90 minutes, they were irradiated with thermal neutron flux up to a dose of 8.4 Gy. The parameters analyzed were free radical production, cell cycle progression, cell death signaling pathways, cycling D1, caspase-3 and extracellular matrix synthesis produced, beyond the mitochondrial electric potential analysis. Results: After BNCT treatment, MEWO cells showed an amount of free radical increase about 10 times. Still, there was a significant decrease of cyclin D1, G0/G1 proliferation, synthesis and G2/M cell cycle phases. BNCT induced a mitochondrial electrical potential decrease, as well as fibrillar proteins of extracellular matrix. BNCT had a significant number of dead cell increase, mainly by necrosis. However, BNCT induced phosphorylated caspase 3 increase. Discussion/Conclusion: BNCT induced cell death increase by necrosis, mitochondrial electric potential decrease and free radical production increase. BNCT is cytotoxic to melanoma cells. Besides necrosis, phosphorylated caspase 3 increase was observed, accompanied by a proliferative response decrease regulated by the G1/S checkpoint and matrix extracellular synthesis reduction

  3. Antiproliferative effect and apoptosis induction in melanoma treatment by boron neutron capture therapy (BCNT)

    Energy Technology Data Exchange (ETDEWEB)

    Faiao-Flores, Fernanda; Coelho, Paulo; Arruda-Neto, Joao; Maria, Durvanei [University of Sao Paulo (USP), SP (Brazil)

    2011-07-01

    Full text: Introduction: Boron neutron capture therapy (BNCT) is an experimental radiotherapy where a compound having {sup 10}B is administered to cancer patients and is accumulated in tumor tissues. Thus, the tumor is irradiated with thermal neutrons, {sup 10}B absorbs and destroys them, producing alpha radiation. Boronophenylalanine (BPA) is the agent responsible for delivering boron to the tumor tissue. After BPA administration, BNCT is used as a localized radiotherapy for many tumors treatment, mainly melanoma, which has a high mortality rate among all types of tumors. The aim of this study was to evaluate in vitro antiproliferative and antitumor effects of BNCT application in human melanoma treatment. Materials and Methods: MEWO cells (human melanoma) were cultured and treated with different concentrations of BPA (8.36 to 0.52 mg/ml). After 90 minutes, they were irradiated with thermal neutron flux up to a dose of 8.4 Gy. The parameters analyzed were free radical production, cell cycle progression, cell death signaling pathways, cycling D1, caspase-3 and extracellular matrix synthesis produced, beyond the mitochondrial electric potential analysis. Results: After BNCT treatment, MEWO cells showed an amount of free radical increase about 10 times. Still, there was a significant decrease of cyclin D1, G0/G1 proliferation, synthesis and G2/M cell cycle phases. BNCT induced a mitochondrial electrical potential decrease, as well as fibrillar proteins of extracellular matrix. BNCT had a significant number of dead cell increase, mainly by necrosis. However, BNCT induced phosphorylated caspase 3 increase. Discussion/Conclusion: BNCT induced cell death increase by necrosis, mitochondrial electric potential decrease and free radical production increase. BNCT is cytotoxic to melanoma cells. Besides necrosis, phosphorylated caspase 3 increase was observed, accompanied by a proliferative response decrease regulated by the G1/S checkpoint and matrix extracellular synthesis

  4. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy

    International Nuclear Information System (INIS)

    We treated a 54-year-old Japanese female with a recurrent radiation-induced osteosarcoma arising from left occipital skull, by reactor-based boron neutron capture therapy (BNCT). Her tumor grew rapidly with subcutaneous and epidural extension. She eventually could not walk because of cerebellar ataxia. The tumor was inoperable and radioresistant. BNCT showed a marked initial therapeutic effect: the subcutaneous/epidural tumor reduced without radiation damage of the scalp except hair loss and the patient could walk again only 3 weeks after BNCT. BNCT seems to be a safe and very effective modality in the management of radiation-induced osteosarcomas that are not eligible for operation and other treatment modalities

  5. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: An experimental study that supports a potential new application of BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Monti Hughes, A.; Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Pozzi, E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Research and Production Reactors, Ezeiza Atomic Center, CNEA, Buenos Aires (Argentina); Nigg, D.W. [Idaho National Laboratory, Idaho Falls, Idaho (United States); Calzetta, O.; Blaumann, H.; Longhino, J. [Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, Rio Negro (Argentina); Nievas, S.I. [Department of Chemistry, CNEA, Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Trivillin, V.A. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina)], E-mail: schwint@cnea.gov.ar

    2009-07-15

    We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na{sub 2}{sup 10}B{sub 10}H{sub 10}) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.

  6. Building of scientific information system for sustainable development of BNCT in Bulgaria

    International Nuclear Information System (INIS)

    Building a boron neutron capture therapy (BNCT) facility is foreseen within the reconstruction of the Research Reactor IRT (IRT) of the Institute for Nuclear Research and Nuclear Energy of the Bulgaria Academy of Sciences (INRNE). The development of BNCT at IRT plays a very significant role in the plan for sustainable application of the reactor. A centralized scientific information system on BNCT is being built at the INRNE with the purpose to collect and sort new information as knowledge accumulated during more than thirty years history of BNCT. This BNCT information system will help the creation and consolidation of a well informed and interconnected interdisciplinary team of physicists, chemists, biologists, and radio-oncologists for establishing BNCT cancer treatment in Bulgaria. It will strengthen more intensive development of the national network as well as its enlargement to the Balkan region countries. Furthermore, to acquaint the public at large with the opportunity for BNCT cancer treatment will be addressed. Human, social, and economics results due to BNCT for many patients from Balkan region are expected.

  7. Building of scientific information system for sustainable development of BNCT in Bulgaria

    Energy Technology Data Exchange (ETDEWEB)

    Mitev, M. [Institute for Nuclear Research and Nuclear Energy of the Bulgarian Academy of Sciences, Boul. Tsarigradsko shossee 72, Sofia (Bulgaria)], E-mail: mlmitev@inrne.bas.bg; Ilieva, K.; Apostolov, T. [Institute for Nuclear Research and Nuclear Energy of the Bulgarian Academy of Sciences, Boul. Tsarigradsko shossee 72, Sofia (Bulgaria)

    2009-07-15

    Building a boron neutron capture therapy (BNCT) facility is foreseen within the reconstruction of the Research Reactor IRT (IRT) of the Institute for Nuclear Research and Nuclear Energy of the Bulgaria Academy of Sciences (INRNE). The development of BNCT at IRT plays a very significant role in the plan for sustainable application of the reactor. A centralized scientific information system on BNCT is being built at the INRNE with the purpose to collect and sort new information as knowledge accumulated during more than thirty years history of BNCT. This BNCT information system will help the creation and consolidation of a well informed and interconnected interdisciplinary team of physicists, chemists, biologists, and radio-oncologists for establishing BNCT cancer treatment in Bulgaria. It will strengthen more intensive development of the national network as well as its enlargement to the Balkan region countries. Furthermore, to acquaint the public at large with the opportunity for BNCT cancer treatment will be addressed. Human, social, and economics results due to BNCT for many patients from Balkan region are expected.

  8. Determination of the irradiation field at the research reactor TRIGA Mainz for BNCT.

    Science.gov (United States)

    Nagels, S; Hampel, G; Kratz, J V; Aguilar, A L; Minouchehr, S; Otto, G; Schmidberger, H; Schütz, C; Vogtländer, L; Wortmann, B

    2009-07-01

    For the application of the BNCT for the excorporal treatment of organs at the TRIGA Mainz, the basic characteristics of the radiation field in the thermal column as beam geometry, neutron and gamma ray energies, angular distributions, neutron flux, as well as absorbed gamma and neutron doses must be determined in a reproducible way. To determine the mixed irradiation field thermoluminescence detectors (TLD) made of CaF(2):Tm with a newly developed energy-compensation filter system and LiF:Mg,Ti materials with different (6)Li concentrations and different thicknesses as well as thin gold foils were used. PMID:19380234

  9. Dose calculations with SERA for the application of the BNCT at the TRIGA Mainz

    International Nuclear Information System (INIS)

    The BNCT shall be applied for an explantated organ with metastases at the TRIGA reactor Mainz, Germany. After the treatment of the patient with 10B pharmaceutical the liver will be explanted, irradiated in the thermal column and then implantated again (autotransplantation). This was first successfully done in 12/2001 for a 48 years old male patient at the TRIGA reactor in Pavia. For a treatment with BNCT it is necessary to determine the total dose and partial radiation doses like the boron and gamma dose. Since several parts of the dose can not be measured, calculations are necessary. For this procedure the program Simulation Environment for Radiotherapy Applications (SERA) developed by INEEL, Idaho, U.S., can be applied, which allows an individual dosimetry for the patient. The SERA program consists of a manual and semi-automated geometric modeling of the treatment objects like the liver derived from MRI, CT or other medical imaging modalities. The dose for these geometric models is calculated with the INEEL radiation transport computer code and the dose contouring is also derived. The SERA program was adapted at MHH to calculate the radiation dose in the case of liver autotransplantation. Also, the technical characteristics and the physical environment of the thermal column were programmed for SERA. For the first reactor model the core of the MHH TRIGA reactor and the thermal column of the Mainz TRIGA reactor were used. The thermal column was modulated with layers of bismuth and lead to minimize the gamma dose. (author)

  10. Summary of recent BNCT Polish programme and future plans.

    Science.gov (United States)

    Gryziński, M A; Maciak, M; Wielgosz, M

    2015-12-01

    In this work we present Polish achievements on the ground of BNCT research. Starting from preliminary built therapeutic stand at MARIA reactor going through designing of unique detectors for in-phantom and in-beam measurements for mixed radiation fields and finally coming to boron carriers synthesizing and examination in cellular and animal models. Now it is planned to restart research on boron compounds in specially designed BIMA line, to set up epithermal neutron irradiation facility for BNCT research and education and to improve recombination detectors for neutron beams characterisation. PMID:26293009

  11. Extra-corporeal liver BNCT for the treatment of diffuse metastases: What was learned and what is still to be learned

    Energy Technology Data Exchange (ETDEWEB)

    Zonta, A. [Department of Surgery, University of Pavia, Pavia (Italy)], E-mail: aris.zonta@pv.infn.it; Pinelli, T. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Prati, U.; Roveda, L. [Oncologic Surgery, Cancer Center of Excellence Fond. ' T. Campanella' , Catanzaro (Italy); Ferrari, C.; Clerici, A.M.; Zonta, C. [Department of Surgery, University of Pavia, Pavia (Italy); Mazzini, G. [Department of Animal Biol., IGM-CNR Histochemistry and Cytometry Section, Pavia (Italy); Dionigi, P. [Department of Surgery, University of Pavia, Pavia (Italy); Altieri, S.; Bortolussi, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); Fossati, F. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy)

    2009-07-15

    Almost eight years ago, in December 2001, we performed for the first time in the world thermal neutron irradiation on an isolated liver of a patient. The organ was affected by diffuse metastases of a colon carcinoma and had been previously loaded with a {sup 10}B compound. In July 2003, the same procedure was applied again on a patient for the treatment of unresectable and incurable hepatic metastases of a carcinoma of the rectum. Both patients are dead at present. Now we can analyze in depth the clinical history of these patients and evaluate the effectiveness of this therapy. From this exciting experience we learned much, and we also found out about complications till then unknown, which need to be studied and addressed experimentally. Unfortunately we can base our conclusions just on the experience we had with these two patients. We could have been much more detailed and firm in our statements if the number of clinical cases was larger. The BNCT Pavia project has been suspended, but it is more than likely to resume in a short time. Good findings were many. The procedure is feasible; the original concept of complete immersion of the diseased liver in a homogeneous neutron field proved effective and winning. The tumor masses resulted completely necrotic and unknown metastases too appeared radically treated; healthy hepatic tissue was preserved from both morphological and functional points of view; no symptoms of cirrhosis appeared even four years after treatment. For the long term surviving patient, quality of life was excellent. Other findings require to be tackled in depth. The 'post-irradiation syndrome' we observed in both patients, with identical symptoms and biochemical derangements, creates a dramatic-even though totally reversible-clinical condition, that is the probable cause of death for our second patient, suffering from cardiomyopathy, 33 days after treatment. For the first patient, recurrences were a late yet fatal complication, for which

  12. INEL BNCT Research Program annual report, 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-05-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database.

  13. INEL BNCT Research Program annual report, 1992

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1992. Contributions from all the principal investigators about their individual projects are included, specifically, chemistry (pituitary tumor targeting compounds, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (small and large animal models tissue studies and efficacy studies). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented, results of 21 spontaneous-tumor-bearing dogs that have been treated with BNCT at the Brookhaven National Laboratory (BNL) Medical Research Reactor (BMRR) are discussed, and predictions for an epithermal-neutron beam at the Georgia Tech Research Reactor (GTRR) are shown. Cellular-level boron detection and localization by secondary ion mass spectrometry, sputter-initiated resonance ionization spectroscopy, low atomization resonance ionization spectroscopy, and alpha track are presented. Boron detection by ICP-AES is discussed in detail. Several boron carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors with BNCT is presented. Measurement of the epithermal-neutron flux at BNL and comparison to predictions are shown. Calculations comparing the GTRR and BMRR epithermal-neutron beams are also presented. Individual progress reports described herein are separately abstracted and indexed for the database

  14. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J. [Brookhaven National Lab., Upton, NY (United States); Diaz, A.Z.; Chadha, M. [Univ. Hospital, State Univ. of New York, NY (United States)] [and others

    1997-12-31

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains.

  15. An in-phantom comparison of neutron fields for BNCT

    International Nuclear Information System (INIS)

    Previously, the authors have developed the in-phantom neutron field assessment parameters T and D (Tumor) for the evaluation of epithermal neutron fields for use in BNCT. These parameters are based on an energy-spectrum-dependent neutron normal-tissue RBE and the treatment planning methodology of Gahbauer and his co-workers, which includes the effects of dose fractionation. In this paper, these neutron field assessment parameters were applied to The Ohio State University (OSU) design of an Accelerator Based Neutron Source (ABNS) (hereafter called the OSU-ABNS) and the Brookhaven Medical Research Reactor (BMRR) epithermal neutron beam (hereafter called the BMRR-ENB), in order to judge the suitability of the OSU-ABNS for BNCT. The BMRR-ENB was chosen as the basis for comparison because it is presently being used in human clinical trials of BNCT and because it is the standard to which other neutron beams are most often compared

  16. Computerized radiation treatment planning

    International Nuclear Information System (INIS)

    Following a general introduction, a chain consisting of three computer programs which has been developed for treatment planning of external beam radiotherapy without manual intervention is described. New score functions used for determination of optimal incidence directions are presented and the calculation of the position of the isocentre for each optimum combination of incidence directions is explained. A description of how a set of applicators, covering fields with dimensions of 4 to 20 cm, for the 6 to 20 MeV electron beams of a MEL SL75-20 linear accelerator was developed, is given. A computer program for three dimensional electron beam treatment planning is presented. A microprocessor based treatment planning system for the Selectron remote controlled afterloading system for intracavitary radiotherapy is described. The main differences in treatment planning procedures for external beam therapy with neutrons instead of photons is discussed. A microprocessor based densitometer for plotting isodensity lines in film dosimetry is described. A computer program for dose planning of brachytherapy is presented. Finally a general discussion about the different aspects of computerized treatment planning as presented in this thesis is given. (Auth.)

  17. Radiation treatment planning system verification

    International Nuclear Information System (INIS)

    Optimum radiotherapy requires accurate and consistent radiation doses. To fulfil this requirement, it is necessary to make quality checks of the equipment and software included in the planning process. Treatment planning system is used to calculate monitor units required to deliver prescribed dose to a designated volume with acceptable distribution of radiation dose. The aim of this study was to verify the Theraplan Plus treatment program used in our Department to calculate treatment times for radiation therapy with 60Co unit. To run a Theraplan Plus system, it is necessary to input data describing mechanical and radiation aspects of treatment unit. One of the checks included a comparison of the measured depth doses and off-axis ratios with those calculated using the treatment program. The second step included the measurement of the dose using ionisation chamber and thermoluminescent dosimeters (TLD), which was then compared with calculated values for several treatment scenarios (central axis dose on specified depth of square fields, elongated fields, under the block and wedges etc.). The third step involved the comparison between the dose calculated for a specific treatment plan with the doses measured with TLD dosimeters in the Alderson phantom.(author)

  18. Current treatments for radiation retinopathy

    Energy Technology Data Exchange (ETDEWEB)

    Giuliari, Gian Paolo; Simpson, E. Rand (Princess Margaret Hospital, Univ. of Toronto, Dept. of Ophthalmology and Vision Sciences, Toronto (Canada)), e-mail: gpgiuliari@gmail.com; Sadaka, Ama (Schepens Eye Research Inst., Boston, MA (United States)); Hinkle, David M. (Massachusetts Eye Research and Surgery Institution, Cambridge, MA (United States))

    2011-01-15

    Background. To review the currently available therapeutic modalities for radiation retinopathy (RR), including newer investigational interventions directed towards specific aspects of the pathophysiology of this refractory complication. Methods. A review of the literature encompassing the pathogenesis of RR and the current therapeutic modalities available was performed. Results. RR is a chronic and progressive condition that results from exposure to any source of radiation. It might be secondary to radiation treatment of intraocular tumors such as choroidal melanomas, retinoblastomas, and choroidal metastasis, or from unavoidable exposure to excessive radiation from the treatment of extraocular tumors like cephalic, nasopharyngeal, orbital, and paranasal malignancies. After the results of the Collaborative Ocular Melanoma Study, most of the choroidal melanomas are being treated with plaque brachytherapy increasing by that the incidence of this radiation complication. RR has been reported to occur in as many as 60% of eyes treated with plaque radiation, with higher rates associated with larger tumors. Initially, the condition manifests as a radiation vasculopathy clinically seen as microaneurysms and telangiectasis, with posterior development of retinal hard exudates and hemorrhages, macular edema, neovascularization and tractional retinal detachment. Regrettably, the management of these eyes remains limited. Photodynamic therapy, laser photocoagulation, oral pentoxyphylline and hyperbaric oxygen have been attempted as treatment modalities with inconclusive results. Intravitreal injections of anti-vascular endothelial growth factor such as bevacizumab, ranibizumab and pegaptanib sodium have been recently used, also with variable results. Discussion. RR is a common vision threatening complication following radiation therapy. The available therapeutic options are limited and show unsatisfactory results. Further large investigative studies are required for developing

  19. Current treatments for radiation retinopathy

    International Nuclear Information System (INIS)

    Background. To review the currently available therapeutic modalities for radiation retinopathy (RR), including newer investigational interventions directed towards specific aspects of the pathophysiology of this refractory complication. Methods. A review of the literature encompassing the pathogenesis of RR and the current therapeutic modalities available was performed. Results. RR is a chronic and progressive condition that results from exposure to any source of radiation. It might be secondary to radiation treatment of intraocular tumors such as choroidal melanomas, retinoblastomas, and choroidal metastasis, or from unavoidable exposure to excessive radiation from the treatment of extraocular tumors like cephalic, nasopharyngeal, orbital, and paranasal malignancies. After the results of the Collaborative Ocular Melanoma Study, most of the choroidal melanomas are being treated with plaque brachytherapy increasing by that the incidence of this radiation complication. RR has been reported to occur in as many as 60% of eyes treated with plaque radiation, with higher rates associated with larger tumors. Initially, the condition manifests as a radiation vasculopathy clinically seen as microaneurysms and telangiectasis, with posterior development of retinal hard exudates and hemorrhages, macular edema, neovascularization and tractional retinal detachment. Regrettably, the management of these eyes remains limited. Photodynamic therapy, laser photocoagulation, oral pentoxyphylline and hyperbaric oxygen have been attempted as treatment modalities with inconclusive results. Intravitreal injections of anti-vascular endothelial growth factor such as bevacizumab, ranibizumab and pegaptanib sodium have been recently used, also with variable results. Discussion. RR is a common vision threatening complication following radiation therapy. The available therapeutic options are limited and show unsatisfactory results. Further large investigative studies are required for developing

  20. Radiation treatment of molasses

    International Nuclear Information System (INIS)

    Molasses are a by-product of the sugar industry. Their annual production in Mexico is around 1 million tons and they are mainly used as a complement for animal feeding and for the production of alcohols. Their value is relatively low compared with other chemicals. When molasses are irradiated with gamma radiation or accelerated electrons in the presence of nitric acid and oxygen, oxalic acid and several polymeric compounds are obtained. The same products are obtained in both cases, but the yield is greater with electrons. The effect of dose and dose rate on the yields has been studied. As example, when mixtures of molasses-nitric acid, with an initial concentration of 26% of total sugar reductors, are irradiated with 1.0 MeV electrons, in a continuous flow reactor, at 0.11 Gy/sec to a total dose of 30 KGy, the oxalic acid yield is around 44% of the total chemical reductors used. The separations of the radiolytic products were made by successive decantations and concentrations, and purified by recrystallizations. From the analytical information, the minimal formulae were calculated for the acid product and the polymeric compounds. (author)

  1. Surgical treatment of radiation enteritis

    International Nuclear Information System (INIS)

    Radiation enteritis is a progressive, disease process that causes intestinal fibrosis and obliterative endarteritis, which results in significant morbidity and mortality. The authors' clinical experience involving 20 patients over a 22-year period from 1967 through 1989 who underwent various surgical procedures to alleviate chronic symptoms secondary to radiation enteritis is described. Eight men and 12 women with a mean age of 52 years (24 to 81 years) underwent a total of 27 procedures for complications of radiation enteritis. Radiation therapy was delivered for treatment of gynecologic malignancies (55%), colorectal cancer (20%), prostate malignancies (10%), and others (15%). The mean average dose of radiation delivered was 5,514 rads with a range of 2,613 to 7,000 rads. The interval from radiation treatment to time of surgery averaged 9 years. Operative procedures consisted of 12 resection and primary anastomosis procedures and 15 resections with stoma creation. Formation of a stoma was used in patients with more severe disease. The 30-day operative mortality was 0% and morbidity was 55%. There were no anastomotic leaks or intra-abdominal abscesses. The authors conclude that resection and primary anastomosis can safely be performed in selected patients but that judicious use of stoma formation can avoid major mortality and morbidity associated with surgery in this setting

  2. Successful BNCT for patients with cutaneous and mucosal melanomas. Report of 4 cases

    International Nuclear Information System (INIS)

    Since 2003 we have conducted BNCT clinical trials on melanomas at the Kyoto University Research Reactor (KUR) and Japan Research Reactor No.4 (JRR-4). We report 4 patients given BNCT for malignant melanomas: 2 with superficial spreading types on the heel, 1 with mucosal melanoma in the nasal cavity, and 1 with a melanoma on the vulva and in the vagina. The two cutaneous melanomas and the nasal cavity mucosal melanoma showed a complete response (CR) by 6 months after BNCT. The residual melanoma showed a partial response (PR) by 3 months after treatment and no regrowth since then. Although two patients experienced normal-tissue damage that exceeded the tolerance level, all the participants were cured within a few months of treatment. BNCT was shown to be a promising treatment for mucosal, as well as for cutaneous, melanomas. (author)

  3. FiR 1 Reactor in Service for Boron Neutron Capture Therapy (BNCT) and Isotope Production

    International Nuclear Information System (INIS)

    The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose to run the reactor is now the Boron Neutron Capture Therapy (BNCT). Although BNCT dominates the current utilization of the reactor, it also has an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics, etc. with isotope produc- tion and activation analysis services. The whole reactor building has been renovated, creating a dedicated clinical BNCT facility at the reactor. Close to 30 patients have been treated since May 1999, when the licence for patient treatment was granted to the responsible BNCT treatment organization. The treatment organization has a close connection to the Helsinki University Central Hospital. (author)

  4. Carborane-containing metalloporphyrins for BNCT

    International Nuclear Information System (INIS)

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of 10B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 μg B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses

  5. Carborane-containing metalloporphyrins for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Joel, D.D.; Nawrocky, M.M.; Micca, P.L. [and others

    1996-12-31

    For BNCT of malignant brain tumors, it is crucial that there be relatively high boron concentrations in tumor compared with normal tissues within the neutron-irradiated treatment volume. Fairchild and Bond estimated that major advances in BNCT should be possible if ratios of {sup 10}B concentrations in tumor to those in normal tissue (e.g. brain and blood) were at least 5: 1. Given that the only current boron carrier being tested clinically in the U.S., p-boronophenyl-alanine[BPA], yields tumor blood and tumor brain ratios of about 3:1, the criteria for new boronated compounds should be to at least match these ratios and maintain tumor boron concentrations greater than 30 {mu}g B/g. Although previously tested boronated porphyrins have not only matched but surpassed these ratios, it was at a cost of greater toxicity. Chemical and hematological assays of blood analytes; showed marked thrombocytopenia, a decrease to about one-tenth the normal concentration of platelets circulating in the blood, in addition to abnormalities in concentrations of circulating enzymes, that indicated liver toxicity. The physical appearance and behavior of the affected mice were different from those of mice injected with solvent only. Although thrombocytopenia and other toxic effects had disappeared after a few days, previously tested porphyrins would not be safe to infuse into patients for BNCT of potentially hemorrhagic malignant tumors in the brain such as glioblastoma multiforme and metastatic melanoma. We synthesized a different boronated porphyrin, tetracarboranylphenylporphyrin, [TCP] and inserted nickel, copper, or manganese into its coordination center. Biological studies of NiTCP in mice and of CuTCP in rats show that these compounds elicit little or no toxicity when given at potentially therapeutic doses.

  6. Radiation treatment of wastewater, (11)

    International Nuclear Information System (INIS)

    High-energy electron treatment of wastewaters from dyeing factories (in Kiryu city, Gunma Prefecture) was investigated in a series on wastewater treatment by radiation. Experiments were made on decoloration f printing and dip dyeing wastewaters using a dual-tube bubbling column reactor. Changes in absorption spectra and pH of irradiated solutions and influence of dissolved oxygen on decoloration were examined. Water soluble dyes were decolored at low doses, but disperse dyes were not easily decolored. Although the wastewaters included number of different additives such as sizing stuff, surfactant and other chemicals, the decoloration was not influenced by these substances under the experimental conditions. The irradiation cost by electron beams was estimated as a function of plant capacity. A hybrid system of biological and radiation processes to reduce BOD and color in the wastewaters is presented, with this treatment cost also estimated. (author)

  7. Gemstone enhancement by radiation treatment

    International Nuclear Information System (INIS)

    Since the discovery of radioactivity, investigations on the effects of atomic rays on precious stones began and Crookes established that alpha rays from radium produced green colour in diamonds. Gamma rays, x-rays, electrons, neutrons, protons etc. are effective in producing colour in precious stone like topaz and corundum. Some of these also produce considerable amount of radioactivity which is not acceptable if the radioactivity exceeds permissible limits. Colour enhancement by radiation treatment, different radiations, safety of irradiated gem stones and market related aspects are discussed. (author)

  8. Histological and biochemical analysis of DNA damage after BNCT in rat model

    International Nuclear Information System (INIS)

    To understand the mechanism of tumor cell death induced by boron neutron capture therapy (BNCT) and to optimize BNCT condition, we used rat tumor graft models and histological and biochemical analyses were carried out focusing on DNA damage response. Rat lymphosarcoma cells were grafted subcutaneously into male Wister rats. The rats with developed tumors were then treated with neutron beam irradiation 45 min after injection of 330 mg/kg bodyweight boronophenylalanine (10BPA) (+BPA) or saline control (–BPA). BNCT was carried out in the National Nuclear Center of the Republic of Kazakhstan (neutron flux: 1×109 nvt/s, fluence: 6×1011 nvt) with the presence of background γ-irradiation of 33 Gy. 6 and 20 h after BNCT treatment, tumors were resected, fixed and subjected to immunohistochemistry and biochemical analyses. Immunostaining of nuclei showed that double strand break (DSB) marker gamma H2AX staining was high in 20 h/+BPA sample but not in 20 h/–BPA samples. Poly(ADP-ribose), DSB and single strand break markers of DNA, also demonstrated this tendency. These two markers were observed at low levels in unirradiated tissues or 6 h after BNCT either under −BPA and +BPA conditions. HMGB1 level increased in 6 h/+BPA but not in 6 h/−BPA or 20 h/+BPA samples. The persistent staining of γH2AX and poly(ADP-ribose) in +BPA group suggests accumulated DSB damage after BNCT. The early HMGB1 upregulation and γH2AX and poly(ADP-ribose) observed later might be the markers for monitoring the DNA damage induced by BNCT. - Highlights: • We used rat tumor graft models and DNA damage response in BNCT was analyzed. • HMGB1 upregulation was suggested to be an early marker for BNCT. • The persistent presence of γH2AX and PAR in the nuclei might serve as late markers

  9. Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model

    International Nuclear Information System (INIS)

    Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare malignant tumor with no effective treatment. This study demonstrates the efficacy of BNCT with the use of human CCS-bearing nude mice. Groups A and C were administered saline, and groups B and D were injected with p-borono-L-phenylalanine-fructose complex. Groups C and D were then irradiated with thermal neutrons. The tumors in only group D disappeared, demonstrating that BNCT is a potentially new option for the treatment of human CCS. - Highlights: ► Human clear cell sarcoma (CCS)-bearing nude mice were used in this study. ► The human CCS in the nude mice disappeared after BNCT. ► The efficacy of BNCT for human CCS is demonstrated here for the first time

  10. Calculational evaluations of the proposal for a reference dosimetric phantom for BNCT

    International Nuclear Information System (INIS)

    Standard dosimetric phantoms are used in radiotherapy to compare irradiations under standard conditions. They provide volumes of tissue substitute for the measurement of absorbed dose and are large enough to ensure that full contribution to the absorbed dose from scattered radiation is received at the point of measurement. Aim of this study was to find out a recommendation for the boundary values of size of a reference phantom. These reference conditions for the reference measurement methods are created for 'A code of practise for dosimetry, of BNCT in Europe' project. The major objective of the project is to prepare detailed guidelines for the dosimetry of epithermal neutron beams to be used for treatment of cancer patients by Boron Neutron Capture Therapy (BNCT) at European research reactors and accelerators. For this objective Monte Carlo simulations have been carried out with MCNP 4B code in three different cubic phantoms for studying effect of different phantom sizes in important radiation components. These three phantoms are the proposed reference (measurement) phantom (20*20*20 cm), a phantom that was assumed to model an infinite phantom, and a smaller (15*15*15 cm) cubic phantom which exists in Petten BNCT facility in Netherlands. Function of the smallest phantom was to study acceptable lower limit to the phantom size to still reach the reference conditions. All the simulated phantoms were cubic water phantoms with one 0.5 cm thick (beam side) wall and three 1 cm thick walls of PMMA (polymethyl-methacrylate). The comparisons were done with calculations of the thermal, epithermal and fast neutron fluence rates in analogous points. The source specification of the MCNP runs were accordance of 250 kW FiR 1 research reactor neutron beam with 14 cm beam aperture. In order to minimise the statistical error of the Monte Carlo calculations, over 60*106 source particles were simulated for infinite and reference phantom cases. Calculation results were in good

  11. Application of HVJ envelope system to boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) has been used clinically for the treatment of malignant tumors. Two drugs, p-boronophenylalanine (BPA) and sulfhydral borane (BSH), have been used as boron delivery agents. These drugs seem to be taken up preferentially in solid tumors, but it is uncertain whether therapeutic quantities of boron atoms are taken up by micro-invasive or distant tumor cells. High accumulation and high selective delivery of boron into tumor tissues are the most important requirements to achieve efficient BNCT for malignant tumor. The HVJ envelope (HVJ-E) vector system is a novel fusion-mediated gene delivery system based on inactivated hemagglutinating virus of Japan (HVJ; Sendai virus). Although we developed this vector system for gene transfer, it can also deliver proteins, synthetic oligonucleotides, and drugs. HVJ-liposome, which is liposome fused with HVJ-E, has higher boron trapping efficiency than HVJ-E alone. We report the boron delivery into cultured cells with HVJ-liposome systems. The cellular 10B concentration after 60 min incubation with HVJ-E containing BSH was 24.9 μg/g cell pellet for BHK-21 cells (baby hamster kidney cells) and 19.4 μg/g cell pellet for SCC VII cells (murine squamous cell carcinoma). These concentrations are higher than that of 60 min incubated cells with BSH containing (100μg 10B/ml) medium. These results indicate the HVJ-E fused with tumor cell membrane and rapidly delivered boron agents, and that the HVJ-E-mediated delivery system could be applicable to BNCT. Plans are underway to begin neutron radiation experiments in vivo and in vitro. (author)

  12. Feasibility of BNCT radiobiological experiments at the HYTHOR facility

    Science.gov (United States)

    Esposito, J.; Ceballos, C.; Soncin, M.; Fabris, C.; Friso, E.; Moro, D.; Colautti, P.; Jori, G.; Rosi, G.; Nava, E.

    2008-06-01

    HYTHOR (HYbrid Thermal spectrum sHifter tapirO Reactor) is a new thermal-neutron irradiation facility, which was installed and became operative in mid 2005 at the TAPIRO (TAratura PIla Rapida potenza 0) fast reactor, in the Casaccia research centre (near Rome) of ENEA (Ente per le Nuove tecnologie Energia ed Ambiente). The facility has been designed for in vivo radiobiological studies. In HYTHOR irradiation cavity, 1-6 mice can be simultaneously irradiated to study skin melanoma treatments with the BNCT (boron neutron capture therapy). The therapeutic effects of HYTHOR radiation field on mouse melanoma has been studied as a preliminary investigation before studying the tumour local control due to boron neutron capture effect after boronated molecule injection. The method to properly irradiate small animals has been precisely defined. Results show that HYTHOR radiation field is by itself effective in reducing the tumour-growth rate. This finding has to be taken into account in studying the effectiveness of new 10B carriers. A method to properly measure the reduction of the tumour-growth rate is reported and discussed.

  13. INEEL BNCT research program. Annual report, January 1, 1996--December 31, 1996

    International Nuclear Information System (INIS)

    This report is a summary of the progress and research produced for the Idaho National Engineering and Environmental Laboratory (INEEL) Boron Neutron Capture Therapy (BNCT) Research Program for calendar year 1996. Contributions from the individual investigators about their projects are included, specifically, physics: treatment planning software, real-time neutron beam measurement dosimetry, measurement of the Finnish research reactor epithermal neutron spectrum, BNCT accelerator technology; and chemistry: analysis of biological samples and preparation of 10B enriched decaborane

  14. Boron neutron capture therapy (BNCT) for glioblastoma multiforme (GBM), using the epithermal neutron beam at the Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    Objective: BNCT is a binary treatment modality based on the nuclear reactions that occur when boron (10B) is exposed to thermal neutrons. Preclinical studies have demonstrated the therapeutic efficacy of p-boronophenylalanine (BPA)-based BNCT. The objective of the Phase I/II trial was to evaluate BPA-fructose (BPA-F) as a boron delivery agent for GBM and to study the feasibility and safety of a single-fraction of BNCT. Materials and Methods: The trial design required i) a BPA-F biodistribution study performed at the time of craniotomy; and ii) BNCT within 4 weeks of the craniotomy. From September 94 to July 95, 10 patients with biopsy proven GBM were treated. All but 1 patient underwent a biodistribution study receiving IV BPA-F at the time of craniotomy. Multiple tissue samples and concurrent blood and urine samples were collected for evaluation of the boron concentration and clearance kinetics. For BNCT all patients received 250 mg/kgm of BPA-F (IV infusion over 2 hrs) followed by neutron irradiation. The blood 10B concentration during irradiation was used to calculate the time of neutron exposure. The 3D treatment planning was done using the BNCT treatment planning software developed at the Idaho National Engineering Laboratory. The BNCT dose is expressed as the sum of the physical dose components corrected for both the RBE and the 10B localization factor with the unit Gy-Eq. The photon-equivalent dose, where the thermal neutron fluence reaches a maximum, is the peak-dose equivalent. A single-fraction of BNCT was delivered prescribing 10.5 Gy-Eq (9 patients) and 13.8 Gy-Eq (1 patient) as the peak dose-equivalent to the normal brain. The peak dose rate was kept below 27 cGy-Eq/min. Results: Biodistribution data: The maximum blood 10B concentration was observed at the end of the infusion and scaled as a linear function of the administered dose. The 10B concentration in the scalp and in the GBM tissue was higher than in blood by 1.5 x and at least 3.5 x

  15. The BNCT project in the Czech Republic

    International Nuclear Information System (INIS)

    The start of clinical trials is expected before NCT Osaka 2000. The experiences from different part of project are presented. The BNCT facility at LVR-15 reactor of NRI consists of epithermal neutron beam with improved construction (6.98 x 108/cm2s with acceptable background of fast neutrons and gammas) and irradiation and control rooms equipped by appropriate devices. Internationally-recognized software MacNCTPLAN is utilized for computational dosimetry and treatment planning. In the part of protocol the following parameters have been assessed: patient selection, BSH dosage, fractionation, starting dose, dose escalation steps. At the LVR-15, at horizontal channel, a prompt gamma ray analysis (PGRA) system has been developed and is operated for BNCT purposes. Some human blood samples were analyzed and compared with classical ICP method. During the process of licensing the experience was obtained, some notes are discussed in the paper. The first results were received for the study of biological effect of the LVR source for small animal model. (author)

  16. Radiation treatment of sewage effluent

    International Nuclear Information System (INIS)

    The water demand of the past several years increased rapidly. Recycling of municipal wastewater is the effective means of coping with water shortage in Tokyo. We studied the radiation treatment method of further purification of the effluent from sewage treatment plant. By gamma irradiation the refractory organic substances in effluent were decomposed. The COD values decreased and the light brown color faded with increasing dose. The high molecular weight components in effluent were degraded to lower molecular weight substances and were decomposed finally to carbon dioxide. Recent attention has been given to the disadvantages of using chlorine as a disinfectant of municipal wastewater effluents. It has been shown that the chlorination of organic substances in water may produce chlorinated hydrocarbons with carcinogenic properties. So a development of the effective sterilization method for the effluent has been needed instead of chlorine. The radiation sterilization of coliforms and total bacteria in primary effluent, secondary effluent and rapid sand filtered effluent were studied. Coliforms were very sensitive to radiation treatment in comparison with total bacteria. Especially, coliforms in secondary and rapid sand filtered effluents were disinfected to 10 % of initial at 0.1 kGy. (author)

  17. Treatment of radiation burns, 1987 [videorecording

    International Nuclear Information System (INIS)

    After the accident at Chernobyl, patients with various degrees of radiation burns were given treatment at Moscow hospital No. 6. The video shows the radiation injuries as well as therapy and treatment in detail

  18. Effect of different BNCT protocols on DNA synthesis in precancerous and normal tissues in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    We previously reported the therapeutic success of different BNCT protocols in the treatment of oral cancer, employing the hamster cheek pouch model. The aim of the present study was to evaluate the effect of these BNCT protocols on DNA synthesis in precancerous and normal tissue in this model and assess the potential lag in the development of second primary tumors in precancerous tissue. The data are relevant to potential control of field cancerized tissue and tolerance of normal tissue. We evaluated DNA synthesis in precancerous and normal pouch tissue 1-30 days post-BNCT mediated by BPA, GB-10 or BPA + GB-10 employing incorporation of bromo-deoxyuridine as an end-point. The BNCT-induced potential lag in the development of second primary tumors in precancerous tissue was monitored. A drastic, statistically significant reduction in DNA synthesis occurred in pacancerous tissue as early as 1 day post-BNCT and was sustained at virtually all time points until 30 days post-BNCT for all protocols. The histological categories evaluated individually within precancerous tissue (dysplasia, hyperplasia and NUMF [no unusual microscopic features]) responded similarly. DNA synthesis in normal tissue treated with BNCT oscillated around the very low pre-treatment values. A BNCT-induced lag in the development of second primary tumors was observed. BNCT induced a drastic fall in DNA synthesis in precancerous tissue that would be associated to the observed lag in the development of second primary tumors. The minimum variations in DNA synthesis in BNCT-treated normal tissue would correlate with the absence of normal tissue radiotoxicity. The present data would contribute to optimize therapeutic efficacy in the treatment of field-cancerized areas. (author)

  19. Neutron field characterization in the installation for BNCT study in the IEA-R1 reactor; Caracterizacao do campo de neutrons na instalacao para estudo em BNCT no reator IEA-R1

    Energy Technology Data Exchange (ETDEWEB)

    Carneiro Junior, Valdeci

    2008-07-01

    This work aims to characterize the mixed neutron and gamma field, in the sample irradiation position, in a research installation for Boron Neutron Capture Therapy (BNCT), in the IPEN IEA-R1 reactor. The BNCT technique has been studied as a safe and selective option in the treatment of resistant cancerigenous tumors or considered non-curable by the conventional techniques, for example, the Glioblastoma Multiform - a brain cancerigenous tumor. Neutron flux measurements were carried out: thermal, resonance and fast, as well as neutron and gamma rays doses, in the sample position, using activation foils detectors and thermoluminescent dosimeters. For the determination of the neutron spectrum and intensity, a set of different threshold activation foils and gold foils covered and uncovered with cadmium irradiated in the installation was used, analyzed by a high Pure Germanium semiconductor detector, coupled to an electronic system suitable for gamma spectrometry. The results were processed with the SAND-BP code. The doses due to gamma and neutron rays were determined using thermoluminescent dosimeters TLD 400 and TLD 700 sensitive to gamma and TLD 600, sensitive to neutrons. The TLDs were selected and used for obtaining the calibration curves - dosimeter answer versus dose - from each of the TLD three types, which were necessary to calculate the doses due to neutron and gamma, in the sample position. The radiation field, in the sample irradiation position, was characterized flux for thermal neutrons of 1.39.10{sup 8} {+-} 0,12.10{sup 8} n/cm{sup 2}s the doses due to thermal neutrons are three times higher than those due to gamma radiation and confirm the reproducibility and consistency of the experimental findings obtained. Considering these results, the neutron field and gamma radiation showed to be appropriated for research in BNCT. (author)

  20. Development of local radiation therapy

    International Nuclear Information System (INIS)

    The major limitations of radiation therapy for cancer are the low effectiveness of low LET and inevitable normal tissue damage. Boron Neutron Capture Therapy (BNCT) is a form of potent radiation therapy using Boron-10 having a high propensityof capturing theraml neutrons from nuclear reactor and reacting with a prompt nuclear reaction. Photodynamic therapy is a similiar treatment of modality to BNCT using tumor-seeking photosenistizer and LASER beam. If Boron-10 and photosensitizers are introduced selectively into tumor cells, it is theoretically possible to destroy the tumor and to spare the surrounding normal tissue. Therefore, BNCT and PDT will be new potent treatment modalities in the next century. In this project, we performed PDT in the patients with bladder cancers, oropharyngeal cancer, and skin cancers. Also we developed I-BPA, new porphyrin compounds, methods for estimation of radiobiological effect of neutron beam, and superficial animal brain tumor model. Furthermore, we prepared preclinical procedures for clinical application of BNCT, such as the macro- and microscopic dosimetry, obtaining thermal neutron flux from device used for fast neutron production in KCCH have been performed

  1. Development of local radiation therapy

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Seung Hoon; Lim, Sang Moo; Choi, Chang Woon; Chai, Jong Su; Kim, Eun Hee; Kim, Mi Sook; Yoo, Seong Yul; Cho, Chul Koo; Lee, Yong Sik; Lee, Hyun Moo

    1999-04-01

    The major limitations of radiation therapy for cancer are the low effectiveness of low LET and inevitable normal tissue damage. Boron Neutron Capture Therapy (BNCT) is a form of potent radiation therapy using Boron-10 having a high propensityof capturing theraml neutrons from nuclear reactor and reacting with a prompt nuclear reaction. Photodynamic therapy is a similiar treatment of modality to BNCT using tumor-seeking photosenistizer and LASER beam. If Boron-10 and photosensitizers are introduced selectively into tumor cells, it is theoretically possible to destroy the tumor and to spare the surrounding normal tissue. Therefore, BNCT and PDT will be new potent treatment modalities in the next century. In this project, we performed PDT in the patients with bladder cancers, oropharyngeal cancer, and skin cancers. Also we developed I-BPA, new porphyrin compounds, methods for estimation of radiobiological effect of neutron beam, and superficial animal brain tumor model. Furthermore, we prepared preclinical procedures for clinical application of BNCT, such as the macro- and microscopic dosimetry, obtaining thermal neutron flux from device used for fast neutron production in KCCH have been performed.

  2. Cell death following BNCT: A theoretical approach based on Monte Carlo simulations

    International Nuclear Information System (INIS)

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called 'lethal aberrations' (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the 10B(n,α) 7Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the 14N(n,p)14C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death.

  3. Cell death following BNCT: A theoretical approach based on Monte Carlo simulations

    Energy Technology Data Exchange (ETDEWEB)

    Ballarini, F., E-mail: francesca.ballarini@pv.infn.it [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bakeine, J. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Bortolussi, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Bruschi, P. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy); Cansolino, L.; Clerici, A.M.; Ferrari, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Protti, N.; Stella, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy); Zonta, A.; Zonta, C. [University of Pavia, Department of Surgery, Experimental Surgery Laboratory, Pavia (Italy); Altieri, S. [University of Pavia, Department of Nuclear and Theoretical Physics, via Bassi 6, Pavia (Italy)] [INFN (National Institute of Nuclear Physics)-Sezione di Pavia, via Bassi 6, Pavia (Italy)

    2011-12-15

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called 'lethal aberrations' (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the {sup 10}B(n,{alpha}) {sup 7}Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the {sup 14}N(n,p){sup 14}C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death.

  4. Cell death following BNCT: a theoretical approach based on Monte Carlo simulations.

    Science.gov (United States)

    Ballarini, F; Bakeine, J; Bortolussi, S; Bruschi, P; Cansolino, L; Clerici, A M; Ferrari, C; Protti, N; Stella, S; Zonta, A; Zonta, C; Altieri, S

    2011-12-01

    In parallel to boron measurements and animal studies, investigations on radiation-induced cell death are also in progress in Pavia, with the aim of better characterisation of the effects of a BNCT treatment down to the cellular level. Such studies are being carried out not only experimentally but also theoretically, based on a mechanistic model and a Monte Carlo code. Such model assumes that: (1) only clustered DNA strand breaks can lead to chromosome aberrations; (2) only chromosome fragments within a certain threshold distance can undergo misrejoining; (3) the so-called "lethal aberrations" (dicentrics, rings and large deletions) lead to cell death. After applying the model to normal cells exposed to monochromatic fields of different radiation types, the irradiation section of the code was purposely extended to mimic the cell exposure to a mixed radiation field produced by the (10)B(n,α) (7)Li reaction, which gives rise to alpha particles and Li ions of short range and high biological effectiveness, and by the (14)N(n,p)(14)C reaction, which produces 0.58 MeV protons. Very good agreement between model predictions and literature data was found for human and animal cells exposed to X- or gamma-rays, protons and alpha particles, thus allowing to validate the model for cell death induced by monochromatic radiation fields. The model predictions showed good agreement also with experimental data obtained by our group exposing DHD cells to thermal neutrons in the TRIGA Mark II reactor of the University of Pavia; this allowed to validate the model also for a BNCT exposure scenario, providing a useful predictive tool to bridge the gap between irradiation and cell death. PMID:21481595

  5. Towards a new therapy protocol for liver metastases. Effect of boron compounds and BNCT on normal liver regeneration

    International Nuclear Information System (INIS)

    The Taormina project developed a new method for BNCT treatment of multifocal unresectable liver metastases based on whole liver autograft. The Roffo Institute liver surgeons propose a new technique based on partial liver autograft that would pose less risk to the patient but would require significant healthy liver regeneration following BNCT. The aim of the present study was to assess the effect of BPA, GB-10 (Na210B10H10) and (GB-10 + BPA) and of BNCT mediated by these boron compounds on normal liver regeneration in the Wistar rat. Normal liver regeneration, body weight, hemogram, liver and kidney function were assessed following partial hepatectomy post administration of BPA, GB-10 or (GB-10 + BPA) and post in vivo BNCT at the RA-6 Reactor. These end-points were evaluated 9 days following partial hepatectomy, the time at which complete liver regeneration occurs in untreated controls. The corresponding biodistribution studies were conducted to perform dosimetric calculations. BPA, GB-10 and (GB-10 + PBA) and in vivo BNCT mediated by these boron compounds in dose ranges compatible with therapy did not cause alterations in the outcome of normal liver regeneration, and did not induce alterations in body weight, hemogram, liver or kidney function. The experimental data available to date support the development of a new BNCT protocol for the treatment of liver metastases that requires the regeneration of normal liver past-BNCT. (author)

  6. Clinical BNCT, where are we and where should we be going?

    International Nuclear Information System (INIS)

    The future in cancer treatment is with dedicated targeted therapies, selectively destroying tumour cells whilst sparing surrounding healthy tissue, so leading to increased efficacy and decreased toxicity. Boron Neutron Capture Therapy (BNCT) is a radiotherapeutic modality that through the limited spatial distribution of its effects provides a highly selective delivery of dose. It exploits the ability of the non-radioactive isotope boron-10 to readily capture thermal neutrons, to immediately produce particles with high Linear Energy Transfer, high Relative Biological Effectiveness and a limited range in tissue of 10 microns. In addition BNCT offers physical targeting methods such as optimised beam delivery and extra-corporal irradiation, which makes the global approach even more likely to succeed than cellular targeting based on a drug only approach. To be effective, B-10 has to be delivered selectively to the target cells, which is not the case at present in BNCT. Currently, clinical BNCT has been proven feasible using different neutron beams and clinical approaches (intraoperative, external beam and extracorporal irradiation), pharmacokinetic studies including tissue uptake evaluation and phase I trials have been performed using the drugs BSH and BPA. The efficacy of BNCT has been shown in single cases and phase II trials are now open for patient recruitment. In order to develop BNCT further, dedicated trial strategies have to be developed that allow the investigation of this binary treatment modality. Special emphasis has to be spent to the development of new targeting compounds, which is especially difficult because the drugs by themselves do not have any effect. If one day BNCT has been proven to be in specific situations superior to conventional treatments, then cheap and hospital based neutron sources must become available in order to introduce it in routine

  7. Clinical results of BNCT for malignant brain tumors in children

    International Nuclear Information System (INIS)

    It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue. However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells. We evaluated the clinical results and courses in patients with malignant glioma under 15 years. Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years. They included 4 patients under 3 years. There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma. All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth. All pontine glioma patients died due to regrowth of the tumor. Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence. BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation. Although it can achieve the local control in the primary site, it cannot prevent CSF dissemination in patients with glioblastoma.

  8. Clinical results of BNCT for malignant brain tumors in children

    Energy Technology Data Exchange (ETDEWEB)

    Nakagawa, Yoshinobu [Department of Neurosurgery, Kagawa National Children' s Hospital, Kagawa 765-8501 (Japan)], E-mail: ynakagawa0517@yahoo.co.jp; Kageji, Teruyoshi; Mizobuchi, Yoshifumi [Department of Neurosurgery, University of Tokushima, Tokushima 770-8503 (Japan); Kumada, Hiroaki [Department of Research Reactor, Japan Atomic Energy Research Institute, Ibaragi 319-1195 (Japan); Nakagawa, Yoshiaki [Department of Medical Informatics, Post Graduated School, Kyoto University, Kyoto (Japan)

    2009-07-15

    It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue. However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells. We evaluated the clinical results and courses in patients with malignant glioma under 15 years. Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years. They included 4 patients under 3 years. There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma. All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth. All pontine glioma patients died due to regrowth of the tumor. Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence. BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation. Although it can achieve the local control in the primary site, it cannot prevent CSF dissemination in patients with glioblastoma.

  9. Development of an accelerator based BNCT facility. Following the Ibaraki BNCT project development process

    International Nuclear Information System (INIS)

    An accelerator-based BNCT (Boron Neutron Capture Therapy) facility is being constructed at the Ibaraki Neutron Medical Research Center. It consists of a proton linac (8 MeV energy and 10 mA average current), a beryllium target, and a moderator system to provide an epi-thermal neutron flux for patient treatment. The technology choices for this present system were driven by the need to site the facility in a hospital and where low residual activity is essential. The maximum neutron energy produced from an 8 MeV-proton is 6 MeV, which is below the threshold energy of the main nuclear reactions which produce radioactive products. The down side of this technology choice is that it produces a high density heat load on the target so that cooling and hydrogen blistering amelioration prevent sever challenges requiring successful R and D progress. The latest design of the target and moderator system shows that a flux of 2.5x109 epi-thermal neutrons/cm2/sec can be obtained. This is two times higher than the flux from the existing nuclear reactor based BNCT facility at JAEA (JRR-4). (author)

  10. In vitro biological models in order to study BNCT

    International Nuclear Information System (INIS)

    Undifferentiated thyroid carcinoma (UTC) lacks an effective treatment. Boron neutron capture therapy (BNCT) is based on the selective uptake of 10B-boronated compounds by some tumours, followed by irradiation with an appropriate neutron beam. The radioactive boron originated (11B) decays releasing 7Li, gamma rays and alpha particles, and these latter will destroy the tumour. In order to explore the possibility of applying BNCT to UTC we have studied the biodistribution of BPA. In vitro studies: the uptake of p-10borophenylalanine (BPA) by the UTC cell line ARO, primary cultures of normal bovine thyroid cells (BT) and human follicular adenoma (FA) thyroid was studied. No difference in BPA uptake was observed between proliferating and quiescent ARO cells. The uptake by quiescent ARO, BT and FA showed that the ARO/BT and ARO/FA ratios were 4 and 5, respectively (p< 0.001). The present experimental results open the possibility of applying BNCT for the treatment of UTC. (author)

  11. Measurement and simulation of the TRR BNCT beam parameters

    Science.gov (United States)

    Bavarnegin, Elham; Sadremomtaz, Alireza; Khalafi, Hossein; Kasesaz, Yaser; Golshanian, Mohadeseh; Ghods, Hossein; Ezzati, Arsalan; Keyvani, Mehdi; Haddadi, Mohammad

    2016-09-01

    Recently, the configuration of the Tehran Research Reactor (TRR) thermal column has been modified and a proper thermal neutron beam for preclinical Boron Neutron Capture Therapy (BNCT) has been obtained. In this study, simulations and experimental measurements have been carried out to identify the BNCT beam parameters including the beam uniformity, the distribution of the thermal neutron dose, boron dose, gamma dose in a phantom and also the Therapeutic Gain (TG). To do this, the entire TRR structure including the reactor core, pool, the thermal column and beam tubes have been modeled using MCNPX Monte Carlo code. To measure in-phantom dose distribution a special head phantom has been constructed and foil activation techniques and TLD700 dosimeter have been used. The results show that there is enough uniformity in TRR thermal BNCT beam. TG parameter has the maximum value of 5.7 at the depth of 1 cm from the surface of the phantom, confirming that TRR thermal neutron beam has potential for being used in treatment of superficial brain tumors. For the purpose of a clinical trial, more modifications need to be done at the reactor, as, for example design, and construction of a treatment room at the beam exit which is our plan for future. To date, this beam is usable for biological studies and animal trials. There is a relatively good agreement between simulation and measurement especially within a diameter of 10 cm which is the dimension of usual BNCT beam ports. This relatively good agreement enables a more precise prediction of the irradiation conditions needed for future experiments.

  12. BNCT with linac, feasibility study

    International Nuclear Information System (INIS)

    High energy photon beams from Medical Linear Accelerators (linacs) which are used in radiotherapy produce undesirable neutrons, beside the clinically useful electron and photon beams. Neutrons are produced from the photonuclear reaction (γ,n) of high energy photons with high Z-materials which compose the accelerator head. In this paper the possible use of these undesirable neutrons for BNCT is investigated, making use of high energy linacs already installed in hospitals, primarily for high energy electron and photon therapy and applying them in the context of BNCT. The photoneutron components emitted by the accelerator is the source for Monte Carlo simulations of the interactions that take place within the head of a voxel-based phantom. The neutron flux across the phantom head is calculated using different moderator arrangements and different techniques in the aim of increasing the thermal neutron flux at the targeted site. Also, we shall test different configurations of the linac head to maximize the exposure of high-Z materials to the photon beam, including the removal of the flattening filter, so as to boost the photoneutron production in the linac head. Experimental work will be conducted in hospitals to validate the Monte Carlo simulations. To make use of linacs for BNCT will be advantageous in the sense that the setting in a hospital department is much more acceptable by the public than a reactor installation. This will mean less complications regarding patient positioning and movement with respect to the beams, additional patient transportation and management will be more cost effective. (author)

  13. Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats Introduction: Boron Neutron Capture Therapy (BNCT) is based on selective tumor uptake of boron compounds, followed by neutron irradiation. BNCT was proposed for the treatment of unresectable, diffuse lung metastases. The aim of the present study was to perform BNCT studies in an experimental model of lung metastases. Materials and Methods: 3 x 106/0.5 ml colon carcinoma cells (DHD/K12/TRb) were injected iv in syngeneic BDIX rats. Three weeks post-inoculation, rats with diffuse lung metastases were used for in vivo BNCT studies in the RA-3 Nuclear Reactor. Based on previous biodistribution studies and computational dosimetry with Monte Carlo simulation, 2 doses were prescribed, i.e. 4 Gy and 8 Gy minimum absorbed dose to tumor. The animals were assigned to 5 experimental groups (n= 4 to 8) at each dose level: T0 (euthanized pre-treatment), BPA-BNCT, Comb-BNCT (BPA+GB-10), Beam only (background dose) and Sham (same manipulation, no treatment). Boron concentration was measured in a blood sample taken pre-irradiation to verify that the value was in the range established in previous biodistribution studies. The animals were followed clinically for 2 weeks after neutron irradiation and then euthanized to assess the response of tumor and normal lung, macroscopically and histologically. To date we have evaluated the end-point weight of lung (normal lung + metastases) and % lung weight/body weight as an indicator of tumor growth. Results: The statistical analysis (ANOVA) of % lung weight/body weight showed statistically significant differences (p<0.05) between groups T0 (0.79 ± 0.38) and Sham (1.87 ± 0.91). No statistically significant differences were observed between the Beam only groups (at both dose levels) and Sham. Similar and statistically significant tumor control was induced in the groups BPA-BNCT Low dose (LD) (0.56 ± 0.11), BPA-BNCT High dose (HD) (0.80 ± 0.16), Comb-BNCT

  14. Medical setup of intraoperative BNCT at JRR-4

    International Nuclear Information System (INIS)

    Since October 1999, we have been performing clinical trials of intraoperative boron neutron capture therapy (IOBNCT) using a mixed thermal-epithermal beam at the Japan Research Reactor No. 4 (JRR-4). For immediate pre-BNCT care, including administration of a boron compound as well as post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of JRR-4. Following craniotomy in the treatment room, anesthetized patients were transported into the irradiation room for BNCT. The boron concentration in tissue was measured by the PGA and ICP-AES methods. The long-term follow-up was done at the University of Tsukuba Hospital. IOBNCT is a complex clinical procedure, which requires sophisticated operating team and co-medical staffs and also cooperation with physicist team. IOBNCT is a complex clinical procedure requiring a high level of cooperation among the operating team, co-medical staff, and physicists. For the safe and successful performance of IOBNCT, we have made the program including critical pathway and prepared various equipments for IOBNCT. To ensure the safe and successful performance of IOBNCT, we developed a critical pathway for use during the procedure, and prepared various apparatus for IOBNCT. (author)

  15. A Tandem-electrostatic-quadrupole for accelerator-based BNCT

    International Nuclear Information System (INIS)

    A project to develop a Tandem-electrostatic-quadrupole (TESQ) accelerator for accelerator-based boron neutron capture therapy (AB-BNCT) is described. A folded Tandem, with 1.25 MV terminal voltage, combined with an electrostatic quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p, n)7Be reaction slightly beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7Li(p, n)7Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT

  16. Tandem-ESQ for accelerator-based BNCT

    International Nuclear Information System (INIS)

    A project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) is described. A folded tandem, with 1.25 MV terminal voltage, combined with an ElectroStatic Quadrupole (ESQ) chain is being proposed. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p,n)7Be reaction beyond its resonance at 2.25 MeV. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the '7Li(p,n)7Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is the technologically simplest and cheapest solution for optimized AB-BNCT. (author)

  17. Microwave digestion techniques applied to determination of boron by ICP-AES in BNCT program

    International Nuclear Information System (INIS)

    Recently, boron neutron capture therapy (BNCT) has merged as an interesting option for the treatment of some kind of tumors where established therapies show no success. A molecular boronated species, enriched in 10B is administrated to the subject; it localizes in malignant tissues depending the kind of tumor and localization. Therefore, a very important fact in BNCT research is the detection of boron at trace or ultra trace levels precisely and accurately. This is extremely necessary as boronated species do localize in tumoral tissue and also localize in liver, kidney, spleen, skin, membranes. By this way, before testing a boronated species, it is mandatory to determine its biodistribution in a statistically meaning population, that is related with managing of a great number of samples. In the other hand, it is necessary to exactly predict when to begin the irradiation and to determine the magnitude of radiation to obtain the desired radiological dose for a specified mean boron concentration. This involves the determination of boron in whole blood, which is related with boron concentration in the tumor object of treatment. The methodology selected for the analysis of boron in whole blood and tissues must join certain characteristics: it must not be dependant of the chemical form of boron, it has to be fast and capable to determine boron accurately and precisely in a wide range of concentrations. The design and validation of experimental models involving animals in BNCT studies and the determination of boron in blood of animals and subjects upon treatment require reliable analytical procedures to determine boron quantitatively in those biologic materials. Inductively coupled plasma-atomic emission spectrometry (ICP-AES) using pneumatic nebulization is one of the most promising methods for boron analysis, but the sample must be liquid and have low solid concentration. In our case, biological tissues and blood, it is mandatory to mineralize and/or dilute samples

  18. Biomedical Engineering 2008. New methods for cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Vanninen, J.; Koskelainen, A.; Ilmoniemi, R.J. (eds.)

    2008-07-01

    The report consists of 11 student papers presented in 2008 at the Seminar on Biomedical Engineering at Helsinki University of Technology (Finland). The topics of the seminar included: cancer risk factors and diagnosis, radiation therapy, boron neutron capture treatment (BNCT), chemotherapy, cooling and heating therapy, immunotherapy, angiogenesis inhibition approaches, gene therapy and ablation therapy of liver cancer

  19. Feasibility study of using laser-generated neutron beam for BNCT

    International Nuclear Information System (INIS)

    The feasibility of using a laser-accelerated proton beam to produce a neutron source, via (p,n) reaction, for Boron Neutron Capture Therapy (BNCT) applications has been studied by MCNPX Monte Carlo code. After optimization of the target material and its thickness, a Beam Shaping Assembly (BSA) has been designed and optimized to provide appropriate neutron beam according to the recommended criteria by International Atomic Energy Agency. It was found that the considered laser-accelerated proton beam can provide epithermal neutron flux of ∼2×106 n/cm2 shot. To achieve an appropriate epithermal neutron flux for BNCT treatment, the laser must operate at repetition rates of 1 kHz, which is rather ambitious at this moment. But it can be used in some BNCT researches field such as biological research. - Highlights: • Feasibility of using laser-accelerated proton beam for BNCT has been investigated. • The considered beam can provide epithermal neutron flux of ~2×106 (n/cm2.shot). • For BNCT treatment, the laser must operate at repetition rates of 1 kHz

  20. Improvements at the biological shielding of BNCT research facility in the IEA-R1 reactor

    International Nuclear Information System (INIS)

    The technique of neutron capture in boron is a promising technique in cancer treatment, it uses the high LET particles from the reaction 10B (n, α) 7Li to destroy cancer cells.The development of this technique began in the mid-'50s and even today it is the object of study and research in various centers around the world, Brazil has built a facility that aims to conduct research in BNCT, this facility is located next to irradiation channel number three at the research nuclear reactor IEA-R1 and has a biological shielding designed to meet the radiation protection standards. This biological shielding was developed to allow them to conduct experiments with the reactor at maximum power, so it is not necessary to turn on and off the reactor to irradiate samples. However, when the channel is opened for experiments the background radiation in the experiments salon increases and this background variation makes it impossible to perform measurements in a neutron diffraction research that utilizes the irradiation channel number six. This study aims to further improve the shielding in order to minimize the variation of background making it possible to perform the research facility in BNCT without interfering with the action of the research group of the irradiation channel number six. To reach this purpose, the code MCNP5, dosimeters and activation detectors were used to plan improvements in the biological shielding. It was calculated with the help of the code an improvement that can reduce the average heat flow in 71.2% ± 13 and verified experimentally a mean reduce of 70 ± 9% in dose due to thermal neutrons. (author)

  1. Clinical experience of BNCT for brain and skin tumors at Kyoto University Reactor

    International Nuclear Information System (INIS)

    The research nuclear reactor of Kyoto University (KUR), which was established in 1963, has the power of 5 MW and has rendered services to scientists in various fields including biology and medicine. The first clinical application was carried out on a brain tumor patient by Professor Hatanaka in 1974. Eight Japanese, 2 German and one American patients were treated. The ages of patients were 9-66 years and all were male. Skin tumors were irradiated at KUR to measure 10B content in the tissues by Nickel Mirror Neutron Guide Tube (NMNGT) attached to KUR, before BNCT. Except in a few cases, patients had recurrent tumours after previous treatment by chemotherapy, radiotherapy or surgical treatments. The absorbed dose used in the previous radiotherapy before BNCT was a curative dose. The time intervals between previous radiotherapy and BNCT varied. The treated skin tumours included various grades of melanoma. Some cases appeared to be astrocytoma grade IV

  2. BNCT activities at Slovenian TRIGA research reactor

    International Nuclear Information System (INIS)

    It has been reported that satisfactory thermal/epithermal neutron beams for Boron Neutron Capture Therapy (BNCT) could be designed at TRIGA research reactors These reactors are generally perceived as being safe to install and operate in populated areas. This contribution presents the most recent BNCT research activities on the 'Jozef Stefan' Institute, where epithermal neutron beam for 'in-vitro' irradiation has been developed and experimentally verified. Furthermore, The Monte Carlo feasibility study of development of the epithermal neutron beam for BNCT clinical trials of human patients in thermalising column (TC) of TRIGA reactor has been carried out. The simulation results prove, that a BNCT irradiation facility with performances, comparable to existing beam throughout the world, could be installed in TC of the TRIGA reactor. (author)

  3. Clinical results of BNCT for malignant meningiomas

    International Nuclear Information System (INIS)

    Malignant meningiomas is difficult pathology to be controlled as well as GBM. Since June of 2005, we applied BNCT for 7 cases of malignancy related meningiomas with 13 times neutron irradiation. Five were anaplastic, one was atypical meningiomas and one was sarcoma transformed from meningioma with cervical lymph node metastasis. All cases were introduced after repetitive surgeries and XRT or SRS. Follow-up images were available for 6 cases with observation duration between 2 to 9 months. We applied F-BPA-PET before BNCT in 6 out of 7 cases. One case was received methionine-PET. Five out of 6 cases who received BPA-PET study showed good BPA uptake more than 3 of T/N ratio. One atypical meningiomas cases showed 2.0 of T/N ratio. Original tumor sizes were between 9.2 to 92.7 ml. Two out of 5 anaplastic meningiomas showed CR and all six cases showed radiographic improvements. Clinical symptoms before BNCT such as hemiparesis and facial pain were improved after BNCT, except one case. An huge atypical meningiomas which arisen from tentorium and extended bilateral occipital lobes and brain stem, visual problems were worsened after repetitive BNCT with increase of peritumoral edema. Malignant meningiomas are seemed to be good candidate for BNCT. (author)

  4. Boron neutron capture therapy (BNCT) for liver metastasis in an experimental model: dose–response at five-week follow-up based on retrospective dose assessment in individual rats

    Energy Technology Data Exchange (ETDEWEB)

    Emiliano C. C. Pozzi; Veronica A. Trivilin; Lucas L. Colombo; Andrea Monti Hughes; Silvia I. Thorp; Jorge E. Cardoso; Marcel A. Garabalino; Ana J. Molinari; Elisa M. Heber; Paula Curotto; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Amanda E. Schwint

    2013-11-01

    Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. Employing an experimental model of liver metastases in rats, we recently demonstrated that BNCT mediated by boronophenylalanine (BPA-BNCT) at 13 Gy prescribed to tumor is therapeutically useful at 3-week follow-up. The aim of the present study was to evaluate dose–response at 5-week follow-up, based on retrospective dose assessment in individual rats. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT (n = 19), Beam only (n = 8) and Sham (n = 7) (matched manipulation, no treatment). For each rat, neutron flux was measured in situ and boron content was measured in a pre-irradiation blood sample for retrospective individual dose assessment. For statistical analysis (ANOVA), individual data for the BPA-BNCT group were pooled according to absorbed tumor dose, BPA-BNCT I: 4.5–8.9 Gy and BPA-BNCT II: 9.2–16 Gy. At 5 weeks post-irradiation, the tumor surface area post-treatment/pre-treatment ratio was 12.2 +/- 6.6 for Sham, 7.8 +/- 4.1 for Beam only, 4.4 +/- 5.6 for BPA-BNCT I and 0.45 +/- 0.20 for BPA-BNCT II; tumor nodule weight was 750 +/- 480 mg for Sham, 960 +/- 620 mg for Beam only, 380 +/- 720 mg for BPA-BNCT I and 7.3 +/- 5.9 mg for BPA-BNCT II. The BPA-BNCT II group exhibited statistically significant tumor control with no contributory liver toxicity. Potential threshold doses for tumor response and significant tumor control were established at 6.1 and 9.2 Gy, respectively.

  5. Radiation treatment of toxic chemicals

    International Nuclear Information System (INIS)

    Polychlorinated biphenyls (PCBs) were commercially produced from 1920s as complex mixtures containing multiple isomers for a variety of applications. They are very toxic, chemically stable and resist microbial, photochemical, chemical, and thermal degradation. The public, legal, and scientific concerns about PCBs arose from research indicating they were environmental contaminants that had a potential to adversely impact the environment, and, therefore, were undesirable as commercial products. Eventually, most producers reduced or stopped production of PCBs in the 1970s. Stockholm convention on POPs (Persistent Organic Pollutants), which was effective on May 2004 and 151 nations including Korea were joined on June 2005, asked to dispose of PCBs by 2028 with environmental friendly methods. Korean government also has declared to conduct by 2015. According to the Environmental law of Korea, over 2 ppm of PCBs has to be decomposed by legal methods of incineration and thermal destruction. But those are inapplicable owing to the environmental groups. KAERI(Korea Atomic Energy Research Institute) has recently developed a remarkable technology for radiation treatment of toxic chemicals including chlorides using an electron beam accelerator. Electron beam accelerator of 2.5 MeV energy and 100 kW power capacity was used to decompose of PCBs having been used as a commercial transformer oil for more than 30 years. The oil were irradiated with ∼ 0.1 percent of TEA (Triethyl Amin) to make chloride ion aparted off from the PCBs into precipitate at the conditions of normal temperature and pressure. The concentrations of PCBs were measured by GC (Gas Chromatography) with ECD (Electron Capture Detector) following the KS (Korean Standard) test procedure. Electron beam should be a useful tool for environmental conservation. Residual concentrations of PCBs after irradiation were depended on the absorption dose of electron beam energy. Advantages comparing to other methods such as

  6. Accelerator based-boron neutron capture therapy (BNCT)-clinical QA and QC

    International Nuclear Information System (INIS)

    Alpha-particle and recoil Li atom yielded by the reaction (10B, n), due to their high LET properties, efficiently and specifically kill the cancer cell that has incorporated the boron. Efficacy of this boron neutron capture therapy (BNCT) has been demonstrated mainly in the treatment of recurrent head/neck and malignant brain cancers in Kyoto University Research Reactor Institute (KUR). As the clinical trial of BNCT is to start from 2009 based on an accelerator (not on the Reactor), this paper describes the tentative outline of the standard operation procedure of BNCT for its quality assurance (QA) and quality control (QC) along the flow of its clinical practice. Personnel concerned in the practice involve the attending physician, multiple physicians in charge of BNCT, medical physicists, nurses and reactor stuff. The flow order of the actual BNCT is as follows: Pre-therapeutic evaluation mainly including informed consent and confirmation of the prescription; Therapeutic planning including setting of therapy volume, and of irradiation axes followed by meeting for stuffs' agreement, decision of irradiating field in the irradiation room leading to final decision of the axis, CT for the planning, decision of the final therapeutic plan according to Japan Atomic Energy Agency-Computational Dosimetry System (JCDS) and meeting of all related personnel for the final confirmation of therapeutic plan; and BNCT including the transport of patient to KUR, dripping of boronophenylalanine, setting up of the patient on the machine, blood sampling for pharmacokinetics, boron level measurement for decision of irradiating time, switch on/off of the accelerator, confirmation of patient's movement in the irradiated field after the neutron irradiation, blood sampling for confirmation of the boron level, and patient's leave from the room. The QA/QC check is principally to be conducted with the two-person rule. The purpose of the clinical trial is to establish the usefulness of BNCT, and

  7. Construction of a BNCT facility using an 8-MeV high power proton linac in Ibaraki

    International Nuclear Information System (INIS)

    An accelerator-based BNCT (Boron Neutron Capture Therapy) facility is now under construction and the entire system including the patient treatment system will be installed in the Ibaraki Neutron Advanced Medical Research Center (tentative name). BNCT is expected to give good results for inoperable cancers. In BNCT, pharmaceuticals carry a neutron capture agent containing 10B (Boron 10) selectively into tumor cells. Next thermal or epi-thermal neutrons interact with the 10B and produce α and 7Li-particles. Both of these particles have a very high Linear Energy Transfer (LET) and therefore lose almost all of their energy within a distance comparable to the size of a tumor cell. So far, BNCT has been provided only by nuclear reactors. The promising results shown there by BNCT give the hope that it may become an indispensable treatment modality for many types of cancers. From solely the neutron intensity point of view, nuclear reactors are excellent neutron sources. But as nuclear reactors regularly require long maintenance shut-downs and are subject to strict regulations, hospital operation is completely impractical. Thus we recognize the desirability of an accelerator-based BNCT facility well adapted for use by hospitals. We are aiming at the design and construction of a 'Hospital and Patient friendly' BNCT system. The development of such a BNCT requires multi-disciplinary input and collaboration from a wide spectrum of scientific and technical specialties. To obtain the needed breath and strength, we have organized our team with contributing specialists from diverse institutes and companies. The Ibaraki Medical Center for Advanced Neutron Therapy will be on the IQBRC (Ibaraki Quantum Beam Research Center) campus, which is near the JAEA and KEK Tokai campuses. The building for the BNCT is now under renovation by the Ibaraki prefectural government. We are tentatively calling this project 'I-BNCT' because of the Ibaraki prefectural sponsorship. Investigation of an 8

  8. Spatial and spectral characteristics of a compact system neutron beam designed for BNCT facility

    International Nuclear Information System (INIS)

    The development of suitable neutron sources and neutron beam is critical to the success of Boron Neutron Capture Therapy (BNCT). In this work a compact system designed for BNCT is presented. The system consists of 252Cf fission neutron source and a moderator/reflector/filter/shield assembly. The moderator/reflector/filter arrangement has been optimized to maximize the epithermal neutron component which is useful for BNCT treatment of deep seated tumors with the suitably low level of beam contamination. The MCMP5 code has been used to calculate the different components of neutrons, secondary gamma rays originating from 252Cf source and the primary gamma rays emitted directly by this source at the exit face of the compact system. The fluence rate distributions of such particles were also computed along the central axis of a human head phantom

  9. Spatial and spectral characteristics of a compact system neutron beam designed for BNCT facility

    Energy Technology Data Exchange (ETDEWEB)

    Ghassoun, J. [EPRA, Departement de Physique, Faculte des Sciences Semlalia, B.P. 2390, 40000 Marrakech (Morocco)], E-mail: ghassoun@ucam.ac.ma; Chkillou, B.; Jehouani, A. [EPRA, Departement de Physique, Faculte des Sciences Semlalia, B.P. 2390, 40000 Marrakech (Morocco)

    2009-04-15

    The development of suitable neutron sources and neutron beam is critical to the success of Boron Neutron Capture Therapy (BNCT). In this work a compact system designed for BNCT is presented. The system consists of {sup 252}Cf fission neutron source and a moderator/reflector/filter/shield assembly. The moderator/reflector/filter arrangement has been optimized to maximize the epithermal neutron component which is useful for BNCT treatment of deep seated tumors with the suitably low level of beam contamination. The MCMP5 code has been used to calculate the different components of neutrons, secondary gamma rays originating from {sup 252}Cf source and the primary gamma rays emitted directly by this source at the exit face of the compact system. The fluence rate distributions of such particles were also computed along the central axis of a human head phantom.

  10. Spatial and spectral characteristics of a compact system neutron beam designed for BNCT facility.

    Science.gov (United States)

    Ghassoun, J; Chkillou, B; Jehouani, A

    2009-04-01

    The development of suitable neutron sources and neutron beam is critical to the success of Boron Neutron Capture Therapy (BNCT). In this work a compact system designed for BNCT is presented. The system consists of (252)Cf fission neutron source and a moderator/reflector/filter/shield assembly. The moderator/reflector/filter arrangement has been optimized to maximize the epithermal neutron component which is useful for BNCT treatment of deep seated tumors with the suitably low level of beam contamination. The MCMP5 code has been used to calculate the different components of neutrons, secondary gamma rays originating from (252)Cf source and the primary gamma rays emitted directly by this source at the exit face of the compact system. The fluence rate distributions of such particles were also computed along the central axis of a human head phantom. PMID:19168369

  11. Characterisation of an accelerator-based neutron source for BNCT versus beam energy

    CERN Document Server

    Agosteo, S; D'Errico, F; Nath, R; Tinti, R

    2002-01-01

    Neutron capture in sup 1 sup 0 B produces energetic alpha particles that have a high linear energy transfer in tissue. This results in higher cell killing and a higher relative biological effectiveness compared to photons. Using suitably designed boron compounds which preferentially localize in cancerous cells instead of healthy tissues, boron neutron capture therapy (BNCT) has the potential of providing a higher tumor cure rate within minimal toxicity to normal tissues. This clinical approach requires a thermal neutron source, generally a nuclear reactor, with a fluence rate sufficient to deliver tumorcidal doses within a reasonable treatment time (minutes). Thermal neutrons do not penetrate deeply in tissue, therefore BNCT is limited to lesions which are either superficial or otherwise accessible. In this work, we investigate the feasibility of an accelerator-based thermal neutron source for the BNCT of skin melanomas. The source was designed via MCNP Monte Carlo simulations of the thermalization of a fast ...

  12. Photocoagulation treatment of radiation retinopathy

    Energy Technology Data Exchange (ETDEWEB)

    Kinyoun, J.L.; Chittum, M.E.; Wells, C.G.

    1988-05-15

    We studied the visual and anatomic effects of focal photocoagulation for clinically significant radiation macular edema in five eyes of four patients and panretinal photocoagulation for proliferative radiation retinopathy in six eyes of three patients. Focal and limited scatter photocoagulation was successful in preventing further vision loss in all five eyes treated for macular edema. Three eyes treated with panretinal photocoagulation had regression of neovascularization. The other three eyes treated for proliferative retinopathy subsequently had dense vitreous hemorrhages that required vitrectomy for restoration of useful vision.

  13. Photocoagulation treatment of radiation retinopathy

    International Nuclear Information System (INIS)

    We studied the visual and anatomic effects of focal photocoagulation for clinically significant radiation macular edema in five eyes of four patients and panretinal photocoagulation for proliferative radiation retinopathy in six eyes of three patients. Focal and limited scatter photocoagulation was successful in preventing further vision loss in all five eyes treated for macular edema. Three eyes treated with panretinal photocoagulation had regression of neovascularization. The other three eyes treated for proliferative retinopathy subsequently had dense vitreous hemorrhages that required vitrectomy for restoration of useful vision

  14. Conceptual design of epithermal neutron beam for BNCT in the thermalizing column of TRIGA reactor

    International Nuclear Information System (INIS)

    The Monte Carlo feasibility study of development of the epithermal neutron beam for BNCT clinical trials in thermalising column (TC) of TRIGA reactor is presented. The investigation of the possible use of fission converter as well as the set-up of TRIGA reactor core is performed. The optimization of the irradiation facility components is carried out and the configuration with the most favorable cost/performance ratio is proposed. The results prove, that a BNCT irradiation facility with performances, comparable to existing beams throughout the world, could be installed in TC/DC of the TRIGA reactor, quite suitable for the clinical treatments of human patients.(author)

  15. Study of the potential of using 9B(p,n) for BNCT clinical trials

    International Nuclear Information System (INIS)

    The potential of using a 30-MeV proton accelerator utilizing the 9Be(p,n)9B reaction as a neutron source for BNCT (Boron Neutron Capture Therapy) was investigated. MCNPX (Monte Carlo Neutron Photon-transport code X) was used to calculated neutron spectra and yields for comparison against existing experimental data and for the moderator optimization. Moderator performance was assessed using MCNPX and clinical efficacy was assessed using BNCT-RTPE to estimate in-phantom dose distributions and neutron fluences. The optimized source and moderator gave comparable tumor doses and treatment times to the clinical trials recently completed at the Brookhaven Medical Research Reactor (BMRR). (author)

  16. Hyperbaric oxygen treatment in radiation reactions

    International Nuclear Information System (INIS)

    Background: A national hyperbaric centre was established in 1994 at Haukeland Hospital with responsibility of all hyperbaric oxygen (HBO) treatment in Norway. In hypoxic tissues with symptomatic radiation reactions, hyperbaric oxygen induces the formation of collagen and angiogenesis resulting in permanently improved local microcirculation. Material and method: 234 patients received elective HBO treatment at Haukeland Hospital in 12997 with total of 4048 treatments. All 47 patients treated for radiation reactions in the pelvic area in 1997 received a questionnaire 3-15 months after HBO therapy, 81% reported. Results: Rectal bleeding and haematuria were reported as much improved in 61% and 55% respectively, while bladder incontinence was much improved in 46%. Interpretation: this treatment modality may be an alternative in symptomatic radiation reactions at the urinary bladder and the bowel when conventional treatment has given unsatisfactory results

  17. Diagnosis and treatment of radiation injuries

    International Nuclear Information System (INIS)

    This publication is the translation of IAEA Safety Reports Series No.2 ,Diagnosis and Treatment of Radiation Injuries. This report is directed at medical professionals who may be involved in the management of radiation injuries starting from the first few hours or days after an exposure of undefined severity. The principal aim of this publication is to provide guidelines to enable medical professionals to carry out prompt diagnostic measure and to offer emergency treatment. This report provides information in tabulated form on clinical criteria for dose assesment. Additionally, it discusses the appropriate dose-effect relationship in cases of external radiation involving either total body or local exposures, as well as internal contamination

  18. Cutaneous reaction to radiation and their treatment

    International Nuclear Information System (INIS)

    Acute radiation dermatitis were reported of iridium 172 under poor administration which radiated locally on the skin of hands and fingers of oil company workers. Atomic bomb over Hiroshima and Nagasaki killed many people by total body skin exposure. Many workers and firemen were radiated by beta and gamma rays in the Chernobyl' accident, where 19 of 28 death cases died by radiation burn. 8 patients with 60-100% burn area died in 15-24 days after the explosion. Of 12 patients with 30-60% burn area, 6 died by burn. 21 cases of 30% burn area did not die in spite of mild or severe bone marrow depression. In all these cases, areas of skin ulcers epithelized with dry and wet scales till 50-60 days after the explosion, except large area (20-25cm2) transplanted. In this accident, severe radiation burn due to the beta ray irradiation occured with endogeneous intoxication, renal disturbance, blood biochemical changes and bleeding. Oral, pharyngeal and intestinal membrane were irradiated by beta ray and were ulcerated so they could hardly eat. The treatment of these cases with acute radiation dermatitis should be performed by the procedure of treatment of burn, locally and systematically. Local treatment should be performed by topical application of antibiotic ointment or adrenocortical steroid ointment with antibiotics. In severe burn, systemic treatment with plasma and other fluids for burn shock should be performed, corresponding to the area and depth of radiation burn. (A.Y.)

  19. Radiation treatment and radiation reactions in dermatology. 2. ed.

    Energy Technology Data Exchange (ETDEWEB)

    Panizzon, Renato G. [Univ. Hospital CHUV, Lausanne (Switzerland). Dept. of Dermatology; Seegenschmiedt, M. Heinrich (ed.) [Strahlenzentrum Hamburg (Germany)

    2015-03-01

    Explains the use of radiation treatment in the full range of skin cancers and precancerous lesions. Covers physical and radiobiological principles, dose definitions, radiation reactions, and risk assessments. Revised and updated edition that includes new chapters and numerous additional figures. In this book, leading experts in the dermatological and oncological field describe the use of radiation therapy for the treatment of the full range of dermatological malignancies - including basal cell carcinoma, squamous cell carcinoma, cutaneous lymphomas, Kaposi's sarcoma, melanoma, and Merkel cell tumor - as well as those precancerous lesions and non-malignant dermatological disorders which are amenable to radiation therapy. In each case the specific indications for the use of radiotherapy and its application are clearly explained with the aid of numerous high-quality illustrations. In addition, the book provides a concise introduction to physical and radiobiological principles, selection of radiation factors, dose definitions, radiation reactions, and risk assessments. The new edition has been thoroughly revised and updated to reflect advances in practical knowledge and clinical practice. It will be an invaluable source of information on the management of skin tumors and related non-malignant disorders for both dermatologists, oncologists and radiation oncologists.

  20. Radiation treatment and radiation reactions in dermatology. 2. ed.

    International Nuclear Information System (INIS)

    Explains the use of radiation treatment in the full range of skin cancers and precancerous lesions. Covers physical and radiobiological principles, dose definitions, radiation reactions, and risk assessments. Revised and updated edition that includes new chapters and numerous additional figures. In this book, leading experts in the dermatological and oncological field describe the use of radiation therapy for the treatment of the full range of dermatological malignancies - including basal cell carcinoma, squamous cell carcinoma, cutaneous lymphomas, Kaposi's sarcoma, melanoma, and Merkel cell tumor - as well as those precancerous lesions and non-malignant dermatological disorders which are amenable to radiation therapy. In each case the specific indications for the use of radiotherapy and its application are clearly explained with the aid of numerous high-quality illustrations. In addition, the book provides a concise introduction to physical and radiobiological principles, selection of radiation factors, dose definitions, radiation reactions, and risk assessments. The new edition has been thoroughly revised and updated to reflect advances in practical knowledge and clinical practice. It will be an invaluable source of information on the management of skin tumors and related non-malignant disorders for both dermatologists, oncologists and radiation oncologists.

  1. Pelvic radiation disease: Updates on treatment options.

    Science.gov (United States)

    Frazzoni, Leonardo; La Marca, Marina; Guido, Alessandra; Morganti, Alessio Giuseppe; Bazzoli, Franco; Fuccio, Lorenzo

    2015-12-10

    Pelvic cancers are among the most frequently diagnosed neoplasms and radiotherapy represents one of the main treatment options. The irradiation field usually encompasses healthy intestinal tissue, especially of distal large bowel, thus inducing gastrointestinal (GI) radiation-induced toxicity. Indeed, up to half of radiation-treated patients say that their quality of life is affected by GI symptoms (e.g., rectal bleeding, diarrhoea). The constellation of GI symptoms - from transient to long-term, from mild to very severe - experienced by patients who underwent radiation treatment for a pelvic tumor have been comprised in the definition of pelvic radiation disease (PRD). A correct and evidence-based therapeutic approach of patients experiencing GI radiation-induced toxicity is mandatory. Therapeutic non-surgical strategies for PRD can be summarized in two broad categories, i.e., medical and endoscopic. Of note, most of the studies have investigated the management of radiation-induced rectal bleeding. Patients with clinically significant bleeding (i.e., causing chronic anemia) should firstly be considered for medical management (i.e., sucralfate enemas, metronidazole and hyperbaric oxygen); in case of failure, endoscopic treatment should be implemented. This latter should be considered the first choice in case of acute, transfusion requiring, bleeding. More well-performed, high quality studies should be performed, especially the role of medical treatments should be better investigated as well as the comparative studies between endoscopic and hyperbaric oxygen treatments. PMID:26677440

  2. Summaries on various researches aiming at the closed head BNCT

    International Nuclear Information System (INIS)

    As in the boron neutron capture therapy (BNCT) flight of alpha particle formed by reaction of neutron and boron is nearly equal to diameter of cancer cell, when a boron compound accumulates selectively to a cancer cell to be radiated onto the cell by enough amount of neutron beam the alpha particles are irradiated onto the cancer cells nearly selectively. Like this, this is a curing means capable of overcoming a problem undecidable by a paradigm of radiation remedy in the 20th Century, a micro dose amount effect supposing to be a paradigm in the 21st Century, the very (biological) dose concentration into cancer cell is a curing method matching to upgrading on rate of cancer control and improvement on post-cure of the patients without increase of subreaction in every tumors. Here were summarized on characteristic comparison of thermal outer-neutron beams in KUR, JRR-4 and the Peten HFR reactors, development of new boron compounds, effect of BNCT on re-oxygenation of the cancer, and induction of mutation by neutron beam. (G.K.)

  3. Quality management in BNCT at a nuclear research reactor

    International Nuclear Information System (INIS)

    Each medical intervention must be performed respecting Health Protection directives, with special attention to Quality Assurance (QA) and Quality Control (QC). This is the basis of safe and reliable treatments. BNCT must apply QA programs as required for performance and safety in (conventional) radiotherapy facilities, including regular testing of performance characteristics (QC). Furthermore, the well-established Quality Management (QM) system of the nuclear reactor used has to be followed. Organization of these complex QM procedures is offered by the international standard ISO 9001:2008.

  4. Advances in boron neutron capture therapy (BNCT) at kyoto university - From reactor-based BNCT to accelerator-based BNCT

    Science.gov (United States)

    Sakurai, Yoshinori; Tanaka, Hiroki; Takata, Takushi; Fujimoto, Nozomi; Suzuki, Minoru; Masunaga, Shinichiro; Kinashi, Yuko; Kondo, Natsuko; Narabayashi, Masaru; Nakagawa, Yosuke; Watanabe, Tsubasa; Ono, Koji; Maruhashi, Akira

    2015-07-01

    At the Kyoto University Research Reactor Institute (KURRI), a clinical study of boron neutron capture therapy (BNCT) using a neutron irradiation facility installed at the research nuclear reactor has been regularly performed since February 1990. As of November 2014, 510 clinical irradiations were carried out using the reactor-based system. The world's first accelerator-based neutron irradiation system for BNCT clinical irradiation was completed at this institute in early 2009, and the clinical trial using this system was started in 2012. A shift of BCNT from special particle therapy to a general one is now in progress. To promote and support this shift, improvements to the irradiation system, as well as its preparation, and improvements in the physical engineering and the medical physics processes, such as dosimetry systems and quality assurance programs, must be considered. The recent advances in BNCT at KURRI are reported here with a focus on physical engineering and medical physics topics.

  5. The time-of-flight epithermal neutron spectrum measurement from accelerator based BNCT facility

    International Nuclear Information System (INIS)

    Results of epithermal neutrons spectrum measurement by time-of-flight method for different beam shaping assembly designed for BNCT purposes are presented. Discuss method to realize time-of-flight measurement at accelerator. Results looks are important for beam shaping assembly optimization and accurate and reliable treatment planning. (author)

  6. First tomographic image of neutron capture rate in a BNCT facility

    International Nuclear Information System (INIS)

    This work discusses the development of online dosimetry of the boron dose via Single Photon Emission Computed Tomography (SPECT) during a BNCT treatment irradiation. Such a system will allow the online computation of boron dose maps without the large current uncertainties in the assessment of the boron concentration in different tissues. The first tomographic boron dose image with a SPECT prototype is shown.

  7. Guidelines for treatment naming in radiation oncology.

    Science.gov (United States)

    Denton, Travis R; Shields, Lisa B E; Hahl, Michael; Maudlin, Casey; Bassett, Mark; Spalding, Aaron C

    2015-01-01

    Safety concerns may arise from a lack of standardization and ambiguity during the treatment planning and delivery process in radiation therapy. A standardized target and organ-at-risk naming convention in radiation therapy was developed by a task force comprised of several Radiation Oncology Societies. We present a nested-survey approach in a community setting to determine the methodology for radiation oncology departments to standardize their practice. Our Institution's continuous quality improvement (CQI) committee recognized that, due to growth from one to three centers, significant variability existed within plan parameters specific to patients' treatment. A multidiscipline, multiclinical site consortium was established to create a guideline for standard naming. Input was gathered using anonymous, electronic surveys from physicians, physicists, dosimetrists, chief therapists, and nurse managers. Surveys consisted of several primary areas of interest: anatomical sites, course naming, treatment plan naming, and treatment field naming. Additional concepts included capitalization, specification of later-ality, course naming in the event of multiple sites being treated within the same course of treatment, primary versus boost planning, the use of bolus, revisions for plans, image-guidance field naming, forbidden characters, and standard units for commonly used physical quantities in radiation oncology practice. Guidelines for standard treatment naming were developed that could be readily adopted. This multidisciplinary study provides a clear, straightforward, and easily implemented protocol for the radiotherapy treatment process. Standard nomenclature facilitates the safe means of communication between team members in radiation oncology. The guidelines presented in this work serve as a model for radiation oncology clinics to standardize their practices. PMID:27074449

  8. Improving sewage wastewater characteristics using radiation treatment

    International Nuclear Information System (INIS)

    Raw and treated sewage wastewater, collected from El-Gabal El-Asfar wastewater treatment plant (WWTP), irradiated and non-irradiated, were tested in order to determine the lethal radiation dose for total coliform and the effect of radiation on biological oxygen demand (BOD) and chemical oxygen demand (COD). Various gamma radiation and electron beam doses (0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 KGy) were used in this study. A negative relationship between the radiation dose and the total coliform population was recorded. The increase in the radiation dose was accompanied by a decrease in total coliform count. The lethal doses of gamma radiation for total coliform in raw and treated sewage wastewater were 1.5 and 1.0 KGy, respectively, whereas the lethal doses of the electron beam for total coliform in raw and treated sewage wastewater were 3.0 and 2.0 KGy, respectively. Gamma radiation resulted in a reduction of BOD and COD by about 70% whereas the electron beam resulted in 55% reduction in BOD and COD at a dose of 4 KGy. The different sources of radiation (gamma and electron beam) used in this study caused variations in the magnitude of total coliform elimination. At any radiation dose received, gamma radiation proved to be more efficient than electron beam in total coliform elimination

  9. Hyperbaric oxygen treatment for haemorrhagic radiation cystitis

    Energy Technology Data Exchange (ETDEWEB)

    Bevers, R.F.M.; Kurth, K.H. [Amsterdam Univ. (Netherlands). Academic Medical Center; Bakker, D.J. [Amsterdam Univ. (Netherlands). Depts. of Urology and Surgery

    1995-09-23

    Radiation-induced severe haemorrhagic cystitis is difficult to treat. Conventional treatments may decrease haematuria but do not affect the radiocystitis itself. Hyperbaric oxygen treatment has been reported to do both. We report the results of a prospective study of hyperbaric oxygen (20 sessions of 100% oxygen inhalation at 3 bar for 90 min in a multiplace hyperbaric chamber) to 40 patients with biopsy-proven radiation cystitis and severe haematuria. Haematuria disappeared completely or improved in 37 patients after treatment. Mean follow-up was 23.1 months (range 1-74); and the recurrence rate was 0.12/year. There were no adverse effects. Hyperbaric oxygen treatment should be considered for patients with severe radiation-induced haematuria. (author).

  10. Might iodomethyl-{alpha}-tyrosine be a surrogate for BPA in BNCT?

    Energy Technology Data Exchange (ETDEWEB)

    Miura, Michiko; Micca, P.L.; Nawrocky, M.M.; Slatkin, D.N.

    1996-12-31

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with {sup 10}B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that {sup 10}B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing {sup 18}F-fluoroboronophenylaianine [FBPA] as a positron {sup 18}F (T{sub 1/2} = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of {sup 123}I alpha methyltyrosine as a surrogate for BPA in BNCT.

  11. Might iodomethyl-α-tyrosine be a surrogate for BPA in BNCT?

    International Nuclear Information System (INIS)

    A single-photon emission computed tomography [SPECT] imaging agent that is an analogue of a boron carrier for boron neutron-capture therapy [BNCT] of cerebral gliomas would be useful for assessing the kinetics of boron uptake in tumors and in the surrounding brain tissues noninvasively. BNCT is based on the interaction of thermalized neutrons with 10B nuclei in the targeted tumor. For BNCT of brain tumors, it is crucial that 10B concentrations in radiosensitive regions of the brain be minimal since malignant cells and vital brain tissues are often inter-mingled at the margins of the tumor. Currently, boronophenylalanine [BPA]-mediated BNCT is undergoing preliminary clinical study for postoperative radiotherapy of glioblastorna multiforme at Brookhaven National Laboratory. Investigators in Japan are developing 18F-fluoroboronophenylaianine [FBPA] as a positron 18F (T1/2 = 110 min), which is usually emission tomography [PET] surrogate for BPA. generated at a cyclotron dedicated to PET, is generally a minimally perturbing substitute for the 2-H on the aromatic ring because of its small size and the strong covalent bond it forms with carbon. However, SPECT has potential advantages over PET: (1) SPECT is clinically more widely available at lower cost; (2) most radioisotopes for the synthesis of SPECT agents can be purchased; (3) SPECT is less difficult to implement. It is thought that the quality of images derived from the two techniques would each be sufficiently informative for BNCT treatment planning purposes, provided that the SPECT and PET agents being considered were both pharmacokinetic surrogates for BPA. This study evaluated the use of 123I alpha methyltyrosine as a surrogate for BPA in BNCT

  12. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    OpenAIRE

    Samia de Freitas Brandao; Tarcisio Passos Ribeiro de Campos

    2013-01-01

    Objective Comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and Methods Simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted int...

  13. Medical set-up of boron neutron capture therapy (BNCT) for malignant glioma at the Japan research reactor (JRR)-4

    International Nuclear Information System (INIS)

    The University of Tsukuba project for boron neutron capture therapy (BNCT) was initiated at the Japan Atomic Energy Research Institute (JAERI) in 1992. The clinical study for BNCT began at the Japan Research Reactor (JRR)-2 of the JAERI in November 1995. By the end of 1998, a new medical irradiation facility had been installed in JRR-4 of that included a new medical treatment room and patient-monitoring area adjacent to the irradiation room. The medical treatment room was built to reflect a hospital-type operation room that includes an operating table with a carbon head frame, anesthesia apparatus with several cardiopulmonary monitors, etc. Following craniotomy in the treatment room, a patient under anesthesia is transported into the irradiation room for BNCT. The boron concentration in tissue is measured with prompt gamma ray analysis (PGA) and simultaneously by inductively coupled plasma atomic emission spectroscopy (ICP-AES) methods. For the immediate pre- and post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of the JAERI. The long term follow-up is done at the University of Tsukuba Hospital. Epithermal neutron beam also became available at the new JRR-4. By changing the thickness and/or the configuration of heavy water, a cadmium plate, and a graphite reflector, the JRR-4 provides a variety of neutron beams, including three typical beams (Epithermal mode and Thermal modes I and II). Intraoperative BNCT using the thermal beam is planned to study at the beginning of the clinical trial. The ongoing development of the JAERI Computational Dosimetry System (JCDS) and radiobiological studies have focused in the application of the epithermal beam for BNCT. After obtaining these basic data, we are planning to use the epithermal beam for intraoperative BNCT. (author)

  14. Radiation treatment of drugs, biochemicals and vaccines

    International Nuclear Information System (INIS)

    The concise and tabulated review reports experimental results on the effects of radiation treatment on drugs, vaccines, biochemicals and adjuvants including enzymes as well. Irradiation was mostly performed by γ-radiation using 60Co and to a lesser extent by 137Cs, 182Ta, X-rays and accelerators. Ionizing radiation proved to be a useful tool for sterilization and inactivation in producing drugs, vaccines, and bioactive agents and will contribute to realize procedures difficultly solvable as to engineering and economy, respectively. 124 refs

  15. Head and Neck Radiation Treatment and Your Mouth

    Science.gov (United States)

    ... Mouth Head and Neck Radiation Treatment and Your Mouth Main Content Are You Being Treated With Radiation ... How Does Head and Neck Radiation Affect the Mouth? Doctors use head and neck radiation to treat ...

  16. Clinical results of BNCT for malignant gliomas using BSH and BPA simultaneously

    International Nuclear Information System (INIS)

    Since 2002 to 2006, we applied BNCT for 41 cases of malignant gliomas. We used 3 different protocols. In each protocol, we used BSH and BPA simultaneously. In protocol 1, BSH 5g/body and BPA 250 mg/kg were used for consecutive 13 cases. Median survival time (MST) of newly diagnosed 4 cases of GB was 23 months after diagnosis. 2 cases were still alive. All cases including recurrent ones showed radiographic improvement. Eight out of 12 cases showed more than 50% mass reduction on images. Major cause of death was CSF dissemination. In protocol 2, BNCT were applied for 4 patients, two times with one to 2 week-interval. MST after BNCT was 13.3 months. In protocol 3, BPA 700 mg/kg were used with 20 to 30 Gy XRT after BNCT. XRT boost was applied especially for deeper part of the tumor. In protocol 3, 6 newly diagnosed GB patients were observed more than 16 months. 3 were dead and 3 were still alive on the preparation of this abstract. MST of these 6 patients was 17.3 months after diagnosis. In each protocol, radiation necrosis was the problem for recurrent cases, while removal of the necrosis prolonged the survival and recovered the neurological deficits. (author)

  17. Residual water treatment for gamma radiation

    International Nuclear Information System (INIS)

    The treatment of residual water by means of gamma radiation for its use in agricultural irrigation is evaluated. Measurements of physical, chemical, biological and microbiological contamination indicators were performed. For that, samples from the treatment center of residual water of San Juan de Miraflores were irradiated up to a 52.5 kGy dose. The study concludes that gamma radiation is effective to remove parasites and bacteria, but not for removal of the organic and inorganic matter. (author). 15 refs., 3 tabs., 4 figs

  18. Treatment of coffee wastewater by gamma radiation

    International Nuclear Information System (INIS)

    Radiation energy can be an important resource in the treatment of wastewaters from different industries both directly and in combination with other processes to improve economics. The aim of this study was to evaluate the effect of an ionizing radiation on coffee wastewater in order to decompose chemical organic refractory substances which cannot be degradated by biological treatment. One of the approaches employed in the survey was the chemical treatment followed by the irradiation of the samples since no nuclear changes of the coagulant solution or wastewater samples were expected. Irradiation is a high cost treatment although it has increased its applications nowadays. The method is safe, fast and effective and it does not generate any pollution

  19. Radiation treatment of landfill leachate

    International Nuclear Information System (INIS)

    The removal of organic substance from landfill leachate by gamma irradiation has been studied by the authors. In this report, the combination of gamma irradiation and activated sludge treatment for this purpose is introduced. The leachate was collected at the reclaimed land in Tokyo Bay. Gamma irradiation was made by a 5 kCi Co-60 source, and the maximum irradiation dose was 6 Mrad. Activated sludge was added to the irradiated and unirradiated samples. After stirring and filtration, COD, TOC and BOD were measured. The amounts of COD and TOC decreased with the increase of irradiation dose. The linear relation between the logarithm of concentration and irradiation time was seen. The amount of BOD increased rapidly with irradiation dose, and reached the maximum (68 mg/l) at the dose of 1.7 Mrad. After the addition of activated sludge, the amount of BOD in the irradiated and unirradiated samples decreased. The amounts of COD and TOC in unirradiated samples did not make appreciable change 8 hours after the addition. These amounts in the irradiated samples stirred with activated sludge decreased. The rate of removal of organic substances was also studied. (Kato, T.)

  20. Optimization of the BNCT filter

    International Nuclear Information System (INIS)

    The Czech Boron Neutron Capture Therapy (BNCT) facility works by an epithermal neutron beam installed at the LVR-15 reactor at Rez near Prague. Several configurations of moderating and shielding materials have been designed in order to ensure appropriate parameters of the beam. The beam filter consists of cylindrical layers of Al, AlF3 and Ti. To decrease the gamma two layers of Pb are implemented. The filter geometry and composition has been optimized with the aim to increase the epithermal neutron fluence rate and decrease the fast neutron dose rate using the MCNP-4B Monte Carlo code with the DLC-189 library. Suitable patterns of the reactor core were also studied especially in regard to a possible installation of fuel units close to the filter input. Results of calculations show that the optimized variant of the reactor core is able to increase the intensity of the fast neutron source incident to the filter by a factor of 2.0. An experimental verification of the beam parameters was performed using different measurement techniques. The neutron energy spectrum was measured with a set of activation foils, by a Bonner spheres spectrometer and a fast neutron spectrometer with a stilbene crystal. The fast neutron kerma rate was calculated from the spectral measurement. Al-P TLD were used to measure the photon absorbed dose. The beam parameters were measured at 10 MW and were found as follows: the epithermal neutron fluence rate (an energy range from 1 eV to 10 keV) of 9.29 x 1012 m-2 s-1, the fast neutron kerma rate in tissue of 2.63 Gy h-1 and the incident gamma dose rate in tissue of 29 Gy h-1. (author)

  1. BNCT treatment planning for superficial and deep-seated tumors: Experience from clinical trial of recurrent head and neck cancer at THOR.

    Science.gov (United States)

    Liu, Yen-Wan Hsueh; Chang, Chih-Ting; Yeh, Lan-Yun; Wang, Ling-Wei; Lin, Tzung-Yi

    2015-12-01

    Under the collaboration between National Tsing Hua University and Taipei Veterans General Hospital, clinical trial of recurrent head-and-neck cancer by Boron neutron capture therapy at Tsing Hua open-pool reactor started on August 11, 2010. Up to January 2014, 17 patients were treated. Based on the treatment planning experiences of clinical trials using in-house designed THORplan, different setups should be used for superficial and deep-seated tumors. Superficial tumor treatment gains benefits from the use of patient collimator, while direct irradiation is a better choice for deep-seated tumor. PMID:26278349

  2. Development of Radiation Technique for Environmental Treatment

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Myun Joo; Kuk, Il Hiun; Jin, Joon Ha (and others)

    2007-02-15

    The purpose of this research is to development of technologies for 1) the removal of toxic organic chemicals in sewage sludges and the volume reduction of the sewage sludge 2) the recycling/reuse of sewage sludge 3) the reconvey of resource from fishery waste by using radiation technologies. This research project focused on the study of treatment, disposal, and recycling/reuse of sewage sludge by radiation technology, and recovery of highly value-added resources from the wastes. As basic studies with a radiation technology, an enhancement of dewaterbilities of sewage sludge, development of dewatering conditioner, reduction of trace toxic organic chemicals, and the toxicities of the byproducts were studied. Based on the basic experimental results, we developed the pilot-scale system with the continuous e-beam and dewatering unit and the advanced treatment system with the use of carbon source recovered from sewage sludge.

  3. Classification and treatment of radiation maculopathy.

    LENUS (Irish Health Repository)

    Horgan, Noel

    2012-02-01

    PURPOSE OF REVIEW: Radiation maculopathy is a sight-limiting consequence of radiotherapy in the management of uveal melanoma and other intraocular tumors. In this review, we consider clinical, fluorescein angiographic and optical coherence tomographic findings, propose a classification for radiation maculopathy and discuss the management of this condition. RECENT FINDINGS: Radiation macular edema (RME) can be classified by optical coherence tomography into noncystoid or cystoid edema, with foveolar or extrafoveolar involvement. Optical coherence tomographic grading of RME has been found to correlate with visual acuity. Focal argon laser might have some limited benefit in the treatment of RME. Intravitreal triamcinolone and intravitreal antivascular endothelial growth factor agents can be of short-term benefit in the treatment of RME. In a randomized controlled trial, periocular triamcinolone significantly reduced rates of RME and vision loss up to 18 months following plaque radiotherapy for uveal melanoma. SUMMARY: Currently, there is no proven treatment for established RME, though periocular triamcinolone has been shown to have a preventive benefit. An accepted classification system for radiation maculopathy would be of benefit in planning and comparing future treatment trials.

  4. The BNCT facility at the HFR Petten: Quality assurance for reactor facilities in clinical trials

    International Nuclear Information System (INIS)

    The first clinical trial in Europe of Boron Neutron Capture Therapy (BNCT) for the treatment of glioblastoma was opened in July 1997. The trial is a Phase I study with the principal aim to establish the maximum tolerated radiation dose and the dose limiting toxicity under defined conditions. It is the first time that a clinical application could be realised on a completely multi-national scale. The treatment takes place at the High Flux Reactor (HFR) in Petten, the Netherlands, is operated by an international team of experts under the leadership of a German radiotherapist, and treats patients coming from different European countries. It has therefore been necessary to create a very specialised organisation and contractual structure with the support of administrations from different countries, who had to find and adapt solutions within existing laws that had never foreseen such a situation. Furthermore, the treatment does not take place in an hospital environment and even more so, the facility is at a nuclear research reactor. Hence, special efforts were made on quality assurance, in order that the set-up at the facility and the personnel involved complied, as closely as possible, with similar practices in conventional radiotherapy departments. (author)

  5. INEL BNCT Program: Volume 5, No. 9

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1991-01-01

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory's (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  6. Radiation treatment of secondary effluent from a sewage treatment plant

    Energy Technology Data Exchange (ETDEWEB)

    Jung, Jinho E-mail: jjung@korea.ac.kr; Yoon, J.-H.; Chung, H.-H.; Lee, M.-J

    2002-11-01

    Radiation treatment using gamma-rays was investigated in order to reclaim the secondary effluent from a sewage treatment plant. The radiation treatment reduced BOD by 85% irrespective of absorbed dose, and the removals of COD, TOC and color were up to 64%, 34% and 88%, respectively, at a dose of 15 kGy. Gamma-rays effectively disinfected microorganisms and completely removed them at a dose of 0.3 kGy. The combination of gamma-rays and titanium dioxide significantly improved the treatment process. The increases of COD, TOC and color removals were 40%, 10% and 20%, respectively. As confirmed by EPR and the spin-trapping method, this increase was partly caused by the increase of hydroxyl radicals in the presence of titanium dioxide.

  7. Radiation treatment of secondary effluent from a sewage treatment plant

    International Nuclear Information System (INIS)

    Radiation treatment using gamma-rays was investigated in order to reclaim the secondary effluent from a sewage treatment plant. The radiation treatment reduced BOD by 85% irrespective of absorbed dose, and the removals of COD, TOC and color were up to 64%, 34% and 88%, respectively, at a dose of 15 kGy. Gamma-rays effectively disinfected microorganisms and completely removed them at a dose of 0.3 kGy. The combination of gamma-rays and titanium dioxide significantly improved the treatment process. The increases of COD, TOC and color removals were 40%, 10% and 20%, respectively. As confirmed by EPR and the spin-trapping method, this increase was partly caused by the increase of hydroxyl radicals in the presence of titanium dioxide

  8. The first main steps for development of BNCT neutron sources at the Ukrainian and Uzbek Research Reactors

    International Nuclear Information System (INIS)

    Both in Ukraine and in Uzbekistan, epithermal neutron irradiation facilities for Boron Neutron Capture Therapy (BNCT) are under consideration, as the need for them is very large. Based on information from medical cancer treatment institutions of the total number of patients identified with cancer, about 5000 have brain tumours. The most prospective method of their treatment is BNCT. Both in Ukraine and in Uzbekistan, this method can be implemented on existing research reactors. Modification of research reactors may be a relatively straightforward and inexpensive way to develop a BNCT neutron source, especially in comparison with construction of new reactors specialized for BNCT. However, prior to any reactor modification, careful calculations need to be performed, which take into account all the peculiarities of the specific reactor system. Based on the world experience in epithermal neutron beam development, it is very clear that the research reactors in Kyiv (Kyiv Research Reactor-KRR) and Tashkent (Tashkent Research Reactor-TRR) may be reconstructed into epithermal irradiation facilities. Selection of the most suitable materials for moderator, collimator, shielding, etc., demands carrying out calculations considering their individual characteristics. Since the KRR and TRR are the same kind of research reactors, with for example similar thermal columns, the development of a BNCT neutron source at these research reactors may be achieved in a like manner. The development plan and the first experience in this direction (using preliminary MCNP calculation results) are presented here. (author)

  9. Online external beam radiation treatment simulator

    International Nuclear Information System (INIS)

    Radiation therapy is an effective and widely accepted form of treatment for many types of cancer that requires extensive computerized planning. Unfortunately, current treatment planning systems have limited or no visual aid that combines patient volumetric models extracted from patient-specific CT data with the treatment device geometry in a 3D interactive simulation. We illustrate the potential of 3D simulation in radiation therapy with a web-based interactive system that combines novel standards and technologies. We discuss related research efforts in this area and present in detail several components of the simulator. An objective assessment of the accuracy of the simulator and a usability study prove the potential of such a system for simulation and training. (orig.)

  10. Synthesis and evaluation of boron folates for Boron-Neutron-Capture-Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Kettenbach, Kathrin; Schieferstein, Hanno; Grunewald, Catrin; Hampel, Gabriele; Schuetz, Christian L. [Mainz Univ. (Germany). Inst. of Nuclear Chemistry; Iffland, Dorothee; Bings, Nicolas H. [Mainz Univ. (Germany). Inst. of Inorganic Chemistry and Analytical Chemistry; Reffert, Laura M. [Hannover Medical School (Germany). Radiopharmaceutical Chemistry; Ross, Tobias L. [Mainz Univ. (Germany). Inst. of Nuclear Chemistry; Hannover Medical School (Germany). Radiopharmaceutical Chemistry

    2015-07-01

    Boron neutron capture therapy (BNCT) employs {sup 10}B-pharmaceuticals administered for the treatment of malignancies, and subsequently irradiated with thermal neutrons. So far, clinical established pharmaceuticals like boron phenylalanine (BPA) or sodium boron mercaptate (BSH) use imperfect (BPA) or passive (BSH) targeting for accumulation at target sites. Due to the need of a selective transportation of boron drugs into cancer cells and sparing healthy tissues, we combined the BNCT approach with the specific and effective folate receptor (FR) targeting concept. The FR is overexpressed on many human carcinomas and provides a selective and specific target for molecular imaging as well as for tumor therapy. We synthesized and characterized a carborane-folate as well as a BSH-folate to study their in vitro characteristics and their potential as new boron-carriers for BNCT. Uptake studies were carried out using human KB cells showing a significant increase of the boron content in cells and demonstrating the successful combination of active FR-targeting and BNCT.

  11. Characteristics of the new THOR epithermal neutron beam for BNCT

    International Nuclear Information System (INIS)

    A characterization of the new Tsing Hua open-pool reactor (THOR) epithermal neutron beam designed for boron neutron capture therapy (BNCT) has been performed. The facility is currently under construction and expected in completion in March 2004. The designed epithermal neutron flux for 1 MW power is 1.7x109 n cm-2 s-1 in air at the beam exit, accompanied by photon and fast neutron absorbed dose rates of 0.21 and 0.47 mGy s-1, respectively. With 10B concentrations in normal tissue and tumor of 11.4 and 40 ppm, the calculated advantage depth dose rate to the modified Snyder head phantom is 0.53 RBE-Gy min-1 at the advantage depth of 85 mm, giving an advantage ratio of 4.8. The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard-MIT clinical trial were compared with results of the MITR-II M67 beam. The present study confirms the suitability of the new THOR beam for possible BNCT clinical trials

  12. Mass spectral investigations of boron neutron capture therapy (BNCT) agents

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a promising technique for the treatment of selected types of brain tumor and potentially for other tumor types. In this therapy, a 10B-enriched species is administered to the bloodstream and selectively deposited in the tumor. The selective deposition in the tumor is due to either the breakdown of the blood-grain barrier or to the chemical nature of the boron-containing compounds. Once a sufficient concentration of boron is attained in the tumor (approximately 25 ppm), the tumor is irradiated with a controlled energy neutron beam (preferable epithermal, 1 eV to 10 keV), at which time neutrons are captured by the incorporated boron atoms. The capture results in the reaction, 10B(n, ) Li, which produces a localized nuclear reaction capable of destroying the tumor cell containing the boron. A variety of boron containing compounds have been evaluated for use in BNCT. This paper addresses some of the most promising of the compounds, the disodium salt of mercaptoundecahydrododecaborate (Na2B12H11SH), commonly referred to as BSH

  13. Radiation treatment of polluted water and wastewater

    International Nuclear Information System (INIS)

    Strategies to tackle environmental pollution have been receiving increasing attention throughout the world in recent years. Radiation processing using electron beam accelerators and gamma irradiators has shown very promising results in this area. Radiation processing in wastewater treatment is an additive-free process that uses the short lived reactive species formed during the radiolysis of water for efficient decomposition of pollutants therein. The rapid growth of the global population, together with the increased development of agriculture and industry, have led to the generation of large quantities of polluted industrial and municipal wastewater. The recognition that these polluted waters may pose a serious threat to humans has led technologists to look for cost effective technologies for their treatment. A variety of methods based on biological, chemical, photochemical and electrochemical processes are being explored for decomposing the chemical and biological contaminants present in the wastewaters. Studies in recent years have demonstrated the effectiveness of ionizing radiation such as, gamma rays and electron beams or in combination with other treatments, in the decomposition of refractory organic compounds in aqueous solutions and in the effective removal or inactivation of various microorganisms and parasites. The application of electron beam processing for drinking water, wastewater and groundwater treatment offers the promise of a cost effective process. The installation of the first full scale electron beam plant in Daegu, Republic of Korea, to treat 10 000 m3 day-1 textile wastewater has demonstrated that the process is a cost effective technology when compared to conventional treatment. The regular operation of this facility provides operational data on reliability and additional data for a detailed economic evaluation. The IAEA has been supporting activities in this area by organizing advisory group meetings, consultants meetings, symposia and

  14. Treatment of radiation enteritis: a comparison study

    Energy Technology Data Exchange (ETDEWEB)

    Loiudice, T.A.; Lang, J.A.

    1983-08-01

    Twenty-four patients with severe radiation injury to the small bowel seen over a 4-year period were randomized to four treatment groups: 1) methylprednisolone 80 mg intravenously plus Vivonex-HN, 2 L/day po, 2) methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day, 3) total parenteral nutrition, 2.5 L/day, and 4) Vivonex-HN, 2 L/day po. Patients received nothing by mouth except water in groups II and III, and only Vivonex-HN in groups I and IV. Patients were treated for 8-wk periods. Improvement was gauged by overall nutritional assessment measurements, nitrogen balance data and by radiological and clinical parameters. No significant difference between groups I, II, III, and IV could be found for age, sex, mean radiation dosage, time of onset after radiation therapy, or initial nutritional assessment data. Differences statistically could be found between groups II and III and I and IV regarding nutritional assessment data, nitrogen balance, radiographic and clinical parameters after therapy, with marked improvement noted in groups II and III. We conclude that a treatment regimen consisting of total parenteral nutrition and bowel rest is beneficial in the treatment of radiation enteritis. Methylprednisolone appears to enhance this effect and indeed, may be responsible for a longer lasting response.

  15. Treatment of radiation enteritis: a comparison study.

    Science.gov (United States)

    Loiudice, T A; Lang, J A

    1983-08-01

    Twenty-four patients with severe radiation injury to the small bowel seen over a 4-year period were randomized to four treatment groups: 1) methylprednisolone 80 mg intravenously plus Vivonex-HN, 2 L/day po, 2) methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day, 3) total parenteral nutrition, 2.5 L/day, and 4) Vivonex-HN, 2 L/day po. Patients received nothing by mouth except water in groups II and III, and only Vivonex-HN in groups I and IV. Patients were treated for 8-wk periods. Improvement was gauged by overall nutritional assessment measurements, nitrogen balance data and by radiological and clinical parameters. No significant difference between groups I, II, III, and IV could be found for age, sex, mean radiation dosage, time of onset after radiation therapy, or initial nutritional assessment data. Differences statistically could be found between groups II and III and I and IV regarding nutritional assessment data, nitrogen balance, radiographic and clinical parameters after therapy, with marked improvement noted in groups II and III. We conclude that a treatment regimen consisting of total parenteral nutrition and bowel rest is beneficial in the treatment of radiation enteritis. Methylprednisolone appears to enhance this effect and indeed, may be responsible for a longer lasting response. PMID:6410908

  16. Treatment of radiation enteritis: a comparison study

    International Nuclear Information System (INIS)

    Twenty-four patients with severe radiation injury to the small bowel seen over a 4-year period were randomized to four treatment groups: 1) methylprednisolone 80 mg intravenously plus Vivonex-HN, 2 L/day po, 2) methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day, 3) total parenteral nutrition, 2.5 L/day, and 4) Vivonex-HN, 2 L/day po. Patients received nothing by mouth except water in groups II and III, and only Vivonex-HN in groups I and IV. Patients were treated for 8-wk periods. Improvement was gauged by overall nutritional assessment measurements, nitrogen balance data and by radiological and clinical parameters. No significant difference between groups I, II, III, and IV could be found for age, sex, mean radiation dosage, time of onset after radiation therapy, or initial nutritional assessment data. Differences statistically could be found between groups II and III and I and IV regarding nutritional assessment data, nitrogen balance, radiographic and clinical parameters after therapy, with marked improvement noted in groups II and III. We conclude that a treatment regimen consisting of total parenteral nutrition and bowel rest is beneficial in the treatment of radiation enteritis. Methylprednisolone appears to enhance this effect and indeed, may be responsible for a longer lasting response

  17. Retrospective review of the clinical BNCT trial at Brookhaven National Laboratory

    Energy Technology Data Exchange (ETDEWEB)

    Diaz, A.Z.; Chanana, A.D.; Coderre, J.A.; Ma, R. [Brookhaven National Laboratory, Medical Department, Upton, NY (United States)

    2000-10-01

    The primary objective of the phase I/II dose escalation studies was to evaluate the safety of the boronophenylalanine-fructose (BPA-F) mediated boron neutron capture therapy (BNCT) in subjects with glioblastoma multiforme (GBM). A secondary objective was to retrospectively assess the palliation of GBM by BNCT. Fifty-three subjects with GBM were treated under multiple dose escalation protocols at the Brookhaven Medical Research Reactor (BMRR). Twenty-six subjects were treated using one field, 17 subjects were treated using 2 fields and 10 subjects were treated using 3 fields. BPA-F related toxicity was not observed. The maximum radiation dose to a volume of approximately 1 cc of the normal brain varied from 8.9 to 15.9 gray-equivalent (Gy-Eq). The volume-weighted average radiation dose to normal brain varied from 1.9 to 9.5 Gy-Eq. Six RTOG (Radiation Therapy Oncology Group) grade 3 or 4 toxicities were attributed to BNCT. Four of the 53 subjects are still alive with 3 of them free of recurrent disease with over two years follow-up. The median times to progression and median survival time from diagnosis were 28.4 weeks and 12.8 months respectively. (author)

  18. Retrospective review of the clinical BNCT trial at Brookhaven National Laboratory

    International Nuclear Information System (INIS)

    The primary objective of the phase I/II dose escalation studies was to evaluate the safety of the boronophenylalanine-fructose (BPA-F) mediated boron neutron capture therapy (BNCT) in subjects with glioblastoma multiforme (GBM). A secondary objective was to retrospectively assess the palliation of GBM by BNCT. Fifty-three subjects with GBM were treated under multiple dose escalation protocols at the Brookhaven Medical Research Reactor (BMRR). Twenty-six subjects were treated using one field, 17 subjects were treated using 2 fields and 10 subjects were treated using 3 fields. BPA-F related toxicity was not observed. The maximum radiation dose to a volume of approximately 1 cc of the normal brain varied from 8.9 to 15.9 gray-equivalent (Gy-Eq). The volume-weighted average radiation dose to normal brain varied from 1.9 to 9.5 Gy-Eq. Six RTOG (Radiation Therapy Oncology Group) grade 3 or 4 toxicities were attributed to BNCT. Four of the 53 subjects are still alive with 3 of them free of recurrent disease with over two years follow-up. The median times to progression and median survival time from diagnosis were 28.4 weeks and 12.8 months respectively. (author)

  19. A colorimetric determination of boron in biological sample for boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    The boron neutron capture therapy (BNCT) has shown better prognosis in the treatment of glyemas and gluoblastomas grade III and IV than other therapies. During the treatment the levels of Na210B12H11SH must be known in several compartiments of the organism and with this purpose the method of colorimetric determination of boron using curcumine was established. This method is simple, reprodutible and adequate sensitivity for this control. (author)

  20. An economic model to assess the cost-benefit of BNCT.

    Science.gov (United States)

    Kulvik, Martti; Hermans, Raine; Linnosmaa, Ismo; Shalowitz, Joel

    2015-12-01

    We have constructed a formal model on cost-benefit of new technology in health care, and apply it on boron neutron capture therapy (BNCT). We assume that the patient health benefit from getting cured in acute treatment is always higher than the patient utility resulting from any long term treatment or death. This assumption makes it possible to evaluate the monetary cost impacts of a new technology and relate these measures to the patient health benefit. PMID:26365901

  1. Simulation and radiation treatment in external radiotherapy

    International Nuclear Information System (INIS)

    It is well known that in order to obtain a uniform dose in the treated volume as defined in ICRU 50, there should be a 10% maximum difference between maximum and minimum dose values in treatment planning. Clinical target volume (CTV) should be related to external areas of body sections where tumour is located. These areas are important because different radiation beams enter through them. Therefore, verification of the planning target volume (PTV) through the external areas is highly significant. In this work we point out the importance of controlling that PTV is irradiated as planned considering some error sources usually found in radiotherapy practice with equipment that has been intensively used for a long time. Moreover, I think this experience will be helpful for those centers around the world where radiation treatment is carried out with reconditioned units. (author)

  2. Radiation treatment of subfoveal exsudative macular degeneration

    International Nuclear Information System (INIS)

    Treatment of patients with neovascular age-related macular degeneration (AMD) presenting with CNV which extend under the center of the fovea is discouraging. A new therapeutic regimen is the application of radiation, but the results of initial studies are contradictory. In a prospective study 40 patients - 9 males and 31 females - with a mean age of 74 years and exsudative AMD with involvement of the fovea were treated with radiation. Eight patients had classic, well-defined CNV, 32 had occult lesions. Radiation was administered on the posterior pole with a 8 MV-photon beam at a linear accelerator. A dose of 14.4 Gy, 1.8 Gy per day, 5 fractions per week was delivered through a single lateral port. After a follow-up of one year the visual acuity was stable in 6 patients and deteriorated by two or more lines in 34 patients. The central visual fields decreased significantly from 16.5 dB to 12.4 dB. The neovascular changes progressed in all patients. Our results did not show a beneficial effect of the radiation treatment with a dosage of 14.4 Gy whether on visual acuity nor on exsudative changes in patients with AMD. (author)

  3. A preclinical study of boron neutron capture therapy (BNCT) of spontaneous tumors in cats at RA-6 in Argentina

    International Nuclear Information System (INIS)

    BNCT is a binary treatment modality that combines irradiation with a thermal or epithermal neutron beam with tumor-seeking, boron containing drugs to produce selective irradiation of tumor tissue. Having demonstrated that BNCT mediated by boronophenylalanine (BPA) induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of RA-1. Having demonstrated partial tumor control with no radio toxic effects, the aim of the present study was to evaluate the effect of BPA-BNCT on tumor and normal tissue in 3 cases of spontaneous SCC in feline patients employing a higher neutron fluence than in the previous study. The present study was performed at RA-6 with the thermalized epithermal neutron beam. All three irradiations were successful. Except for an initial, moderate and reversible mucositis, no significant radio toxic effects were observed in terms of clinical follow-up, histological examination, biochemical analysis and assessment of autopsy material. Partial tumor control was evidenced in terms of growth inhibition and partial necrosis and improvement in the quality of life during the survival period. Optimization of the therapeutic efficacy of BNCT would require improvement in boron tumor targeting and strategies to increase in-depth dose in large tumors. (author)

  4. Delayed radiation effects of the skin - malignization and treatment

    International Nuclear Information System (INIS)

    44 cases of radiation cancer are analyzed. The malignization is related to late radiation ulcera and other radiation-induced changes such as fibrosis and dermatitis. The types of malignization are described and treatment plans are discussed

  5. Preliminary computational model for BNCT for breast cancer

    International Nuclear Information System (INIS)

    For the large number of women who are diagnosed with breast cancer every year, the available treatment options are effective, though physically and mentally taxing. This work begins a study of the efficacy of boron neutron capture therapy as an alternative treatment for this type of cancer. Using HER2-specific monoclonal antibodies coupled with a boron rich oligomeric phosphate diester, it may be possible to deliver large amounts of boron-10 to a tumor of the breast, which would allow for selective cell destruction via irradiation with a thermal neutron beam. A preliminary computational model (MCNP) of a deep-seated breast tumor is described as well as the calculated thermal neutron distribution within the tumor resulting from a thermal neutron source similar to those used for BNCT. A linear decrease in flux across the tumor volume is observed due to attenuation within the tissue prior to the tumor. Suggestions for future work are included. (author)

  6. Manufacturing of thin films of boron for the measurement of the {sup 10}B(n, {alpha}){sup 7} Li reaction used in BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Smilgys, Barbara; Oliveira, Sandro Guedes de; Hadler Neto, Julio Cesar; Vellame, Igor Alencar [Universidade Estadual de Campinas (UNICAMP), SP (Brazil). Inst. de Fisica Gleb Wataghin; Soares, Cleber Jose; Salim, Leonardo Alfredo [Universidade Estadual Paulista (UNESP), Rio Claro, SP (Brazil). Inst. de Geociencias e Ciencias Exatas; Coelho, Paulo Rogerio Pinto [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil). Centro de Engenharia Nuclear

    2011-07-01

    Full text: The Boron Neutron Capture Therapy (BNCT) is considered to be a possible treatment for different types of aggressive cancers located in areas of difficult access or which already have metastasis. The working principle of this therapy is the selective delivery of a greater amount of boron to the tumor cells than to the healthy ones, followed by the neutron irradiation that will induce the emission of {alpha} particles through the {sup 10}B(n, {alpha}){sup 7} Li reaction used in BNCT reaction. The high energy deposition of the product particles causes the death of the cells and this therapy becomes much effective if the healthy tissue is less exposed to this radiation. The objective of this work is to develop a method for measuring the rate of this reaction by using thin films of boron. We have manufactured thin films with different concentrations of boron deposited on mica and the thin films were exposed to different irradiation time intervals at the reactor IEA-R1 located at IPEN, Sao Paulo. Here we show our first results on the density and uniformity of the thin films, where the detection of the particles is made using plastic track detectors (CR-39) which have their structures damaged by the passage of ions. (author)

  7. Definition of treatment geometry in radiation therapy

    International Nuclear Information System (INIS)

    When accurate systems for quality assurance and treatment optimization are employed, a precise system for fixation and dosimetric and portal verification are as important as a continued and standardized code of practice for dosimetry and patient follow-up, including registration of tumour responses and acute and late normal tissue reactions. To improve the accuracy of existing dose response relations in order to improve future therapy the treatment geometry and dose delivery concepts have to be accurately defined and uniformly employed. A Nordic working group was set up in 1991 (by Nordic Association of Clinica Physics) to standardize the concepts and quantities used during the whole radiotherapy process in the Nordic countries. Now the group is finalizing its report ''Specification of Dose Delivery in Radiation Therapy''. The report emphasizes that the treatment geometry shall be consistent with the geometry used during the diagnostic work up. The patient fixation is of importance early in the diagnostic phase to ensure that the same reference points and patients position will be used both during the diagnostic work up, simulation and treatment execution. Reference Coordinate System of the patient is a concept based on defined anatomic reference points. This Patient Reference System is a local system which has validity for the tissues, organs and volumes defined during radiotherapy. The reference points of the Patient Reference System should in turn be used for beam set-up. The treatment geometry is then defined by using different concepts describing tissues which are mobile in the Patient Reference System, and finally, volumes which are fixed in this coordinate system. A Set-up Margin has to be considered for movements of the volumes defined in the Reference Coordinate System of the Patient in relation to the radiation beam. The Set-up Margin is dependent on the treatment technique and it is needed in the treatment planning procedure to ensure that the prescribed

  8. Monte Carlo simulations of the cellular S-value, lineal energy and RBE for BNCT

    International Nuclear Information System (INIS)

    Due to the non-uniform uptake of boron-containing pharmaceuticals in cells and the short-ranged alpha and lithium particles, microdosimetry provides useful information on the cellular dose and response of boron neutron capture therapy (BNCT). Radiation dose and quality in BNCT may be expressed in terms of the cellular S-value and the lineal energy spectrum. In the present work, Monte Carlo simulations were performed to calculate these microdosimetric parameters for different source-target configurations and sizes in cells. The effective relative biological effectiveness (RBE) of the Tsing Hua Open-pool Reactor (THOR) epithermal neutron beam was evaluated using biological weighting functions that depended on the lineal energy. RBE changes with source-target configurations and sizes were analyzed. (author)

  9. Combined TL and 10B-alanine ESR dosimetry for BNCT.

    Science.gov (United States)

    Bartolotta, A; D'Oca, M C; Lo Giudice, B; Brai, M; Borio, R; Forini, N; Salvadori, P; Manera, S

    2004-01-01

    The dosimetric technique described in this paper is based on electron spin resonance (ESR) detectors using an alanine-boric compound acid enriched with (10)B, and beryllium oxide thermoluminescent (TL) detectors; with this combined dosimetry, it is possible to discriminate the doses due to thermal neutrons and gamma radiation in a mixed field. Irradiations were carried out inside the thermal column of a TRIGA MARK II water-pool-type research nuclear reactor, also used for Boron Neutron Capture therapy (BNCT) applications, with thermal neutron fluence from 10(9) to 10(14) nth cm(-2). The ESR dosemeters using the alanine-boron compound indicated ESR signals about 30-fold stronger than those using only alanine. Moreover, a negligible correction for the gamma contribution, measured with TL detectors, almost insensitive to thermal neutrons, was necessary. Therefore, a simultaneous analysis of our TL and ESR detectors allows discrimination between thermal neutron and gamma doses, as required in BNCT. PMID:15353720

  10. Advances in radiation treatment of natural fibers

    International Nuclear Information System (INIS)

    A long term project has been developed to improve the properties of fibers of henequen. The fibers, impregnated with a monomer and with monomer-dye mixtures, were irradiated with Cobalt-60 gamma radiation. The properties of the materials depend on the amount of the polymer included in the fiber structure as a result of the radiation effect. This amount has been evaluated by means of spectroscopy and microscopical analysis, and related with dose and dose rate. The materials obtained by this treatment have better mechanical and surface properties than the non-treated ones. Also, the fibers dyed by the inclusion of the dye in the structure have a significant color solidity. The steps of the process have been optimized, particularly the impregnation. (author)

  11. FiR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

    International Nuclear Information System (INIS)

    The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT), but FiR 1 has also an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics etc. with isotope production and activation analysis services. In the 1990's a BNCT treatment facility was built at the FiR 1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material FluentalTM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality after a major renovation of the whole reactor building in 1997. Recently the lithiated polyethylene neutron shielding of the beam aperture was modified to ease the positioning of the patient close to the beam aperture. Increasing the reactor power to 500 kW would allow positioning of the patient further away from the beam aperture. Possibilities to accomplish a safety analysis for this is currently under considerations. Over thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. Currently three clinical trial protocols for tumours in the brain as well as in the head and neck region are recruiting patients. (author)

  12. Application of radiation for wastewater treatment

    International Nuclear Information System (INIS)

    Electron beam processing of wastewater is non-chemical, and uses fast formation of short-lived reactive radicals that can interact with a wide range of pollutants. Such reactive radicals are strong oxidizing or reducing agents that can transform the pollutants in the liquids wastes. The first studies on the radiation treatment of wastes were carried out in the 1950s principally for disinfection. In the 1960s, these studies were extended to the purification of water and wastewater. After some laboratory research on industrial wastewaters and polluted groundwater in 1970s and 1980s, several pilot plants were built for extended research in the 1990s. The first full-scale application was reported for the purification of wastewater at the Voronezh synthetic rubber plant in Russia. Two accelerators (50 kW each) were used to convert the non-biodegradable emulsifier, 'nekal', present in the wastewater to a biodegradable form . The installation treats up to 2000 m3 of effluent per day. A pilot plant of 1000 m3/d for treating textile-dyeing wastewater has been constructed in Daegu, Korea with 1 MeV, 40 kW electron accelerator. High-energy irradiation produces instantaneous radiolytical transformations by energy transfer from accelerated electrons to orbital electrons of water molecules. Absorbed energy disturbs the electron system of the molecule and results in breakage of inter-atomic bonds. Hydrated electron eaq, H atom, .OH and HO2. radicals and hydrogen peroxide H2O2 and H2 are the most important products of the primary interactions (radiolysis products). Generally, radiation processing of wastewater has maximum efficiency at pollutant concentration less than 10-3 mol/L (∼100 ppm). The treatment of such wastewater is simple, requires low dose (about 1 kGy or less) and gives almost complete elimination of odor, color, taste and turbidity. The radiation processing of polluted water containing specific contaminants may require creation of special conditions to achieve

  13. INEL BNCT Research Program, January/February 1993

    International Nuclear Information System (INIS)

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  14. INEL BNCT Research Program, May/June 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (IBPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  15. INEL BNCT Research Program, March/April 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-09-01

    This report presents summaries for two months of current research for the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murino screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronopheoylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  16. INEL BNCT research program, July--August 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-10-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  17. INEL BNCT Research Program, September--October 1992

    International Nuclear Information System (INIS)

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotain. carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophonylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  18. INEL BNCT Research Program, May/June 1992

    International Nuclear Information System (INIS)

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (IBPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed

  19. INEL BNCT Research Program, January/February 1993

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R. [ed.

    1993-04-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotein, carboranyl alanine, and liposome boron containing compounds. Pituitary tumor cell culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophenylaianine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  20. INEL BNCT Research Program, September--October 1992

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1992-12-01

    This report presents summaries for two months of current research of the Idaho National Engineering Laboratory (INEL) Boron Neutron Capture Therapy (BNCT) Program. Information is presented on development and murine screening experiments of low-density lipoprotain. carboranyl alanine, and liposome boron containing compounds. Pituitary tumor call culture studies are described. Drug stability, pharmacology and toxicity evaluation of borocaptate sodium (BSH) and boronophonylalanine (BPA) are described. Treatment protocol development via the large animal (canine) model studies and physiological response evaluation in rats are discussed. Supporting technology development and technical support activities for boron drug biochemistry and purity, analytical and measurement dosimetry, and noninvasive boron quantification activities are included for the current time period. Current publications for the two months are listed.

  1. Microbiological investigations for radiation treatment of pharmaceuticals

    Science.gov (United States)

    Dám, A.; Gazsó, L. G.; Grigorova, P.

    Several antibiotics, excipients were investigated in dry state to estimate the safety sterilization dose as well as herbs extract powders to reduce the microbial count by radiation treatment. The sterilization dose of pharmaceuticals were calculated individually for each product based on the bioburden, the radiosensitivity of contaminating microflora and the required sterility assurance level. According to our results all of the materials investigated can be sterilized by less than 10 kGy. For herbs extract 1 kGy was enough to reduce the initial count close to the acceptable level.

  2. Microbiological investigations for radiation treatment of pharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Dam, A.; Gazso, L.G. (' Frederic Joliot-Curie' National Research Inst. for Radiobiology and Radiohygiene, Budapest (Hungary)); Grigorova, P. (Pharmachim, Sofia (Bulgaria))

    1990-01-01

    Several antibiotics, excipients were investigated in dry states to estimate the safety sterilization dose as well as herbs extract powders to reduce the microbial count by radiation treatment. The sterilization dose of pharmaceuticals were calculated individually for each product based on the bioburden, the radiosensitivity of contaminating microflora and the required sterility assurance level. According to our results all of the materials investigated can be sterilized by less than 10 kGy. For herbs extract 1 kGy was enough to reduce the initial count close to the acceptable level. (author).

  3. Microbiological investigations for radiation treatment of pharmaceuticals

    International Nuclear Information System (INIS)

    Several antibiotics, excipients were investigated in dry states to estimate the safety sterilization dose as well as herbs extract powders to reduce the microbial count by radiation treatment. The sterilization dose of pharmaceuticals were calculated individually for each product based on the bioburden, the radiosensitivity of contaminating microflora and the required sterility assurance level. According to our results all of the materials investigated can be sterilized by less than 10 kGy. For herbs extract 1 kGy was enough to reduce the initial count close to the acceptable level. (author)

  4. Epithermal BNCT neutron beam design for a TRIGA II reactor

    International Nuclear Information System (INIS)

    In Finland a collaborative effort by Helsinki University Central Hospital, MAP Medical Technologies Inc. and VTT Reactor Laboratory has started aiming at BNCT of glioma patients. For this the capabilities of the FiR-1 TRIGA II 250 kW research reactor have been evaluated. The FiR-1 is located in the middle of the Otaniemi campus eight kilometers from the center of Helsinki and four kilometers from the Central Hospital. The power of the reactor was increased in 1965 to 250 kW and the instrumentation modernised in 1981. It is a pool reactor with graphite reflector and a core loading of 3 kg 20w% 235U in the special TRIGA uranium-zirconium hydride fuel (8-12 w% U, 91% Zr, 1% H). The advantages of using a TRIGA reactor for BNCT have already been pointed out earlier by Whittemore and have been verified in practice by the thermal neutron treatment work done at the Musashi 100 kW reactor. The advantages include a wide core face area and a wide spatial angle covered by the thermal-epithermal column system, large flux-per-Watt feature and inherent safety of the TRIGA fuel. Because of its wider applicability and less stringent requirements for clinical operation conditions, an epithermal neutron beam has been selected as the design goal. The epithermal flux should be sufficient for glioblastoma patient treatment: 109 epithermal neutrons/cm2/s with low enough fast neutron (-13Gy/epithermal n/cm2) and gamma contamination

  5. Radiation Treatment of Postmastectomy Lymph angiosarcoma

    International Nuclear Information System (INIS)

    Since the entity of postmastectomy lymphangiosarcoma was first reported by Stewart and Traves in 1948, postmastectomy lymphangiosarcoma has become a well recognized, uncommon malignant tumor which occurs in the upper extremity following mastectomy for mammary carcinoma. The postmastectomy lymphangiosarcoma occurred at an average age of 63.9 years and at an average of 10 years and 3 months following mastectomy. The lymphangiosarcoma raised from blood and lymphatic vessel. The histologic appearance has been observed edematous dermis and dilated lymphatics lining with malignant cells. Most authors recommend radical amputation for treatment, either shoulder disarticulation or forequarter amputation. Other modalities of treatment including radiotherapy were considered as ineffective. The present report provides a case of the regression of postmastectomy lymphangiosarcoma with chronic lymphedima by external irradiation. Radiation therapy was used as primary therapy. Total tumor dose of 6500 cGy in 9 weeks was delivered using 6 MV x-ray and 8 MeV electron

  6. Movement of the diaphragm during radiation treatment

    International Nuclear Information System (INIS)

    Movement of the target volume during the exposure to radiation results in decreased accuracy in radiotherapy. We carried out the quantitative evaluation of the movement of the diaphragm during the radiation therapy. Seventy seven patients, who received radiation therapy for lung cancer from December 1988 to February 1990 at the Osaka-prefectural Habikino Hospital, were studied. The movement was recorded with a sonoprinter at the time of treatment planning for radiotherapy, and the length of movement was evaluated at 6 points on the diaphragm. In a study of 402 points in 77 patients, the average movement was 12 mm, and the maximum movement was 40 mm. At the 17% of the points, the movement exceeded 20 mm. The largest movement was observed at the outer point of the right lung. Movement was greater in men than in women. Performance status was not related to the degree of movement. We concluded that in chest and abdominal irradiation, movement caused by respiration is not negligible, and synchronized radiotherapy should be developed in the future. (author)

  7. Tumor development in field-cancerized tissue is inhibited by a double application of Boron neutron capture therapy (BNCT) without exceeding radio-tolerance

    International Nuclear Information System (INIS)

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of a 'single' application of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-1(Na210B10H10) or (GB-10+BPA) to treat hamster cheek pouch tumors with no normal tissue radiotoxicity. Based on these results, we developed a model of precancerous tissue in the hamster cheek pouch for long-term studies. Employing this model we evaluated the long-term potential inhibitory effect on the development of second primary tumors from precancerous tissue and eventual radiotoxicity of a single application of BNCT mediated by BPA, GB-10 or (GB-10+BPA), in the RA-6. The clinical rationale of this study was to search for a BNCT protocol that is therapeutic for tumor, not radio-toxic for the normal tissue that lies in the neutron beam path, and exerts the desired inhibitory effect on the development of second primary tumors, without exceeding the radio-tolerance of precancerous tissue, the dose limiting tissue in this case. Second primary tumors that arise in precancerous tissue (also called locoregional recurrences) are a frequent cause of therapeutic failure in head and neck tumors. Aim: Evaluate the radiotoxicity and inhibitory effect of a 'double' application of the same BNCT protocols that were proved therapeutically successful for tumor and precancerous tissue, with a long term follow up (8 months). A 'double' application of BNCT is a potentially useful strategy for the treatment of tumors, in particular the larger ones, but the cost in terms of side-effects in dose-limiting tissues might preclude its application and requires cautious evaluation. Materials and methods: We performed a double application of 1) BPA-BNCT; 2) (GB- 10+BPA)-BNCT

  8. Preventive treatment of combined radiation injuries

    International Nuclear Information System (INIS)

    The risk of sepsis development increases when thermal burns and other trauma occur in combination with exposure to radiation. Only surgical correction of the life-threatening state recommends within 48 hours after irradiation. All other arrangements have to carry out when hemopoiesis recovery will complete. However exposed patients with combined injuries (CI) die during the first two or three weeks mainly due to sepsis. Therefore prophylaxis and preventive therapy of infectious complications are need early. Actual difficulties in choice of valid treatment procedure for acute radiation syndrome (ARS) exhibit additional aggravation under CI. The available facts prove decreasing early therapy efficiency for rather high dose exposure and wound trauma occurrence. The own results showed that bacterial polysaccharide pyrogenal, glycopin (synthetic analogue of muramil-dipeptide), thymus preparations (thymozin, thymotropin, thymogen), tuftsin, heterologic human and bovine immunoglobulins did not modify the low values of 30-day survival under CI (irradiation + thermal burn). Single injection of prodigiozan, zymozan and some other yeast polysaccharides in 1 hr after CI resulted at moderate increasing of survival. The main purpose of this study, which bases upon our understanding of CI pathogenesis, was search more effective means for preventive treatment of combined radiation injuries. Two groups of remedies were under study. The first group included so called 'biological response modifiers' (BRM). These agents may increase host defences to infection, macrophage's activity and hemopoietic growth factor's secretion. The second group included antibiotics that should be directed against the potential gram-negative as well as gram-positive pathogens and simultaneously be useful for selective decontamination of gastrointestinal tract. (author)

  9. Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis

    International Nuclear Information System (INIS)

    Purpose: To investigate the feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma (MPM) from a viewpoint of dose distribution analysis using Simulation Environment for Radiotherapy Applications (SERA), a currently available BNCT treatment planning system. Methods and Materials: The BNCT treatment plans were constructed for 3 patients with MPM using the SERA system, with 2 opposed anterior-posterior beams. The 1B concentrations in the tumor and normal lung in this study were assumed to be 84 and 24 ppm, respectively, and were derived from data observed in clinical trials. The maximum, mean, and minimum doses to the tumors and the normal lung were assessed for each plan. The doses delivered to 5% and 95% of the tumor volume, D05 and D95, were adopted as the representative dose for the maximum and minimum dose, respectively. Results: When the D05 to the normal ipsilateral lung was 5 Gy-Eq, the D95 and mean doses delivered to the normal lung were 2.2-3.6 and 3.5-4.2 Gy-Eq, respectively. The mean doses delivered to the tumors were 22.4-27.2 Gy-Eq. The D05 and D95 doses to the tumors were 9.6-15.0 and 31.5-39.5 Gy-Eq, respectively. Conclusions: From a viewpoint of the dose-distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses

  10. The treatment progress of radiation dermatitis from external exposure

    International Nuclear Information System (INIS)

    Radiation dermatitis is often seen and is often a complication of radiation therapy of tumors. It is characterized by poor healing, stubborn relapse, and carcinogenesis.. The treatment include drug, physical therapy and surgery. This article describes the treatment progress of radiation dermatitis from external exposure. (authors)

  11. Radiation ulcer of the thoracic wall and its surgical treatment

    International Nuclear Information System (INIS)

    Examples of successful application of the method of plastic closure of antirior thoracic wall radiation defects are presented. Radiation ulcers were observed as a delayed radiation effects of radiotherapy against breast cancer and thymus gland tumor. Efficiency of the application of the given method in surgical treatment of patients with radiation ulcers of the thoracic wall is shown

  12. Quality control and quality assurance procedures at the THOR BNCT facility

    International Nuclear Information System (INIS)

    Various quality control (QC) and quality assurance (QA) procedures of the boron neutron capture therapy (BNCT) beam at the Tsing Hua Open-pool Reactor (THOR) are established to ensure beam availability and quality. The QC/QA methods mainly employ foil activation and paired ionization chambers, respectively, for beam intensity check and dose assessment. Beam intensity is monitored on-line by using three dead-time corrected fission chambers. In addition to the periodic QC/QA activities regarding beam quality and the monitoring system, the quick QC/QA performed in an all-in-one phantom will be executed less than 70 min before the clinical treatment to guarantee beam quality. The QC/QA procedures have been gradually established and the actual performance satisfied the preset criteria defined for the BNCT facility at THOR.

  13. Towards the final BSA modeling for the accelerator-driven BNCT facility at INFN LNL

    International Nuclear Information System (INIS)

    Some remarkable advances have been made in the last years on the SPES-BNCT project of the Istituto Nazionale di Fisica Nucleare (INFN) towards the development of the accelerator-driven thermal neutron beam facility at the Legnaro National Laboratories (LNL), aimed at the BNCT experimental treatment of extended skin melanoma. The compact neutron source will be produced via the 9Be(p,xn) reactions using the 5 MeV, 30 mA beam driven by the RFQ accelerator, whose modules construction has been recently completed, into a thick beryllium target prototype already available. The Beam Shaping Assembly (BSA) final modeling, using both neutron converter and the new, detailed, Be(p,xn) neutron yield spectra at 5 MeV energy recently measured at the CN Van de Graaff accelerator at LNL, is summarized here.

  14. The experience from the construction of BNCT facility at the LVR-15 reactor

    International Nuclear Information System (INIS)

    The BNCT project at LVR-15 reactor of NRI for treatment of human brain gliomas is before start of clinical trials. A survey of present conditions is included, the attention is devoted to BNCT facility with epithermal neutron beam first of all. The different materials for filter composition were studied, the calculational methods have been used for the determination of neutron and gamma rays in the reactor geometry. Some configurations were experimentally verified. The effort for improvement of epithermal neutron beam parameters in configuration 1998 was concentrated to block of filters remodelling, improvement of collimator-shutter geometry, the choice of optimal reactor core edge configuration. Awaited results from experiment in June 1999 are described. (author)

  15. Towards the final BSA modeling for the accelerator-driven BNCT facility at INFN LNL

    Energy Technology Data Exchange (ETDEWEB)

    Ceballos, C. [Centro de Aplicaciones Tecnlogicas y Desarrollo Nuclear, 5ta y30, Miramar, Playa, Ciudad Habana (Cuba); Esposito, J., E-mail: juan.esposito@lnl.infn.it [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Agosteo, S. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy); Colautti, P.; Conte, V.; Moro, D. [INFN, Laboratori Nazionali di Legnaro (LNL), via dell' Universita, 2, I-35020 Legnaro (PD) (Italy); Pola, A. [Politecnico di Milano, Dipartimento di Energia, Piazza Leonardo da Vinci 32, 20133 Milano (Italy)] [INFN, Sezione di Milano, via Celoria 16, 20133 Milano (Italy)

    2011-12-15

    Some remarkable advances have been made in the last years on the SPES-BNCT project of the Istituto Nazionale di Fisica Nucleare (INFN) towards the development of the accelerator-driven thermal neutron beam facility at the Legnaro National Laboratories (LNL), aimed at the BNCT experimental treatment of extended skin melanoma. The compact neutron source will be produced via the {sup 9}Be(p,xn) reactions using the 5 MeV, 30 mA beam driven by the RFQ accelerator, whose modules construction has been recently completed, into a thick beryllium target prototype already available. The Beam Shaping Assembly (BSA) final modeling, using both neutron converter and the new, detailed, Be(p,xn) neutron yield spectra at 5 MeV energy recently measured at the CN Van de Graaff accelerator at LNL, is summarized here.

  16. Monitoring total boron in blood for BNCT by a novel atomic emission method

    International Nuclear Information System (INIS)

    In BNCT the duration and timing of the is adjusted by 10B concentrations in whole blood. Time-frame for determinations is less than 20 minutes. Therefore fast and accurate boron determinations are a prerequisite for BNCT. We present a method based on ICP-AES instrument for whole blood and plasma boron determinations with protein precipitation with trichloroacetic acid as sample pre-treatment and beryllium as an internal standard. The method was compared to established but tedious ICP-mass spectrometric method with wet ashing as a sample pre-treatment. The ICP-AES method is in good agreement (correlation coefficient 0.99) the ICP-MS. Within-day and between-day imprecisions were less than 3,5% CV for whole blood samples. Samples taken during and after BPA-F infusion (290 mg/kg) revealed an uneven distribution between plasma and erythrocytes. The present method is feasible and one of the fastest currently available for BNCT. Our results indicate that BPA-F or its metabolites do not seem to be tightly bound to plasma proteins. It also seems that determination of boron in plasma sample may be preferable than measuring boron in whole blood. (author)

  17. Quality assurance for BNCT at nuclear facilities. A necessary burden or the unavoidable seal of approval

    International Nuclear Information System (INIS)

    The BNCT clinical trial at the HFR Petten is performed on a completely multi-national basis. The irradiation facility is located in one country (The Netherlands), is operated by an international team of experts under the leadership of a radiotherapist from another country (Germany) and treats patients coming from different European countries. In gaining the necessary approval, it became apparent, especially in the many discussions with the (Dutch) Health authorities that Quality Assurance (QA) would be and is a critical aspect. This is even more so, in the case of BNCT, where it was not only a (relatively) new experimental treatment (in 1996/97) about to be performed for the first time in Europe, but it was to be performed in a non-hospital environment and furthermore in a nuclear research reactor. It was necessary therefore to comply, as closely as possible, with similarly accepted practices in conventional radiotherapy. Despite QA being a sometimes burdensome task, this paper nevertheless raises the issue as to whether it is necessary or whether it is the seal of approval for BNCT as an acceptable mode of treatment in mainstream radiotherapy. (author)

  18. In-phantom dosimetry for BNCT with Fricke and normoxic-polymer gels

    Science.gov (United States)

    Gambarini, G.; Agosteo, S.; Carrara, M.; Gay, S.; Mariani, M.; Pirola, L.; Vanossi, E.

    2006-05-01

    Measurements of in-phantom dose distributions and images are important for Boron Neutron Capture Therapy treatment planning. The method for spatial determination of absorbed doses in thermal or epithermal neutron fields, based on Fricke-xylenol-orange-infused gel dosimeters in form of layers, has revealed to be very reliable, as gel layer dosimeters give the possibility of obtaining spatial dose distributions and measurements of each dose contribution in neutron fields, by means of a properly studied procedure. Quite recently, BNCT has been applied to treat liver metastases; in this work the results of in-phantom dosimetry for explanted liver in BNCT treatments are described. Moreover, polyacrylamide gel (PAG) dosimeters in which a polymerization process appears as a consequence of absorbed dose, have been recently tested, because of their characteristic absence of diffusion. In fact, due to the diffusion of ferric ions, Fricke-gel dosimeters require prompt analysis after exposure to avoid spatial information loss. In this work the preliminary results of a study about the reliability of polymer gel in BNCT dosimetry are also discussed. Gel layers have been irradiated in a phantom exposed in the thermal column of the TRIGA MARK II reactor (Pavia). The results obtained with the two kinds of gel dosimeter have been compared.

  19. Radiological protection considerations during the treatment of glioblastoma patients by boron neutron capture therapy at the high flux reactor in Petten, The Netherlands

    International Nuclear Information System (INIS)

    A clinical trial of Boron Neutron Capture Therapy (BNCT) for glioblastoma patients has been in progress at the High Flux Reactor (HFR) at Petten since October 1997. The JRC (as licence holder of the HFR) must ensure that radiological protection measures are provided. The BNCT trial is a truly European trial, whereby the treatment takes place at a facility in the Netherlands under the responsibility of clinicians from Germany and patients are treated from several European countries. Consequently, radiological protection measures satisfy both German and Dutch laws. To respect both laws, a BNCT radioprotection committee was formed under the chairmanship of an independent radioprotection expert, with members representing all disciplines in the trial. A special nuance of BNCT is that the radiation is provided by a mixed neutron/gamma beam. The radiation dose to the patient is thus a complex mix due to neutrons, gammas and neutron capture in boron, nitrogen and hydrogen, which, amongst others, need to be correctly calculated in non-commercial and validated treatment planning codes. Furthermore, due to neutron activation, measurements on the patient are taken regularly after treatment. Further investigations along these lines include dose determination using TLDs and boron distribution measurements using on-line gamma ray spectroscopy. (author)

  20. Radiation chemical studies on the treatment of waste water

    International Nuclear Information System (INIS)

    The radiation induced reaction in aqueous solution was studied to develope the radiation treatment as a new technique for waste water and to elevate the effectiveness of radiation. The effectiveness of radiation was enhanced by combination of radiation induced reaction with conventional methods such as biological treatment and coagulation treatment. The synergistic effect of radiation and ozone was studied by using phenol and ethylene glycol. The chain reaction was observed in the radiation induced oxidation. The combination of radiation and ozone is considered to be one of the most useful method. In this report, the mechanism of each reaction and the applicability of the reaction to the treatment of waste water are discussed. (author)

  1. Radioprotective agents to reduce BNCT (Boron Neutron Capture Therapy) induced mucositis in the hamster cheek pouch

    International Nuclear Information System (INIS)

    Introduction: BNCT is based on the capture reaction between boron, selectively targeted to tumor tissue, and thermal neutrons which gives rise to lethal, short-range high linear energy transfer particles that selectively damage tumor tissue, sparing normal tissue. We previously evidenced a remarkable therapeutic success of BNCT mediated by boronophenylalanine (BPA) in the hamster cheek pouch oral cancer and pre cancer model. Despite therapeutic efficacy, mucositis induced in premalignant tissue was dose limiting and favored, in some cases, tumor development. In a clinical scenario, oral mucositis limits the dose administered to head and neck tumors. Aim: Our aim was to evaluate the effect of the administration of different radioprotective agents, seeking to reduce BNCT-induced mucositis to acceptable levels in dose-limiting premalignant tissue; without compromising therapeutic effect evaluated as inhibition on tumor development in premalignant tissue; without systemic or local side effects; and without negative effects on the biodistribution of the boron compound used for treatment. Materials and methods: Cancerized hamsters with DMBA (dimethylbenzanthracene) were treated with BPA-BNCT 5 Gy total absorbed dose to premalignant tissue, at the RA-3 Nuclear Reactor, divided into different groups: 1-treated with FLUNIXIN; 2- ATORVASTATIN; 3-THALIDOMIDE; 4-HISTAMINE (two concentrations: Low -1 mg/ml- and High -5 mg/ml-); 5-JNJ7777120; 6-JNJ10191584; 7-SALINE (vehicle). Cancerized animals without any treatment (neither BNCT nor radioprotective therapy) were also analyzed. We followed the animals during one month and evaluated the percentage of animals with unacceptable/severe mucositis, clinical status and percentage of animals with new tumors post treatment. We also performed a preliminary biodistribution study of BPA + Histamine “low” concentration to evaluate the potential effect of the radioprotector on BPA biodistribution. Results: Histamine

  2. On radiation treatment of pharmaceutical products

    International Nuclear Information System (INIS)

    The progress made in the GDR over the past decade in the field of radiosterilization of products of the medical industry, has naturally raised the question of radiosterilization in pharmaceutics. However, because of the diversity and complicated nature of pharmaceutical products and, consequently, longer periods of time required for preliminary studies, their radiosterilization has not yet been applied on an industrial scale, in contrast to the situation in the medical industry. The studies carried out so far have been mainly concerned with ascertaining the permissibility and effectiveness of radiosterilization of individual products under particular conditions rather than with laying down a broad theoretical basis. Accordingly, the present paper does not describe results of special studies but presents a brief rewiev of some studies on radiation treatment of pharmaceutical products undertaken in the GDR. (author)

  3. Effects of radiation treatment on foodstuffs

    International Nuclear Information System (INIS)

    The purpose of this study is to discuss and compile methods and results of irradiation experiments carried out on 54 plant and animal foodstuffs in order to obtain a survey on chemical changes, in particular as regards the reduction of nutritional value and savoriness of irradiated foodstuffs. According to this task, microbiological aspects as well as an interpretation of the experimental results as to the physiology of nutrition and toxicology were not included. The results published by the authors of the original papers were compiled in a kind of dictionary which contains all relevant information such as radiation sources, irradiation conditions, investigation methods, results of chemical or organoleptical changes etc. The most important results were summarized in tables and can be found at the end of this study. Because of the abundance of existing literature the series 'Effects of radiation treatment on foodstuffs' will be continued in Part IV, and the final discussion of the results will be published separately after further data have been included. (orig.)

  4. Radiation-induced proctitis: Symptoms, pathophysiology and treatment

    International Nuclear Information System (INIS)

    Radiotherapy is a major treatment of pelvic tumours. It exposes to the risk of acute and long-term side effects, such as radiation proctitis. Radiation proctitis is a complex disease requiring support ranging from initial contact with the patient until several years after completion of radiotherapy. This care includes preventive measures (clinical and dosimetric factors), detection and medical and surgical treatments. This article aims to make a review of radiation proctitis induced during the treatment of pelvic cancers. (authors)

  5. Radiation utilization for service water treatment

    International Nuclear Information System (INIS)

    The sure supply of the potable water of good quality becomes more necessary with the maturity of society, and the needs of good-tasting water have heightened. In the raw water for service water, the compounds of more than 2000 kinds are contained, and it has been said that among them, 18 kinds of carcinogenic substances and 56 kinds of mutative substances exist. It is very difficult to remove, decompose or neutralize the poison of these substances in large quantity of water. Radiochemical processes has the excellent properties of oxidizing and decomposing dissolved organic compounds, and it seems suitable to the raw water for service water in which the concentration of organic substances is relatively low, and the treatment in large quantity is required. From the standpoint of evaluating the possibility of radiation utilization for the treatment of service water for drinking, the authors have carried out a number of experiments, therefore, those are reported. The decomposition of the precursor of methane trihalide, the examination of the decomposed substances of humic acid, the irradiation effect to odored substances, the decomposition of contaminating substances in high-tech industry and the examination of safety by the test of mutative substances are described. (K.I.)

  6. American brain tumor patients treated with BNCT in Japan

    International Nuclear Information System (INIS)

    The purpose of this work is to establish and maintain a database for patients from the United States who have received BNCT in Japan for malignant gliomas of the brain. This database will serve as a resource for the DOE to aid in decisions relating to BNCT research in the United States, as well as assisting the design and implementation of clinical trials of BNCT for brain cancer patients in this country. The database will also serve as an information resource for patients with brain tumors and their families who are considering this form of therapy

  7. An accelerator-based epithermal photoneutron source for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Nigg, D.W.; Mitchell, H.E.; Harker, Y.D.; Yoon, W.Y. [and others

    1995-11-01

    Therapeutically-useful epithermal-neutron beams for BNCT are currently generated by nuclear reactors. Various accelerator-based neutron sources for BNCT have been proposed and some low intensity prototypes of such sources, generally featuring the use of proton beams and beryllium or lithium targets have been constructed. This paper describes an alternate approach to the realization of a clinically useful accelerator-based source of epithermal neutrons for BNCT that reconciles the often conflicting objectives of target cooling, neutron beam intensity, and neutron beam spectral purity via a two stage photoneutron production process.

  8. American brain tumor patients treated with BNCT in Japan

    Energy Technology Data Exchange (ETDEWEB)

    Laramore, G.E.; Griffin, B.R.; Spence, A.

    1995-11-01

    The purpose of this work is to establish and maintain a database for patients from the United States who have received BNCT in Japan for malignant gliomas of the brain. This database will serve as a resource for the DOE to aid in decisions relating to BNCT research in the United States, as well as assisting the design and implementation of clinical trials of BNCT for brain cancer patients in this country. The database will also serve as an information resource for patients with brain tumors and their families who are considering this form of therapy.

  9. Studies of recombination chambers filled with nitrogen for BNCT dosimetry

    International Nuclear Information System (INIS)

    Dosimetric characterization of therapy beams for boron neutron capture therapy (BNCT) involves determination of dose components and among them the '' nitrogen '' dose due to protons generated by neutron capture on 14N. In this work, investigations were carried out using a graphite recombination chamber in order to determine the 14N capture, gamma, and fast neutron dose components. The separation of the dose components is based on differences in the shape of the saturation curve, depending on the LET spectrum of the investigated radiation. The measurements were performed in reference radiation fields at the Institute of Atomic Energy at Swierk and at a reactor beam of the INP Rez (the Czech Republic). The gamma component was determined with an accuracy of about 5%, while the variations in its value could be monitored with an accuracy of about 0.5%. Relative changes in the beam components (thermal/fast neutrons) could be detected on line with an accuracy of about 5%. It was shown that the chamber with tissue-equivalent cups could be used for the determination of the 14N capture dose at different depths in tissue. (authors)

  10. Current clinical results of the Tsukuba BNCT trial

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, T.; Matsumura, A. E-mail: matsumur@md.tsukuba.ac.jp; Nakai, K.; Shibata, Y.; Endo, K.; Sakurai, F.; Kishi, T.; Kumada, H.; Yamamoto, K.; Torii, Y

    2004-11-01

    Nine high grade gliomas (5 glioblastomas and 4 anaplastic astrocytomas) were treated with BSH-based intaoperative boron neutron capture therapy (IOBNCT). BSH (100 mg/kg body weight) was intravenously injected, followed by single fraction irradiation using the mixed thermal/epithermal beam of Japan Research Reactor 4. The blood boron level at the time of irradiation averaged 29.9 (18.8-39.5) {mu}g/g. The peak thermal neutron flux as determined by post-irradiation measurements varied from 1.99 to 2.77x10{sup 9} n cm{sup -2} s{sup -1}. No serious BSH-related toxicity was observed in this series. The interim survival data in this study showed median survival times of 23.2 months for glioblastoma and 25.9 months for anaplastic astrocytoma, results which are consistent with the current conventional radiotherapy with/without boost radiation. Of the 4 residual tumors, 2 showed complete response (CR) and 2 showed partial response (PR) within 6 months following BNCT. No linear correlation was proved between the dose and the occurrence of early neurological events. The maximum boron dose of 11.7-12.2 Gy in the brain related to the occurrence of radiation necrosis. The clinical application of a mixed thermal/epithermal beam and JRR-4 facilities on BSH-based IOBNCT proved to be safe and effective in this series.

  11. Whole-body dose evaluation with an adaptive treatment planning system for boron neutron capture therapy

    International Nuclear Information System (INIS)

    Dose evaluation for out-of-field organs during radiotherapy has gained interest in recent years. A team led by University of Tsukuba is currently implementing a project for advancing boron neutron capture therapy (BNCT), along with a radiation treatment planning system (RTPS). In this study, the authors used the RTPS (the 'Tsukuba-Plan') to evaluate the dose to out-of-field organs during BNCT. Computed tomography images of a whole-body phantom were imported into the RTPS, and a voxel model was constructed for the Monte Carlo calculations, which used the Particle and Heavy Ion Transport Code System. The results indicate that the thoraco-abdominal organ dose during BNCT for a brain tumour and maxillary sinus tumour was 50-360 and 120-1160 mGy-Eq, respectively. These calculations required ∼29.6 h of computational time. This system can evaluate the out-of-field organ dose for BNCT irradiation during treatment planning with patient-specific irradiation conditions. (authors)

  12. A multigroup treatment of radiation transport

    International Nuclear Information System (INIS)

    A multi-group radiation package is outlined which will accurately handle radiation transfer problems in laser-produced plasmas. Bremsstrahlung, recombination and line radiation are included as well as fast electron Bremsstrahlung radiation. The entire radiation field is divided into a large number of groups (typically 20), which diffuse radiation energy in real space as well as in energy space, the latter occurring via electron-radiation interaction. Using this model a radiation transport code will be developed to be incorporated into MEDUSA. This modified version of MEDUSA will be used to study radiative preheat effects in laser-compression experiments at the Central Laser Facility, Rutherford Laboratory. The model is also relevant to heavy ion fusion studies. (author)

  13. Reprint of Bioneutronics: Thermal scattering in organics tissues and its impact on BNCT dosimetry.

    Science.gov (United States)

    Ramos, R L; Sztejnberg Gonçalves-Carralves, M L; Cantargi, F

    2015-12-01

    Neutron transport calculation is a key factor in BNCT numerical dosimetry assessments where thermal neutron flux is intimately related to the neutron dose, specially, the therapeutic boron dose. In this work, numerical calculations in phantoms were performed to determine the importance of utilizing the appropriate thermal scattering treatment for different organic tissues. Two thermal treatments for the neutron scattering were included in the simulations: hydrogen bounded in bulk water and hydrogen bounded in a lipid like carbon chain (polyethylene). The results showed difference between both thermal treatments that can reach several percent points depending on the type of source and irradiated geometry. PMID:26515135

  14. Bioneutronics: Thermal scattering in organics tissues and its impact on BNCT dosimetry.

    Science.gov (United States)

    Ramos, R L; Gonçalves-Carralves, M L Sztejnberg; Cantargi, F

    2015-10-01

    Neutron transport calculation is a key factor in BNCT numerical dosimetry assessments where thermal neutron flux is intimately related to the neutron dose, specially, the therapeutic boron dose. In this work, numerical calculations in phantoms were performed to determine the importance of utilizing the appropriate thermal scattering treatment for different organic tissues. Two thermal treatments for the neutron scattering were included in the simulations: hydrogen bounded in bulk water and hydrogen bounded in a lipid like carbon chain (polyethylene). The results showed difference between both thermal treatments that can reach several percent points depending on the type of source and irradiated geometry. PMID:26141296

  15. Biodistribution of Boron compounds in an experimental model of liver metastases for Boron Neutron Capture (BNCT) Studies

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality that involves the selective accumulation of 10B carriers in tumors followed by irradiation with thermal or epithermal neutrons. The high linear energy transfer alpha particles and recoiling 7Li nuclei emitted during the capture of a thermal neutron by a 10B nucleus have a short range and a high biological effectiveness. Thus, BNCT would potentially target neoplastic tissue selectively. In previous studies we demonstrated the therapeutic efficacy of different BNCT protocols in an experimental model of oral cancer. More recently we performed experimental studies in normal rat liver that evidenced the feasibility of treating liver metastases employing a novel BNCT protocol proposed by JEC based on ex-situ treatment and partial liver auto-transplant. The aim of the present study was to perform biodistribution studies with different boron compounds and different administration protocols to determine the protocols that would be therapeutically useful in 'in vivo' BNCT studies at the RA-3 Nuclear Reactor in an experimental model of liver metastases in rats. Materials and Methods. A total of 70 BDIX rats (Charles River Lab., MA, USA) were inoculated in the liver with syngeneic colon cancer cells DH/DK12/TRb (ECACC, UK) to induce the development of subcapsular metastatic nodules. 15 days post-inoculation the animals were used for biodistribution studies. A total of 11 protocols were evaluated employing the boron compounds boronophenylalanine (BPA) and GB-10 (Na210B1-0H10), alone or combined employing different doses and administration routes. Tumor, normal tissue and blood samples were processed for boron measurement by ICP-OES. Results. Several protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue, i.e. BPA 15.5 mg 10B/kg iv + GB-10 50 mg 10B/kg iv; BPA 46.5 mg 10B/kg ip; BPA 46.5 mg 10B/kg ip + iv; BPA 46

  16. Current status of radiation treatment of water and wastewater

    International Nuclear Information System (INIS)

    This is a brief review of the current status of radiation treatment of surface water, groundwater, wastewaters, and sewage sludges. Sources of ionizing radiation, and combination radiation methods for purification are described in some detail. Special attention is paid to pilot and industrial facilities. (author)

  17. Measurement of thermal neutron flux for BNCT in JRR-2

    International Nuclear Information System (INIS)

    For Boron Neutron Capture Therapy (BNCT) on brain tumor, a medical irradiation facility has been installed in the Japan Research Reactor No.2 (JRR-2) in Japan Atomic Energy Research Institute (JAERI). The first BNCT using by this facility was performed in August 1990. Since then, irradiations for 15 BNCT were performed until March 1993 in JRR-2. Two kinds of devices has been equipped for the measurement of thermal neutron flux at the diseased part of patients. The one is for the measurement of activation of thin gold wire using β-γ coincidence equipment, and the other is for the simultaneous monitoring of neutron fluxes during BNCT using silicon semiconductor detectors. The measurements using these devices are reported in this paper. (author)

  18. Present status of BNCT at Kyoto University Research Reactor Institute

    International Nuclear Information System (INIS)

    At Kyoto University Research Reactor Institute, we have two facilities for BNCT such as a reactor-based and an accelerator-based neutron source. In this article, we will present the characteristics overview of both facilities. (author)

  19. Compatibilization of recycled polymers through radiation treatment

    International Nuclear Information System (INIS)

    Complete text of publication follows. The use of compatibilizers is crucial in composites of apolar, synthetic matrix such as PP and fibrous, polar, natural reinforcement. Radiation treatment using small EB- or gamma dose of about 8 kGy - may enhance the effect of reactive compatibilizer, involving both matrix and reinforcement into a chemically attached system. In the present work we applied byproducts of textile- and woodworking industry as reinforcing additives for polypropylene (PP), reprocessed from waste car-bumpers and recollected bottle-caps. Hemp fibers and waste-wood fibers can be mixed into the PP on a continuously operating twin-screw extruder. Various additives have been tries out in our laboratory including maleic acid anhydride, acrylic-acid grafted compatibilizers, unsaturated oligomers and vinylsilanes. The effect of different compatibilizing methods have been evaluated by comparing mechanical properties (tensile- and flexural strength, modulus of elasticity etc.), dynamic mechanical analysis (DMA) and rheological properties. The ensemble of properties is clearly enhanced by the efficient compatibilization. The reinforced - recycled products can be applied in advanced sandwich molding processing technologies of coextrusion and co-injection molding, where the dark coloured, recycled product forms the inner core of the product, covered on both side with virgin thermoplastic

  20. Treatment of late radiation ulcers of the skin with baliz

    International Nuclear Information System (INIS)

    The efficacy of the new drug baliz, a biologically active substance obtained under the conditions of directional antagonism of active strains of yeast and actinomycetes and used in the treatment of experimental skin ulcers and late radiation injuries of the skin was studied. Baliz is especially effective in the treatment of marked inflammation in radiation ulcer

  1. Thermal facility for BNCT in RA-1 Argentine research reactor

    International Nuclear Information System (INIS)

    Full text: A thermal facility for BNCT experiments is being developed in an Argentine Research Reactor: RA-1 'Enrico Fermi'. RA-1 research nuclear reactor is working at Constituyentes Atomic Center, near Buenos Aires, and started operations in 1958. It worked at several power levels, up to 120 k W. Today, RA-1 is licensed to work at 40 k W. RA-1 was used to produce radioisotopes in the early 60's, and today gives irradiation services to test materials, to calibrate detectors and activation analysis. RA-1 users are CNEA researchers, Nuclear Regulatory Authority staff and private laboratories. Boron Neutron Capture Therapy (BNCT) is a method to fight against cancer. It consists to irradiate cancer tumors using thermal neutrons. The tumor tissue should include a dose of a boron solution. The Boron irradiation produces the following nuclear reactions: n + B10→ α + Li7 + γ. Being the α particle a radiation with short range, but high destructive energy, the tumor cells are destroyed. The neutron flux should be of 109 n/cm2seg, and the gamma dose lower than 0.48 s V/h. This method is oriented to treat brain tumors. Taking in account that the brain tumors usually are several centimeters deep in the head, to get thermal neutrons in the tumor is convenient to irradiate the patient using epithermal neutrons. moderation in the cells of the brain will permit to get more thermal neutrons in the tumor. In CNEA BNCT program there is in construction an epithermal clinical facility in the RA-6, a 500 k W research reactor that is at Bariloche Atomic Center. To perform some experiments for instance to test the boron compounds, RA-1 is used. In this experiments little animals like hamsters or bottles with cultivated cells are used, for that reasons thermal neutrons are used. The project in RA-1 consists in several stages. As the first stage a preliminary thermal facility was built. Irradiation times of 45-60 minutes were estimated, at power operation levels of 40 k W. Several

  2. Characterisation of the TAPIRO BNCT thermal facility

    International Nuclear Information System (INIS)

    Dosimetry and spectrometry measurements have been carried out in the thermal column of the research fast reactor RSV-TAPIRO (ENEA-Casaccia, Rome) in order to investigate its suitability for irradiation of cells or mice, with a view to research in the interests of boron neutron capture therapy (BNCT). The thermal column consists of a graphite moderator (40 cm thick) containing a lead shield (13 cm thick) in order to shield reactor background. The irradiation volume, inside this structure, has cubic shape (18 x 18 x 18 cm3). Besides measurements of fluence and dose rates in air or in phantom performed with thermoluminescence dosemeters (TLDs) and using the activation technique, dose and fluence profiles have been generated using a method based on gel dosemeters analysed with optical imaging. To check the consistency of the results, spectrometry measurements in the same irradiation volume have been performed by means of bubble detectors. (authors)

  3. Hodgkin lymphoma: Evolution and dilemma in radiation treatments

    International Nuclear Information System (INIS)

    Multiple new developments in the treatments of patients with Hodgkin lymphoma have occurred in the last 10 years. Radiation treatments have become extremely precise in localized Hodgkin lymphomas, on the other hand, they have almost completely disappeared in advanced stages. For patients with refractory or recurrent disease, it is strongly advocated, whenever feasible, to deliver a mantle field radiation treatment after an autologous stem cell transplant to avoid any further recurrence of the disease. (authors)

  4. BNCT for skin melanoma in extremities: Updated Argentine clinical results

    International Nuclear Information System (INIS)

    As part of phase I/II melanoma BNCT clinical trial conducted in Argentina in a cooperative effort of the Argentine Atomic Energy Commission (CNEA) and the Oncology Institute Angel H. Roffo (IOAHR), 7 patients (6 female-1 male) received eight treatment sessions covering ten anatomical areas located in extremities. Mean age of the patients was 64 years (51-74). The treatments were performed between October 2003 and June 2007. All patients presented multiple subcutaneous skin metastases of melanoma and received an infusion containing ∼14 gr/m2 of 10borophenyl-alanine (BPA) followed by the exposition of the area to a mixed thermal-epithermal neutron beam at the RA-6 reactor. The maximum prescribed dose to normal skin ranged from 16.5 to 24 Gy-Eq and normal tissue administered dose varied from 15.8 to 27.5 Gy-Eq. Considering evaluable nodules, 69.3% of overall response and 30.7% of no changes were seen. The toxicity was acceptable, with 3 out of 10 evaluable areas showing ulceration (30% toxicity grade 3).

  5. Potential applications of synchrotron radiation to the treatment of cancer

    International Nuclear Information System (INIS)

    Although conventional radiotherapy remains to be one of the most useful treatments for cancer, it is not the best strategy to maximize the effects on the tumors and minimize the damage to the surrounding tissues due to its physical and biological characteristics. Synchrotron radiation (SR) with uniquely physical and biological advantages may represent an innovative approach for cancer treatment. In recent years, SR-based photon activation therapy, stereotactic synchrotron radiation therapy and micro-beam radiation treatment have been developed, and the results of in vitro and in vivo experiments are very promising. It is necessary to understand the physical and radiobiological principle of those novel strategies before the approach is applied to the clinic. In this paper, we summarize the advances of SR in terms of physical, radiobiological advantages and its potential clinical applications. With the successful operation of shanghai synchrotron radiation, good opportunities in China have been provided for investigations on the treatment of cancer with synchrotron radiation. (authors)

  6. Hyperbaric oxygen (HBO) in the treatment of radiation side effects

    International Nuclear Information System (INIS)

    Aim: Many reports show that late complications of radiotherapy can be successfully treated by hyperbaric oxygen (HBO). This synopsis attempts to review the literature to identify areas of clinical use and further research. Patients and Methods: Clinical and experimental data about HBO treatment of radiation late effects are analysed. Mechanisms of hyperbaric oxygen in the treatment of late radiation side effects are discussed. Results: There is evidence in the literature that HBO is beneficial in the treatment of radiation cystitis, osteoradionecrosis of the mandible, hemorrhagic proctitis, soft tissue necrosis and neurologic deficits. The prophylactic use of HBO has shown to prevent the development of osteoradionecrosis after tooth removal and the loss of titanium implants in irradiated facial bones. The physiologic basis of HBO can be referred to induction of neoangiogenesis and revascularisation. Conclusions: Clinicians can be encouraged to use hyperbaric oxygen for the treatment of radiation cystitis, osteonecrosis of the mandible, hemorrhagic proctitis, soft tissue necrosis and neurologic deficits following radiation therapy. (orig.)

  7. Neutron and gamma dose rates determined in a cell phantom at the Finnish BNCT facility

    International Nuclear Information System (INIS)

    Radiation dosimetry studies have played an essential role in the Finnish BNCT (Boron Neutron Capture Therapy) project. Various phantom studies have been carried out in the FiR I epithermal neutron beam to characterise the gamma and the neutron dose distributions involved in the patient treatment circumstances and to evaluate the beam model used for dose planning. During the summer 1999 cell-line phantom irradiations were done. Dose calculations and measurements were required to determine the dose delivered to the cells at the different locations in the phantom. A cylindrical water-filled polyethylene phantom was used in contact with the 14 cm diameter circular beam aperture. The phantom was modelled by deterministic DORT code. Activation detectors (MT-AI wires), twin (Mg and TE) ionisations chambers (IC) and TL detectors were used to establish the measured dose and 55Mn(n,γ) reaction rates compared to the calculated values. The measured (IC) and calculated gamma and neutron dose rates at three depths in the phantom will be presented. The measured gamma dose rates were about 10 % lower, and the neutron dose rates about 35% lower than the calculations. The difference between the measured 55Mn reaction rates and the calculations was insignificant (= 1%). During the measurements the reactor was operated at the nominal power of 250 kW. The measured (IC) gamma dose rates were in fair agreement with the calculated values but the neutron dose rates displayed considerable discrepancy. However, the activation results, having the best accuracy, were very consistent with the calculated 55Mn reaction rates and therefore the dose determination could be based on the simulated results (author)

  8. Radiation treatment for newly diagnosed esophageal cancer with prior radiation to the thoracic cavity

    Energy Technology Data Exchange (ETDEWEB)

    Sponseller, Patricia, E-mail: sponselp@uw.edu [University of Wisconsin at La Crosse, La Crosse, WI (United States); Lenards, Nishele [Department of Radiation Oncology, University of Washington, Seattle, WA (United States); Kusano, Aaron; Patel, Shilpen [University of Wisconsin at La Crosse, La Crosse, WI (United States)

    2014-10-01

    The purpose of this report is to communicate the use of single-positron emission computed tomography scan in planning radiation treatments for patients with a history of radiation to the thoracic cavity. A patient presented with obstructive esophageal cancer, having previously received chemotherapy and radiation therapy to the mediastinum for non-Hodgkin lymphoma 11 years earlier. Owing to a number of comorbidities, the patient was not a surgical candidate and was referred to the University of Washington Medical Center for radiation therapy. Prior dose to the spinal cord and lung were taken into account before designing the radiation treatment plan.

  9. Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases

    International Nuclear Information System (INIS)

    BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25–76 ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung. - Highlights: • We performed experimental boron biodistribution studies for lung metastases. • 3 protocols employing BPA and GB-10 would be therapeutically useful. • BNCT at RA-3 would be potentially therapeutic for experimental lung metastases

  10. Studies for radiation treatment of polluted water in Shanghai

    International Nuclear Information System (INIS)

    The basic point is controlling stage before 2000 and improving stage after 2000 in Shanghai. Therefore, refined process with high efficiency of removal, low operating energy and no-second pollution was needed. Some studies on radiation treatment of aqueous solution and polluted water were conducted and some projects were suggested: radiation-induced degradation and decoloration of dye wastewater, radiolytic decomposition of bleached pulp-mill effluents, radiation regeneration of polluted activated carbon, application of radiation technique to sewage sludge treatment and to emulsifier breaking. Pulse radiolysis was also carried out for the typical dye of Rhodamine. (author)

  11. Improved treatment of radiation effects on the skin

    International Nuclear Information System (INIS)

    The treatment concept developed by K.H. Kaercher was extended by a therapy using Elasten S cream. In the course of a highvoltage therapy using fast electrons or cobalt-60, interesting aspects in the treatment and progression of the radiation reactions of the skin were established. The dermato-therapeutic principles layed down by K.H. Kaercher with the treatment palette used hitherto, have without doubt invariably proven their value. The exclusive powder treatment, however, may be made more practical by application of the new treatment cream in accordance with the intervals in radiation treatment or as a basic treatment towards the end of therapy. Furthermore it is ideally suited for the care and after-treatment of skin, strained by radiation. It reduces considerably the remaining visible radiation reactions. The treatment with powder and emulsion has for more than 10 years proven effective. After the excellent results of the new cream during radiation treatment, additional positive effects are expected in a long-term trial which will be reported on separately. (orig.)

  12. Neutron beam experiments using nuclear research reactors: honoring the retirement of professor Bernard W. Wehring -I. 3. A Comparison of Neutron Beams for BNCT

    International Nuclear Information System (INIS)

    product of the high-LET absorbed-dose rate to the tumor and the treatment time. A difference between our design methods and the design methods of others should be mentioned. The difference is that we chose to not take credit for the absorbed dose from gamma rays contributing to the control of gliomas. This assumption does not mean that we have completely ignored gamma rays in the development of our neutron field assessment parameters T and DTumor. For example, the radiation damage to normal tissue from gamma rays is included in the calculation of the treatment time T. The values of T and DTumor depend upon the 10B concentration in blood, the product of the RBE and the compound factor for the boron absorbed dose, the number of treatment fractions, and the ratio of the 10B concentration in tumor to the 10B concentration in blood. The values, which were assumed for these parameters, are appropriate for BNCT with BSH as the capture agent. For this paper, it is less important to know the exact values of the parameters that were used than it is to appreciate that the values of the parameters that were assumed were identical for the analysis of each neutron source that was evaluated. We calculated T and DTumor in a 14 x 14 x 14 cm Lucite cube phantom. Their calculation required the calculation of several intermediate quantities, such as the neutron absorbed dose rate (D·n), the gamma-ray absorbed dose rate (D·γ), and the 10B specific absorbed dose rate (d·B) as a function of depth in the phantom. Values for D·n, D·γ, d·B were calculated for all the neutron sources other than the BMRR-ENB, using the MCNP Monte Carlo radiation transport code. For the BMRR-ENB, the values of D·n, D·γ, d·B were supplied to us by our colleagues at Brookhaven National Laboratory. MCNP was run in n/p (neutron/photon) mode. The neutron and photon fluxes were calculated in the phantom along the phantom centerline. Trac k length estimators were used to tally neutron and photon fluxes in small

  13. Radiation accidents affecting the eye and their treatment

    International Nuclear Information System (INIS)

    Eye injuries which can occur as a result of radiation accidents or leaks in nuclear power plants are described and their treatment discussed. The trauma may be due to mechanical or thermal influences or the result of exposure to chemicals or radioactivity. After stopping the bepharospasm careful inspection of the conjunctiva is mandatory. If the bulbus is intact, rinsing with a pulsating water jet (Waterpik) is recommended, while if it is perforated primary operative treatment of the injury must be performed before radiation demages sets in. It is pointed out that the special medical centers for the treatment of radiation damage are equipped for ophthalmic surgery. (orig.)

  14. Radiation ulceration of the skin and its treatment

    International Nuclear Information System (INIS)

    Radiation ulcera are a permanent source of danger. Their treatment may be long and difficult. Surgical competence is the clue to treatment. Conservative treatment is justified only in the beginning and for short periods. The goal of surgery is excision of damaged tissue and plastic cover with healthy skin. The technique will have to be chosen according to findings and localisation.(orig.)

  15. Gamma residual radioactivity measurements on rats and mice irradiated in the thermal column of a TRIGA Mark II reactor for BNCT.

    Science.gov (United States)

    Protti, Nicoletta; Manera, Sergio; Prata, Michele; Alloni, Daniele; Ballarini, Francesca; di Tigliole, Andrea Borio; Bortolussi, Silva; Bruschi, Piero; Cagnazzo, Marcella; Garioni, Maria; Postuma, Ian; Reversi, Luca; Salvini, Andrea; Altieri, Saverio

    2014-12-01

    The current Boron Neutron Capture Therapy (BNCT) experiments performed at the University of Pavia, Italy, are focusing on the in vivo irradiations of small animals (rats and mice) in order to evaluate the effectiveness of BNCT in the treatment of diffused lung tumors. After the irradiation, the animals are manipulated, which requires an evaluation of the residual radioactivity induced by neutron activation and the relative radiological risk assessment to guarantee the radiation protection of the workers. The induced activity in the irradiated animals was measured by high-resolution open geometry gamma spectroscopy and compared with values obtained by Monte Carlo simulation. After an irradiation time of 15 min in a position where the in-air thermal flux is about 1.2 × 10(10) cm(-2) s(-1), the specific activity induced in the body of the animal is mainly due to 24Na, 38Cl, 42K, 56Mn, 27Mg and 49Ca; it is approximately 540 Bq g(-1) in the rat and around 2,050 Bq g(-1) in the mouse. During the irradiation, the animal body (except the lung region) is housed in a 95% enriched 6Li shield; the primary radioisotopes produced inside the shield by the neutron irradiation are 3H by the 6Li capture reaction and 18F by the reaction sequence 6Li(n,α)3H → 16O(t,n)18F. The specific activities of these products are 3.3 kBq g(-1) and 880 Bq g(-1), respectively. PMID:25353239

  16. High neutronic efficiency, low current targets for accelerator-based BNCT applications

    International Nuclear Information System (INIS)

    The neutronic efficiency of target/filters for accelerator-based BNCT applications is measured by the proton current required to achieve a desirable neutron current at the treatment port (109 n/cm2/s). In this paper the authors describe two possible targeyt/filter concepts wihch minimize the required current. Both concepts are based on the Li-7 (p,n)Be-7 reaction. Targets that operate near the threshold energy generate neutrons that are close tothe desired energy for BNCT treatment. Thus, the filter can be extremely thin (∼ 5 cm iron). However, this approach has an extremely low neutron yield (n/p ∼ 1.0(-6)), thus requiring a high proton current. The proposed solutino is to design a target consisting of multiple extremely thin targets (proton energy loss per target ∼ 10 keV), and re-accelerate the protons between each target. Targets operating at ihgher proton energies (∼ 2.5 MeV) have a much higher yield (n/p ∼ 1.0(-4)). However, at these energies the maximum neutron energy is approximately 800 keV, and thus a neutron filter is required to degrade the average neutron energy to the range of interest for BNCT (10--20 keV). A neutron filter consisting of fluorine compounds and iron has been investigated for this case. Typically a proton current of approximately 5 mA is required to generate the desired neutron current at the treatment port. The efficiency of these filter designs can be further increased by incorporating neutron reflectors that are co-axial with the neutron source. These reflectors are made of materials which have high scattering cross sections in the range 0.1--1.0 MeV

  17. Bioneutronics: Thermal scattering in organics tissues and its impact on BNCT dosimetry

    International Nuclear Information System (INIS)

    Neutron transport calculation is a key factor in BNCT numerical dosimetry assessments where thermal neutron flux is intimately related to the neutron dose, specially, the therapeutic boron dose. In this work, numerical calculations in phantoms were performed to determine the importance of utilizing the appropriate thermal scattering treatment for different organic tissues. Two thermal treatments for the neutron scattering were included in the simulations: hydrogen bounded in bulk water and hydrogen bounded in a lipid like carbon chain (polyethylene). The results showed difference between both thermal treatments that can reach several percent points depending on the type of source and irradiated geometry. - Highlights: • The impact of the thermal scattering data in BNCT dosimetry calculations was studied. • Thermal treatment for H in bulk water and H in a carbon chain was considered. • Calculations of thermal neutron flux and dose profiles in phantoms were performed. • The results show differences between both thermal treatments. • The importance of utilizing the correct thermal data for tissues was determined

  18. SBNCT plan: A 3-dimensional treatment planning system for boron neutron capture therapy

    International Nuclear Information System (INIS)

    The need for accurate and comprehensive 3-dimensional treatment planning for boron neutron capture therapy (BNCT) has been debated for the past several years. Although many argue against the need for elaborate and expensive treatment planning programs which mimic conventional radiotherapy planning systems, it is clear that in order to realize significant gains over conventional fractionated radiation therapy, patients must be treated to the edge of normal tissue tolerance. Just how close to this edge is dictated by the uncertainties in dosimetry. Hence the focus of BNCT planning is the determination of dose distribution throughout normal tissue volumes. Although precise geometric manipulation of the epithermal neutron beam is not achievable, the following variables play an important role in BNCT optimization: patient orientation, dose fractionation, number of fields, megawatt-minutes per fraction, use of surface bolus, and use of collimation. Other variables which are not as easily adjustable and would not, therefore, be part of treatment planning optimization, include external patient contour, internal patient heterogeneities, boron compound distributions, and RBE's. The boron neutron capture therapy planning system developed at SUNY Stony Brook (SBNCT-Plan) was designed as an interactive graphic tool to assist the radiation oncologist in generating the optimum plan for a neutron capture treatment

  19. Nominal effective radiation doses delivered during clinical trials of boron neutron capture therapy

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) is a binary system that, in theory, should selectively deliver lethal, high linear energy transfer (LET) radiation to tumor cells dispersed within normal tissues. It is based on the nuclear reaction 10-B(n, α)7-Li, which occurs when the stable nucleus of boron-10 captures a thermal neutron. Due to the relatively high cross-section of the 10-B nucleus for thermal neutron capture and short ranges of the products of this reaction, tumor cells in the volume exposed to thermal neutrons and containing sufficiently high concentration of 10-B would receive a much higher radiation dose than the normal cells contained within the exposed volume. Nevertheless, radiation dose deposited in normal tissue by gamma and fast neutron contamination of the neutron beam, as well as neutron capture in nitrogen, 14-N(n,p)14-C, hydrogen, 1-H(n,γ)2-H, and in boron present in blood and normal cells, limits the dose that can be delivered to tumor cells. It is, therefore, imperative for the success of the BNCT the dosed delivered to normal tissues be accurately determined in order to optimize the irradiation geometry and to limit the volume of normal tissue exposed to thermal neutrons. These are the major objectives of BNCT treatment planning

  20. Treatment of cloud radiative effects in general circulation models

    Energy Technology Data Exchange (ETDEWEB)

    Wang, W.C.; Dudek, M.P.; Liang, X.Z.; Ding, M. [State Univ. of New York, Albany, NY (United States)] [and others

    1996-04-01

    We participate in the Atmospheric Radiation Measurement (ARM) program with two objectives: (1) to improve the general circulation model (GCM) cloud/radiation treatment with a focus on cloud verticle overlapping and layer cloud optical properties, and (2) to study the effects of cloud/radiation-climate interaction on GCM climate simulations. This report summarizes the project progress since the Fourth ARM Science Team meeting February 28-March 4, 1994, in Charleston, South Carolina.

  1. Collimator and shielding design for boron neutron capture therapy (BNCT) facility at TRIGA MARK II reactor

    International Nuclear Information System (INIS)

    The geometry of reactor core, thermal column, collimator and shielding system for BNCT application of TRIGA MARK II Reactor were simulated with MCNP5 code. Neutron particle lethargy and dose were calculated with MCNPX code. Neutron flux in a sample located at the end of collimator after normalized to measured value (Eid Mahmoud Eid Abdel Munem, 2007) at 1 MW power was 1.06 x 108 n/ cm2/ s. According to IAEA (2001) flux of 1.00 x 109 n/ cm2/ s requires three hours of treatment. Few modifications were needed to get higher flux. (Author)

  2. 9Be(d,n)10B-based neutron sources for BNCT

    International Nuclear Information System (INIS)

    In the frame of accelerator-based BNCT, the 9Be(d,n)10B reaction was investigated as a possible source of epithermal neutrons. In order to determine the configuration in terms of bombarding energy, target thickness and Beam Shaping Assembly (BSA) design that results in the best possible beam quality, a systematic optimization study was carried out. From this study, the optimal configuration resulted in tumor doses ≥40 Gy-Eq, with a maximum value of 51 Gy-Eq at a depth of about 2.7 cm, in a 60 min treatment. The optimal configuration was considered for the treatment planning assessment of a real Glioblastoma Multiforme case. From this, the resulted dose performances were comparable to those obtained with an optimized 7Li(p,n)-based neutron source, under identical conditions and subjected to the same clinical protocol. - Highlights: • Study of the 9Be(d,n)10B reaction as a source of epithermal neutrons for BNCT. • Evaluation of the optimal configuration of target thickness, deuteron energy and BSA design. • Computational dose assessment for brain tumor treatments using the MCNP code. • Treatment planning assessment of a particular clinical Glioblastoma Multiforme case. • Dose performances were comparable to those obtained with an optimized 7Li(p,n)-based source

  3. Physical and biological dosimetry at the RA-3 facility for small animal irradiation: preliminary BNCT studies in an experimental model of oral cancer

    International Nuclear Information System (INIS)

    Boron Neutron Capture Therapy (BNCT) is a binary treatment modality based on the capture reaction that occurs between thermal neutrons and boron-10 atoms that accumulate selectively in tumor tissue, emitting high linear energy transfer (LET), short range (5-9 microns) particles (alpha y 7Li). Thus, BNCT would potentially target tumor tissue selectively, sparing normal tissue. Herein we evaluated the feasibility of treating experimental oral mucosa tumors with BNCT at RA-3 (CAE) employing the hamster cheek pouch oral cancer model and characterized the irradiation field at the RA-3 facility. We evaluated the therapeutic effect on tumor of BNCT mediated by BPA in the hamster cheek pouch oral cancer model and the potential radio toxic effects in normal tissue. We evidenced a moderate biological response in tumor, with no radio toxic effects in normal tissue following irradiations with no shielding for the animal body. Given the sub-optimal therapeutic response, we designed and built a 6Li2CO3 shielding for the body of the animal to increase the irradiation dose to tumor, without exceeding normal tissue radio tolerance. The measured absolute magnitude of thermal neutron flux and the characterization of the beam with and without the shielding in place, suggest that the irradiation facility in the thermal column of RA-3 would afford an excellent platform to perform BNCT studies in vitro and in vivo in small experimental animals. The present findings must be confirmed and extended by performing in vivo BNCT radiobiological studies in small experimental animals, employing the shielding device for the animal body. (author)

  4. Dosimetric analysis of BNCT - Boron Neutron Capture Therapy - coupled to 252Cf brachytherapy

    International Nuclear Information System (INIS)

    The incidence of brain tumors is increasing in world population; however, the treatments employed in this type of tumor have a high rate of failure and in some cases have been considered palliative, depending on histology and staging of tumor. Its necessary to achieve the control tumor dose without the spread irradiation cause damage in the brain, affecting patient neurological function. Stereotactic radiosurgery is a technique that achieves this; nevertheless, other techniques that can be used on the brain tumor control must be developed, in order to guarantee lower dose on health surroundings tissues other techniques must be developing. The 252Cf brachytherapy applied to brain tumors has already been suggested, showing promising results in comparison to photon source, since the active source is placed into the tumor, providing greater dose deposition, while more distant regions are spared. BNCT - Boron Neutron Capture Therapy - is another technique that is in developing to brain tumors control, showing theoretical superiority on the rules of conventional treatments, due to a selective irradiation of neoplasics cells, after the patient receives a borate compound infusion and be subjected to a epithermal neutrons beam. This work presents dosimetric studies of the coupling techniques: BNCT with 252Cf brachytherapy, conducted through computer simulation in MCNP5 code, using a precise and well discretized voxel model of human head, which was incorporated a representative Glioblastoma Multiform tumor. The dosimetric results from MCNP5 code were exported to SISCODES program, which generated isodose curves representing absorbed dose rate in the brain. Isodose curves, neutron fluency, and dose components from BNCT and 252Cf brachytherapy are presented in this paper. (author)

  5. Hyperbaric oxygen treatment in radiation reactions; Hyperbar oksygenbehandling ved straalereaksjoner

    Energy Technology Data Exchange (ETDEWEB)

    Aanderud, Leif; Thorsen, Einar; Bratteboe, Guttorm; Forland, Martha; Kristensen, Gunnar

    2000-07-01

    Background: A national hyperbaric centre was established in 1994 at Haukeland Hospital with responsibility of all hyperbaric oxygen (HBO) treatment in Norway. In hypoxic tissues with symptomatic radiation reactions, hyperbaric oxygen induces the formation of collagen and angiogenesis resulting in permanently improved local microcirculation. Material and method: 234 patients received elective HBO treatment at Haukeland Hospital in 12997 with total of 4048 treatments. All 47 patients treated for radiation reactions in the pelvic area in 1997 received a questionnaire 3-15 months after HBO therapy, 81% reported. Results: Rectal bleeding and haematuria were reported as much improved in 61% and 55% respectively, while bladder incontinence was much improved in 46%. Interpretation: this treatment modality may be an alternative in symptomatic radiation reactions at the urinary bladder and the bowel when conventional treatment has given unsatisfactory results.

  6. Sexuality in gynecological patients undergoing radiation therapy treatments

    International Nuclear Information System (INIS)

    The gynecology patient undergoing radiation therapy treatments may experience physiological and psychological problems related to sexuality. The needs of this group must be met by the radiation oncology staff by their being informed, interested, and experienced in dealing with sexual problems created by radiation therapy treatments. Opportunities to obtain information and for discussion about how the disease and its treatments will affect sexual functioning must be provided for the patient and partner. It is important to remember that the ability to seek and preserve gratifying sexual function is of great importance to almost all women, regardless of age. The patient may feel much personal distress related to the disease, the treatments, and how they affect the way she feels as a sexual human being. Opportunities must be provided to share the feelings created by the treatment process and trained therapists should be available when intensive sexual counseling is needed

  7. Challenges With the Diagnosis and Treatment of Cerebral Radiation Necrosis

    Energy Technology Data Exchange (ETDEWEB)

    Chao, Samuel T., E-mail: chaos@ccf.org [Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio (United States); Ahluwalia, Manmeet S. [Department of Medical Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio (United States); Barnett, Gene H. [Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio (United States); Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio (United States); Stevens, Glen H.J. [Department of Neurology, Cleveland Clinic, Cleveland, Ohio (United States); Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio (United States); Murphy, Erin S. [Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio (United States); Stockham, Abigail L. [Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Shiue, Kevin [Case Western Reserve University School of Medicine, Cleveland, Ohio (United States); Suh, John H. [Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Rose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio (United States)

    2013-11-01

    The incidence of radiation necrosis has increased secondary to greater use of combined modality therapy for brain tumors and stereotactic radiosurgery. Given that its characteristics on standard imaging are no different that tumor recurrence, it is difficult to diagnose without use of more sophisticated imaging and nuclear medicine scans, although the accuracy of such scans is controversial. Historically, treatment had been limited to steroids, hyperbaric oxygen, anticoagulants, and surgical resection. A recent prospective randomized study has confirmed the efficacy of bevacizumab in treating radiation necrosis. Novel therapies include using focused interstitial laser thermal therapy. This article will review the diagnosis and treatment of radiation necrosis.

  8. Analytical signals from cancer patients following radiation treatment

    International Nuclear Information System (INIS)

    Cancer patients are treated with high energy (8 to 30 MeV) gamma radiation. This treatment modality provides better depth dose distribution than more conventional low-energy gamma treatments, in particular for deeply located tumors. A by-product of the high-energy treatment is gamma-induced activity in the treatment volume following photonuclear reactions. These reactions are endogenic and require that the gamma radiation energy be above threshold value in order for the reaction to take place. For most elements, the threshold value is above 8 MeV; however, for low Z elements, this threshold may reach 18 MeV as is the case for oxygen. The cross sections for the (γ, n) reactions are few millibarns for low Z elements and increases up to few hundreds of millibarns for the heavy elements. The radionuclides resulting from photonuclear reaction are typically positron emitter or decay by electron capture. Thus, it is possible to monitor either the annihilation radiation (511 KeV) or the characteristic gamma radiation. The present work demonstrates that the activity induced in cancer patients following a single treatment (300 rad) enables the monitoring of nitrogen and phosphorus in the irradiated volume. The results from measurements in phantom, cadavers, and cancer patients from different regions in the body are presented. The hypothesis to be tested is whether there are local changes in these two elements during the course of radiation treatment which might correlate with the efficacy of the treatment

  9. Main trends of radiation application for food stuff treatment

    International Nuclear Information System (INIS)

    The methods of radiation treatment of food stuff using γ, X-rays and electrons are presented. Radiation doses of various products permitted by the Expert Committee of WHO and other international organizations are presented. The problem of grain disinfestation permitted irradiation doses are in the interval between 50 and 100 krad is stiudied. The harmless effect of these doses for products is shown. The experience of raw fish, fish products, raw meat, meat and vegetable products radappertization is reviewed. The intensification of technological processes of food production using radiation treatment is also considered. The advantages and disadvantages of radiation devices with different radiation sources are shown. It is shown that the choice of this or that type should be primarily determined by the parameter of irradiated objects, the periodicity of their coming to the device and conditions of treating these objects

  10. Insights from radiation treatment for benign disease

    Energy Technology Data Exchange (ETDEWEB)

    Bleehen, N.M.

    1987-08-29

    This note compares mortality figures for patients treated with low dose ionizing radiation for benign conditions between the 1920's and 1950's with figures available from the Japanese A-bomb survivors. X radiation for ringworm, ankylosing spondylitis and post-partum mastitis are considered. Figures for leukemia are roughly comparable between radiotherapy groups and A-bomb survivors. Figures for the increased relative risk of breast cancer in spondylitis patients were in marked contrast to bomb survivors who received comparable doses, but compatible with the increase among women given x-rays for acute post-partum mastitis in the 1940's and 1950's. This study also suggests the possibility of different time patterns of risk between different cancers. (U.K.).

  11. Insights from radiation treatment for benign disease

    International Nuclear Information System (INIS)

    This note compares mortality figures for patients treated with low dose ionizing radiation for benign conditions between the 1920's and 1950's with figures available from the Japanese A-bomb survivors. X radiation for ringworm, ankylosing spondylitis and post-partum mastitis are considered. Figures for leukemia are roughly comparable between radiotherapy groups and A-bomb survivors. Figures for the increased relative risk of breast cancer in spondylitis patients were in marked contrast to bomb survivors who received comparable doses, but compatible with the increase among women given x-rays for acute post-partum mastitis in the 1940's and 1950's. This study also suggests the possibility of different time patterns of risk between different cancers. (U.K.)

  12. Status of radiation treatment of liquid sample in Korea

    International Nuclear Information System (INIS)

    For the wastewater treatment, electron beam pilot plant for treating 1,000 m3/day of wastewater from 60,000 m3/day of total dyeing wastewater was constructed and has been successfully operated. In addition to this pilot plant study, construction of commercial scale plant for treatment of dyeing wastewater is being done under TC project organized by IAEA together with E-B Tech. Co., Ltd., Korea Atomic Energy Research Institute (KAERI) and dye wastewater treatment station in Korea. On the other hand, several studies using radiation are being carried out in the field of treatment of polluted groundwater, advanced treatment of sewage, sterilization of discharged water from sewage treatment plants. Many researches on water and wastewater treatment using radiation will be carried out under support of long term basis nuclear R and D program by government. (author)

  13. A virtual model of the patient's head for BNCT

    International Nuclear Information System (INIS)

    The aim of the present work was creating a virtual phantom of a human head for BNCT, as a part of the BNCT programme project. This model is an amplification of the simple model described in earlier publications. It takes into account the major head organs as well as the scalp and skull. The chemical composition of all tissues was modelled according to the recommendations of the ICRP. The organs were parameterized using mathematical formulas based on the human head magnetic resonance images. The model was used for calculating the thermal neutron flux and the injuring (fast neutron, nitrogen and gamma) dose components for the head irradiated using the therapeutic neutron beam, whose parameters were obtained as the result of the modelling of the filter/moderator system for the BNCT therapeutic beam from the MARIA reactor. (authors)

  14. Proceedings of neutron irradiation technical meeting on BNCT

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2000-10-01

    The 'Neutron Irradiation Technical Meeting for Boron Neutron Capture Therapy (BNCT)' was held on March 13, 2000 at Tokai Research Establishment. The Meeting is aimed to introduce the neutron beam facility for medical irradiation at JRR-4 to Japanese researchers widely, as well as providing an opportunity for young researchers, engineers, medical representatives such surgeons and doctors of pharmacology to present their research activities and to exchange valuable information. JAERI researcher presented the performance and the irradiation technology in the JRR-4 neutron beam facility, while external researchers made various and beneficial presentations containing such accelerator-based BNCT, spectrum-shifter, biological effect, pharmacological development and so on. In this meeting, a special lecture titled 'The Dawn of BNCT and Its Development.' was given by MD, Prof. Takashi Minobe, an executive director of Japan Foundation for Emergency Medicine. The 11 of the presented papers are indexed individually. (J.P.N.)

  15. Large area radiation source for water and wastewater treatment

    Science.gov (United States)

    Mueller, Michael T.; Lee, Seungwoo; Kloba, Anthony; Hellmer, Ronald; Kumar, Nalin; Eaton, Mark; Rambo, Charlotte; Pillai, Suresh

    2011-06-01

    There is a strong desire for processes that improve the safety of water supplies and that minimize disinfection byproducts. Stellarray is developing mercury-free next-generation x-ray and UV-C radiation sources in flat-panel and pipe form factors for water and wastewater treatment applications. These new radiation sources are designed to sterilize sludge and effluent, and to enable new treatment approaches to emerging environmental concerns such as the accumulation of estrogenic compounds in water. Our UV-C source, based on cathodoluminescent technology, differs significantly from traditional disinfection approaches using mercury arc lamps or UV LEDs. Our sources accelerate electrons across a vacuum gap, converting their energy into UV-C when striking a phosphor, or x-rays when striking a metallic anode target. Stellarray's large area radiation sources for wastewater treatment allow matching of the radiation source area to the sterilization target area for maximum coverage and improved efficiency.

  16. Radiation Recall Pneumonitis During Systemic Treatment With Everolimus.

    Science.gov (United States)

    Clark, Douglas; Gauchan, Dron; Ramaekers, Ryan; Norvell, Max; Copur, Mehmet Sitki

    2014-01-01

    Radiation recall syndrome is an acute inflammatory reaction developing at anatomical sites of previously irradiated tissue, weeks to months after the completion of radiation therapy. The distribution pattern of inflammation typically involves, and remains limited to, the boundaries of prior radiation treatment fields. Several classical chemotherapy drugs have been reported to have the potential for causing radiation recall syndrome. With the increasing availability and expanding use of novel biologic and targeted therapy anticancer drugs, isolated reports of radiation recall syndrome secondary to this class of agents are starting to appear in the literature. We describe a case of everolimus-induced radiation recall pneumonitis in a patient with metastatic renal cell cancer. PMID:26629944

  17. Research on sewage treatment by radiation

    International Nuclear Information System (INIS)

    Recently the demand for water in urban districts is increasing, and the utilization of the water from sewage treatment, which has been discharged to rivers and seas, is considered. Therefore, the sterilization treatment of the water from sewage treatment by gamma-ray and the remultiplication of microorganisms after the treatment were examined. In the secondary treatment water without filtration, the remultiplication of general bacteria was observed up to 4 kGy, but by carrying out filtration treatment, the remultiplication was suppressed by about 2 kGy irradiation. Coli bacteria were sterilized almost completely by the irradiation of about 1 kGy, and the remultiplication was able to be prevented. As the samples, the treated water without sterilization and that with chlorine sterilization were used. Co-60 gamma-ray was irradiated at the dose rate of 0.2∼6 kGy. The measurement of the number of bacteria and the measurement of water quality were carried out. The typical survival curves of bacteria when gamma-ray was irradiated to treated water and sand-filtrated water are shown. (K.I.)

  18. IRT-Sofia BNCT beam tube optimization study

    International Nuclear Information System (INIS)

    An optimization study of IRT-Sofia BNCT beam tube is presented. In the study we used the MIT/FCB experience. The enlarging of filter/moderator cross section dimensions and the decreasing of collimator length within the limits of the IRT-Sofia reactor design were analyzed. The influence of beam and reactor core axes non-coincidence on the beam properties was also evaluated. The irradiation resistance of polytetrafluoroethylene (Teflon®) was also evaluated. The results provide information for making decisions on the IRT-Sofia BNCT beam construction.

  19. IRT-Sofia BNCT beam tube optimization study

    Energy Technology Data Exchange (ETDEWEB)

    Belousov, S., E-mail: belousov@inrne.bas.bg [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria); Mitev, M.; Ilieva, K. [Institute for Nuclear Research and Nuclear Energy (INRNE) of the Bulgarian Academy of Sciences, Tsarigradsko 72, Sofia (Bulgaria); Riley, K. [Radiation Monitoring Devices, Watertown, MA (United States); Harling, O. [Nuclear Science and Engineering Department, Massachusetts Institute of Technology, Cambridge, MA (United States)

    2011-12-15

    An optimization study of IRT-Sofia BNCT beam tube is presented. In the study we used the MIT/FCB experience. The enlarging of filter/moderator cross section dimensions and the decreasing of collimator length within the limits of the IRT-Sofia reactor design were analyzed. The influence of beam and reactor core axes non-coincidence on the beam properties was also evaluated. The irradiation resistance of polytetrafluoroethylene (Teflon{sup Registered-Sign }) was also evaluated. The results provide information for making decisions on the IRT-Sofia BNCT beam construction.

  20. Considerations for boron neutron capture therapy studies; Consideracoes sobre o estudo da BNCT (terapia de captura neutronica por boro)

    Energy Technology Data Exchange (ETDEWEB)

    Faria Gaspar, P. de

    1994-12-31

    Radiotherapy is indispensable as a mean to eradicate deeply or infiltrating tumor tissue that can not be removed surgically. Therefore, it is not selective and may also kill the surrounding health tissue. The principle of BNCT (Boron Neutron Capture Therapy) consist in targeting a tumor selectively with a boron-10 compound. This nuclide has a large capture cross section for thermal neutrons and the nuclear reaction and the delivered energy in locus will selective the tumor. Since its initial proposal in 1963 BNCT has made much progress, however it is not used in a routine treatment. In this work it was approached some complex procedures, as the obtention of selective boron compounds, the adequate set up of neutron beams, the biodistribution, the in vivo and in vitro studies, and also human patients treatments. This work provide fundamentals about BNCT to professional of different areas of knowledge since it comprises multidisciplinary study. It includes appendixes for the ones not related to the field for a better comprehension of the many aspects involved. It is also presented a glossary containing technical and basic aspects involved. It is also presented a glossary containing technical and basic terms referred in the work. (author). 174 refs, 1 fig, 12 apps.

  1. Clinical treatment planning for subjects undergoing boron neutron capture therapy at Harvard-MIT

    International Nuclear Information System (INIS)

    Treatment planning is a crucial component of the Harvard-MIT boron neutron capture therapy (BNCT) clinical trials. Treatment planning can be divided into five stages: (1) pre-planning, based on CT and MRI scans obtained when the subject arrives at the hospital and on assumed boron-10 distribution parameters; (2) subject set-up, or simulation, in the MITR-II medical therapy room to determine the boundary conditions for possible set-up configurations; (3) re-planning, following the subject simulation; (4) final localization of the subject in the medical therapy room for BNCT; and (5) final post facto recalculation of the doses delivered based on firm knowledge of the blood boron-10 concentration profiles and the neutron flux histories from precise online monitoring. The computer-assisted treatment planning is done using a specially written BNCT treatment planning code called MacNCTPLAN. The code uses the Los Alamos National Laboratory's Monte Carlo n-particle radiation transport code MCNPv.4b as the dose calculation engine and advanced anatomical model simulation based on an automatic evaluation of CT scan data. Results are displayed as isodose contours and dose-volume histograms, the latter correlated precisely with corresponding anatomical CT or MRI image planes. Examples of typical treatment planning scenarios will be presented. (author)

  2. Stereotactic Body Radiation Therapy for Treatment of Spinal Bone Metastasis.

    Science.gov (United States)

    Cihan, Yasemin Benderli

    2016-01-01

    Stereotactic body radiation therapy (SBRT) appears an effective and safe treatment modality for spinal bone metastasis, which can enhance local control and improve quality of life. Life expectation, predicted fracture risk, localization, quality, size and number of metastasis and presence or absence of nerve compression seem to be important factors in decision-making for treatment. Further studies are needed to identify subsets of patient which will most benefit from treatment. PMID:27039816

  3. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Brandao, Samia de Freitas, E-mail: samiabrandao@gmail.com [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil). Departamento de Engenharia Nuclear; Campos, Tarcisio Passos Ribeiro de [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil)

    2013-06-15

    Objective: comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and methods: simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results: intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h{sup -1}.p{sup -1}.s, respectively, on the healthy tissue, on the balloon periphery and on the /{sub 1} and /{sub 2} tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h{sup -1}.p{sup -1}.s, respectively on the healthy tissue, on the target tumor and on the /{sub 1} and /{sub 2} infiltration zones. Conclusion: Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones. (author)

  4. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    Directory of Open Access Journals (Sweden)

    Samia de Freitas Brandao

    2013-07-01

    Full Text Available Objective Comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and Methods Simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results Intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h-1.p-1.s, respectively, on the healthy tissue, on the balloon periphery and on the I 1 and I 2 tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h-1.p-1.s, respectively on the healthy tissue, on the target tumor and on the I 1 and I 2 infiltration zones. Conclusion Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones.

  5. Comparative dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for brain tumors

    International Nuclear Information System (INIS)

    Objective: comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and methods: simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results: intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h-1.p-1.s, respectively, on the healthy tissue, on the balloon periphery and on the /1 and /2 tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h-1.p-1.s, respectively on the healthy tissue, on the target tumor and on the /1 and /2 infiltration zones. Conclusion: Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones. (author)

  6. Radiation treatment for endocrine disrupters in water

    International Nuclear Information System (INIS)

    The radiation-induced decomposition of a trace amount of 17 β-estradiol (E2) in water was studied as a function of the dose of 60Co γ-rays. Concentration of both E2 and E2 activity were estimated by LC-MS and ELISA, and decreased with an increase in the dose of γ-rays. E2 at 1.8-nM in water was degraded almost completely by irradiation at 10 Gy (=J/kg), but the E2 activity of the same sample still remained, and decreased by 30 Gy to be lower than the threshold level of contamination to induce some estrogenic effects on the environmental ecology. (author)

  7. Wastewater treatment by radiation grafted lignocellulosic materials

    International Nuclear Information System (INIS)

    Radiation induced graft copolymerization of acrylamide/acrylic acid (AAm/AAc) binary monomers system onto pulped bagasse and rice straw has been performed. The surface and structure morphology of the pulped bagasse and rice straw were investigated by scanning electron microscopy (SEM) and infrared spectroscopy (FTIR). the factors affecting the abilities of the prepared materials for removing heavy metal ions and dyes from aqueous solution were studied. It was found that the maximum metal uptake is ordered in the sequence of Pb2+> Cu2+>Ni2+. Also the adsorption was found to be increased with the Ph of the feeding solution. The possibility of the removal of four dyes: acid blue 7 (xylene blue), wegocet yellow 4 Gl (direct yellow 44), congo red (direct red 28) and romacryl blue 3 G (blue 3) were investigated. The adsorption capacity of such investigated dyes was found to be remarkably affected by Ph of the feed solution

  8. Dose-rate scaling factor estimation of THOR BNCT test beam

    International Nuclear Information System (INIS)

    In 1998, an epithermal neutron test beam was designed and constructed at the Tsing Hua Open-Pool Reactor (THOR) for the purpose of preliminary dosimetric experiments in boron neutron capture therapy (BNCT). A new epithermal neutron beam was designed at this facility, and is currently under construction, with clinical trials targeted in late 2004. Depth dose-rate distributions for the THOR BNCT test beam have been measured by means of activation foil and dual ion chamber techniques. Neutron and structure-induced gamma spectra measured at the test beam exit were configured into a source function for the Monte Carlo-based treatment planning code NCTPlan. Dose-rate scaling factors (DRSFs) were determined to normalize computationally derived dose-rate distributions with experimental measurements in corresponding mathematical and physical phantoms, and to thus enable accurate treatment planning using the NCTPlan code. A similar approach will be implemented in characterizing the new THOR epithermal beam in preparation for clinical studies. This paper reports the in-phantom calculated and experimental dosimetry comparisons and derived DRSFs obtained with the THOR test beam

  9. Alleviation of acute radiation damages by post-irradiation treatments

    International Nuclear Information System (INIS)

    Radiation induced hematopoietic and gastro-intestinal damages in mice were tried to alleviate experimentally by post-treatment. Combined treatment of OK-432 and aztreonam clearly prevented the radiation induced sepsis and elevated the survival rate in mice; the survival was 80% in the OK-432 plus aztreonam group while it was 55% in the group treated with OK-432 alone and 0% with saline. Irsogladine maleate, an anti-ulcer drug, increased the survival rate of jejunal crypt stem cells with a clear dose-related trend. The D0 for irsogladine maleate was 2.8 Gy although it was 2.3 Gy for saline, These findings suggest that some conventional drugs are effective for radiation induced hematopoietic and gastro-intestinal damages and the possibility that they can be applied for people exposed to radiation accidentally. (author)

  10. [Radiation-induced xerostomia: prevention, treatment, perspectives].

    Science.gov (United States)

    Guinand, N; Dulguerov, P; Giger, R

    2007-10-01

    Most of head and neck cancer patients will undergo radiotherapy. Xerostomia is probably its most frequent side effect. Subjective and objective criteria allow evaluating and grading xerostomia. New radiotherapy techniques and use of cytoprotectants can help to preserve salivary gland function. Parasym-pathicomimetics and saliva substitutes reduce symptoms. Strict mouth cleaning and fluoride's use prevent teeth deterioration and infections. Important breakthroughs have been made in the pathophysiology of xerostomia and new treatments are developed. PMID:17970157

  11. Superficial Radiation Therapy for the Treatment of Nonmelanoma Skin Cancers

    Science.gov (United States)

    Minni, John; Herold, David

    2015-01-01

    Superficial radiation therapy has become more widely available to dermatologists. With the advent of more portable machines, it has become more convenient for dermatology practices to employ in an office-based setting. The goal of this paper is to provide a deeper insight into the role of superficial radiation therapy in dermatology practice and to review the current literature surrounding its use in the treatment of both basal and squamous cell carcinomas. PMID:26705443

  12. Boron Neutron Capture Therapty (BNCT) in an Oral Precancer Model: Therapeutic Benefits and Potential Toxicity of a Double Application of BNCT with a Six-Week Interval

    Energy Technology Data Exchange (ETDEWEB)

    Andrea Monti Hughes; Emiliano C.C. Pozzi; Elisa M. Heber; Silvia Thorp; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; Ana J. Molinari; Marcela A. Garabalino; David W. Nigg; Veronica A. Trivillin; Amanda E. Schwint

    2011-11-01

    Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10 + BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB- 10 + BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10 + BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.

  13. Boron Neutron Capture Therapy (BNCT) in an Oral Precancer Model: Therapeutic Benefits and Potential Toxicity of a Double Application of BNCT with a Six-Week Interval

    International Nuclear Information System (INIS)

    Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA ((GB-10 + BPA)-BNCT) or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB- 10 + BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10 + BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.

  14. Pathophysiology and surgical treatment for radiation enteritis

    International Nuclear Information System (INIS)

    We analyzed 23 patients (5 males and 18 females, mean age 60) who had been operated on in our department for radiation enteritis. 1) These patients were divided into two types according to the time of surgery. Sixteen of 23 (79%) patients were operated on a median of 12 months after radiotherapy, while 7 (30%) underwent surgery more than 10 years later. 2) They were also divided according to the dominant symptoms. Fourteen of 23 (60%) complained of nausea and abdominal distension suggestive of small bowel injury, whereas 7 (30%) had tenesmus and anal bleeding indicating proctitis. Two patients developed perforative peritonitis. 3) The operations performed were as follows: extensive intestinal resection and anastomosis (13), pull-through procedure (3), rectal excision (2), ileostomy (3), by-pass operation (2). Two patients with peritonitis died despite open drainage. Nineteen intestinal anastomoses were all successfully performed. Patients who underwent extensive small bowel resection could resume ordinary daily life without symptoms. Our analysis showed that small bowel injury should be treated by generous resection of the affected bowels followed by anastomosis of the disease-free ends, while rectal lesions are best dealt with by restorative proctectomy. This may provide a good quality of life and minimize major postoperative complications such as leakage. (author)

  15. Radiation Treatment of Wastewater Containing Pharmaceutical Compounds

    International Nuclear Information System (INIS)

    High-energy ionizing radiation induced degradation of maleic acid, fumaric acid and 20 aromatic molecules was investigated in air saturated aqueous solutions. Hydroxyl radicals were generated water radiolysis. The decomposition was followed by chemical oxygen demand (COD) and total organic carbon content (TOC) measurements. Up to ∼50% decrease of COD the dose dependence was linear. By the ratio of the decrease of COD and the amount of reactive radiolysis intermediates introduced into the solution the oxidation efficiencies were calculated. Efficiencies around 0.5-1 (O2 molecule built in products/OH) found for most of the compounds show that the one-electron-oxidant OH induces 2-4 electron oxidations. The high oxidation rates were explained by OH addition to unsaturated bonds and subsequent reactions of the dissolved O2 with organic radicals. In amino substituted molecules or in Acid Red 1 azo dye, O2 cannot compete efficiently with the unimolecular transformation of organic radicals and the efficiency is lower (0.2-0.5). (author)

  16. INEL BNCT Program: Volume 5, No. 9. Bulletin, September 1991

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. [ed.

    1991-12-31

    This Bulletin presents a summary of accomplishments and highlights of the Idaho National Engineering Laboratory`s (INEL) Boron Neutron Capture Therapy (BNCT) Program for September 1991. This bulletin includes information on the brain tumor and melanoma research programs, Power Burst Facility (PBF) technical support and modifications, PBF operations, and updates to the animal data charts.

  17. Quality control in radiotherapy treatment: Radiation induced myelopathy

    International Nuclear Information System (INIS)

    Direct injury of the spinal cord has been reported many times, particularly in cases of overexposures with radiotherapy of neoplasm that occurred outside the Central Nervous System. Permanent damage to the spinal cord is the most feared complication of radiation therapy treatments and one of the relatively common causes of litigation for medical malpractice in the context of cancer treatment. We have learned from clinical experience, data from randomized trials and animal experimentation, the dose tolerance as well as the interfraction interval for hyperfractionation regimes. We are still lacking precious clinical information, in particular the dose tolerance in combined modality treatments that represent the vast majority of modern treatments. (author)

  18. Application of Ionizing Radiation on the Cork Wastewater Treatment

    International Nuclear Information System (INIS)

    In the framework of the CRP on “Radiation treatment of wastewater for reuse with particular focus on wastewaters containing organic pollutants” Portuguese team is been developed studies on the implementation of ionizing radiation technology as a complementary treatment for industrial effluents and increase the added value of these wastewaters. Based on these assumptions, preliminary studies of the gamma radiation effects on the antioxidant compounds present in cork cooking water were carried out. Radiation studies were performed by using radiation between 20 and 50 kGy at 0.4 kGy/h and 2.4 kGy/h. The radiation effects on organic matter content were evaluated by Chemical Oxygen Demand (COD). The antioxidant activity was measured by Ferric Reducing Power (FRAP) assay. The total phenolic content was studied by Folin-Ciocalteau method. Results point out that gamma radiation increases both the amount of phenolic compounds and antioxidant capacity of cork cooking water. By the other hand, the radiolytic degradation by ionizing radiation of gallic acid and esculetin as models for recalcitrants were studied. The objective of this study was to find out if radiolytic degradation, followed by microbial degradation could increase the treatment efficiency. A natural cork wastewater bacterium was selected from the irradiated wastewater at 9 kGy. The applied methodology was based on the evaluation of growth kinetics of the selected bacteria by turbidimetry and colony forming units, in minimal salt medium with non-irradiated and irradiated phenolic as substrate. The overall obtained results highlights the potential of this technology for increase the add value of cork waters and raised some issues to explain by new methodological setup on biodegradation studies. (author)

  19. The treatment of late radiation effects with hyperbaric oxygenation (HBO)

    International Nuclear Information System (INIS)

    Background: Late radiation injuries may impose a negative influence on the quality of life in the affected patients. In several entities, standardized treatment protocols are lacking. Hyperbaric oxygenation (HBO) has been shown to have beneficial effects in the treatment of late radiation sequelae. Material and methods: The basic principles of HBO are reviewed as well as clinical issues. Current study protocols are presented. Results: During HBO-therapy the patient breathes pure oxygen at pressures above 100 kPa. The oxygen solubility within the fluid phase of the blood is largely increased. Biological effects include an increased oxygen diffusibility, improved collagen synthesis and neoangiogenesis as well as an enhancement of antimicrobial defenses. By decreasing the capillary filtration pressure a reduction of edema becomes possible. HBO has been shown to prevent complications following surgery in irradiated tissues. Its efficacy as an adjunct in the treatment of osteonecroses in radiation patients could be demonstrated. In addition, the loss of osseointegrated implants in the maxillofacial bones of these patients could be significantly reduced. Further indications include soft tissue necroses, hemorrhagic cystitis and proctitis in tumor patients that have been treated by radiotherapy as part of a multimodality approach. Conclusions: HBO in the treatment of late radiation effects is still subject of investigation, but remarkable results have been reported. Optimized treatment protocols need to be determined in various entities. The rate of side effects is acceptable low. (orig.)

  20. Boron neutron capture therapy for the treatment of oral cancer in the hamster cheek pouch model

    International Nuclear Information System (INIS)

    We have proposed and validated the hamster cheek pouch model of oral cancer for BNCT studies separately. We herein report the first evidence of the usefulness of BNCT for the treatment of oral cancer in an experimental model. We assessed the response of hamster cheek pouch tumors, precancerous tissue and normal oral tissue to BPA-mediated BNCT employing the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. BNCT leads to complete remission by 15 days post-treatment in 78% of tumors and partial remission in a further 13% of tumors with virtually no damage to normal tissue. (author)

  1. Treatment of radiation proctitis with hyperbaric oxygen: what is the optimal number of HBO treatments?

    International Nuclear Information System (INIS)

    Aim: Our objective was to investigate the effectiveness of hyperbaric oxygenation (HBO) in the treatment of radiation proctitis. The current literature was reviewed with regard to the necessary number of HBO treatments. Patients and Methods: Two patients with proctitis after pelvic irradiation were treated with 40 and 38 HBO treatments, respectively. Hyperbaric oxygenation was delivered at 240 kPa over 90 min. Results: In one patient, proctosigmoidoscopy showed a significant improvement after 40 HBO sessions. The other patient interrupted therapy after 38 HBO treatments without subjective change. The reported number of HBO sessions for a succesful treatment of radiation proctitis ranges from 12 to 90. Conclusion: HBO should be considered before more invasive treatment modalities are performed for radiation proctitis. (orig.)

  2. Neutron flux measurements with Monte Carlo verification at the thermal column of a TRIGA MARK II reactor: Feasibility study for a BNCT facility

    International Nuclear Information System (INIS)

    The treatment of the malignant brain tumor through Boron Neutron Capture Therapy (BNCT) requires a high-flux neutron source. The Malaysian TRIGA Mark II reactor was investigated for a proposed BNCT facility. The neutron flux was measured along the central stringer of the thermal column and the outermost positions of the other stringers. The unfolding foil method was applied here. We have used Al, As, Au, Co, In, Mo, Ni and Re foils and Cd as a cover with 19 useful reactions in this study. The infinitely diluted foil activity was calculated and used in the SAND-II code (Spectrum Analysis by Neutron Detectors) to calculate the neutron flux. The reactor was also simulated using Monte Carlo code (MCNP5) and the neutron flux was calculated along the thermal column. The measured and calculated neutron flux along the thermal column show good agreement. The minimum epithermal neutron intensity required for BNCT is achieved up to position 22 with a mixed neutron-gamma beam. A suggested MCNP simulated modification of the reactor thermal column increased the neutron flux at distant positions from the reactor core but the epithermal neutron part was below the minimum requirement for a BNCT facility. The photon flux calculations along the thermal column show relatively high results which should be filtered. The calculation of the neutron and gamma dose in a head phantom (water) indicated that the available neutron spectrum requires modifications to increase the epithermal part of the neutrons and filter the gamma ray contamination. (author)

  3. Are high energy proton beams ideal for AB‐BNCT? A brief discussion from the viewpoint of fast neutron contamination control

    International Nuclear Information System (INIS)

    High energy proton beam (>8 MeV) is favorable for producing neutrons with high yield. However, the produced neutrons are of high energies. These high energy neutrons can cause severe fast neutron contamination and degrade the BNCT treatment quality if they are not appropriately moderated. Hence, this study aims to briefly discuss the issue, from the viewpoint of fast neutron contamination control, whether high energy proton beam is ideal for AB-BNCT or not. In this study, D2O, PbF4, CaF2, and Fluental™ were used standalone as moderator materials to slow down 1-, 6-, and 10-MeV parallelly incident neutrons. From the calculated results, we concluded that neutrons produced by high energy proton beam could not be easily moderated by a single moderator to an acceptable contamination level and still with reasonable epithermal neutron beam intensity. Hence, much more complicated and sophisticated designs of beam shaping assembly have to be developed when using high energy proton beams. - Highlights: • The fast neutron contamination profiles of 3 different moderator materials were discussed. • D2O, PbF4 and Fluental™ were tested as standalone moderators. • Standalone moderator cannot effectively suppress fast neutrons higher than 1 MeV. • AB-BNCT by high energy proton beam suffers serious fast neutron contamination. • The use of high energy protons (>8 MeV) for AB-BNCT should be carefully evaluated

  4. Improvements at the biological shielding of BNCT research facility in the IEA-R1 reactor; Projeto e implantacao de melhorias na blindagem biologica da instalacao para estudos em BCNT

    Energy Technology Data Exchange (ETDEWEB)

    Souza, Gregorio Soares de

    2011-07-01

    The technique of neutron capture in boron is a promising technique in cancer treatment, it uses the high LET particles from the reaction {sup 10}B (n, {alpha}) {sup 7}Li to destroy cancer cells.The development of this technique began in the mid-'50s and even today it is the object of study and research in various centers around the world, Brazil has built a facility that aims to conduct research in BNCT, this facility is located next to irradiation channel number three at the research nuclear reactor IEA-R1 and has a biological shielding designed to meet the radiation protection standards. This biological shielding was developed to allow them to conduct experiments with the reactor at maximum power, so it is not necessary to turn on and off the reactor to irradiate samples. However, when the channel is opened for experiments the background radiation in the experiments salon increases and this background variation makes it impossible to perform measurements in a neutron diffraction research that utilizes the irradiation channel number six. This study aims to further improve the shielding in order to minimize the variation of background making it possible to perform the research facility in BNCT without interfering with the action of the research group of the irradiation channel number six. To reach this purpose, the code MCNP5, dosimeters and activation detectors were used to plan improvements in the biological shielding. It was calculated with the help of the code an improvement that can reduce the average heat flow in 71.2% {+-} 13 and verified experimentally a mean reduce of 70 {+-} 9% in dose due to thermal neutrons. (author)

  5. Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial

    Energy Technology Data Exchange (ETDEWEB)

    Kankaanranta, Leena [Department of Oncology, Helsinki University Central Hospital, Helsinki (Finland); Seppaelae, Tiina; Koivunoro, Hanna [Department of Physics, University of Helsinki, Helsinki (Finland); Boneca Corporation, Helsinki (Finland); Saarilahti, Kauko [Department of Oncology, Helsinki University Central Hospital, Helsinki (Finland); Atula, Timo [Department of Otorhinolaryngology, Helsinki University Central Hospital, Helsinki (Finland); Collan, Juhani [Department of Oncology, Helsinki University Central Hospital, Helsinki (Finland); Salli, Eero; Kortesniemi, Mika [Helsinki and Uusimaa Hospital District Medical Imaging Center, Helsinki University Central Hospital, Helsinki (Finland); Uusi-Simola, Jouni [Department of Physics, University of Helsinki, Helsinki (Finland); Helsinki and Uusimaa Hospital District Medical Imaging Center, Helsinki University Central Hospital, Helsinki (Finland); Vaelimaeki, Petteri [Department of Physics, University of Helsinki, Helsinki (Finland); Boneca Corporation, Helsinki (Finland); Maekitie, Antti [Department of Otorhinolaryngology, Helsinki University Central Hospital, Helsinki (Finland); Seppaenen, Marko [Turku PET Centre, Turku University Hospital, Turku (Finland); Minn, Heikki [Department of Oncology, Turku University Central Hospital, Turku (Finland); Revitzer, Hannu [Aalto University School of Science and Technology, Esopo (Finland); Kouri, Mauri [Department of Oncology, Helsinki University Central Hospital, Helsinki (Finland); Kotiluoto, Petri; Seren, Tom; Auterinen, Iiro [VTT Technical Research Centre of Finland, Espoo (Finland); Savolainen, Sauli [Department of Physics, University of Helsinki, Helsinki (Finland); Helsinki and Uusimaa Hospital District Medical Imaging Center, Helsinki University Central Hospital, Helsinki (Finland); Joensuu, Heikki, E-mail: heikki.joensuu@hus.fi [Department of Oncology, Helsinki University Central Hospital, Helsinki (Finland)

    2012-01-01

    Purpose: To investigate the efficacy and safety of boron neutron capture therapy (BNCT) in the treatment of inoperable head-and-neck cancers that recur locally after conventional photon radiation therapy. Methods and Materials: In this prospective, single-center Phase I/II study, 30 patients with inoperable, locally recurred head-and-neck cancer (29 carcinomas and 1 sarcoma) were treated with BNCT. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 50 to 98 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed by use of the RECIST (Response Evaluation Criteria in Solid Tumors) and adverse effects by use of the National Cancer Institute common terminology criteria version 3.0. Intravenously administered L-boronophenylalanine-fructose (400 mg/kg) was administered as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Twenty-six patients received BNCT twice; four were treated once. Of the 29 evaluable patients, 22 (76%) responded to BNCT, 6 (21%) had tumor growth stabilization for 5.1 and 20.3 months, and 1 (3%) progressed. The median progression-free survival time was 7.5 months (95% confidence interval, 5.4-9.6 months). Two-year progression-free survival and overall survival were 20% and 30%, respectively, and 27% of the patients survived for 2 years without locoregional recurrence. The most common acute Grade 3 adverse effects were mucositis (54% of patients), oral pain (54%), and fatigue (32%). Three patients were diagnosed with osteoradionecrosis (each Grade 3) and one patient with soft-tissue necrosis (Grade 4). Late Grade 3 xerostomia was present in 3 of the 15 evaluable patients (20%). Conclusions: Most patients who have inoperable, locally advanced head-and-neck carcinoma that has recurred at a previously irradiated site respond to boronophenylalanine-mediated BNCT, but cancer recurrence after BNCT remains frequent. Toxicity was

  6. Numerical chromosomal instability mediates susceptibility to radiation treatment

    Science.gov (United States)

    Bakhoum, Samuel F.; Kabeche, Lilian; Wood, Matthew D.; Laucius, Christopher D.; Qu, Dian; Laughney, Ashley M.; Reynolds, Gloria E.; Louie, Raymond J.; Phillips, Joanna; Chan, Denise A.; Zaki, Bassem I.; Murnane, John P.; Petritsch, Claudia; Compton, Duane A.

    2015-01-01

    The exquisite sensitivity of mitotic cancer cells to ionizing radiation (IR) underlies an important rationale for the widely used fractionated radiation therapy. However, the mechanism for this cell cycle-dependent vulnerability is unknown. Here we show that treatment with IR leads to mitotic chromosome segregation errors in vivo and long-lasting aneuploidy in tumour-derived cell lines. These mitotic errors generate an abundance of micronuclei that predispose chromosomes to subsequent catastrophic pulverization thereby independently amplifying radiation-induced genome damage. Experimentally suppressing whole-chromosome missegregation reduces downstream chromosomal defects and significantly increases the viability of irradiated mitotic cells. Further, orthotopically transplanted human glioblastoma tumours in which chromosome missegregation rates have been reduced are rendered markedly more resistant to IR, exhibiting diminished markers of cell death in response to treatment. This work identifies a novel mitotic pathway for radiation-induced genome damage, which occurs outside of the primary nucleus and augments chromosomal breaks. This relationship between radiation treatment and whole-chromosome missegregation can be exploited to modulate therapeutic response in a clinically relevant manner. PMID:25606712

  7. Experimental results analysis and simulation to evaluate flux and dose at the irradiation sample position of the BNCT research facility

    International Nuclear Information System (INIS)

    To study the BNCT (Boron Neutron Capture Therapy) researchers of the IPEN developed and constructed a facility in the IEA-R1 reactor from IPEN/CNEN-SP, using the beam hole number 3. This facility was constructed to perform experiments of radiation field characterization (neutrons and gammas) suitable to the application of the BNCT technique along with other kinds of experiments in several fields of physics and biology. The purpose of this work is to analyze experimental results, and the simulation to evaluate neutron flux and dose due to gamma radiation at the sample irradiation position of the facility. For the thermal and epithermal flux measurements, the cadmium rate technique with activation foil detector was used, and for the dose determination due to gamma radiation, thermo luminescent dosimeters were used. In the simulation part of this work, the computational transport code DOT 3.5 was utilized. With activation foil detector, a thermal neutron flux of 2.31.108 ± 0.03.108 n/cm2s, and for epithermal neutrons of 4.6.106 ± 0.1.106 n/cm2s were observed at the facility sample irradiation position. With thermoluminescent dosimeters, a dose rate for gamma radiation of 21 ± 1 Gy/h was observed at the sample irradiation position. The observed simulation results show agreement with those experimental flux measurements. (author)

  8. Backgrounds of computer-assisted treatment planning in radiation therapy

    International Nuclear Information System (INIS)

    Interaction of ionising radiation and living materials causes biological damage of tempory or permanent nature. In radiation therapy this phenomenon is used in a controlled fashion in order to stop the proliferation of malignant cells, while at the same time limiting the permanent damage to healthy tissues and organs to at least tolerable levels. Because of the often relatively small differences in response of malignant growths and normal tissues, the margins between tolerable and intolerable are so small that the greatest precision in treatment planning and execution is required. The nature of this treatment agent implies that the radiation therapist has to rely very much on instrumentally obtained and processed information, in all phases of this medical activities around the patient. In this paper a description is given of the backgrounds of computer-assisted methods which have enabled modern individualised and optimised planning for therapy with high energy X- and gamma beams. (orig.)

  9. Treatment of Radiation Induced Biological Changes by Bone Marrow Transplantation

    International Nuclear Information System (INIS)

    Preventing the propagation of radiation induced oxidative damage has been a subject of considerable investigations. The ultimate goal of the present study is to use bone marrow cells to ameliorate or to treat the radiation sickness. Transplantation of bone marrow cell has shown promising results in the present experimental radiation treatment. In this report, suspension of bone marrow cells was injected into rats 12 h. after exposure to 4.5 Gy whole body gamma irradiation. Significant results were recorded on the successful control of the radiation induced disorders in a number of biochemical parameters including certain enzymatic and nonenzymatic antioxidants (superoxide dismutase and glutathione) and certain parameters related to kidney function including creatinine, urea as well as Atpase Activity in blood serum, urine and kidney tissue

  10. Boron Neutron Capture Therapy at the TRIGA Mark II of Pavia, Italy - The BNCT of the diffuse tumours

    Energy Technology Data Exchange (ETDEWEB)

    Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Gadan, M.A. [University of Pavia (Italy); INFN - National Institute for Nuclear Physics, of Pavia (Italy)

    2008-10-29

    The selectivity based on the B distribution rather than on the irradiation field makes Boron neutron Capture Therapy (BNCT) a valid option for the treatment of the disseminated tumours. As the range of the high LET particles is shorter than a cell diameter, the normal cells around the tumour are not damaged by the reactions occurring in the tumoral cells. PAVIA 2001: first treatment of multiple hepatic metastases from colon ca by BNCT and auto-transplantation technique: TAOrMINA project. The liver was extracted after BPA infusion, irradiated in the Thermal Column of the Pavia TRIGA Mark II reactor, and re-implanted in the patient. Two patients were treated, demonstrating the feasibility of the therapy and the efficacy in destroying the tumoral nodules sparing the healthy tissues. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research are presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. The dose distribution in the thorax are simulated using MCNP and the anthropomorphic model ADAM. To have a good thermal flux distribution inside the lung epithermal neutrons must be used, which thermalize crossing the first tissue layers. Thermal neutrons do not penetrate and the obtained uniformity is poor. In the future, the construction of a PGNAA facility using a horizontal channel of the TRIGA Mark II is planned. With this method the B concentration can be measured also in liquid samples (blood, urine) and

  11. Radiation treatment effect on sensibility of lead azide

    International Nuclear Information System (INIS)

    One presents the results of the radiation treatment effect on probability of lead azide explosion. Dependence of explosion probability on preliminary irradiation dose is shown to be of nonmonotonic nature: growth in the field of low doses and drop under high doses. The obtained experimental results agree with a divacancy model of initiation of heavy metal azides

  12. Radiation treatment of the ceramic and polymer implants

    Science.gov (United States)

    Korobeynikov, M. V.; Bryazgin, A. A.; Bezuglov, V. V.; Shtarklev, E. A.; Vlasov, A. Yu; Voronin, L. A.; Tkachenko, V. O.

    2016-02-01

    Implants are used in medical practice during decades. The ceramic implants are the new trend in medicine. The polymer implants are used for many years, and they are mainly sterilized by the radiation treatment. The article describes the new ceramic and polymer implants that were treated in the Budker Institute of Nuclear Physics.

  13. Epithermal neutron beam adoption for liver cancer treatment by boron and gadolinium neutron capture therapy

    International Nuclear Information System (INIS)

    Comparative evaluation was made on depth-dose distribution in boron neutron capture therapy (B-NCT) and gadolinium one (Gd-NCT) for the treatments of liver cancers. At present, epithermal neutron beam is expected to be applicable to the treatment of deep and widespread tumors. ICRU computational model of ADAM and EVA was used as a liver phantom loading a tumor at depth of 6 cm in its central region. Epithermal neutron beam of Musashi reactor was used as the primary neutron beam for the depth-dose calculation. Calculation was conducted using the three-dimensional continuous-energy Monte Carlo code MCNP4A. The doses observed in both NCTs were bumped over the tumor region but the dose for Gd-NCT was not so tumor-specific compared with that for BNCT because radiation in Gd-NCT was due to γ-ray. The mean physical dose was 4 Gy/h for boron 30 ppm and 5 Gy/h for Gd 1000 ppm when exposed to an epithermal neutron flux of 5x108 n/cm-2/sec and the dose ratio of tumor-to normal tissue was 2.7 for boron and 2.5 for Gd. The lethal dose of 50 Gy for the liver can be accomplished under conditions where the dose has not reached 25 Gy, the tolerance dose of the normal tissue. This seems very encouraging and indicating that both B-NCT and Gd-NCT are applicable for the treatment for liver cancer. However, if normal tissue contain 1/4 of the tumor concentration of boron or Gd, the BNCT would still possible when considering a large RBE value for 10B(n, α) reaction but the Gd-NCT would impossible for deep liver treatment. (M.N.)

  14. Anti-infection treatment of iatrogenic acute radiation sickness

    International Nuclear Information System (INIS)

    Objective: To occumulatle experience of anti-infection treatment in acute radiation sickness (ARS) induced by medical treatment in order to provide beneficial help for victims of accidental of acute radiation sickness. Methods: The changes of peripheral blood indices, body temperature and clinical symptoms of 17 cases who were clinically irradiated with 6.0-7.2 Gy X-rays were observed both before peripheral blood stem cell transplantation(PBSCT) and after anti-infection treatment. Results: WBC count began to decrease to below 1 x 109/L from the 8th to 10th days after irradiation and maintained at row level for 4 days or for 13.3 days if the patients had not received rhG-CSF treatment. In 29.4% of patients the body temperature was higher than 38.5 degree C. After comprehensive enviromental protection and anti-infection treatment, all patients could successfully tide over the period of bone marrow depression without appearance of the typical critical phase of ARS. Conclusion: PBSCT and rhG-CSF treatment can reduce the time span for reconstruction of bone marrow. Comprehensive enviromental protection and combined anti-infection treatment are key points fm successful treatment. (authors)

  15. Computer calculations in interstitial seed therapy: I. Radiation treatment planning

    International Nuclear Information System (INIS)

    Interstitial seed therapy computers can be used for radiation treatment planning and for dose control after implantation. In interstitial therapy with radioactive seeds there are much greater differences between planning and carrying out radiation treatment than in teletherapy with cobalt-60 or X-rays. Because of the short distance between radioactive sources and tumour tissue, even slight deviations from the planned implantation geometry cause considerable dose deviations. Furthermore, the distribution of seeds in an actual implant is inhomogeneous. During implantation the spatial distribution of seeds cannot be examined exactly, though X-rays are used to control the operation. The afterloading technique of Henschke allows a more exact implantation geometry, but I have no experience of this method. In spite of the technical difficulty of achieving optimum geometry, interstitial therapy still has certain advantages when compared with teletherapy: the dose in the treated volume can be kept smaller than in teletherapy, the radiation can be better concentrated in the tumour volume, the treatment can be restricted to one or two operations, and localized inoperable tumours may be cured more easily. The latter may depend on an optimal treatment time, a relatively high tumour dose and a continuous exponentially decreasing dose rate during the treatment time. A disadvantage of interstitial therapy is the high personnel dose, which may be reduced by the afterloading technique of Henschke (1956). However, the afterloading method requires much greater personnel and instrumental expense than free implantation of radiogold seeds and causes greater trauma for the patient

  16. Design of a SPECT tomographic image system for online dosimetry in BNCT

    International Nuclear Information System (INIS)

    We present here a numerical analysis of a projected tomographic image system for online dose measurements in Boron Neutron Capture Therapy. In 94% of neutron capture reactions in boron, the 7Li ion is emitted in an excited state which decays through a characteristic 478 keV prompt gamma ray. In BNCT a large fraction of this radiation escapes from the patient body. Its detection is thus attractive for a noninvasive boron dose measurement and an online absorbed dose evaluation. For this purpose we have proposed a dedicated SPECT (Single Photon Emission Computed Tomography) imaging system. The proposed system can obtain images of 21x21cm2 divided in 1x1cm2 pixels by measuring 20 projections with 41 bins each, with 8% uncertainties in reconstructed dose. (author)

  17. Experiences with radiation treatment of soft tissue tumours in childhood

    International Nuclear Information System (INIS)

    The authors review the trends in the treatment of soft tissue tumours in childhood mainly after radiation treatment which is an integral part of the combined therapy. During the last 9 years 23 children with soft tissue tumours were treated with radiotherapy. It was found that in this type of tumours only moderate results could be achieved. This necessitates the early diagnosis and the early start of the combined treatment method. In the authors' material the 2 years survival was 16,6%. The radiotherapy improves the results only if it is based on adequate radiobiological and radiophysical planning ensuring the use of adequate doses and radiation sources. (author) 18 refs.; 3 figs.; 3 tables

  18. Treatment and Recycling Process for Biosolids by Radiation

    International Nuclear Information System (INIS)

    The volume of sludge is increasing rapidly on a yearly basis in Korea. Liquid sewage sludge generated in Korea has been treated as reuse (7%), landfill (5%), incineration (12%) and ocean dump (72%) in 2003 [1]. Ocean dump is the main treatment of sewage sludge up to date but incineration and landfill will be increased because Korean government will restrict ocean dump in the near future. Desirable treatment of sewage sludge is still a sensitive issue though many scientists have vigorously studied the safe and environmentally sound treatment of sewage sludge and reducing sludge cake. Therefore reduction of moisture content in sludge and recycling by radiation is the main objective in this work. Here we studied the radiation technique as a pretreatment process to enhance sludge dewaterability, to disinfect micro-organisms, and to remove the toxic organics in sewage sludge simultaneously. The improvement of sludge compost after irradiation was also observed to develop the method for recycling of sludge

  19. Boron neutron capture therapy as new treatment for clear cell sarcoma: Trial on different animal model

    International Nuclear Information System (INIS)

    Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In our previous study, the tumor disappeared under boron neutron capture therapy (BNCT) on subcutaneously-transplanted CCS-bearing animals. In the present study, the tumor disappeared under this therapy on model mice intramuscularly implanted with three different human CCS cells. BNCT led to the suppression of tumor-growth in each of the different model mice, suggesting its potentiality as an alternative to, or integrative option for, the treatment of CCS. - Highlights: • BNCT with the use of L-BPA was applied for three human clear cell sarcoma (CCS) cell lines. • BNCT trial was performed on a newly established intramuscularly CCS-bearing animal model. • A significant decrease of the tumor-volume was seen by single BNCT with the use of L-BPA. • A multiple BNCT application would be required for controlling the growth of any residual tumors

  20. A study of computational dosimetry and boron biodistribution for ex – situ lung BNCT at RA-3 Reactor

    International Nuclear Information System (INIS)

    Within the context of the preclinical ex-situ BNCT Project for the treatment of diffuse lung metastases, we performed boron biodistribution studies in a sheep model and computational dosimetry studies in human lung to evaluate the potential therapeutic efficacy of the proposed technique. Herein we report preliminary data that supports the use of the sheep model as an adequate human surrogate in terms of boron kinetics and uptake in clinically relevant tissues. Furthermore, the estimation of the potential therapeutic efficacy of the proposed treatment in humans, based on boron uptake values in the large animal model, yields promising tumor control probability values even in the most conservative scenario considered. (author)

  1. 3D volume visualization in remote radiation treatment planning

    Science.gov (United States)

    Yun, David Y.; Garcia, Hong-Mei C.; Mun, Seong K.; Rogers, James E.; Tohme, Walid G.; Carlson, Wayne E.; May, Stephen; Yagel, Roni

    1996-03-01

    This paper reports a novel applications of 3D visualization in an ARPA-funded remote radiation treatment planning (RTP) experiment, utilizing supercomputer 3D volumetric modeling power and NASA ACTS (Advanced Communication Technology Satellite) communication bandwidths at the Ka-band range. The objective of radiation treatment is to deliver a tumorcidal dose of radiation to a tumor volume while minimizing doses to surrounding normal tissues. High performance graphics computers are required to allow physicians to view a 3D anatomy, specify proposed radiation beams, and evaluate the dose distribution around the tumor. Supercomputing power is needed to compute and even optimize dose distribution according to pre-specified requirements. High speed communications offer possibilities for sharing scarce and expensive computing resources (e.g., hardware, software, personnel, etc.) as well as medical expertise for 3D treatment planning among hospitals. This paper provides initial technical insights into the feasibility of such resource sharing. The overall deployment of the RTP experiment, visualization procedures, and parallel volume rendering in support of remote interactive 3D volume visualization will be described.

  2. Prospects for radiation-beam treatment of materials for atomics

    International Nuclear Information System (INIS)

    A consideration is given to various types of radiation-beam technology (ion, plasma, ion-plasma treatments, irradiation with concentrated fluxes of energy) as well as to prospects of their use for optimization of structural and phase states of reactor materials and for surface finishing. The results of corrosion tests and structural studies are presented for fuel tubes of Eh110 and Eh635 zirconium alloys and steels ChS-68, EhJ847, EhP172, EhP450, EhP753 before and after radiation-beam treatments. It is revealed that corrosion resistance and wear resistance are enhanced due to structural changes in a subsurface layer. The advantages of radiation-beam technology are noted to be ecological safety, low power consumption, high controllability and predictability of the results of action, a possibility to vary essentially the element composition and the phase state of a surface layer, as well as to form a specified surface relief. The radiation-beam technology is shown to be promising for treatment of nuclear reactor core components operating under severe conditions

  3. Dynamic infrared imaging of cutaneous melanoma and normal skin in patients treated with BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Santa Cruz, G.A. [Dpto. de Instrumentacion y Control, Comision Nacional de Energia Atomica, Av. del Libertador 8250 (1429), Buenos Aires (Argentina)], E-mail: santacr@cnea.gov.ar; Bertotti, J.; Marin, J. [Universidad Favaloro, Solis 453 (1078), Buenos Aires (Argentina); Gonzalez, S.J. [Dpto. de Instrumentacion y Control, Comision Nacional de Energia Atomica, Av. del Libertador 8250 (1429), Buenos Aires (Argentina); CONICET, Avda. Rivadavia 1917 (1033), Buenos Aires (Argentina); Gossio, S. [FCEyN, Pabellon II, Ciudad Universitaria (1428), Buenos Aires (Argentina); Alvarez, D. [Fundacion Favaloro, Av. Belgrano 1746 (1093), Buenos Aires (Argentina); Roth, B.M.C.; Menendez, P. [Instituto de Oncologia Angel H. Roffo, Av. San Martin 5481 (1417), Buenos Aires (Argentina); Pereira, M.D. [Agencia Nacional de Promocion Cientifica y Tecnologica, PAV 22393 (Argentina); Albero, M.; Cubau, L.; Orellano, P. [INVAP S.E., F.P. Moreno 1089 (R8400AMU), S.C. de Bariloche, Rio Negro (Argentina); Liberman, S.J. [Dpto. de Instrumentacion y Control, Comision Nacional de Energia Atomica, Av. del Libertador 8250 (1429), Buenos Aires (Argentina)

    2009-07-15

    We recently initiated a program aimed to investigate the suitability of dynamic infrared imaging for following-up nodular melanoma patients treated with BNCT. The reason that makes infrared imaging attractive is the fact that it constitutes a functional and non-invasive imaging method, providing information on the normal and abnormal physiologic response of the nervous and vascular systems, as well as the local metabolic rate and inflammatory processes that ultimately appear as differences in the skin temperature. An infrared camera, with a focal plane array of 320x240 uncooled ferroelectric detectors is employed, which provides a video stream of the infrared emission in the 7-14 {mu}m wavelength band. A double blackbody is used as reference for absolute temperature calibration. After following a protocol for patient preparation and acclimatization, a basal study is performed. Subsequently, the anatomic region of interest is subjected to a provocation test (a cold stimulus), which induces an autonomic vasoconstriction reflex in normal structures, thus enhancing the thermal contrast due to the differences in the vasculature of the different skin regions. Radiation erythema reactions and melanoma nodules possess typically a faster temperature recovery than healthy, non-irradiated skin. However, some other non-pathological structures are also detectable by infrared imaging, (e.g. scars, vessels, arteriovenous anastomoses and injuries), thus requiring a multi-study comparison in order to discriminate the tumor signal. Besides the superficial nodules, which are readily noticeable by infrared imaging, we have detected thermal signals that are coincident with the location of non-palpable nodules, which are observable by CT and ultrasound. Diffuse regions of fast temperature recovery after a cold stimulus were observed between the third and sixth weeks post-BNCT, concurrent with the clinical manifestation of radiation erythema. The location of the erythematous visible and

  4. Recent developments in radiation therapy planning and treatment optimization

    International Nuclear Information System (INIS)

    Radiation therapy of cancer is today going through a very dynamic development with the introduction of a large number of new treatment principles, new types of treatment units and new radiobiologically based optimization algorithms for treatment planning. All of these make use of the recent developments in three dimensional tumor diagnostics, molecular biology of cancer, the fractionation sensitivity of different tissues and most recently predictive assays of radiation sensitivity. The most efficient but also least developed area of treatment optimization is to use a few non uniform radiation beams directed towards the tumor. Today patient individual collimation with beam blocks or multi leaf collimators protect organs at risk laterally outside the tumor volume. Non uniform dose delivery also allows protection of normal tissues anterior, posterior and even inside the target volume by shaping the isodoses tightly around the tumor tissues and thereby also allowing longitudinal protection of normal tissues. Some of the most advanced new algorithms are even treating therapy optimization as an inverse problem where the optimal incident beam shapes are determined directly from the location of gross disease, presumed microscopic tumor spread and organs at risk. The optimization is then performed such that the probability, P+, to eradicate all clonogenic tumor cells without severely damaging healthy normal tissues is as high as possible. Already with a few non uniform beams the treatment outcome is within a few percent of what can be achieved with infinitely many co-planar beams in a dynamic mood. With such optimized non uniform treatments it should be possible to improve the treatment outcome by as much as 20% and more, particularly in patients with a local complex spread of the disease or several organs at risk. 78 refs., 1 tab., 7 figs

  5. Potential of radiation sterilization in solid waste treatment

    International Nuclear Information System (INIS)

    Different categories of solid waste are examined from the viewpoint of origins, characteristics and quantities. The composition of household garbage in a Mediterranean municipal zone has been determined in the course of one year, demonstrating the potential application of ionizing radiation to sterilization of certain raw materials (putrescible matter, plastics and paper stock) obtained after separation of the garbage into components. An economic feasibility study of a planned separation and processing plant (1,000-1,200 ton/day) is discussed. A pilot plant (200-300 ton/day) to demonstrate the technologic and economic feasibility of the process is described as is research presently being conducted in several institutes for the production of radiation sterilized feed. The potential of ionizing radiation in solid waste treatment, as a tool facilitating resource recovery from solid municipal and agricultural wastes, is evaluated on the basis of the data presented. (orig.)

  6. Radiation treatment for age-related macular degeneration

    International Nuclear Information System (INIS)

    Fifteen eyes of age-related macular degeneration were treated by low-dose radiation. All the affected eyes had subfoveal neovascular membrane. Seventeen nontreated eyes with similar macular lesion served as control. Radiation was performed using photon beam at 6MV. Each eye received daily dose of 2 Gy for 5 consecutive days. When evaluated 9 to 12 months after treatment, the size of neovascular membrane had decreased in 47% of treated eyes and 7% of control eyes. The visual acuity improved by 2 lines or more in 13% of treated eyes and in none of control eyes. When the initial neovascular membrane was less than 1.5 disc diameter in size, the visual acuity had improved or remained stationary in 90% of treated eyes and in 36% of control eyes. The findings show the potential beneficial effect of radiation for age-related macular degeneration. (author)

  7. Phenomenological modelling of second cancer incidence for radiation treatment planning

    International Nuclear Information System (INIS)

    It is still an unanswered question whether a relatively low dose of radiation to a large volume or a higher dose to a small volume produces the higher cancer incidence. This is of interest in view of modalities like IMRT or rotation therapy where high conformity to the target volume is achieved at the cost of a large volume of normal tissue exposed to radiation. Knowledge of the shape of the dose response for radiation-induced cancer is essential to answer the question of what risk of second cancer incidence is implied by which treatment modality. This study therefore models the dose response for radiation-induced second cancer after radiation therapy of which the exact mechanisms are still unknown. A second cancer risk estimation tool for treatment planning is presented which has the potential to be used for comparison of different treatment modalities, and risk is estimated on a voxel basis for different organs in two case studies. The presented phenomenological model summarises the impact of microscopic biological processes into effective parameters of mutation and cell sterilisation. In contrast to other models, the effective radiosensitivities of mutated and non-mutated cells are allowed to differ. Based on the number of mutated cells present after irradiation, the model is then linked to macroscopic incidence by summarising model parameters and modifying factors into natural cancer incidence and the dose response in the lower-dose region. It was found that all principal dose-response functions discussed in the literature can be derived from the model. However, from the investigation and due to scarcity of adequate data, rather vague statements about likelihood of dose-response functions can be made than a definite decision for one response. Based on the predicted model parameters, the linear response can probably be rejected using the dynamics described, but both a flattening response and a decrease appear likely, depending strongly on the effective cell

  8. Phenomenological modelling of second cancer incidence for radiation treatment planning

    Energy Technology Data Exchange (ETDEWEB)

    Pfaffenberger, Asja; Oelfke, Uwe [Deutsches Krebsforschungszentrum, Heidelberg (Germany). Abt. fuer Medizinische Physik in der Strahlentherapie; Schneider, Uwe [Triemli Hospital and Vetsuisse Faculty, Zurich Univ. (Switzerland). Dept. of Radiation Oncology and Nuclear Medicine; Poppe, Bjoern [Oldenburg Univ. (Germany). Arbeitsgruppe Medizinische Strahlenphysik

    2009-07-01

    It is still an unanswered question whether a relatively low dose of radiation to a large volume or a higher dose to a small volume produces the higher cancer incidence. This is of interest in view of modalities like IMRT or rotation therapy where high conformity to the target volume is achieved at the cost of a large volume of normal tissue exposed to radiation. Knowledge of the shape of the dose response for radiation-induced cancer is essential to answer the question of what risk of second cancer incidence is implied by which treatment modality. This study therefore models the dose response for radiation-induced second cancer after radiation therapy of which the exact mechanisms are still unknown. A second cancer risk estimation tool for treatment planning is presented which has the potential to be used for comparison of different treatment modalities, and risk is estimated on a voxel basis for different organs in two case studies. The presented phenomenological model summarises the impact of microscopic biological processes into effective parameters of mutation and cell sterilisation. In contrast to other models, the effective radiosensitivities of mutated and non-mutated cells are allowed to differ. Based on the number of mutated cells present after irradiation, the model is then linked to macroscopic incidence by summarising model parameters and modifying factors into natural cancer incidence and the dose response in the lower-dose region. It was found that all principal dose-response functions discussed in the literature can be derived from the model. However, from the investigation and due to scarcity of adequate data, rather vague statements about likelihood of dose-response functions can be made than a definite decision for one response. Based on the predicted model parameters, the linear response can probably be rejected using the dynamics described, but both a flattening response and a decrease appear likely, depending strongly on the effective cell

  9. Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-18F-fluoro-L-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT

    International Nuclear Information System (INIS)

    A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2 h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2-4 h post PBAD-lipiodol injection.

  10. Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-{sup 18}F-fluoro-L-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Liao, A.H. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China); Chou, F.I. [Institute of Nuclear Engineering and Science, National Tsing-Hua University, Hsinchu, Taiwan (China); Kuo, Y.C. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China); Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan (China); Chen, H.W. [Department of Radiation Oncology and Hospice Center, Mackay Memorial Hospital, Taipei, Taiwan (China); Kai, J.J. [Institute of Nuclear Engineering and Science, National Tsing-Hua University, Hsinchu, Taiwan (China); Chang, C.W. [Department of Nuclear Medicine, Veterans General Hospital, Taipei, Taiwan (China); Chen, F.D. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China); Hwang, J.J. [Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong St., Bei-tou, 112 Taipei, Taiwan (China)], E-mail: jjhwang@ym.edu.tw

    2010-03-15

    A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2 h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2-4 h post PBAD-lipiodol injection.

  11. Prevention and treatment of the gastric symptoms of radiation sickness

    International Nuclear Information System (INIS)

    Currently available treatments for radiation-induced nausea and vomiting either are ineffective or reduce performance. The new antiemetic and gastrokinetic agent zacopride was tested in rhesus monkeys to assess its behavioral toxicity and its ability to inhibit radiation-induced emesis. Zacopride (intragastric, 0.3 mg/kg) or a placebo was given blindly and randomly in the basal state and 15 min before a whole-body 800 cGy 60Co gamma-radiation dose (except for the legs which were partially protected to permit survival of some bone marrow). We determined (1) gastric emptying rates; (2) the presence and frequency of retching and vomiting; and (3) the effect of zacopride on the performance of a visual discrimination task in nonirradiated subjects. No vomiting, retching, or decreased performance was observed after either placebo or zacopride in the control state. Following irradiation plus placebo, 70 emeses were observed in 5 of 6 monkeys, and 353 retches were observed in all 6 monkeys. In contrast, only 1 emesis was observed in 1 of 6 monkeys and 173 retches were seen in 4 of 6 monkeys after irradiation plus zacopride (P less than 0.01). Zacopride also significantly inhibited radiation-induced suppression of gastric emptying. When given after the first vomiting episode in a separate group of irradiated monkeys, zacopride completely prevented any subsequent vomiting. The present results demonstrate that intragastric administration of zacopride significantly inhibited radiation-induced retching, vomiting, and suppression of gastric emptying in rhesus monkeys and did not cause detectable behavioral side effects when given to nonradiated monkeys. This observation has important implications in the treatment of radiation sickness

  12. The refinement of dose assessment of the THOR BNCT beam

    International Nuclear Information System (INIS)

    A refined dose assessment method has been used now in the THOR BNCT facility, which takes into account more delicate corrections, carefully handled calibration factors, and the spectrum- and kerma-weighted kt value. The refined method solved the previous problem of negative derived neutron dose in phantom at deeper positions. With the improved dose assessment, the calculated and measured gamma-ray dose rates match perfectly in a 15×15×15 cm3 PMMA phantom.

  13. Bone marrow transplantation for treatment of radiation disease. Problems involved

    International Nuclear Information System (INIS)

    Transplantation of bone marrow cells still is one of the major means available for treatment of radiation injuries. The decisive indication is the diagnostic of irreversible damage to the hemopoietic stem cells, which becomes manifest about 5 or 6 days after exposure, by severe granulocytopenia and simultaneous, progressive thrombopenia. The radiation dose provoking such severe injury is estimated to be at least 9-10 Gy of homogeneous whole-body irradiation. Preparatory measures for transplantation include proof of tissue compatibility of donor and patient, sufficient immunosuppression prior to and/or after irradiation and bone marrow transplantation. The donor's marrow should be free of T-cells. In spite of preparatory treatment, complications such as immunological reactions or disturbance of organ functions are to be very probable. These are treated according to therapy protocols. (orig./MG)

  14. Treatment of radiation- and chemotherapy-induced stomatitis

    International Nuclear Information System (INIS)

    Severe stomatitis is a common problem encountered during either radiation therapy or chemotherapy. Most therapeutic regimens are empirical, with no scientific basis. The purpose of this study is to determine the efficacy of various topical solutions in the treatment of radiation- or chemotherapy-induced stomatitis. Eighteen patients were entered into a prospective double-blinded study to test several topical solutions: (1) viscous lidocaine with 1% cocaine; (2) dyclonine hydrochloride 1.0% (Dyclone); (3) kaolin-pectin solution, diphenhydramine plus saline (KBS); and (4) a placebo solution. Degree of pain relief, duration of relief, side effects, and palatability were evaluated. The results showed that Dyclone provided the most pain relief. Dyclone and viscous lidocaine with 1% cocaine provided the longest pain relief, which averaged 50 minutes This study provides objective data and defines useful guidelines for treatment of stomatitis

  15. Radiation disinfestation as a quarantine treatment for solo papaya

    International Nuclear Information System (INIS)

    Solo papaya is subject to infestation by the Oriental fruit fly, Bactrocera dorsalis (Hendel). Since ethylene dibromide has been banned for use as a fumigant for fruits, gamma radiation was investigated as an alternative quarantine disinfestation treatment for solo papaya. Results of small-scale laboratory tests showed that 150 Gy completely prevented the emergence of B. dorsalis. For egg-infested solo papaya, pupal recovered decreased with increasing dose while insect survival was not associated with fruit maturity. For larvae-infested ones, insect survival, in general, was highest in the full-ripe stage and lowest in the one-fourth-ripe stage of the fruit. Confirmatory tests of the proposed treatment using more than 100,000 test insects revealed that 150 Gy radiation dose is sufficient to provide Probit 9 quarantine security for solo papaya. (author). 10 refs.; 1 fig.; 4 tabs

  16. Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.

    Science.gov (United States)

    Yanai, Shunichi; Nakamura, Shotaro; Ooho, Aritsune; Nakamura, Shigeo; Esaki, Motohiro; Azuma, Koichi; Kitazono, Takanari; Matsumoto, Takayuki

    2015-06-01

    Sorafenib, an oral inhibitor of multiple tyrosine kinase receptors, has been widely used as a standard medical treatment for advanced hepatocellular carcinoma (HCC). Here, we report a 66-year-old male patient who developed gastrointestinal bleeding due to radiation-induced hemorrhagic duodenitis associated with sorafenib treatment. We started oral administration of sorafenib because of the recurrence of HCC with lung metastases. The patient had been treated by radiotherapy for para-aortic lymph node metastases from HCC 4 months before the bleeding. Esophagogastroduodenoscopy (EGD) revealed edematous reddish mucosa with friability and telangiectasia in the second portion of the duodenum. Computed tomography and capsule endoscopy revealed that the hemorrhagic lesions were located in the distal duodenum. After discontinuation of sorafenib, the bleeding disappeared and a follow-up EGD confirmed improvement of duodenitis. Based on these findings, the diagnosis of radiation-induced hemorrhagic duodenitis associated with sorafenib was made. PMID:25832768

  17. Acupuncture treatment of patients with radiation-induced xerostomia

    Energy Technology Data Exchange (ETDEWEB)

    Blom, M.; Dawidson, I.; Johnson, G.; Angmar-Maansson, B. [Karolinska Inst., Huddinge (Sweden). Dept. of Cardiology; Fernberg, J.-O. [Karolinska Hospital, Stockholm (Sweden). Dept. of General Oncology

    1996-05-01

    Xerostomia is a common and usually irreversible side effect in patients receiving radiation therapy (>50 Gy) for head and neck cancer. Of 38 patients with radiation-induced xerostomia, 20 in the experimental group were treated with classical acupuncture and 18 patients in the control group received superficial acupuncture as placebo. Within both groups the patients showed significantly increased salivary flow rates after the acupuncture treatment. In the experimental group 68% and in the control group 50% of the patients had increased salivary flow rates at the end of the observation period. Among those patients who had had all their salivary glands irradiated, 50% in both groups showed increased salivary flow rates (>20%) by the end of the observation period of 1 year. The study indicates that among the patients who had increased salivary flow rates already after the first 12 acupuncture sessions, the majority had high probability of continual improvement after the completion of acupuncture treatment. (Author).

  18. Acupuncture treatment of patients with radiation-induced xerostomia

    International Nuclear Information System (INIS)

    Xerostomia is a common and usually irreversible side effect in patients receiving radiation therapy (>50 Gy) for head and neck cancer. Of 38 patients with radiation-induced xerostomia, 20 in the experimental group were treated with classical acupuncture and 18 patients in the control group received superficial acupuncture as placebo. Within both groups the patients showed significantly increased salivary flow rates after the acupuncture treatment. In the experimental group 68% and in the control group 50% of the patients had increased salivary flow rates at the end of the observation period. Among those patients who had had all their salivary glands irradiated, 50% in both groups showed increased salivary flow rates (>20%) by the end of the observation period of 1 year. The study indicates that among the patients who had increased salivary flow rates already after the first 12 acupuncture sessions, the majority had high probability of continual improvement after the completion of acupuncture treatment. (Author)

  19. Design of compact electromagnetic impulse radiating antenna for melanoma treatment.

    Science.gov (United States)

    Arockiasamy, Petrishia; Mohan, Sasikala

    2016-01-01

    Cancer therapy is one of the several new applications which use nanosecond and subnanosecond high voltage pulses. New treatment based on electromagnetic (EM) fields have been developed as non-surgical and minimally invasive treatments of tumors. In particular, subnanosecond pulses can introduce important non-thermal changes in cell biology, especially the permeabilization of the cell membrane. The motivation behind this work is to launch intense subnanosecond pulses to the target (tumors) non-invasively. This works focuses on the design of a compact intense pulsed EM radiating antenna. In tense EM waves radiated at the first focal point of the Prolate Spheroidal Reflector (PSR) are focused at the second focal point where the target (tumor) is present. Two antennas with PSR but fed with different compact wave radiator are designed to focus pulsed field at the second focal point. The PSR with modified bicone antenna feed and PSR with elliptically tapered horn antenna feed are designed. The design parameters and radiation performance are discussed. PMID:25651405

  20. Gamma radiation induced effects on slaughterhouse wastewater treatment

    International Nuclear Information System (INIS)

    A preliminary study using gamma radiation on slaughterhouse wastewater samples was carried out. Chemical oxygen demand (COD), biochemical oxygen demand (BOD) and total suspended solids (TSS) results were obtained at a dose rate of 0.9 kGy h-1. A decrease of COD, BOD and colour was observed after irradiation at high absorbed doses. The microbiological results, following irradiation in the same conditions, correlated with the BOD results. The results obtained highlight the potential of this technology for wastewater treatment

  1. An Australian survey of current practice regarding radiation treatment records

    International Nuclear Information System (INIS)

    Thirty one Radiation Oncology Departments were surveyed to assess the structure and content of their external photon beam treatment sheets. A master index of standard data items was compiled from previously published recommendations and the frequency of recording these items was tabulated. A wide variation in practice was observed. The data highlights the need for agreed common data recording for quality assurance, outcome analysis and participation in clinical trials. 4 tabs

  2. INDUSTRIAL EFFLUENT TREATMENT USING IONIZING RADIATION COMBINED TO TITANIUM DIOXIDE

    Energy Technology Data Exchange (ETDEWEB)

    Duarte, C.L.; Oikawa, H.; Mori, M.N.; Sampa, M.H.O.

    2004-10-04

    The Advanced Oxidation Process (AOP) with OH radicals are the most efficient to mineralize organic compounds, and there are various methods to generate OH radicals as the use of ozone, hydrogen peroxide and ultra-violet radiation and ionizing radiation. The irradiation of aqueous solutions with high-energy electrons results in the excitation and ionizing of the molecules and rapid (10{sup -14} - 10{sup -9} s) formation of reactive intermediates. These reactive species will react with organic compounds present in industrial effluent inducing their decomposition. Titanium dioxide (TiO{sub 2}) catalyzed photoreaction is used to remove a wide range of pollutants in air and water media, combined to UV/VIS light, FeO{sub 2}, and H{sub 2}O{sub 2}, but as far as known there is no report on the combination with ionizing radiation. In some recent studies, the removal of organic pollutants in industrial effluent, such as Benzene, Toluene, and Xylene from petroleum production using ionizing radiation was investigated. It has been ob served that none of the methods can be used individually in wastewater treatment applications with good economics and high degree of energy efficiency. In the present work, the efficiency of ionizing radiation in presence of TiO{sub 2} to treat industrial effluent was evaluated. The main aim to combine these technologies is to improve the efficiency for very hard effluents and to reduce the processing cost for future implementation to large-scale design.

  3. Optimization of the application of BNCT to undifferentiated thyroid cancer

    International Nuclear Information System (INIS)

    The possible increase in BNCT efficacy for undifferentiated thyroid carcinoma (UTC) using BPA plus BOPP and nicotinamide (NA) as a radiosensitizer on the BNCT reaction was analyzed. In these studies nude mice were transplanted with the ARO cells and after 14 days they were treated as follows: 1) Control; 2) NCT (neutrons alone); 3) NCT plus NA (100 mg/kg bw/day for 3 days); 4) BPA (350 mg/kg bw) + neutrons; 5) BPA+ NA+ neutrons; 6) BPA+BOPP (60 mg/kg bw) + neutrons. The flux of hyperthermal neutrons was 2.8 108 during 85 min. Neutrons alone or with NA caused some tumor growth delay, while in the BPA, BPA+NA and BPA+BOPP groups a 100% halt of tumor growth was observed. When the initial tumor volume was 50 mm3 or less a complete cure was found in BPA+NA (2/2); BPA (1/4); BPA+BOPP (7/7). After 90 days of complete regression, recurrence of tumor was observed in 2/2 BPA/NA (2/2) and BPA+BOPP (1/7). Caspase 3 activity was increased in BPA+NA (p<0.05 vs controls). BPA plus NA increased tumor apoptosis but only the combination of BPA+BOPP increased significantly BNCT efficiency. (author)

  4. PhoNeS: A novel approach to BNCT with conventional radiotherapy accelerators

    International Nuclear Information System (INIS)

    PhoNeS (Photo Neutron Source) is an INFN project devoted to the optimization of the neutron production and moderation in radiotherapy linear accelerators. LinAcs producing high energy (15-25MeV) photon beams are becoming widespread. At this energy neutron photo-production is unavoidable and the neutron dose must be controlled and reduced during normal radiotherapy. A technique known as BNCT (Boron Neutron Capture Therapy) uses neutrons for radiotherapic treatments: the cells are given a drug containing B10 which undergoes fission after neutron capture, inducing heavy damages to the DNA of the cell itself. This paper will describe the moderator developed by PhoNeS and the results in terms of neutron flux and spectrum and photon contamination of the measurements performed on several radiotherapy accelerators

  5. Therapeutic effect of beta radiation on onychomycosis: An innovative treatment

    International Nuclear Information System (INIS)

    Full text: Onychomycosis is the most frequent cause of nail disease and the most prevalent type of dermatophytosis in Bangladesh. The humid and warm climate of this tropical country is congenial for the growth of fungi. Therapeutic limitations of conventional antimycotic agents in respect of low cure rates, high relapse rate, inherent side effects, long duration of treatment and high cost in treating onychomycosis have provided clear incentives to explore alternative forms of treatment procedure. The objectives of the present thesis work were: (i) To use beta radiation as a curative therapy for Onychomycosis, optimisation of its dosages and to promote an innovative clinical development in the field of therapeutic application of nuclear medicine; (ii) To assess the efficacy of beta radiation either alone or in combination with conventional antifungal therapy; and (iii) To reduce the duration of drug exposure and cost of treatment for onychomycosis. This is a PhD research work under the University of Dhaka and was sponsored by the Ministry of Science and Information and Communication Technology, Government of the people's republic of Bangladesh. This study is an open, randomised and controlled trial to verify the efficacy of beta radiation in patients with onychomycosis. Using the appropriate statistical formula, sample size of the study population was determined and in each group 92 patients were assigned. With an assumption of patients drop out and for better statistical analysis, a total of 330 patients, who fulfilled the inclusion criterion having diagnosed to have onychomycosis clinically and mycological were randomly allocated to enter in therapeutic regimen. Study population was randomised in three groups. Group A (n =110) received griseofulvin orally 500 mg once daily for 12-16 weeks; Group B (n=110) received beta radiation, 500 rads bi-weekly for 3 weeks (total 2500 rads); and Group C (n=110) received combined beta radiation (total 2500 rads in 3 weeks) and

  6. Confirmation of a realistic reactor model for BNCT dosimetry at the TRIGA Mainz

    Energy Technology Data Exchange (ETDEWEB)

    Ziegner, Markus, E-mail: Markus.Ziegner.fl@ait.ac.at [AIT Austrian Institute of Technology GmbH, Vienna A-1220, Austria and Institute of Atomic and Subatomic Physics, Vienna University of Technology, Vienna A-1020 (Austria); Schmitz, Tobias; Hampel, Gabriele [Institut für Kernchemie, Johannes Gutenberg-Universität, Mainz DE-55128 (Germany); Khan, Rustam [Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad PK-44000 (Pakistan); Blaickner, Matthias [AIT Austrian Institute of Technology GmbH, Vienna A-1220 (Austria); Palmans, Hugo [Acoustics and Ionising Radiation Division, National Physical Laboratory, Teddington TW11 0LW, United Kingdom and Medical Physics Group, EBG MedAustron GmbH, Wiener Neustadt A-2700 (Austria); Sharpe, Peter [Acoustics and Ionising Radiation Division, National Physical Laboratory, Teddington TW11 0LW (United Kingdom); Böck, Helmuth [Institute of Atomic and Subatomic Physics, Vienna University of Technology, Vienna A-1020 (Austria)

    2014-11-01

    Purpose: In order to build up a reliable dose monitoring system for boron neutron capture therapy (BNCT) applications at the TRIGA reactor in Mainz, a computer model for the entire reactor was established, simulating the radiation field by means of the Monte Carlo method. The impact of different source definition techniques was compared and the model was validated by experimental fluence and dose determinations. Methods: The depletion calculation code ORIGEN2 was used to compute the burn-up and relevant material composition of each burned fuel element from the day of first reactor operation to its current core. The material composition of the current core was used in a MCNP5 model of the initial core developed earlier. To perform calculations for the region outside the reactor core, the model was expanded to include the thermal column and compared with the previously established ATTILA model. Subsequently, the computational model is simplified in order to reduce the calculation time. Both simulation models are validated by experiments with different setups using alanine dosimetry and gold activation measurements with two different types of phantoms. Results: The MCNP5 simulated neutron spectrum and source strength are found to be in good agreement with the previous ATTILA model whereas the photon production is much lower. Both MCNP5 simulation models predict all experimental dose values with an accuracy of about 5%. The simulations reveal that a Teflon environment favorably reduces the gamma dose component as compared to a polymethyl methacrylate phantom. Conclusions: A computer model for BNCT dosimetry was established, allowing the prediction of dosimetric quantities without further calibration and within a reasonable computation time for clinical applications. The good agreement between the MCNP5 simulations and experiments demonstrates that the ATTILA model overestimates the gamma dose contribution. The detailed model can be used for the planning of structural

  7. The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, T., E-mail: tetsu_tsukuba@yahoo.co.jp [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nakai, K. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo (Japan); Kumada, H.; Okumura, T.; Mizumoto, M.; Tsuboi, K. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Zaboronok, A.; Ishikawa, E.; Aiyama, H.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)

    2011-12-15

    The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m{sup 2}) for the treatment of newly diagnosed GBM. BPA uptake is determined by {sup 18}F-BPA-PET and/or {sup 11}C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.

  8. Advantages of three-dimensional treatment planning in radiation therapy

    International Nuclear Information System (INIS)

    This study was designed to demonstrate the feasibility of three-dimensional (3-D) treatment planning in-patients maxilla, breast, bladder, and lung tumors to explore its potential therapeutic advantage over the traditional dimensional (2-D) approach in these diseases. Conventional two-dimensional (2-D) treatment planning was compared to three-dimensional (3-D) treatment planning. In five selected disease sites, plans calculated with both types of treatment planning were compared. The (3-D) treatment planning system used in this work TMS version 5.1 B from helax AB is based on a monte Carlo-based pencil beam model. The other treatment planning system (2-D 0, introduced in this study was the multi data treatment planning system version 2.35. For the volumes of interest; quality of dose distribution concerning homogeneity in the target volume and the isodose distribution in organs at risk, was discussed. Qualitative and quantitative comparisons between the two planning systems were made using dose volume histograms (DVH's) . For comparisons of dose distributions in real-patient cases, differences ranged from 0.8% to 6.4% for 6 MV, while in case of 18 MV photon, it ranged from 1,8% to 6.5% and was within -+3 standard deviations for the dose between the two planning systems.Dose volume histogram (DVH) shows volume reduction of the radiation-related organs at risk 3-D planning

  9. Present state of the combined treatment with radiation and chemicals

    International Nuclear Information System (INIS)

    Of malignancies in which the results have been markedly improved by combined treatment with radiation and chemicals for the past decade, non-Hodgkin's lymphoma localized in head and neck and intra-oral carcinoma are presented. In the management of non-Hodgkin's lymphoma, the authors stressed the following: 1) Rappaport's classification has been a help to evaluate the prognosis; 2) lymphoma of the Waldeyer's ring should not be included in nodal lymphoma, and also it should be separated from extranodal lymphoma as well, because of different prognosis; 3) It seems that some kinds of chemotherapy would have a role in improving the results of radiotherapy in the management of radiotherapy, even in localized cases. In some types of intra-oral carcinomas, bleomycin was found to be useful in the combined treatment with radiation as follows: 1) A minimum required dose for local control of intra-oral carcinomas could be a combination of 30Gy in 3 weeks and 100mg bleomycin during the same period. 2) Although the end results of patients with carcinoma of tongue or floor of mouth have not been improved by this approach, there was marked improvement in patients with carcinoma of the lower gum. 3) For the treatment, the side effect as limiting factor was mucositis, and none of the cases of the series developed pulmonary complication. In the cases controlled by initial combined treatment, no one developed troubles of the mandible, in the follow-up study for the past 10 years. (author)

  10. Pilocarpine and carbacholine in treatment of radiation-induced xerostomia

    International Nuclear Information System (INIS)

    Twenty-four patients with radiation-related xerostomia were treated with oral pilocarpine solution 6 mg t.i.d., and after a 4-week drug-free period 16 of these patients were treated with carbacholine 2 mg tablets t.i.d. Basal and stimulated whole saliva flow rates were measured before commencing the drug treatment, and after 1 and 12 weeks on treatment. On a subjective linear scale both pilocarpine (p=0.01) and carbacholine (p=0.02) improved mouth moistness. Only 2 of the 8 patients with no basal or stimulated saliva flow reported some subjective benefit from the drug treatment, whereas all 8 patients with less severe xerostomia improved (p=0.007). However, the salivary flow rates measured 12 h after the last drug dose did not improve with either drug. Both drugs were generally well tolerated. It is concluded that both drugs may be useful in the treatment of radiation-induced xerostomia among patients with residual salivary function. (author). 6 refs., tabs

  11. Intracellular targeting of mercaptoundecahydrododecaborate (BSH) to malignant glioma by transferrin-PEG liposomes for boron neutron capture therapy (BNCT)

    International Nuclear Information System (INIS)

    Malignant glioma is one of the most difficult tumor to control with usual therapies. In our institute, we select boron neutron capture therapy (BNCT) as an adjuvant radiation therapy after surgical resection. This therapy requires the selective delivery of high concentration of 10B to malignant tumor tissue. In this study, we focused on a tumor-targeting 10B delivery system (BDS) for BNCT that uses transferrin-conjugated polyethylene-glycol liposome encapsulating BSH (TF-PEG liposome-BSH) and compared 10B uptake of the tumor among BSH, PEG liposome-BSH and TF-PEG liposome-BSH. In vitro, we analyzed 10B concentration of the cultured human U87Δ glioma cells incubated in medium containing 20 μg 10B/ml derived from each BDS by inductively coupled plasma atomic emission spectrometry (ICP-AES). In vivo, human U87Δ glioma-bearing nude mice were administered with each BDS (35mg 10B/kg) intravenously. We analyzed 10B concentration of tumor, normal brain and blood by ICP-AES. The TF-PEG liposome-BSH showed higher absolute concentration more than the other BDS. Moreover, TF-PEG liposome-BSH decreased 10B concentration in blood and normal tissue while it maintained high 10B concentration in tumor tissue for a couple of days. This showed the TF-PEG liposome-BSH caused the selective delivery of high concentration of 10B to malignant tumor tissue. The TF-PEG liposome-BSH is more potent BDS for BNCT to obtain absolute high 10B concentration and good contrast between tumor and normal tissue than BSH and PEG liposome-BSH. (author)

  12. A new NEDO research project towards hospital based accelerator BNCT using advanced DDS system

    International Nuclear Information System (INIS)

    A new national project of developing a hospital based accelerator for boron neutron capture therapy (BNCT) with advanced drug delivery system (DDS) has been started in 2005. In this paper, the outline of the new project will be introduced. The project includes two main topics: 1) a hospital based accelerator for BNCT will be developed by a research consortium of Universities and companies. A fixed field alternating gradient (FFAG) type of accelerator with internal target is planned. 2) New boronated DDS using different methods including porphyrins, virus envelope vector, and liposome are planned. BNCT may become a first line charged particle therapy if the hospital based accelerator become feasible due to broadening the opportunity to use the neutron source. Due to such clinical convenience, there will be also possibility to spread the indication of BNCT for the diseases (cancer and other diseases) which has not been the candidate for BNCT in the nuclear-reactor era. (author)

  13. Experimental study for cancer treatment using synchrotron radiation

    International Nuclear Information System (INIS)

    Radiotherapy is one of the most powerful treatments for brain tumor. Penetrating ionizing particles is aimed toward the tumor, delivering as high radiation to it as is usefully suppressive of tumor growth, and tolerated by normal vital tissues inevitably irradiated with the tumor. The use of a high-energy synchrotron-radiation thin X-ray beams (microplanar beams, or microbeams) produced through a multi-slit collimator has been reported to enhance the tolerance of normal tissue to radiation. The high collimation and dose rate of synchrotron X-ray beams favor radiotherapy. Irradiation with parallel arrays of microbeam, planar slices of spares normal brain, and preferentially damages tumors. The width of the peak region was 20-25 μm, and the spacing between the regions was 100-300 μm. We firstly examined the dose distribution with micro-scale resolution in order to clarify this phenomenon. Secondary, radiotherapy of malignant brain tumors in rats was performed. The treatment results in extended median survival time. The effects are mediated, at least in part, by the tissue's microvasculature that seems to effectively repair itself in normal brain but fails to do so in tumors. (author)

  14. Audio-vestibulary changes following radiation treatment of the epipharynx

    International Nuclear Information System (INIS)

    Audio-vestibular changes are described following radiation treatment of the epipharynx. A total of 83 patients were observed prior to and following radiotherapy. In 70 of them hearing power was diminished: sound perceiving decrease was recorded in 43 patients (51,8 per cent), mixed type of diminished hearing power in 16 patients (19,2 per cent) and sound conduction decrease in 11 patients (13,2 per cent). Apart from the clinical method for testing the power of hearing (whispering and conversation) tonal threshold audiometry is also employed. The patients were asked for vestibulary complaints: the latter were established in seven patients. The studies reveal that radiation therapy affects in a lesser degree the middle ear and more substantially the inner ear with an unpairment of the functions of the labyrinth. These first investigations warrant a more specialized observation (by means of more numerous audiometric tests) and more continuous period of observation with frequent control audiograms. The observed more severe decrease of the power of hearing long after completion of radiation therapy are indicative as regards the process in the organ of Corti. High significance is attributed by the author to these observations who assumes that along with correct planning of radiation therapy rehabilitation of the power of hearing and stimulation therapy of the audio-vestibulary apparatus should simultaneously be initiated. (author)

  15. Treatment of radiation proctitis with hyperbaric oxygen: what is the optimal number of HBO treatments?

    Energy Technology Data Exchange (ETDEWEB)

    Carl, U.M.; Schmitt, G. [Duesseldorf Univ. (Germany). Dept. of Radiotherapy; Peusch-Dreyer, D. [Zentrum fuer Tauch- und Ueberdruckmedizin (ZUETUM), Bremen (Germany); Frieling, T. [Duesseldorf Univ. (Germany). Dept. of Gastroenterology; Hartmann, K.A. [Amsterdam Univ. (Netherlands). Dept. of Radiotherapy

    1998-09-01

    Aim: Our objective was to investigate the effectiveness of hyperbaric oxygenation (HBO) in the treatment of radiation proctitis. The current literature was reviewed with regard to the necessary number of HBO treatments. Patients and Methods: Two patients with proctitis after pelvic irradiation were treated with 40 and 38 HBO treatments, respectively. Hyperbaric oxygenation was delivered at 240 kPa over 90 min. Results: In one patient, proctosigmoidoscopy showed a significant improvement after 40 HBO sessions. The other patient interrupted therapy after 38 HBO treatments without subjective change. The reported number of HBO sessions for a succesful treatment of radiation proctitis ranges from 12 to 90. Conclusion: HBO should be considered before more invasive treatment modalities are performed for radiation proctitis. (orig.) [Deutsch] Ziel: Die Effektivitaet hyperbarer Oxygenation (HBO) zur Behandlung der Strahlenproktitis wurde untersucht. Literaturdaten wurden unter der Fragestellung zusammengestellt, wie viele HBO-Therapien fuer einen Behandlungserfolg notwendig sind. Patienten und Methode: Zwei Patienten mit radiogener Proktitis nach Beckenbestrahlung erhielten 40 bzw. 38 HBO-Therapien. Die hyperbare Oxygenation dauerte pro Sitzung 90 Minuten bei 240 kPa. Ergebnisse: Bei einer Patientin zeigte sich bei der proktoskopischen Verlaufsuntersuchung nach 40 HBO-Behandlungen eine deutliche Besserung der Strahlenproktitis. Der andere Patient brach die Therapie nach 38 HBO-Behandlungen ohne subjektive Befundbesserung ab. In der Literatur zur Behandlung der Strahlenproktitis mit HBO schwankt die Anzahl der notwendigen Behandlungen von 12 bis 90. Schlussfolgerung: HBO sollte als Behandlungsalternative in Erwaegung gezogen werden, bevor invasivere Therapieverfahren zur Behandlung einer Strahlenproktitis angewendet werden. (orig.)

  16. The treatment of late radiation effects with hyperbaric oxygenation (HBO)

    Energy Technology Data Exchange (ETDEWEB)

    Plafki, C. [Center for Hyperbaric Medicine, Luebeck (Germany); Carl, U.M.; Glag, M.; Hartmann, K.A. [Department for Radiotherapy, University Duesseldorf (Germany)

    1998-11-01

    Background: Late radiation injuries may impose a negative influence on the quality of life in the affected patients. In several entities, standardized treatment protocols are lacking. Hyperbaric oxygenation (HBO) has been shown to have beneficial effects in the treatment of late radiation sequelae. Material and methods: The basic principles of HBO are reviewed as well as clinical issues. Current study protocols are presented. Results: During HBO-therapy the patient breathes pure oxygen at pressures above 100 kPa. The oxygen solubility within the fluid phase of the blood is largely increased. Biological effects include an increased oxygen diffusibility, improved collagen synthesis and neoangiogenesis as well as an enhancement of antimicrobial defenses. By decreasing the capillary filtration pressure a reduction of edema becomes possible. HBO has been shown to prevent complications following surgery in irradiated tissues. Its efficacy as an adjunct in the treatment of osteonecroses in radiation patients could be demonstrated. In addition, the loss of osseointegrated implants in the maxillofacial bones of these patients could be significantly reduced. Further indications include soft tissue necroses, hemorrhagic cystitis and proctitis in tumor patients that have been treated by radiotherapy as part of a multimodality approach. Conclusions: HBO in the treatment of late radiation effects is still subject of investigation, but remarkable results have been reported. Optimized treatment protocols need to be determined in various entities. The rate of side effects is acceptable low. (orig.) [Deutsch] Hintergrund: Radiogene Spaeteffekte koennen die Lebensqualitaet der betroffenen Patienten erheblich beeintraechtigen. Bei vielen Erscheinungsformen fehlen standardisierte Therapieschemata. Die hyperbare Sauerstofftherapie (HBO) hat sich als hilfreiche Methode in der Behandlung radiogener Spaeteffekte erwiesen. Material und Methode: Die wesentlichen Grundlagen und klinischen

  17. Demonstration of the importance of a dedicated neutron beam monitoring system for BNCT facility.

    Science.gov (United States)

    Chao, Der-Sheng; Liu, Yuan-Hao; Jiang, Shiang-Huei

    2016-01-01

    The neutron beam monitoring system is indispensable to BNCT facility in order to achieve an accurate patient dose delivery. The neutron beam monitoring of a reactor-based BNCT (RB-BNCT) facility can be implemented through the instrumentation and control system of a reactor provided that the reactor power level remains constant during reactor operation. However, since the neutron flux in reactor core is highly correlative to complicated reactor kinetics resulting from such as fuel depletion, poison production, and control blade movement, some extent of variation may occur in the spatial distribution of neutron flux in reactor core. Therefore, a dedicated neutron beam monitoring system is needed to be installed in the vicinity of the beam path close to the beam exit of the RB-BNCT facility, where it can measure the BNCT beam intensity as closely as possible and be free from the influence of the objects present around the beam exit. In this study, in order to demonstrate the importance of a dedicated BNCT neutron beam monitoring system, the signals originating from the two in-core neutron detectors installed at THOR were extracted and compared with the three dedicated neutron beam monitors of the THOR BNCT facility. The correlation of the readings between the in-core neutron detectors and the BNCT neutron beam monitors was established to evaluate the improvable quality of the beam intensity measurement inferred by the in-core neutron detectors. In 29 sampled intervals within 16 days of measurement, the fluctuations in the mean value of the normalized ratios between readings of the three BNCT neutron beam monitors lay within 0.2%. However, the normalized ratios of readings of the two in-core neutron detectors to one of the BNCT neutron beam monitors show great fluctuations of 5.9% and 17.5%, respectively. PMID:26595774

  18. Clinician and therapist perceptions on radiation therapist-led treatment reviews in radiation oncology practice

    International Nuclear Information System (INIS)

    Background and purpose: To determine whether radiation therapists (RTTs) and radiation oncologists (ROs) believe RTTs can lead patient treatment reviews. Materials and methods: Phase 1 involved the construction of a checklist of the procedures followed during RO treatment reviews. Phase 2 employed the checklist to monitor the frequency of review procedures. From these data, questionnaires regarding RTTs' ability to carry out these procedures to be used in Phase 3 were developed. The questionnaires were distributed to RTTs and ROs at two large public cancer centres. Results: The majority of RTTs and ROs believed that RTTs could provide assurance and answer questions about side effects, treatment techniques, cancer, nutrition and logistics. ROs and RTTs agreed that RTTs were not capable of recommending medication or answering medical questions. Most RTTs thought they could decide if a patient should take a break from treatment if a standard protocol existed, but the ROs disagreed (P < 0.01). ROs believed that RTTs were capable of using the Common Toxicity Criteria system to grade side effects, but RTTs disagreed (P < 0.01). Concerns were raised about training, legalities, workloads, logistics, cost, patients' perspectives and remuneration. Conclusion: RTTs and ROs believed RTTs could lead treatment reviews with training, and support this role development

  19. Treatment of retinoblastoma by precision megavoltage radiation therapy

    Energy Technology Data Exchange (ETDEWEB)

    Schipper, J.; Peperzeel, H.A. van (Rijksuniversiteit Utrecht (Netherlands). Academisch Ziekenhuis); Tan, K.E.W.P. (Royal Dutch Eye Hospital, Utrecht, Netherlands)

    1985-02-01

    The principal treatment concept in the Utrecht Retinoblastoma Centre is megavoltage irradiation, followed by light coagulation and/or cryotherapy if there is any doubt as to whether the residual tumour is still active. Radiation therapy is administered by means of a simple but highly accurate temporal beam technique. A standardized dose of 45 Gy is given in 15 fractions of 3 Gy at 3 fractions per week. From 1971 to 1982, 39 children with retinoblastoma have been irradiated in at least one eye. Of the 73 affected eyes, 18 were primarily enucleated, one received light coagulation only, and 54 received radiation therapy. Of the 54 irradiated eyes, 32 were additionally treated by light coagulation and/or cryotherapy for suspicious residual tumour (in 29 eyes), recurrent tumour (in 1 eye), and/or new tumour (in 3 eyes) and 10 were ultimately enucleated. Two eyes also received hyperthermia. The percentages of cure of the irradiated eyes with a minimum follow-up of 2 years were 100% (14/14), 100% (9/9), 83% (10/12), 79% (11/14) and 0% (0/5) in the Reese-Ellsworth groups I to V-A, respectively. Of the saved eyes 95% achieved useful vision. Eighteen eyes developed a clinically detectable radiation cataract; in five of these the lens was aspirated. Cataracts developed exclusively in those lenses of which a posterior portion of more than 1 mm had to be included in the treatment field. The likelihood and the degree of cataract formation was found to be directly related to the dose of radiation to the germinative zone of the lens epithelium. The minimum cataractogenic dose found in this series was 8 Gy.

  20. Treatment of retinoblastoma by precision megavoltage radiation therapy

    International Nuclear Information System (INIS)

    The principal treatment concept in the Utrecht Retinoblastoma Centre is megavoltage irradiation, followed by light coagulation and/or cryotherapy if there is any doubt as to whether the residual tumour is still active. Radiation therapy is administered by means of a simple but highly accurate temporal beam technique. A standardized dose of 45 Gy is given in 15 fractions of 3 Gy at 3 fractions per week. From 1971 to 1982, 39 children with retinoblastoma have been irradiated in at least one eye. Of the 73 affected eyes, 18 were primarily enucleated, one received light coagulation only, and 54 received radiation therapy. Of the 54 irradiated eyes, 32 were additionally treated by light coagulation and/or cryotherapy for suspicious residual tumour (in 29 eyes), recurrent tumour (in 1 eye), and/or new tumour (in 3 eyes) and 10 were ultimately enucleated. Two eyes also received hyperthermia. The percentages of cure of the irradiated eyes with a minimum follow-up of 2 years were 100% (14/14), 100% (9/9,) 83% (10/12), 79% (11/14) and 0% (0/5) in the Reese-Ellsworth groups I to V-A, respectively. Of the saved eyes 95% achieved useful vision. Eighteen eyes developed a clinically detectable radiation cataract; in five of these the lens was aspirated. Cataracts developed exclusively in those lenses of which a posterior portion of more than 1 mm had to be included in the treatment field. The likelihood and the degree of cataract formation was found to be directly related to the dose of radiation to the germinative zone of the lens epithelium. The minimum cataractogenic dose found in this series was 8 Gy. (Auth.)

  1. Amelioration of radiation damage by pentoxifylline treatment in rats

    International Nuclear Information System (INIS)

    Pentoxifylline (PTX) is a methylxanthine derivative used to treat vascular diseases. It has antioxidant properties, an anti- tumour necrosis factor alpha (TNFα) effect, increase erythrocyte flexibility and vasodilatation. An agent that increases blood flow and tissue oxygen content may contribute to enhanced healing of soft tissue, and inhibit inflammatory reactions. The mechanism of action of the anti-oxidant effect of pentoxifylline is not yet clear and it is an interesting field to explore. This study has investigated the antioxidant pathways through which PTX treatment (1200 mg/ l in drinking water) exerts its effect on radiation-induced changes. Blood reduced glutathione (GSH), glutathione peroxidase (GSH-PX) and serum catalase (CAT), MDA, xanthine oxidase (XO) and xanthine dehydrogenase (XDH), total protein, albumin, uric acid, advanced oxidation protein products (AOPP) and ascorbyl radical (AsR) were measured in female rats. Animals were divided into: Group 1: control, Group 2: administrated PTX for 8 days. Group 3: Exposed to fractionated radiation at the dose level of 4 Gy (2 Gy every 4 days) for 8 days and Group 4: received PTX two h post the onset of irradiation (4 Gy fractionated) till the end of the experiment. All animals were inspected after 8 days from the beginning of the experiment. Fractionated 4 Gy whole body gamma irradiation induced oxidative damage manifested in the significant decreases in blood GSH content, GSH-PX and CAT activities, total protein, albumin, uric acid, and XDH. Conversely, significant elevations were detected in plasma MDA, AOPP and AsR contents as well as XO activity. PTX treatment ameliorated radiation induced oxidative damage through its antioxidant properties and free radical scavenging ability that is partially mediated through inhibition of xanthine oxidase thus could play a role in regulating radiation complications.

  2. New developments in the treatment of the acute radiation syndrome

    International Nuclear Information System (INIS)

    Radiation accidents associated with the use of nuclear power, radiation devices and industrial applications have resulted in a number of individuals with significant partial or total body exposures, in a limited number with lethal outcome. Such exposures generally result in life-threatening suppression of bone marrow and immune functions and may be accompanied by high doses to the skin and underlying tissues. In recent years, new methods of diagnosis and treatment of such patients have entered development, while experience with relatively large-scale accidents, such as the Chernobyl cases, have clearly demonstrated the limitations of previous approaches. In particular bone marrow transplantation has met with limited success, mostly due to the inhomogeneous nature of accidental exposures as well as the frequent occurrence of other injuries other man bone marrow damage. Present day technology allows for direct estimates of the number of residual bone marrow stem cells to enable a rapid decision on the type of treatment indicated, while some twenty-five recombinant hemopoietic growth factors are under investigation to accelerate the recovery of white blood cells and platelets, as well as immune functions. If applied appropriately, such growth factor treatment will successfully replace bone marrow transplantation in the majority of accident cases. Advances in hemopoietic stem cell biology, both in terms of source of stem cells as well as their isolation, will on the other hand make stem cell infusion a much less risky operation than bone marrow transplantation has been in the past

  3. The management of radiation treatment error through incident learning

    International Nuclear Information System (INIS)

    Purpose: To assess efficacy of an incident learning system in the management of error in radiation treatment. Materials and methods: We report an incident learning system implementation customized for radiation therapy where any 'unwanted or unexpected change from normal system behaviour that causes or has the potential to cause an adverse effect to persons or equipment' is reported, investigated and learned from. This system thus captures near-miss (potential) and actual events. Incidents are categorized according to severity, type and origin. Results: Our analysis spans a period of 3 years with an average accrual of 11.6 incidents per week. We found a significant reduction in actual incidents of 28% and 47% in the second and third year when compared to the first year (p < 0.001), which we attribute to the many interventions prompted by the analysis of incidents reported. We also saw a similar significant reduction in incidents generated at the treatment unit correlating with the introduction of direct treatment parameter transfer and electronic imaging (p < 0.001). Conclusions: Implementation of an incident learning system has helped us to establish a just environment where all staff members report deviations from normal system behaviour and thus generate evidence to initiate safety improvements.

  4. Survey of Radiation Oncology Centres in Australia: report of the radiation oncology treatment quality program

    International Nuclear Information System (INIS)

    Full text: One of the first steps towards the development of a comprehensive quality program for radiation oncology in Australia has been a survey of practice. This paper reports on the results of the survey that should inform the development of standards for radiation oncology in Australia. A questionnaire of 108 questions spanning aspects of treatment services, equipment, staff, infrastructure and available quality systems was mailed to all facilities providing radiation treatment services in Australia (n = 45). Information of 42 sites was received by June 2006 providing data on 113 operational linear accelerators of which approximately 2/3 are equipped with multi-leaf collimators. More than 75% of facilities were participating in a formal quality assurance (QA) system, with 63% following a nationally or internationally recognised system. However, there was considerable variation in the availability of policies and procedures specific to quality aspects, and the review of these. Policies for monitoring patient waiting times for treatment were documented at just 71% of all facilities. Although 85% of all centres do, in fact, monitor machine throughput, the number and types of efficiency measures varied markedly, thereby limiting the comparative use of these results. Centres identified workload as the single most common factor responsible for limiting staff involvement in both QA processes and clinical trial participation. The data collected in this 'snapshot' survey provide a unique and comprehensive baseline for future comparisons and evaluation of changes

  5. A computer aided treatment event recognition system in radiation therapy

    Energy Technology Data Exchange (ETDEWEB)

    Xia, Junyi, E-mail: junyi-xia@uiowa.edu; Mart, Christopher [Department of Radiation Oncology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa 52242 (United States); Bayouth, John [Department of Radiation Oncology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa 52242 and Department of Human Oncology, University of Wisconsin - Madison, 600 Highland Avenue, K4/B55, Madison, Wisconsin 53792-0600 (United States)

    2014-01-15

    Purpose: To develop an automated system to safeguard radiation therapy treatments by analyzing electronic treatment records and reporting treatment events. Methods: CATERS (Computer Aided Treatment Event Recognition System) was developed to detect treatment events by retrieving and analyzing electronic treatment records. CATERS is designed to make the treatment monitoring process more efficient by automating the search of the electronic record for possible deviations from physician's intention, such as logical inconsistencies as well as aberrant treatment parameters (e.g., beam energy, dose, table position, prescription change, treatment overrides, etc). Over a 5 month period (July 2012–November 2012), physicists were assisted by the CATERS software in conducting normal weekly chart checks with the aims of (a) determining the relative frequency of particular events in the authors’ clinic and (b) incorporating these checks into the CATERS. During this study period, 491 patients were treated at the University of Iowa Hospitals and Clinics for a total of 7692 fractions. Results: All treatment records from the 5 month analysis period were evaluated using all the checks incorporated into CATERS after the training period. About 553 events were detected as being exceptions, although none of them had significant dosimetric impact on patient treatments. These events included every known event type that was discovered during the trial period. A frequency analysis of the events showed that the top three types of detected events were couch position override (3.2%), extra cone beam imaging (1.85%), and significant couch position deviation (1.31%). The significant couch deviation is defined as the number of treatments where couch vertical exceeded two times standard deviation of all couch verticals, or couch lateral/longitudinal exceeded three times standard deviation of all couch laterals and longitudinals. On average, the application takes about 1 s per patient when

  6. A computer aided treatment event recognition system in radiation therapy

    International Nuclear Information System (INIS)

    Purpose: To develop an automated system to safeguard radiation therapy treatments by analyzing electronic treatment records and reporting treatment events. Methods: CATERS (Computer Aided Treatment Event Recognition System) was developed to detect treatment events by retrieving and analyzing electronic treatment records. CATERS is designed to make the treatment monitoring process more efficient by automating the search of the electronic record for possible deviations from physician's intention, such as logical inconsistencies as well as aberrant treatment parameters (e.g., beam energy, dose, table position, prescription change, treatment overrides, etc). Over a 5 month period (July 2012–November 2012), physicists were assisted by the CATERS software in conducting normal weekly chart checks with the aims of (a) determining the relative frequency of particular events in the authors’ clinic and (b) incorporating these checks into the CATERS. During this study period, 491 patients were treated at the University of Iowa Hospitals and Clinics for a total of 7692 fractions. Results: All treatment records from the 5 month analysis period were evaluated using all the checks incorporated into CATERS after the training period. About 553 events were detected as being exceptions, although none of them had significant dosimetric impact on patient treatments. These events included every known event type that was discovered during the trial period. A frequency analysis of the events showed that the top three types of detected events were couch position override (3.2%), extra cone beam imaging (1.85%), and significant couch position deviation (1.31%). The significant couch deviation is defined as the number of treatments where couch vertical exceeded two times standard deviation of all couch verticals, or couch lateral/longitudinal exceeded three times standard deviation of all couch laterals and longitudinals. On average, the application takes about 1 s per patient when

  7. Process of coping with intracavity radiation treatment for gynecologic cancer

    International Nuclear Information System (INIS)

    The purpose of this study was to describe the process of coping with the experience of receiving intracavity radiation treatment (ICR) for gynecologic cancer. Data were collected on the outcomes of coping, emotion (Profile of Mood States) and level of function (Sickness Impact Profile), and symptom severity and upset the evening before, during, the day after, and 1 to 2 weeks after treatment. The subjects (N = 28) had a mean age of 52 years, 39% were employed full-time, 56% had occupations as manual workers, 57% had completed 12 or more years of education, and 68% were married or widowed. The treatment required the subjects to be hospitalized on complete bedrest with radiation precautions for an average of 48 hours. Intrauterine devices were used to treat 18 subjects and vaginal applications were used to treat 10 subjects. Negative mood and level of disruption in function were generally low. Repeated measures ANOVA showed no change in negative mood over time while the change in function was attributable to the increase in disruption during treatment. Utilization of affective coping strategies and problem-oriented coping strategies was positively correlated with negative mood and disruption in function over the points of measurement. The results indicate that subjects tolerated ICR well and rapidly resumed usual function following discharge from the hospital, despite the persistence of some symptoms 1 to 2 weeks after treatment. The positive association between the utilization of coping strategies and negative outcomes of coping suggests a need to examine the measurement of coping strategies and consider the possibility that these actions represent a response to a stressful situation rather than a method of dealing with the situation

  8. Process of coping with intracavity radiation treatment for gynecologic cancer

    Energy Technology Data Exchange (ETDEWEB)

    Nail, L.M.D.

    1985-01-01

    The purpose of this study was to describe the process of coping with the experience of receiving intracavity radiation treatment (ICR) for gynecologic cancer. Data were collected on the outcomes of coping, emotion (Profile of Mood States) and level of function (Sickness Impact Profile), and symptom severity and upset the evening before, during, the day after, and 1 to 2 weeks after treatment. The subjects (N = 28) had a mean age of 52 years, 39% were employed full-time, 56% had occupations as manual workers, 57% had completed 12 or more years of education, and 68% were married or widowed. The treatment required the subjects to be hospitalized on complete bedrest with radiation precautions for an average of 48 hours. Intrauterine devices were used to treat 18 subjects and vaginal applications were used to treat 10 subjects. Negative mood and level of disruption in function were generally low. Repeated measures ANOVA showed no change in negative mood over time while the change in function was attributable to the increase in disruption during treatment. Utilization of affective coping strategies and problem-oriented coping strategies was positively correlated with negative mood and disruption in function over the points of measurement. The results indicate that subjects tolerated ICR well and rapidly resumed usual function following discharge from the hospital, despite the persistence of some symptoms 1 to 2 weeks after treatment. The positive association between the utilization of coping strategies and negative outcomes of coping suggests a need to examine the measurement of coping strategies and consider the possibility that these actions represent a response to a stressful situation rather than a method of dealing with the situation.

  9. Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment

    International Nuclear Information System (INIS)

    Radiation recall dermatitis (RRD) is an acute skin toxicity caused by different anticancer or antibiotic drugs within a former completely healed irradiation field. Predictive factors for RRD are not known and its mechanisms are not completely understood. A case of RRD induced by docetaxel and successfully treated by an antioxidant ointment (Mapisal registered) is presented here. Such an ointment might be useful not only in RRD therapy, but also in the treatment of high-grade dermatitis induced by radiotherapy and thus may contribute to the improvement of patients' quality of life and to the scheduled completion of cancer therapies. (orig.)

  10. Fractionated BNCT for locally recurrent head and neck cancer: Experience from a phase I/II clinical trial at Tsing Hua Open-Pool Reactor

    International Nuclear Information System (INIS)

    To introduce our experience of treating locally and regionally recurrent head and neck cancer patients with BNCT at Tsing Hua Open-Pool Reactor in Taiwan, 12 patients (M/F=10/2, median age 55.5 Y/O) were enrolled and 11 received two fractions of treatment. Fractionated BNCT at 30-day interval with adaptive planning according to changed T/N ratios was feasible, effective and safe for selected recurrent head and neck cancer in this trial. - Highlights: • We treated 12 patients with recurrent Head and Neck (H and N) cancer after radical surgery and radiotherapy since 2010. • Four complete response (CR) and 3 partial response (PR) were found. Total response rate was 58%. • Two patients had local control longer than one year. • No grade 4 or higher toxicity was noted for both acute and chronic effects

  11. On-line neutron beam monitoring of the Finnish BNCT facility

    International Nuclear Information System (INIS)

    A Boron Neutron Capture Therapy (BNCT) facility has been built at the FiR 1 research reactor of VTT Chemical Technology in Espoo, Finland. The facility is currently undergoing dosimetry characterisation and neutron beam operation research for clinical trials. The healthy tissue tolerance study, which was carried out in the new facility during spring 1998, demonstrated the reliability and user-friendliness of the new on-line beam monitoring system designed and constructed for BNCT by VTT Chemical Technology. The epithermal neutron beam is monitored at a bismuth gamma shield after an aluminiumfluoride-aluminium moderator. The detectors are three pulse mode U235-fission chambers for epithermal neutron fluence rate and one current mode ionisation chamber for gamma dose rate. By using different detector sensitivities the beam intensity can be measured over a wide range of reactor power levels (0.001-250 kW). The detector signals are monitored on-line with a virtual instrumentation (LabView) based PC-program, which records and displays the actual count rates and total counts of the detectors in the beam. Also reactor in-core power instrumentation and control rod positions can be monitored via another LabView application. The main purpose of the monitoring system is to provide a dosimetric link to the dose in a patient during the treatment, as the fission chamber count rates have been calibrated to the induced thermal neutron fluence rate and to the absorbed dose rate at reference conditions in a tissue substitute phantom

  12. On-line neutron beam monitoring of the Finnish BNCT facility

    Science.gov (United States)

    Tanner, Vesa; Auterinen, Iiro; Helin, Jori; Kosunen, Antti; Savolainen, Sauli

    1999-02-01

    A Boron Neutron Capture Therapy (BNCT) facility has been built at the FiR 1 research reactor of VTT Chemical Technology in Espoo, Finland. The facility is currently undergoing dosimetry characterisation and neutron beam operation research for clinical trials. The healthy tissue tolerance study, which was carried out in the new facility during spring 1998, demonstrated the reliability and user-friendliness of the new on-line beam monitoring system designed and constructed for BNCT by VTT Chemical Technology. The epithermal neutron beam is monitored at a bismuth gamma shield after an aluminiumfluoride-aluminium moderator. The detectors are three pulse mode U 235-fission chambers for epithermal neutron fluence rate and one current mode ionisation chamber for gamma dose rate. By using different detector sensitivities the beam intensity can be measured over a wide range of reactor power levels (0.001-250 kW). The detector signals are monitored on-line with a virtual instrumentation (LabView) based PC-program, which records and displays the actual count rates and total counts of the detectors in the beam. Also reactor in-core power instrumentation and control rod positions can be monitored via another LabView application. The main purpose of the monitoring system is to provide a dosimetric link to the dose in a patient during the treatment, as the fission chamber count rates have been calibrated to the induced thermal neutron fluence rate and to the absorbed dose rate at reference conditions in a tissue substitute phantom.

  13. Selective enhancement of boron accumulation with boron-entrapped water-in-oil-water emulsion in VX-2 rabbit hepatic cancer model for BNCT

    International Nuclear Information System (INIS)

    Tumor cell destruction in boron neutron-capture therapy (BNCT) is due to the nuclear reaction between 10B and thermal neutrons. It is necessary for effective BNCT therapy to accumulate 10B atoms in the tumor cells without affecting adjacent healthy cells. Water-in-oil-water (WOW) emulsion was used as the carrier of anti-cancer agents on arterial injections in clinical cancer treatment. In this study, we prepared 10BSH entrapped WOW emulsion for selective arterial infusion for the treatment of hepatocellular carcinoma. WOW emulsion was administrated by arterial injections via proper hepatic artery. The anti-tumor activity of the emulsion was compared with 10BSH-Lipiodol mix emulsion or 10BSH solutions on VX-2 rabbit hepatic tumor models. The 10B concentrations in VX-2 tumor on delivery with WOW emulsion was superior to those by conventional lipiodol mix emulsion. Electro-microscopic figures of WOW emulsion delineated the accumulation of fat droplets of WOW emulsion in the tumor site, but there was no accumulation of fat droplets in lipiodol emulsion. These results indicate that 10B entrapped WOW emulsion is most useful carrier for arterial delivery of boron agents on BNCT to cancer. (author)

  14. SOS switch system (SSS) in the radiation treatment room

    International Nuclear Information System (INIS)

    We applied patient's self-breath hold irradiation system to a device to declare the patient's intentions (SOS switch system: SSS) in the radiation room and examined a utility for problem recognition and improvement of risk management during radiation therapy by induction of SSS. Between May 2005 and October 2006, we used SSS with 65 patients. The study involved 32 men and 33 women with a median age of 65 (range, 26-88) years. The reason for using SSS was as a shell in 57, a history of laryngectomy in 2, a cough in 6, convulsions in 1, and anxiety in 3. The treatment with SSS was performed 1,120 times. The hand switch was pushed 11 times. The reasons the switch was pushed were for nausea, aspiration, pain, and cough one time each. For the others, the reasons were unclear, and it was thought due to the clouding of consciousness from brain metastases. No problems were observed with the use of SSS. SSS was a useful device for improvement of risk management during the radiation therapy. (author)

  15. Detection of radiation treatment of beans using DNA comet assay

    International Nuclear Information System (INIS)

    A simple technique of microgel electrophoresis of single cells (DNA Comet Assay) enabled a quick detection of radiation treatment of several kinds of leguminous beans (azuki, black, black eye, mung, pinto, red kidney and white beans). Each variety was exposed to radiation doses of 0.5, 1 and 5 kGy covering the permissible limits for insect disinfestation. The cells or nuclei from beans were extracted in cold PBS, embedded in agarose on microscope slides, lysed between 15 and 60 min in 2.5% SDS and electrophoresis was carried out at a voltage of 2 V/cm for 2-2.5 min. After silver staining, the slides were evaluated through an ordinary transmission microscope. In irradiated samples, fragmented DNA stretched towards the anode and the damaged cells appeared as a comet. The density of DNA in the tails increased with increasing radiation dose. However, in non-irradiated samples, the large molecules of DNA remained relatively intact and there was only minor or no migration of DNA; the cells were round or had very short tails only. Hence, the DNA comet assay provides an inexpensive, rapid and relatively simple screening method for the detection of irradiated beans

  16. Detection of radiation treatment of beans using DNA comet assay

    Science.gov (United States)

    Khan, Ashfaq A.; Khan, Hasan M.; Delincée, Henry

    2002-03-01

    A simple technique of microgel electrophoresis of single cells (DNA Comet Assay) enabled a quick detection of radiation treatment of several kinds of leguminous beans (azuki, black, black eye, mung, pinto, red kidney and white beans). Each variety was exposed to radiation doses of 0.5, 1 and 5kGy covering the permissible limits for insect disinfestation. The cells or nuclei from beans were extracted in cold PBS, embedded in agarose on microscope slides, lysed between 15 and 60min in 2.5% SDS and electrophoresis was carried out at a voltage of 2V/cm for 2-2.5min. After silver staining, the slides were evaluated through an ordinary transmission microscope. In irradiated samples, fragmented DNA stretched towards the anode and the damaged cells appeared as a comet. The density of DNA in the tails increased with increasing radiation dose. However, in non-irradiated samples, the large molecules of DNA remained relatively intact and there was only minor or no migration of DNA; the cells were round or had very short tails only. Hence, the DNA comet assay provides an inexpensive, rapid and relatively simple screening method for the detection of irradiated beans.

  17. Utility of an Australasian registry for children undergoing radiation treatment

    International Nuclear Information System (INIS)

    The aim of this study was to evaluate the utility of an Australasian registry ('the Registry') for children undergoing radiation treatment (RT). Children under the age of 16years who received a course of radiation between January 1997 and December 2010 and were enrolled on the Registry form the subjects of this study. A total of 2232 courses of RT were delivered, predominantly with radical intent (87%). Registrations fluctuated over time, but around one-half of children diagnosed with cancer undergo a course of RT. The most prevalent age range at time of RT was 10–15years, and the most common diagnoses were central nervous system tumours (34%) and acute lymphoblastic leukaemia (20%). The Registry provides a reflection of the patterns of care of children undergoing RT in Australia and a mechanism for determining the resources necessary to manage children by RT (human, facilities and emerging technologies, such as proton therapy). It lacks the detail to provide information on radiotherapy quality and disease outcomes which should be the subject of separate audit studies. The utility of the Registry has been hampered by its voluntary nature and varying needs for consent. Completion of registry forms is a logical requirement for inclusion in the definition of a subspecialist in paediatric radiation oncology.

  18. Bone marrow transplantation and other treatment after radiation injury

    International Nuclear Information System (INIS)

    This review deals mainly with current concepts about bone marrow transplantation as therapy for serious radiation injury. Such injury can be classified according to the following broadly defined dose ranges: (1) the supralethal range, leading mainly to the cerebral and intestinal syndromes; (2) the potentially lethal or therapeutic range which causes the bone marrow syndrome, and (3) the sublethal range which rarely leads to injury requiring therapy. The bone marrow syndrome of man and animals is discussed in detail. The optimal therapy for this syndrome is bone marrow transplantation in conjunction with conventional supportive treatment. The principal complications of such therapy are Graft versus Host Disease and a slow recovery of the recipient's immune system. Concerted research activities in a number of institutions have led to considerable progress in the field of bone marrow transplantation. Improved donor selection, new techniques for stem-cell separation and preservation, as well as effective barrier-nursing and antibiotic decontamination, have made bone marrow transplantation an accepted therapy for marrow depression, including the aplasia caused by excessive exposure to radiation. The review also contains a number of guidelines for the handling of serious radiation accidents. (Auth.)

  19. INEL BNCT research program publications, 1993

    International Nuclear Information System (INIS)

    This document is a collection of the published reports describing research supporting the Idaho National Engineering Laboratory Boron Neutron Capture Therapy Research Program for calendar year 1993. Contributions from the principal investigators are included, covering chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, ICP-AES analysis of biological samples), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (tissue and efficacy studies of small and large animal models). These reports have previously appeared in the book: Advances in Neutron Capture Therapy, edited by A. H. Soloway, R. F. Barth, D. E. Carpenter, Plenum Press, 1993. Reports have also appeared in three journals: Angewandte Chemie, Strahlentherapie und Onkologie, and Nuclear Science and Engineering. This individual papers have been indexed separately elsewhere

  20. Decision tools for radiation oncology. Prognosis, treatment response and toxicity

    Energy Technology Data Exchange (ETDEWEB)

    Nieder, Carsten [Tromso Univ., Bodo (Norway). Dept. of Oncology; Gaspar, Laurie E. (ed.) [Colorado Univ., Aurora, CO (United States). Dept. of Radiation Oncology

    2014-04-01

    Comprehensive overview of prognostic and predictive models for radiation oncology, stratified by disease site. Identification of models' limits and caveats. Excellent aid to decision making in daily clinical practice. A look at the recent oncology literature or a search of one of the common databases reveals a steadily increasing number of nomograms and other prognostic models, some of which are also available in the form of web-based tools. These models may predict the risk of relapse, lymphatic spread of a given malignancy, toxicity, survival, etc. Pathology information, gene signatures, and clinical data may all be used to compute the models. This trend reflects increasingly individualized treatment concepts and also the need for approaches that achieve a favorable balance between effectiveness and side-effects. Moreover, optimal resource utilization requires prognostic knowledge, for example to avoid lengthy and aggressive treatment courses in patients with a short survival expectation. In order to avoid misuse, it is important to understand the limits and caveats of prognostic and predictive models. This book provides a comprehensive overview of such decision tools for radiation oncology, stratified by disease site, which will enable readers to make informed choices in daily clinical practice and to critically follow the future development of new tools in the field.

  1. Radiation treatment in recurrent squamous cell cancer of the vulva

    International Nuclear Information System (INIS)

    Purpose: To evaluate the treatment and outcome of recurrent vulvar cancer. Methods and Materials: In a retrospective review of 26 women referred to the Department of Radiation Oncology between 1982 and 1995, patient records were analyzed with respect to the findings at original surgery, the time to locoregional recurrence, the location of the recurrence, and the subsequent management and outcome. Results: Sixteen recurrences were managed with a combination of surgery and radiotherapy, and the remainder with radiation treatment, combined with chemotherapy in some cases. The overall survival for the entire cohort at 5 years was 22%. The 5-year survival for those with recurrence confined to the vulva (n = 13) was 46%, compared with 0% for those women with a recurrence located or extending beyond the vulva (p = 0.002). The local control rate was 34.6%. Conclusion: Our results confirm the poor overall prognosis for this condition. In particular, they highlight the importance of the location of the recurrence as a prognostic indicator. Based on this review, we conclude that radiotherapy fields should encompass the region at risk if the intent is curative. Finally, low-dose palliation for groin node recurrence is ineffectual

  2. Decision tools for radiation oncology. Prognosis, treatment response and toxicity

    International Nuclear Information System (INIS)

    Comprehensive overview of prognostic and predictive models for radiation oncology, stratified by disease site. Identification of models' limits and caveats. Excellent aid to decision making in daily clinical practice. A look at the recent oncology literature or a search of one of the common databases reveals a steadily increasing number of nomograms and other prognostic models, some of which are also available in the form of web-based tools. These models may predict the risk of relapse, lymphatic spread of a given malignancy, toxicity, survival, etc. Pathology information, gene signatures, and clinical data may all be used to compute the models. This trend reflects increasingly individualized treatment concepts and also the need for approaches that achieve a favorable balance between effectiveness and side-effects. Moreover, optimal resource utilization requires prognostic knowledge, for example to avoid lengthy and aggressive treatment courses in patients with a short survival expectation. In order to avoid misuse, it is important to understand the limits and caveats of prognostic and predictive models. This book provides a comprehensive overview of such decision tools for radiation oncology, stratified by disease site, which will enable readers to make informed choices in daily clinical practice and to critically follow the future development of new tools in the field.

  3. Radiation to the breast. Complications amenable to surgical treatment

    Energy Technology Data Exchange (ETDEWEB)

    Bostwick, J.; Stevenson, T.R.; Nahai, F.; Hester, T.R.; Coleman, J.J.; Jurkiewicz, M.J.

    1984-10-01

    Major complications of radiation directed to the breast, axilla, and mediastinum were treated in 54 patients from 1974 to 1983. A classification of these complications facilitates both an understanding of the pattern of injury and the development of a treatment plan. Classification: I. Breast necrosis; II. Radionecrosis and Chest Wall Ulceration; III. Accelerated Coronary Atherosclerosis with Median Sternotomy Wound Failure After Coronary Revascularization; IV. Brachial Plexus Pain and Paresis; V. Lymphedema and Axillary Cicatrix; VI. Radiation-induced Neoplasia. The treatment has evolved during the 10-year study period to excision of the necrotic wound, including any tumor, and closure with a transposed muscle or musculocutaneous flap of latissimus dorsi (II, III, V) or rectus abdominis (I, II, VI). This strategy reflects a change from primary use of the omentum during the first years of the study. The vascularity, oxygen and antibiotic delivery of these muscle and musculocutaneous flaps promote wound healing, usually with one operation. The transfer of these muscles has not caused significant functional deficits.

  4. Diagnosis and treatment of radiation-induced burns

    International Nuclear Information System (INIS)

    The utilization of radioactive sources in medicine, industry and research is associated with a probability of accidental overexposures to ionizing radiation, among which localized irradiation are the most frequent events. Moreover, between 5 and 8 % of the patients undergoing therapeutical irradiations could exhibit a higher individual radiosensitivity which could account for severe skin reactions. Localized overexposures may damage not only epidermis and dermis but also deeper connective tissue, vessels, muscles and even bones. Within the framework of a cooperation agreement between the Buenos Aires Burn Hospital and the National Board of Nuclear Regulation, a Radio pathology Committee has been established in 1997 with the purpose of carrying out a collaborative project concerning diagnosis and treatment of radiological burns. The present document particularly considers radiological burns form the point of view of their physiopathology, physical and biological dosimetry, diagnosis prognosis and treatment. It also includes basic concepts of radiation biology and radio pathology. It could be an useful tool for training medical practitioners and also a practical guidance for organizing medical response in accidental overexposures. (author)

  5. Spectrum shaping of accelerator-based neutron beams for BNCT

    CERN Document Server

    Montagnini, B; Esposito, J; Giusti, V; Mattioda, F; Varone, R

    2002-01-01

    We describe Monte Carlo simulations of three facilities for the production of epithermal neutrons for Boron Neutron Capture Therapy (BNCT) and examine general aspects and problems of designing the spectrum-shaping assemblies to be used with these neutron sources. The first facility is based on an accelerator-driven low-power subcritical reactor, operating as a neutron amplifier. The other two facilities have no amplifier and rely entirely on their primary sources, a D-T fusion reaction device and a conventional 2.5 MeV proton accelerator with a Li target, respectively.

  6. Current state of methodological and decisions for radiation treatment of blood, its components and products

    Directory of Open Access Journals (Sweden)

    Gordeev A.V.

    2014-12-01

    Full Text Available This article presents currently used blood transfusion media — components and blood products, therapeutic effects, reactions and complications of blood transfusion, use of radiation treatment for blood transfusion fluids. There had been discussed in detail the practice of radiation processing of blood components and for the prevention of reaction "graft versus host" and studies of plasma radiation treatment for its infectious safety. There was presented the current state of techniques and technical solutions of radiation treatment of transfusion-transmissible environments. There were also considered an alternative to radiation treatment of blood.

  7. INEL BNCT Research Program Annual Report 1993

    Energy Technology Data Exchange (ETDEWEB)

    Venhuizen, J.R.

    1994-08-01

    This report is a summary of the progress and research produced for the Idaho National Engineering Laboratory Boron Neutron Capture Therapy Research Program for calendar year 1993. Contributions from all the principal investigators are included, covering chemistry (pituitary tumor studies, boron drug development including liposomes, lipoproteins, and carboranylalanine derivatives), pharmacology (murine screenings, toxicity testing, boron drug analysis), physics (radiation dosimetry software, neutron beam and filter design, neutron beam measurement dosimetry), and radiation biology (tissue and efficacy studies of small and large animal models). Information on the potential toxicity of borocaptate sodium and boronophenylalanine is presented. Results of 21 spontaneous-tumor-bearing dogs that have been treated with boron neutron capture therapy at the Brookhaven National Laboratory are updated. Boron-containing drug purity verification is discussed in some detail. Advances in magnetic resonance imaging of boron in vivo are discussed. Several boron-carrying drugs exhibiting good tumor uptake are described. Significant progress in the potential of treating pituitary tumors is presented. Measurement of the epithermal-neutron flux of the Petten (The Netherlands) High Flux Reactor beam (HFB11B), and comparison to predictions are shown.

  8. The role of radiation therapy in the multidisciplinary treatment of patients with malignant tumors. Radiation pathological stand point

    International Nuclear Information System (INIS)

    Estimations suggest that about 60% of all cancer patients will require some form of radiation therapy during their lifetime. Although 40 to 50% of cancer patients in Europe and the United States receive radiation therapy, only about 20% of patients with cancer in Japan undergo such treatment. This is largely due to the lack of understanding of the role of radiation therapy by many medical personnel in Japan, as well as to ''''radiation allergy'''' among many of the general population in Japan, a country that has been undergone atomic bombing. From our perspective as specialists in radiation therapy, the chronic shortage of radiation oncologist also poses a serious problem. Although there are approximately 700 hospitals throughout Japan where radiation therapy is available, no more than half this number of medical facilities have a full-time radiation oncologist. Perhaps the reason for this is that radiation therapy is perceived as unnecessary in Japan. However, it is absolutely essential. In our experience, the 5-year relative survival rate of patients with malignant tumors who have undergone radiation therapy in our clinic is 65 percent. Thus, radiation therapy has proven very useful in the treatment of malignant tumors. Moreover, better estimates of prognosis of cancer patients treated with radiation therapy are becoming possible. This article discusses the role of radiation therapy, from a radiation pathological perspective, in a multidisciplinary approach to treatment of cancer patients. I also emphasize the critical importance of training radiation oncologists who can function as part of multidisciplinary teams that care for patients with malignant tumors. (author). 50 refs

  9. A benchmark analysis of radiation flux distribution for Boron Neutron Capture Therapy of canine brain tumors

    International Nuclear Information System (INIS)

    Calculations of radiation flux and dose distributions for Boron Neutron Capture Therapy (BNCT) of brain tumors are typically performed using sophisticated three-dimensional analytical models based on either a homogeneous approximation or a simplified few-region approximation to the actual highly-heterogeneous geometry of the irradiation volume. Such models should be validated by comparison with calculations using detailed models in which all significant macroscopic tissue heterogeneities and geometric structures are explicitly represented as faithfully as possible. This work describes a validation exercise for BNCT of canine brain tumors. Geometric measurements of the canine anatomical structures of interest for this work were performed by dissecting and examining two essentially identical Labrador Retriever heads. Chemical analyses of various tissue samples taken during the dissections were conducted to obtain measurements of elemental compositions for tissues of interest. The resulting geometry and tissue composition data were then used to construct a detailed heterogeneous calculational model of the Labrador Retriever head. Calculations of three-dimensional radiation flux distributions pertinent to BNCT were performed for the model using the TORT discrete-ordinates radiation transport code. The calculations were repeated for a corresponding volume-weighted homogeneous tissue model. Comparison of the results showed that the peak neutron and photon flux magnitudes were quite similar for the two models (within 5%), but that the spatial flux profiles were shifted in the heterogeneous model such that the fluxes in some locations away from the peak differed from the corresponding fluxes in the homogeneous model by as much as 10-20%. Differences of this magnitude can be therapeutically significant, emphasizing the need for proper validation of simplified treatment planning models

  10. A benchmark analysis of radiation flux distribution for Boron Neutron Capture Therapy of canine brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Moran, J.M.

    1992-02-01

    Calculations of radiation flux and dose distributions for Boron Neutron Capture Therapy (BNCT) of brain tumors are typically performed using sophisticated three-dimensional analytical models based on either a homogeneous approximation or a simplified few-region approximation to the actual highly-heterogeneous geometry of the irradiation volume. Such models should be validated by comparison with calculations using detailed models in which all significant macroscopic tissue heterogeneities and geometric structures are explicitly represented as faithfully as possible. This work describes a validation exercise for BNCT of canine brain tumors. Geometric measurements of the canine anatomical structures of interest for this work were performed by dissecting and examining two essentially identical Labrador Retriever heads. Chemical analyses of various tissue samples taken during the dissections were conducted to obtain measurements of elemental compositions for tissues of interest. The resulting geometry and tissue composition data were then used to construct a detailed heterogeneous calculational model of the Labrador Retriever head. Calculations of three-dimensional radiation flux distributions pertinent to BNCT were performed for the model using the TORT discrete-ordinates radiation transport code. The calculations were repeated for a corresponding volume-weighted homogeneous tissue model. Comparison of the results showed that the peak neutron and photon flux magnitudes were quite similar for the two models (within 5%), but that the spatial flux profiles were shifted in the heterogeneous model such that the fluxes in some locations away from the peak differed from the corresponding fluxes in the homogeneous model by as much as 10-20%. Differences of this magnitude can be therapeutically significant, emphasizing the need for proper validation of simplified treatment planning models.

  11. Immobilization for the radiation therapy treatment of the pelvic region

    International Nuclear Information System (INIS)

    Previous experience with the treatment of the pelvic region has shown that geometric setup errors are considerable in extent and incidence. A proposal to alleviate this problem is the introduction of immobilization devices in analogy with head and neck treatment. The practicality and efficacy of such a technique is investigated and compared with an earlier proposed technique using interactive adjustment and Electronic Portal Imaging (EPI). A group of 13 patients treated in the pelvic region using external radiation therapy was immobilized using an Orfit-like cast. Every fraction for every patients was imaged using an EPID. Immediately after obtaining an image it was compared to a digitized simulation image using the in-house developed OPIDUM system. Patient position was adjusted when an error in one of the main directions (transversal or longitudinal) exceeded 5 mm. Time measurements were carried out in order to asses the impact of the immobilization procedure on the patient throughput. In 68% of the cases a corrective action was necessary. The fraction of total treatment time was 50% for 26% of the fields. The range of errors measured in the longitudinal direction was between 29 and -22 mm. In the transversal direction the range was from -7 to 60 mm. A full analysis 13 patients yielding statistics for more than 200 fields is presented. Special attention has been paid to the determination of the nature of the errors (random or systematic) and the impact on patient throughput

  12. Immobilization for the radiation therapy treatment of the pelvic region

    Energy Technology Data Exchange (ETDEWEB)

    Van den Heuvel, F.; De Beukeleer, M.; Nys, F.; Bijdekerke, P.; Robberechts, M.; Van Cauwenbergh, R. [Brussels Univ. (Belgium). Dept. of Radiotherapy

    1995-12-01

    Previous experience with the treatment of the pelvic region has shown that geometric setup errors are considerable in extent and incidence. A proposal to alleviate this problem is the introduction of immobilization devices in analogy with head and neck treatment. The practicality and efficacy of such a technique is investigated and compared with an earlier proposed technique using interactive adjustment and Electronic Portal Imaging (EPI). A group of 13 patients treated in the pelvic region using external radiation therapy was immobilized using an Orfit-like cast. Every fraction for every patients was imaged using an EPID. Immediately after obtaining an image it was compared to a digitized simulation image using the in-house developed OPIDUM system. Patient position was adjusted when an error in one of the main directions (transversal or longitudinal) exceeded 5 mm. Time measurements were carried out in order to asses the impact of the immobilization procedure on the patient throughput. In 68% of the cases a corrective action was necessary. The fraction of total treatment time was 50% for 26% of the fields. The range of errors measured in the longitudinal direction was between 29 and -22 mm. In the transversal direction the range was from -7 to 60 mm. A full analysis 13 patients yielding statistics for more than 200 fields is presented. Special attention has been paid to the determination of the nature of the errors (random or systematic) and the impact on patient throughput.

  13. Radiation injury of the rectum: Evaluation of surgical treatment

    International Nuclear Information System (INIS)

    One hundred four patients, 80 women and 24 men, with radiation injury of the rectum following treatment for gynecologic and urologic malignancy were studied. In 50 patients, the rectal injury was treated surgically; 54 patients were treated conservatively. The age and sex distributions were the same in each group. In 63 patients, symptoms developed one month to one year after radiotherapy. The longest latent interval was 17 years. Of the 50 surgical patients, 23 had associated small bowel injury. The indications for surgery for the rectal injury were 1) proctitis unresponsive to conservative measures in 14 patients, 2) rectal stricture or fistula or both in 32, and 3) rectosigmoid perforation in four. Forty-one patients had external diversions. Eleven had intestinal continuity restored; six of the 11 had required the stoma for proctitis unresponsive to medical measures. Nineteen patients did not undergo colostomy closure, although symptoms were greatly improved. Diversion alone was insufficient treatment in the remaining 11 patients. Twenty-six patients died. The 12 deaths in the surgical group comprised four due to residual malignancy, four from post-operative complications, and four from unrelated causes. Of the 14 deaths in the nonsurgical group, 11 died of the primary malignancy and three of unrelated causes. Diversion is considered the safest form of treatment for rectovaginal fistulae, rectal strictures, and proctitis unresponsive to medical measures. Intestinal resection resulted in a sharp rise in the morbidity and mortality rates

  14. Radiation injury of the rectum: evaluation of surgical treatment

    International Nuclear Information System (INIS)

    One hundred four patients, 80 women and 24 men, with radiation injury of the rectum following treatment for gynecologic and urologic malignancy were studied. In 50 patients, the rectal injury was treated surgically; 54 patients were treated conservatively. The age and sex distributions were the same in each group. In 63 patients, symptoms developed one month to one year after radiotherapy. The longest latent interval was 17 years. Of the 50 surgical patients, 23 had associated small bowel injury. The indications for surgery for the rectal injury were 1) proctitis unresponsive to conservative measures in 14 patients, 2) rectal stricture or fistula or both in 32, and 3) rectosigmoid perforation in four. Forty-one patients had external diversions. Eleven had intestinal continuity restored; six of the 11 had required the stoma for proctitis unresponsive to medical measures. Nineteen patients did not undergo colostomy closure, although symptoms wer greatly improved. Diversion alone was insufficient treatment in the remaining 11 patients. Twenty-six patients died. The 12 deaths in the surgical group comprised four due to residual malignancy, four from postoperative complications, and four from unrelated causes. Of the 14 deaths in the nonsurgical group, 11 died of the primary malignancy and three of unrelated causes. Diversion is considered the safest form of treatment for rectovaginal fistulae, rectal strictures, and proctitis unresponsive to medical measures. Intestinal resection resulted in sharp rise in the morbidity and mortality rates

  15. Improvements in patient treatment planning systems

    International Nuclear Information System (INIS)

    The Boron Neutron Capture Therapy, Radiation treatment planning environment (BNCT-Rtpe) software system is used to develop treatment planning information. In typical use BNCT-Rtpe consists of three main components: (1) Semi-automated geometric modeling of objects (brain, target, eyes, sinus) derived from MRI, CT, and other medical imaging modalities, (2) Dose computations for these geometric models with rtt-MC, the INEL Monte Carlo radiation transport computer code, and (3) Dose contouring overlaid on medical images as well as generation of other dose displays. We continue to develop a planning system based on three-dimensional image-based reconstructions using Bspline surfaces. Even though this software is in an experimental state, it has been applied for large animal research and for an isolated case of treatment for a human glioma. Radiation transport is based on Monte Carlo, however there will be implementations of faster methods (e.g. diffusion theory) in the future. The important thing for treatment planning is the output which must convey, to the radiologist, the deposition of dose to healthy and target tissue. Many edits are available such that one can obtain contours registered to medical image, dose/volume histograms and most information required for treatment planning and response assessment. Recent work has been to make the process more automatic and easier to use. The interface, now implemented for contouring and reconstruction, utilizes the Xwindowing system and the MOTIF graphical users interface for effective interaction with the planner. Much work still remains before the tool can be applied in a routine clinical setting

  16. Application of multiprocessor calculations in IRT BNCT channel design

    International Nuclear Information System (INIS)

    The Research Reactor IRT (IRT) Sofia, of the Institute for Nuclear Research and Nuclear Energy of the Bulgarian Academy of Sciences (INRNE) is in a process of reconstruction. The technical project includes an arrangement of Boron Neutron Capture Therapy (NCT) facility. The development of BNCT for head and neck cancer, and liver cancer is one of the main tasks in the Program for sustainable application of the reactor. The physical design of the BNCT channel proved itself to be a heavy demanding task in terms of investigation of the filter/moderator materials' physical behaviour that will be suitable for the IRT reactor's specific conditions. The IRT-Sofia NCT beam tube optimization study and the followed investigations of different filter/moderator materials and in-phantom biological doses would require a big number of sophisticated 3-dimensional calculations. The computational time for performing these calculations with the current computer setup would be unacceptably great. That is why a new version of the MCNP code with extensive capabilities for multiprocessor calculations was introduced. The compatibility with the results obtained in calculations with previous version is shown. The inheritance between the calculations sequence is justified. The gain in speed is demonstrated. (authors)

  17. Development of low cost computerized radiation treatment planning systems. 131

    International Nuclear Information System (INIS)

    With the development of computer technology in the last few years, there has been a tremendous reduction in cost and improvement in performance. For example, many personal computers use 16 bit microprocessors (8086, 68000) resulting in high performance low cost systems. The manufacturers of radiation treatment planning systems have yet to take advantage of this technology in order to pass the benefit of low cost to the radiotherapy centres. This paper discusses the feasibility of developing more advanced TPS at perhaps one fourth the cost of current TPS systems using microprocessor technology. Apart from the cost, the very nature of the latest systems is that they incorporate totally interactive software technology making it extremely easy for physicists and radiotherapists to use computers without having to learn about computers. Perhaps, time has come when TPS would become part of routine radiotherapy procedures in any centre, rather than restricted to a few privileged large centres. 11 refs.; 1 table

  18. Chronic radiation proctopathy: A practical review of endoscopic treatment.

    Science.gov (United States)

    Lenz, Luciano; Rohr, Rachel; Nakao, Frank; Libera, Ermelindo; Ferrari, Angelo

    2016-02-27

    Chronic radiation proctopathy (CRP) is a troublesome complication of pelvic radiotherapy. The most common presentation is rectal bleeding. CRP symptoms interfere with daily activities and decrease quality of life. Rectal bleeding management in patients with CRP represents a conundrum for practitioners. Medical therapy is ineffective in general and surgical approach has a high morbid-mortality. Endoscopy has a role in the diagnosis, staging and treatment of this disease. Currently available endoscopic modalities are formalin, potassium titanyl phosphate laser, neodymium:yttrium-aluminum-garnet laser, argon laser, bipolar electrocoagulation (BiCAP), heater probe, band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising. PMID:26981189

  19. Photocoagulation treatment for clinically significant radiation macular oedema

    Energy Technology Data Exchange (ETDEWEB)

    Kinyoun, J.L.; Zamber, R.W.; Lawrence, B.S.; Barlow, W.E.; Arnold, A.M. [Washington Univ., Seattle, WA (United States)

    1995-02-01

    Macular oedema is a leading cause of vision loss in patients with radiation retinopathy. In an effort to find an effective treatment for this vision threatening complication, 12 eyes (eight patients) were treated with photocoagulation for clinically significant radiation macular oedema (CSRMO) defined as central macular thickening, exudates threatening the macular centre, or one disc area of thickening in the macula. Median visual acuity improved from 20/100 pre-operatively to 20/90 at the initial post-operative examination (mean follow up 5 months) and to 20/75 at the final post-operative examination (mean follow up 39 months). At the final post-operative examination, visual acuity had improved in eight (67%) eyes and six (50%) eyes had complete resolution of the CSRMO; two (17%) other eyes had improved anatomically in that fewer CSRMO criteria were present. These results suggest that macular photocoagulation is effective in decreasing macular oedema and improving vision in eyes with CSRMO. (author).

  20. Possibilities for Improved Treatment of Persons Exposed in Radiation Accidents

    International Nuclear Information System (INIS)

    The number of persons exposed to acute radiation accidents continues to be small and the clinical experience in handling them is thus obviously limited. The great increase in use of radioactive materials and the growing number of power reactors constitute greatly augmented potential sites for accidents, but fortunately the number of accidents is not increasing. There appears to be some shift in the type of accidents, with a relative increase in those in which excessive dose to a small part of the body is the predominant feature. There has been little progress in treating local radiation injury but methods for handling the hematopoietic syndrome are definitely improved. With platelet transfusions we have a powerful aid in managing hemorrhage; the more difficult problem in persons with severe marrow depression is infection. The development of sterile environment facilities and the availability of better antibiotic therapy are important advances. Where these measures are not adequate, more experimental procedures give some promise: the injection of concentrated leukemic or normal leukocytes, the use of cross circulation, or the injection of allogeneic bone marrow. Classification of the injury and estimation of its severity are more effectively done now than a few years ago, and contribute to better treatment. (author)

  1. Natural radiation monitoring and control treatment in the Hantepe beach

    International Nuclear Information System (INIS)

    This work has been carried out to monitor and decrease the natural radiation exposure at the Hantepe beach (Canakkale (Turkey)). A 0.25- to 0.30-m-thick layer of sand was scraped, removed and deposited in a safe place in order to decrease people's exposure to radiation and to relieve relevant radio-phobia. The original mean value of dose rate on the beach was 1.38 μGy h-1 at the contact and 1.0 μGy h-1 at 1 m above the ground. After the scraping process, the mean value of dose rate decreased to 0.98 μGy h-1 at the contact and to 0.78 μGy h-1 at 1 m above the ground. One year later, these values decreased to 0.70 μGy h-1 at the contact and to 0.56 μGy h-1 at 1 m above the ground. The effective original dose rate of 1.2 mSv y-1 decreased to 0.95 mSv y-1 after the surface treatment and to 0.69 mSv y-1 one year later. (authors)

  2. Photocoagulation treatment for clinically significant radiation macular oedema

    International Nuclear Information System (INIS)

    Macular oedema is a leading cause of vision loss in patients with radiation retinopathy. In an effort to find an effective treatment for this vision threatening complication, 12 eyes (eight patients) were treated with photocoagulation for clinically significant radiation macular oedema (CSRMO) defined as central macular thickening, exudates threatening the macular centre, or one disc area of thickening in the macula. Median visual acuity improved from 20/100 pre-operatively to 20/90 at the initial post-operative examination (mean follow up 5 months) and to 20/75 at the final post-operative examination (mean follow up 39 months). At the final post-operative examination, visual acuity had improved in eight (67%) eyes and six (50%) eyes had complete resolution of the CSRMO; two (17%) other eyes had improved anatomically in that fewer CSRMO criteria were present. These results suggest that macular photocoagulation is effective in decreasing macular oedema and improving vision in eyes with CSRMO. (author)

  3. Optimizing global liver function in radiation therapy treatment planning

    Science.gov (United States)

    Wu, Victor W.; Epelman, Marina A.; Wang, Hesheng; Romeijn, H. Edwin; Feng, Mary; Cao, Yue; Ten Haken, Randall K.; Matuszak, Martha M.

    2016-09-01

    Liver stereotactic body radiation therapy (SBRT) patients differ in both pre-treatment liver function (e.g. due to degree of cirrhosis and/or prior treatment) and radiosensitivity, leading to high variability in potential liver toxicity with similar doses. This work investigates three treatment planning optimization models that minimize risk of toxicity: two consider both voxel-based pre-treatment liver function and local-function-based radiosensitivity with dose; one considers only dose. Each model optimizes different objective functions (varying in complexity of capturing the influence of dose on liver function) subject to the same dose constraints and are tested on 2D synthesized and 3D clinical cases. The normal-liver-based objective functions are the linearized equivalent uniform dose (\\ell \\text{EUD} ) (conventional ‘\\ell \\text{EUD} model’), the so-called perfusion-weighted \\ell \\text{EUD} (\\text{fEUD} ) (proposed ‘fEUD model’), and post-treatment global liver function (GLF) (proposed ‘GLF model’), predicted by a new liver-perfusion-based dose-response model. The resulting \\ell \\text{EUD} , fEUD, and GLF plans delivering the same target \\ell \\text{EUD} are compared with respect to their post-treatment function and various dose-based metrics. Voxel-based portal venous liver perfusion, used as a measure of local function, is computed using DCE-MRI. In cases used in our experiments, the GLF plan preserves up to 4.6 % ≤ft(7.5 % \\right) more liver function than the fEUD (\\ell \\text{EUD} ) plan does in 2D cases, and up to 4.5 % ≤ft(5.6 % \\right) in 3D cases. The GLF and fEUD plans worsen in \\ell \\text{EUD} of functional liver on average by 1.0 Gy and 0.5 Gy in 2D and 3D cases, respectively. Liver perfusion information can be used during treatment planning to minimize the risk of toxicity by improving expected GLF; the degree of benefit varies with perfusion pattern. Although fEUD model optimization is computationally inexpensive and

  4. 21 CFR 579.22 - Ionizing radiation for treatment of animal diets.

    Science.gov (United States)

    2010-04-01

    ... 21 Food and Drugs 6 2010-04-01 2010-04-01 false Ionizing radiation for treatment of animal diets... for treatment of animal diets. Ionizing radiation for treatment of complete diets for animals may be... Bagged complete diets, packaged feeds, feed ingredients, bulk feeds, animal treats and chews...

  5. Potential for a pluripotent adult stem cell treatment for acute radiation sickness

    OpenAIRE

    Rodgerson, Denis O.; Reidenberg, Bruce E; Harris, Alan G; Pecora, Andrew L.

    2012-01-01

    Accidental radiation exposure and the threat of deliberate radiation exposure have been in the news and are a public health concern. Experience with acute radiation sickness has been gathered from atomic blast survivors of Hiroshima and Nagasaki and from civilian nuclear accidents as well as experience gained during the development of radiation therapy for cancer. This paper reviews the medical treatment reports relevant to acute radiation sickness among the survivors of atomic weapons at Hir...

  6. Radiation therapy treatment of acute refractory renal allograft rejection

    International Nuclear Information System (INIS)

    radiation treatment (median 4, range 1-22), number of transplants (one transplant in 77 %), and concomitant immunosuppressive therapy. Independent factors by the Cox regression model were: Sex (P=0.005), Creatinine levels (P=0.000), HLA-DR (P=0.05), PRA-Max > 70% (P=0.014). Each factor was scored using the integral coefficients to generate four different groups. The overall actuarial graft survival from the initiation of RT was 83% at 1 month, 60% at 1 year and 36% at 5 years. The Kaplan-Meier survival analyzed by groups seems to produce an interpretable separation of the risk factors for graft loss. The number of rejections of pre-RT range from 1-6 (median 2) and post-RT range from 0-3 (median 0). Conclusions: Our experience indicates that radiation therapy provides effective treatment for acute refractory renal allograft rejection. The response to radiation therapy in patients treated with acute refractory renal graft rejection can be predicted by a new scoring system

  7. Gene transfer-applied BNCT (g-BNCT) for amelanotic melanoma in brain. Further upregulation of {sup 10}B uptake by cell modulation

    Energy Technology Data Exchange (ETDEWEB)

    Iwakura, M.; Tamaki, N. [Kobe Univ. (Japan). School of Medicine; Kondoh, H.; Mishima, Y. [Mishima Inst. for Dermatol. Res., Kobe, Hyogo (Japan); Hiratsuka, J. [Kawasaki Medical School, Dept. Radiation Oncol., Kurashiki, Okayama (Japan)

    2000-10-01

    Our success in eradicating melanoma by single BNCT with BPA led to the next urgent theme, i.e. application of such BNCT for currently uncurable melanoma metastasis in brain. In order to establish {sup 10}B-BPA-BNCT for melanoma in brain, we have investigated the pharmacokinetics of BPA which is most critical factor for successful BNCT, in melanotic and amelanotic and further tyrosinase gene-transfected amelanotic melanoma proliferating in brain having blood-brain-barrier, as compared to melanoma proliferating in skin. We have established three implanted models for melanoma in brain: 1) A1059 cells, amelanotic melanoma, 2) B16B15b cells, melanotic melanoma cells, highly metastatic to brain, and 3) TA1059 cells, with active melanogenesis induced by tyrosinase gene transfection. We would like to report the results of comparative analysis of the BPA uptake ability in these melanoma cells in both brain and skin. Based on these findings, we are further investigating to enhance {sup 10}B-BPA uptake by not only g-BNCT but also by additional melanogenesis upregulating cell modulation. (author)

  8. Gene transfer-applied BNCT (g-BNCT) for amelanotic melanoma in brain. Further upregulation of 10B uptake by cell modulation

    International Nuclear Information System (INIS)

    Our success in eradicating melanoma by single BNCT with BPA led to the next urgent theme, i.e. application of such BNCT for currently uncurable melanoma metastasis in brain. In order to establish 10B-BPA-BNCT for melanoma in brain, we have investigated the pharmacokinetics of BPA which is most critical factor for successful BNCT, in melanotic and amelanotic and further tyrosinase gene-transfected amelanotic melanoma proliferating in brain having blood-brain-barrier, as compared to melanoma proliferating in skin. We have established three implanted models for melanoma in brain: 1) A1059 cells, amelanotic melanoma, 2) B16B15b cells, melanotic melanoma cells, highly metastatic to brain, and 3) TA1059 cells, with active melanogenesis induced by tyrosinase gene transfection. We would like to report the results of comparative analysis of the BPA uptake ability in these melanoma cells in both brain and skin. Based on these findings, we are further investigating to enhance 10B-BPA uptake by not only g-BNCT but also by additional melanogenesis upregulating cell modulation. (author)

  9. SU-E-J-100: Reconstruction of Prompt Gamma Ray Three Dimensional SPECT Image From Boron Neutron Capture Therapy(BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, D; Jung, J; Suh, T [The Catholic University of Korea, College of medicine, Department of biomedical engineering (Korea, Republic of)

    2014-06-01

    Purpose: Purpose of paper is to confirm the feasibility of acquisition of three dimensional single photon emission computed tomography (SPECT) image from boron neutron capture therapy (BNCT) using Monte Carlo simulation. Methods: In case of simulation, the pixelated SPECT detector, collimator and phantom were simulated using Monte Carlo n particle extended (MCNPX) simulation tool. A thermal neutron source (<1 eV) was used to react with the boron uptake region (BUR) in the phantom. Each geometry had a spherical pattern, and three different BURs (A, B and C region, density: 2.08 g/cm3) were located in the middle of the brain phantom. The data from 128 projections for each sorting process were used to achieve image reconstruction. The ordered subset expectation maximization (OSEM) reconstruction algorithm was used to obtain a tomographic image with eight subsets and five iterations. The receiver operating characteristic (ROC) curve analysis was used to evaluate the geometric accuracy of reconstructed image. Results: The OSEM image was compared with the original phantom pattern image. The area under the curve (AUC) was calculated as the gross area under each ROC curve. The three calculated AUC values were 0.738 (A region), 0.623 (B region), and 0.817 (C region). The differences between length of centers of two boron regions and distance of maximum count points were 0.3 cm, 1.6 cm and 1.4 cm. Conclusion: The possibility of extracting a 3D BNCT SPECT image was confirmed using the Monte Carlo simulation and OSEM algorithm. The prospects for obtaining an actual BNCT SPECT image were estimated from the quality of the simulated image and the simulation conditions. When multiple tumor region should be treated using the BNCT, a reasonable model to determine how many useful images can be obtained from the SPECT could be provided to the BNCT facilities. This research was supported by the Leading Foreign Research Institute Recruitment Program through the National Research

  10. SU-E-J-100: Reconstruction of Prompt Gamma Ray Three Dimensional SPECT Image From Boron Neutron Capture Therapy(BNCT)

    International Nuclear Information System (INIS)

    Purpose: Purpose of paper is to confirm the feasibility of acquisition of three dimensional single photon emission computed tomography (SPECT) image from boron neutron capture therapy (BNCT) using Monte Carlo simulation. Methods: In case of simulation, the pixelated SPECT detector, collimator and phantom were simulated using Monte Carlo n particle extended (MCNPX) simulation tool. A thermal neutron source (<1 eV) was used to react with the boron uptake region (BUR) in the phantom. Each geometry had a spherical pattern, and three different BURs (A, B and C region, density: 2.08 g/cm3) were located in the middle of the brain phantom. The data from 128 projections for each sorting process were used to achieve image reconstruction. The ordered subset expectation maximization (OSEM) reconstruction algorithm was used to obtain a tomographic image with eight subsets and five iterations. The receiver operating characteristic (ROC) curve analysis was used to evaluate the geometric accuracy of reconstructed image. Results: The OSEM image was compared with the original phantom pattern image. The area under the curve (AUC) was calculated as the gross area under each ROC curve. The three calculated AUC values were 0.738 (A region), 0.623 (B region), and 0.817 (C region). The differences between length of centers of two boron regions and distance of maximum count points were 0.3 cm, 1.6 cm and 1.4 cm. Conclusion: The possibility of extracting a 3D BNCT SPECT image was confirmed using the Monte Carlo simulation and OSEM algorithm. The prospects for obtaining an actual BNCT SPECT image were estimated from the quality of the simulated image and the simulation conditions. When multiple tumor region should be treated using the BNCT, a reasonable model to determine how many useful images can be obtained from the SPECT could be provided to the BNCT facilities. This research was supported by the Leading Foreign Research Institute Recruitment Program through the National Research

  11. Nine-year interval recurrence after treatment of boron neutron capture therapy in a patient with glioblastoma: A case report

    International Nuclear Information System (INIS)

    Boron neutron capture therapy (BNCT) has been reported to be effective in the patients with glioblastoma multiforme (GBM). Median survival time (MST) of GBM patients treated with BNCT is approximately two years. GBM patients surviving 2 or 3 years are considered long-term survivors. In general, most recurrences are local and dissemination is rare. We report an unusual patient with three recurrences; the first and the second recurrences were local, and the third recurrence was dissemination nine years after BNCT. - Highlights: • A patients with glioblastoma mutliforme could be alive more than 9 years after BNCT. • BNCT may be effective for the local control of GBM. • The following TMZ and conventional radiation may be effective for prevention of CSF dissemination

  12. Alpha-amino alcohol of para-boronophenylalanine, BPAol, as a potential boron carrier for BNCT

    International Nuclear Information System (INIS)

    α amino alcohol of boronophenylalanine BPAol in which -COOH group is replaced with hydrophilic group of -OH of p-boronophenylalanine (BPA) has been synthesized and its BNCT effect on experimental tumor models have been investigated. Tumor cell killing effect of BPAol on C6 gliosarcoma cells was very high 4.4 times as that of BPA, since it was actively accumulated into tumor cells in 4-5 times as that of BPA. Carboxylic group of BPA might not play as an essential role in uptake of BPA into tumor cells. BPAol-based BNCT strongly inhibited the tumor growth of Green's melanotic melanoma hamsters even under therapeutic dose of BPA-based BNCT. These preliminary findings strongly warrant further extensive pre-clinical study for BPAol as a boron carrier for BNCT. (author)

  13. Increase of the beam intensity for BNCT by changing the core configuration at THOR

    International Nuclear Information System (INIS)

    In this article, we will consider several core configurations and run the core calculation with MCNP to obtain the neutrons distribution at THOR. The thermal neutron flux inside the vertical tubes (VT-B-VT-E) and the fast neutron flux in the first row facing to the boron neutron capture therapy (BNCT) facility (I3-I5) were tallied for indication. Based on these simulation results, the fuel elements were rearranged during the annual repair period in 2007. The epithermal neutron flux at the center of BNCT beam exit in air was measured again, and the results showed that the beam intensity increased by 50%. Comparing the neutron intensities both in reactor core and at the BNCT beam exit for several core configurations, the results show that the BNCT beam intensity can be increased without decreasing the neutron intensity in core.

  14. Development of boron concentration analysis system and techniques for testing performance of BNCT facility

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Hee Dong; Kim, Chang Shuk; Byun, Soo Hyun; Lee, Jae Yun; Sun, Gwang Min; Kim, Suk Kwon [Seoul National University, (Korea)

    2000-04-01

    I. Objectives and Necessity of the Project. Development of a boron concentration analysis system used for BNCT. Development of test techniques for BNCT facility. II. Contents and Scopes of the Project. (1) Design of a boron concentration analysis system at HANARO. (2) Component machining and instruments purchase, performance test. (3) Calculation and measurement of diffracted polychromatic beam quality. (4) Test procedures for boron concentration analysis system and BNCT facility. III. Result of the Project (1) Diffracted neutron beam quality for boron concentration analysis. (neutron flux: 1.2 * 10{sup 8} n/cm{sup 2}s, Cd-ratio : 1,600) (2) Components and instruments of the boron concentration analysis system. (3) Diffracted neutron spectrum and flux. (4) Test procedures for boron concentration analysis system and BNCT facility. 69 refs., 44 figs., 14 tabs. (Author)

  15. The role of PET/CT in radiation treatment planning for cancer patient treatment

    International Nuclear Information System (INIS)

    Positron emission tomography (PET) and, more recently, integrated positron emission tomography/X ray computed tomography (PET/CT) have appeared as significant diagnostic imaging systems in clinical medicine. Accurate recognition of cancers in patients by means of PET scanning with Fluorine-18-fluorodeoxyglucose (18F-FDG) has illustrated a need to determine a mode of therapy to achieve better prognoses. The clinical management of cancer patients has improved dramatically with the introduction of clinical PET. For treatment of cancer patients, on the other hand, radiation therapy (RT) plays an important role as a non-invasive therapy. It is crucial that cancers are encompassed by high dose irradiation, particularly in cases of curative RT. Irradiation should precisely target the entire tumour and aim to minimise the size of microscopic extensions of the cancer, as well as minimize radiation damage to normal tissues. A new imaging technique has therefore been sought to allow precise delineation of the cancer target to be irradiated. Clinical PET, combined with utilization of 18F-FDG, may have an important role in radiation treatment planning (RTP) in lung cancer. In addition to determining if RT is appropriate and whether therapy will be given with curative or palliative intent, 18F-FDG-PET is useful for determining therapy ports. It can be used both to limit ports to spare normal tissue and to include additional involved regions. Several studies have shown that PET has an impact on RTP in an important proportion of patients. It is to be hoped that treatment plans that include all the 18F-FDG-avid lesions or the 18F-FDG-avid portions of a complex mass will result in more effective local control with less unnecessary tissue being treated. The IAEA has placed emphasis on the issue of application of clinical PET for radiation treatment planning in various cancer patients. Two consultants meetings were held in 2006 and their results are summarized into this IAEA

  16. Molecular targeted treatment and radiation therapy for rectal cancer

    International Nuclear Information System (INIS)

    Background: EGFR (epidermal growth factor receptor) and VEGF (vascular endothelial growth factor) inhibitors confer clinical benefit in metastatic colorectal cancer when combined with chemotherapy. An emerging strategy to improve outcomes in rectal cancer is to integrate biologically active, targeted agents as triple therapy into chemoradiation protocols. Material and methods: cetuximab and bevacizumab have now been incorporated into phase I-II studies of preoperative chemoradiation therapy (CRT) for rectal cancer. The rationale of these combinations, early efficacy and toxicity data, and possible molecular predictors for tumor response are reviewed. Computerized bibliographic searches of Pubmed were supplemented with hand searches of reference lists and abstracts of ASCO and ASTRO meetings. Results: the combination of cetuximab and CRT can be safely applied without dose compromises of the respective treatment components. Disappointingly low rates of pathologic complete remission have been noted in several phase II studies. The K-ras mutation status and the gene copy number of EGFR may predict tumor response. The toxicity pattern (radiation-induced enteritis, perforations) and surgical complications (wound healing, fistula, bleeding) observed in at least some of the clinical studies with bevacizumab and CRT warrant further investigations. Conclusion: longer follow-up (and, finally, randomized trials) is needed to draw any firm conclusions with respect to local and distant failure rates, and toxicity associated with these novel treatment approaches. (orig.)

  17. How can laparoscopic management assist radiation treatment in cervix carcinoma?

    International Nuclear Information System (INIS)

    Purpose: To determine the role of laparoscopic lymphadenectomy (pelvis ± para-aortic nodes) and laparoscopic hysterectomy in cervical cancer compared to 'classic radical surgery' in patients undergoing surgery in comparison with modern imaging in patients treated with radiotherapy alone.Materials and methods: The limitations of modern imaging are presented as well as how complication rates can be increased when classic laparotomy is followed by radiation therapy.Laparoscopic procedures are described with particular emphasis on how to provide information on lymph node metastases with the risk of overlooking microscopic involvement. A number of clinical experiences are cited to illustrate this problem and show how treatment approaches can be adapted.Results: The role of laparoscopy is evaluated according to different clinical situations and treatment protocols emphasizing the possibilities offered by this method to the radiotherapist. Conclusion: When developing laparoscopic techniques for the management of cervical carcinoma, caution must be exercised to ensure that these techniques are not detrimental to the prognosis. (Copyright (c) 1999 Elsevier Science B.V., Amsterdam. All rights reserved.)

  18. Primary radiation therapy in the treatment of anal carcinoma

    International Nuclear Information System (INIS)

    From 1966 to 1981, 47 patients with a diagnosis of anal carcinoma were irradiated. This group was composed of 23 males and 24 females, with age ranging from 38 to 84 years (average 64.4 years). Five patients were treated preoperatively and 34 were treated definitively with cancericidal doses of irradiation. Acute radiation reactions requiring a rest-break were noted in 28% of patients, but all were managed as outpatients without untoward chronic sequelae. Chronic complications were noted in 13 patients, including two patients who required colostomy for severe anal stenosis and two who required A-P resection for large painful ulcers. Twenty-eight of 35 patients (80%) treated with irradiation alone have remained locally controlled without further treatment. An additional four have been salvaged by surgery. Only three patients had interstitial implants as part of their treatment course. Actuarial survival at five years for the N0 patients and the group as a whole are 95.6 and 79.3%, respectively. It is concluded that external beam irradiation alone, properly fractionated to cancericidal doses, can control anal carcinoma with acceptable morbidity rates and without the use of either chemotherapy or interstitial implants in most cases. There is also a strong correlation suggesting that anal intercourse and male homosexuality play a significant role in the etiology of this disease

  19. Economic evaluation of radiation processing in urban solid wastes treatment

    Science.gov (United States)

    Carassiti, F.; Lacquaniti, L.; Liuzzo, G.

    During the last few years, quite a number of studies have been done, or are still in course, on disinfection of urban liquid wastes by means of ionizing radiations. The experience gained by SANDIA pilot plant of irradiation on dried sewage sludge, together with the recently presented conceptual design of another plant handling granular solids, characterized by high efficiency and simple running, have shown the possibility of extending this process to the treatment of urban solid wastes. As a matter of fact, the problems connected to the pathogenic aspects of sludge handling are often similar to those met during the disposal of urban solid wastes. This is even more so in the case of their reuse in agriculture and zootechny. The present paper introduces the results of an analysis carried out in order to evaluate the economical advantage of inserting irradiation treatment in some process scheme for management of urban solid wastes. Taking as an example a comprehensive pattern of urban solid wastes management which has been analysed and estimated economically in previous works, we first evaluated the extra capital and operational costs due to the irradiation and then analysed economical justification, taking into account the increasing commercial value of the by-products.

  20. Molecular targeted treatment and radiation therapy for rectal cancer

    Energy Technology Data Exchange (ETDEWEB)

    Marquardt, Friederike; Roedel, Franz; Capalbo, Gianni; Weiss, Christian; Roedel, Claus [Dept. of Radiation Therapy, Univ. of Frankfurt/Main (Germany)

    2009-06-15

    Background: EGFR (epidermal growth factor receptor) and VEGF (vascular endothelial growth factor) inhibitors confer clinical benefit in metastatic colorectal cancer when combined with chemotherapy. An emerging strategy to improve outcomes in rectal cancer is to integrate biologically active, targeted agents as triple therapy into chemoradiation protocols. Material and methods: cetuximab and bevacizumab have now been incorporated into phase I-II studies of preoperative chemoradiation therapy (CRT) for rectal cancer. The rationale of these combinations, early efficacy and toxicity data, and possible molecular predictors for tumor response are reviewed. Computerized bibliographic searches of Pubmed were supplemented with hand searches of reference lists and abstracts of ASCO and ASTRO meetings. Results: the combination of cetuximab and CRT can be safely applied without dose compromises of the respective treatment components. Disappointingly low rates of pathologic complete remission have been noted in several phase II studies. The K-ras mutation status and the gene copy number of EGFR may predict tumor response. The toxicity pattern (radiation-induced enteritis, perforations) and surgical complications (wound healing, fistula, bleeding) observed in at least some of the clinical studies with bevacizumab and CRT warrant further investigations. Conclusion: longer follow-up (and, finally, randomized trials) is needed to draw any firm conclusions with respect to local and distant failure rates, and toxicity associated with these novel treatment approaches. (orig.)

  1. Treatment outcomes for patients with chloroma receiving radiation therapy

    International Nuclear Information System (INIS)

    This study aims to analyse treatment outcomes, disease control and toxicity in patients with chloromas referred for radiation therapy (RT). Medical records were retrospectively reviewed for 41 patients with chloromas treated with RT at our institution. Twenty-five patients were treated with palliative intent, whereas sixteen received RT as a component of curative intent therapy in addition to systemic chemotherapy with or without haematopoietic stem cell transplant (HSCT). All patients received RT for chloroma (median dose 24 Gy). Median survival was 5.4 months after RT (95% confidence interval (CI) 3.5-12.6 months), and no significant difference in overall survival was identified based on prior treatment with systemic chemotherapy alone or HSCT. Patients treated with curative intent had a median survival of 26.2 months (95% CI 6.1-48.9 months) and a Kaplan-Meier estimate of 15% overall survival at 5 years. At the end of the study follow-up period, 38 patients were dead and three patients treated with curative intent remained alive. After palliative RT, 44% of patients experienced partial relief and 48% experienced complete symptomatic improvement without significant acute toxicities. RT provides timely symptom palliation for patients with chloromas with minimal morbidity, but the prognosis remains poor. Long-term remission can be achieved in selected patients with salvage chemotherapy and HSCT.

  2. Primary radiation therapy in the treatment of anal carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Cantril, S.T. (Children' s Hospital of San Francisco, CA); Green, J.P.; Schall, G.L.; Schaupp, W.C.

    1983-09-01

    From 1966 to 1981, 47 patients with a diagnosis of anal carcinoma were irradiated. This group was composed of 23 males and 24 females, with age ranging from 38 to 84 years (average 64.4 years). Five patients were treated preoperatively and 34 were treated definitively with cancericidal doses of irradiation. Acute radiation reactions requiring a rest-break were noted in 28% of patients, but all were managed as outpatients without untoward chronic sequelae. Chronic complications were noted in 13 patients, including two patients who required colostomy for severe anal stenosis and two who required A-P resection for large painful ulcers. Twenty-eight of 35 patients (80%) treated with irradiation alone have remained locally controlled without further treatment. An additional four have been salvaged by surgery. Only three patients had interstitial implants as part of their treatment course. Actuarial survival at five years for the N/sub 0/ patients and the group as a whole are 95.6 and 79.3%, respectively. It is concluded that external beam irradiation alone, properly fractionated to cancericidal doses, can control anal carcinoma with acceptable morbidity rates and without the use of either chemotherapy or interstitial implants in most cases. There is also a strong correlation suggesting that anal intercourse and male homosexuality play a significant role in the etiology of this disease.

  3. Towards in vivo monitoring of neutron distributions for quality control of BNCT

    Science.gov (United States)

    Verbakel, W. F. A. R.; Hideghety, K.; Morrissey, J.; Sauerwein, W.; Stecher-Rasmussen, F.

    2002-04-01

    Dose delivery in boron neutron capture therapy (BNCT) is complex because several components contribute to the dose absorbed in tissue. This dose is largely determined by local boron concentration, thermal neutron distribution and patient positioning. In vivo measurements of these factors would considerably improve quality control and safety. During therapy, a γ-ray telescope measures the γ-rays emitted following neutron capture by hydrogen and boron in a small volume of the head of a patient. Scans of hydrogen γ-ray emissions could be used to verify the actual distribution of thermal neutrons during neutron irradiation. The method was first tested on different phantoms. These measurements showed good agreement with calculations based on thermal neutron distributions derived from a treatment planning program and from Monte Carlo N-particle (MCNP) simulations. Next, the feasibility of telescope scans during patient irradiation therapy was demonstrated. Measurements were reproducible between irradiation fractions. In theory, this method can be used to verify the positioning of the patient in vivo and the delivery of thermal neutrons in tissue. However, differences between measurements and calculations based on a routine treatment planning program were observed. These differences could be used to refine the treatment planning. Further developments will be necessary for this method to become a standard quality control system.

  4. Dose estimation of animal experiments at the THOR BNCT beam by NCTPlan and Xplan

    International Nuclear Information System (INIS)

    Dose estimation of animal experiments affects many subsequent derived quantities, such as RBE and CBE values. It is important to ensure the trustiness of calculated dose of the irradiated animals. However, the dose estimation was normally calculated using simplified geometries and tissue compositions, which led to rough results. This paper introduces the use of treatment planning systems NCTplan and Xplan for the dose estimation. A mouse was taken as an example and it was brought to hospital for micro-PET/CT scan. It was found that the critical organ doses of an irradiated mouse calculated by simplified model were unreliable in comparison to Xplan voxel model. The difference could reach the extent of several tenths percent. It is recommended that a treatment planning system should be introduced to future animal experiments to upgrade the data quality. - Highlights: • This study presents the new BNCT treatment planning system Xplan for animal experiments. • Xplan is based on a pixel-to-pixel conversion which has the same resolution as the CT images. • NCTplan and a simplified geometry for rat were used for the sake of comparison. • The spatial resolution applied in calculation is crucial to the reliability of estimated dose

  5. A feasibility study of the Tehran research reactor as a neutron source for BNCT

    International Nuclear Information System (INIS)

    Investigation on the use of the Tehran Research Reactor (TRR) as a neutron source for Boron Neutron Capture Therapy (BNCT) has been performed by calculating and measuring energy spectrum and the spatial distribution of neutrons in all external irradiation facilities, including six beam tubes, thermal column, and the medical room. Activation methods with multiple foils and a copper wire have been used for the mentioned measurements. The results show that (1) the small diameter and long length beam tubes cannot provide sufficient neutron flux for BNCT; (2) in order to use the medical room, the TRR core should be placed in the open pool position, in this situation the distance between the core and patient position is about 400 cm, so neutron flux cannot be sufficient for BNCT; and (3) the best facility which can be adapted for BNCT application is the thermal column, if all graphite blocks can be removed. The epithermal and fast neutron flux at the beginning of this empty column are 4.12×109 and 1.21×109 n/cm2/s, respectively, which can provide an appropriate neutron beam for BNCT by designing and constructing a proper Beam Shaping Assembly (BSA) structure. - Highlights: • The feasibility of using of TRR for BNCT has been investigated. • Neutron energy spectrum at all external irradiation facilities of TRR have been measured and calculated. • Spatial distribution of neutrons have been measured using copper wire activation method

  6. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors

    International Nuclear Information System (INIS)

    Purpose: To investigate the clinical, histopathological, and radiological features of radiation pneumonitis arising as a complication of selective internal radiation treatment for liver tumors. To correlate the development of radiation pneumonitis with the degree of lung shunting as assessed by 99mTechnetium-labeled macroaggregated albumin (Tc-MAA) scan. Methods and Materials: Five out of 80 patients who had inoperable hepatic tumors and underwent treatment with intraarterial 90Yttrium- (90Y)-microspheres, developed progressive restrictive ventilatory dysfunction without an infective or cardiovascular cause. Histopathological evidence of a pneumonitis and the presence of microspheres in the lung tissue suggested a diagnosis of radiation pneumonitis. The clinical course, radiological and histopathological findings, percentage tumor shunting to the lungs (lung shunting, as predicted by gamma camera scanning after intraarterial Tc-MAA), and the estimated radiation dose to the lungs were analyzed. In an attempt to reduce pulmonary shunting of the microspheres, three patients received partial hepatic embolization with inert particles before selective internal radiation therapy. Results: In the five patients who developed radiation pneumonitis, lung shunting percentages (as predicted by Tc-MAA scan) ranged from 13.1 to 45.6% (median 23.7%). The estimated whole lung radiation dose ranged from 10.43 Gy to 36.44 Gy (median 25.04 Gy). Among 75 patients who did not develop radiation pneumonitis, the percentage lung shunting ranged from less than 1% to 15% (median 6%). Nine patients had lung shunting greater than 13% and five of them developed radiation pneumonitis, whereas this developed in none of those in whom shunting was below 13%. The onset of radiation pneumonitis ranged from 1 to 6 months after internal radiation treatment. All five patients exhibited characteristic plain radiographic and computerized tomographic changes comprising extensive consolidation with well

  7. Proton Radiation Therapy for the Treatment of Retinoblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Mouw, Kent W. [Harvard Radiation Oncology Program, Boston, Massachusetts (United States); Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (United States); Sethi, Roshan V.; Yeap, Beow Y.; MacDonald, Shannon M.; Chen, Yen-Lin E.; Tarbell, Nancy J.; Yock, Torunn I.; Munzenrider, John E.; Adams, Judith [Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (United States); Grabowski, Eric [Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts (United States); Mukai, Shizuo [Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts (United States); Shih, Helen A., E-mail: hshih@partners.org [Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (United States)

    2014-11-15

    Purpose: To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). Methods and Materials: This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. Results: The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Conclusions: Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, even in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed.

  8. Volumetric Spectroscopic Imaging of Glioblastoma Multiforme Radiation Treatment Volumes

    International Nuclear Information System (INIS)

    Purpose: Magnetic resonance (MR) imaging and computed tomography (CT) are used almost exclusively in radiation therapy planning of glioblastoma multiforme (GBM), despite their well-recognized limitations. MR spectroscopic imaging (MRSI) can identify biochemical patterns associated with normal brain and tumor, predominantly by observation of choline (Cho) and N-acetylaspartate (NAA) distributions. In this study, volumetric 3-dimensional MRSI was used to map these compounds over a wide region of the brain and to evaluate metabolite-defined treatment targets (metabolic tumor volumes [MTV]). Methods and Materials: Volumetric MRSI with effective voxel size of ∼1.0 mL and standard clinical MR images were obtained from 19 GBM patients. Gross tumor volumes and edema were manually outlined, and clinical target volumes (CTVs) receiving 46 and 60 Gy were defined (CTV46 and CTV60, respectively). MTVCho and MTVNAA were constructed based on volumes with high Cho and low NAA relative to values estimated from normal-appearing tissue. Results: The MRSI coverage of the brain was between 70% and 76%. The MTVNAA were almost entirely contained within the edema, and the correlation between the 2 volumes was significant (r=0.68, P=.001). In contrast, a considerable fraction of MTVCho was outside of the edema (median, 33%) and for some patients it was also outside of the CTV46 and CTV60. These untreated volumes were greater than 10% for 7 patients (37%) in the study, and on average more than one-third (34.3%) of the MTVCho for these patients were outside of CTV60. Conclusions: This study demonstrates the potential usefulness of whole-brain MRSI for radiation therapy planning of GBM and revealed that areas of metabolically active tumor are not covered by standard RT volumes. The described integration of MTV into the RT system will pave the way to future clinical trials investigating outcomes in patients treated based on metabolic information

  9. Proton Radiation Therapy for the Treatment of Retinoblastoma

    International Nuclear Information System (INIS)

    Purpose: To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). Methods and Materials: This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. Results: The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Conclusions: Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, even in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed

  10. Surgical management of vestibular schwannomas after failed radiation treatment.

    Science.gov (United States)

    Nonaka, Yoichi; Fukushima, Takanori; Watanabe, Kentaro; Friedman, Allan H; Cunningham, Calhoun D; Zomorodi, Ali R

    2016-04-01

    Increasing numbers of patients with vestibular schwannoma (VS) have been treated with focused-beam stereotactic radiation treatment (SRT) including Gamma knife, CyberKnife, X-knife, Novalis, or proton beam therapy. The purpose of this study was to document the incidence of tumor regrowth or symptoms that worsened or first developed following SRT and to discuss surgical strategies for patients who have failed SRT for VS. A consecutive series of 39 patients with SRT failed VS were surgically treated. Clinical symptoms, tumor regrowth at follow-up, intraoperative findings, and surgical outcome were evaluated. There were 15 males and 24 females with a mean age of 51.8 years. Thirty-six patients (92.3 %) demonstrated steady tumor growth after SRT. Two (5.1 %) patients with slight increase of the mass underwent surgical resection because of development of unbearable facial pain. Symptoms that worsened or newly developed following SRT in this series were deafness (41 %), dizziness (35.9 %), facial numbness (25.6 %), tinnitus (20.5 %), facial nerve palsy (7.7 %), and facial pain (7.7 %). Intraoperative findings demonstrated fibrous changes of the tumor mass, cyst formation, and brownish-yellow or purple discoloration of the tumor capsule. Severe adhesions between the tumor capsule and cranial nerves, vessels, and the brainstem were observed in 69.2 %. Additionally, the facial nerve was more fragile and irritable in all cases. Gross total resection (GTR) was achieved in 33.3 % of patients, near-total resection (NTR) in 35.9 %, and subtotal resection (STR) in 30.8 % of patients. New facial nerve palsy was seen in seven patients (19.4 %) postoperatively. Our findings suggest that patients with VS who fail SRT with either tumor progression or worsening of clinical symptoms will have an increased rate of adhesions to the neurovascular structures and may have radiation-influenced neuromalacia. Salvage surgery of radiation-failed tumors is more difficult and will

  11. Plastic and reconstructive surgical treatment of the radiation injuries

    International Nuclear Information System (INIS)

    Eleven cases of radiation injury are reported. Three of them were relatively superficial ''radiation dermatitis''. They received radical excision and free skin-grafting to the cosmetic and functional satisfaction. Eight patients had deeper injury, ''radiation ulcer''. Six cases were treated by ''local flap''. The local flap technique is the simplest and the most effective way to treat the radiation ulcer. The reason is 1) it is a one stage operation, 2) it has a permanent pedicle supplying good blood flow, 3) it has very close texture and color match to the area. However, a skin-grafting performed on one patient of radiation ulcer ended up with failure. The indication of the skin-grafting and the local flap was discussed from the point of the stage or degree of radiation injuries and the recommendable method is the skin-grafting to the radiation dermatitis and the local flap to the radiation ulcer. (auth.)

  12. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

    Energy Technology Data Exchange (ETDEWEB)

    David W. Nigg

    2012-05-01

    Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 [ae-B20H17NH3], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 {+-} 16.1 ppm at 48 h and to 43.9 {+-} 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

  13. Radiation treatment dose optimisation using Poisson tumour control probability parameters

    International Nuclear Information System (INIS)

    This study examines the Poisson tumour control probability (TCP) γ37 and D37 parameters of a uniformly irradiated numerical tumour model using changes in tumour burden as a surrogate for treatment response information. An optimum dose Di for a tumour sub-volume element Vi is described that maximizes TCP as a function of fixed tumour integral dose ξ. TCP was calculated for spatially-varying clonogen density for a total 108 cells and radiosensitivity α with mean radiosensitivity in the range 0.4 – 1.0 Gy−1. A bivariate normal distribution is used to describe the radiosensitivity α and the linear term of the linear-quadratic (LQ) cell kill governed the changes in the regional tumour burden within sub-volumes Vi. The optimum dose distribution, Di, for Vi is obtained as a function of fixed tumour integral dose ξ. For a uniform dose delivery and for TCP = 37%, γ37 and D37 are described by the effective radiosensitivity αeff and the effective clonogen number N0,eff, respectively. αeff is equivalent to differential dose changes in the number of clonogenic cells (tumour burden). The γ37 values were found to be inversely correlated with variance of the probability density function of the α distribution. For the biologically optimum dose distribution, γ37 was found to converge to the theoretical maximum limit and D37 was found to reduce relative to that obtained for the uniform dose case. The TCP parameters γ37 and D37 could thus be useful in optimising individual radiation treatment doses even when tumour heterogeneity is taken into account.

  14. Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment

    Energy Technology Data Exchange (ETDEWEB)

    Duncker-Rohr, Viola; Freund, Ulrich; Momm, Felix [Ortenau-Klinikum Offenburg-Gengenbach Lehrkrankenhaus der Albert-Ludwigs-Universitaet Freiburg i. Br., Radio-Onkologie, Offenburg (Germany)

    2014-05-15

    Radiation recall dermatitis (RRD) is an acute skin toxicity caused by different anticancer or antibiotic drugs within a former completely healed irradiation field. Predictive factors for RRD are not known and its mechanisms are not completely understood. A case of RRD induced by docetaxel and successfully treated by an antioxidant ointment (Mapisal {sup registered}) is presented here. Such an ointment might be useful not only in RRD therapy, but also in the treatment of high-grade dermatitis induced by radiotherapy and thus may contribute to the improvement of patients' quality of life and to the scheduled completion of cancer therapies. (orig.) [German] Die Strahlen-Recall-Dermatitis (RRD) ist eine akute Hauttoxizitaet, die durch verschiedene Chemotherapeutika oder Antibiotika innerhalb eines frueheren, komplett abgeheilten Bestrahlungsfelds hervorgerufen wird. Praediktive Faktoren fuer die RRD sind nicht bekannt und ihr Mechanismus ist nicht vollstaendig geklaert. Es wird ein Fallbericht einer durch Docetaxel induzierten RRD dargestellt, die erfolgreich mit einer antioxidativen Salbe (Mapisal {sup registered}) behandelt wurde. Solche Salben koennten nicht nur zur Therapie der RRD, sondern auch bei der Behandlung einer akuten Dermatitis waehrend der Strahlentherapie nuetzlich sein und damit zur Verbesserung der Lebensqualitaet der Patienten und zur planmaessigen Durchfuehrung der Tumortherapie beitragen. (orig.)

  15. Radiation-induced skin toxicity: prevention and treatments

    International Nuclear Information System (INIS)

    Acute and long term effects are frequent after radiotherapy. They may alter the general status and quality of life of the patients. Chronic radiodermatitis may result in ulceration and in transformation into a squamous cell carcinoma. There is a correlation of the frequency of acute dermatitis with the total dose. Chronic radiodermatitis may develop after repeated small doses of ionizing radiation for cardiac catheterization and coronary angio-plasties. The other prognostic factors for the level of acute and late skin reactions are volume of tissue treated, total daily dose, fractionations schemes... but there are some variation in the degree of reaction in patients treated with identical radiotherapy schedules. There is a patient - to- patient variability. Several diseases as systemic sclerosis, some genetic diseases, perhaps some drugs may increase the cutaneous reactions. So both acute and chronic irradiation injury is a complex process with many regulations. Chronic fibrosis may be caused by mechanism of cell activation (and particularly fibroblasts). Cytokines e.g transforming growth factor β (TGF-β) might be involved in the induction of fibrosis. Treatment use emollients. Superoxide dismutase was used as an ointment for radio-fibrosis therapy and obtains a reduction of the fibrosis. In late phases plastic surgery or sometimes cryo-surgery can be used. (authors)

  16. Physical and tumor biological aspects and calculation model of dosage in boron neutron capture therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Rassow, J.; Poeller, F.; Meissner, P. (Essen Univ. (Gesamthochschule) (Germany). Abt. fuer Medizinische Strahlenphysik); Steinberg, F. (Essen Univ. (Gesamthochschule) (Germany). Inst. fuer Medizinische Strahlenbiologie)

    1993-01-01

    Fundamentally different aspects apply to dosage in boron neutron capture therapy (BNCT) compared to that in the case of normal radiotherapy with photons, electrons or heavy particles such as neutrons. The reason is that the latter only requires a knowledge of the stochastic distribution of the absorbed dose within cells, radiation quality and atomic composition of tissue in the regions of interest, whereas for the former the absolute concentration and microscopic distribution of [sup 10]B atoms in inter- and intracellular spaces of tumor and healthy cells is additionally of equal importance. The effects of radiation without [sup 10]B must always be superimposed on those of heavy particles resulting from neutron capture reactions on [sup 10]B atoms. Complex geometrical calculaations are necessary with respect to ranges of the heavy particles smaller than a cell diameter. Apart from the direct effects of radiation without [sup 10]B, the dosage therefore depends on thermal neutron fluence, [sup 10]B concentration, its extreme inhomogeneous macroscopic distribution in the tumor tissue, the cellular localization of the [sup 10]B atoms in the large intercellular space, the cell membrane, within cytoplasm or the cell nucleus, the geometrical probability of hitting the cell nucleus, and that such a hit finally results in a cell killing, and a Poisson statistical enhancement factor, which describes the dose-effect relation for cell survival. The calculations necessary are demonstrated in the case of a normal and a tumor cell type, each with representative cell diameter and nucleus size. It is evident that the microscopic distribution of [sup 10]B atoms is one of the most critical parameters which is still insufficiently known. (orig.).

  17. Functional and histological assessment of the radiobiology of normal rat lung in BNCT

    International Nuclear Information System (INIS)

    This study investigated the radiobiology and sensitivity of the normal rat lung to Boron Neutron Capture Therapy (BNCT) radiation. Rat thorax irradiations were carried out with x-rays or with neutrons in the presence or absence of p-boronophenylalanine (BPA). Lung damage were assessed functionally with breathing rate measurement up to 180 days after irradiation and then histologically. Breathing rates 20% (∼3 σ) above the control group (sham-irradiated rats) mean were considered as positive responses to lung radiation damage. Though most responding animals demonstrated radiation induced pneumonitis (≤110 days) as well as pulmonary fibrosis (>110 days), some animals receiving neutrons plus BPA showed only the latter. The breathing rate dose response data were fit using probit analysis. The ED50 values measured for x-rays, neutron beam only, and neutrons plus BPA were 11.5±0.4 Gy, 9.2±0.5 Gy, and 6.7±0.4 Gy, respectively. The biological weighting factors for the neutron beam (n+γ), the thermal neutron dose component, and the 10B dose component were determined to be 1.2±0.1, 2.2±0.4, and 2.3±0.3, respectively. The histological dose response curves were linear. Consistent with the functional assay, the weighting factors measured histologically were 1.2±0.1 for the thermal neutron beam and 1.9±0.2 for the 10B dose component. (author)

  18. Quality of Intensity Modulated Radiation Therapy Treatment Plans Using a (60)Co Magnetic Resonance Image Guidance Radiation Therapy System

    DEFF Research Database (Denmark)

    Wooten, H Omar; Green, Olga; Yang, Min;

    2015-01-01

    PURPOSE: This work describes a commercial treatment planning system, its technical features, and its capabilities for creating (60)Co intensity modulated radiation therapy (IMRT) treatment plans for a magnetic resonance image guidance radiation therapy (MR-IGRT) system. METHODS AND MATERIALS: The...... clinical tolerances. CONCLUSIONS: A commercial (60)Co MR-IGRT device can produce highly conformal IMRT treatment plans similar in quality to linac IMRT for a variety of disease sites. Additional work is in progress to evaluate the clinical benefit of other novel features of this MR-IGRT system....

  19. Palliative or curative treatment intent affects communication in radiation therapy consultations.

    NARCIS (Netherlands)

    Timmermans, L.; Maazen, R.W.M. van der; Leer, J.W.H.; Kraaimaat, F.W.

    2006-01-01

    OBJECTIVE: To assess whether communication in radiotherapy consultations is affected by palliative or curative treatment intent. SUBJECTS AND METHODS: The study involved 160 patients and 8 radiation oncologists. Eighty patients visited the radiation oncologist (RO) for palliative treatment and 80 fo

  20. The us of low-energy laser for prevention and treatment of local radiation injuries

    International Nuclear Information System (INIS)

    Possibilities for usage of laser biostimulation therapy in medicine were considered. Laser radiation stimulates activity of enzymatic systems. Nucleic acid synthesis increases under the action of laser radiation (LR). Stimulation of LR was observed at tissue level. Low-energy laser therapy was used to cut short early skin radiation injuries during photon radiotherapy of tumors. Efficiency of laser radiation methods for treatment of early and delayed radiation injuries was shown. Lasers of unimpaired intensity are used for prophylaxis of radiation injuries during radiotherapy of malignant tumors